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Abstract 
Adverse drug reactions (ADRs) are common and should be reported to the CSM, 
particularly for newly marketed drugs. There is under-reporting of ADRs by doctors. 
Involving the patient in self-reporting, particularly when initiated by pharmacists is 
feasible and could help to improve reporting rates. This study investigated a 
comprehensive checklist questionnaire listed symptoms in all body systems to facilitate 
patient self-reporting using both established and new 'black triangle' centrally-acting 
drugs. Symptoms reported were compared to their documentation in medical notes 
and for new drugs to reports from other sources. A novel classification system for 
ADRs was developed to take account of the minimal data available and used to 
evaluate the potential accuracy of symptom attribution by patients. An external 
comparison of a sample of symptom classifications by an ADR expert was also 
obtained. The questionnaire was sent to 464 patients prescribed carbamazepine, 
sodium valproate, trazodone, doxepin and co-proxamol from three participating 
medical practices in a pilot study. Subsequently, it was sent to all patients (n=2307) 
prescribed tramadol, fentanyl patch, venlafaxine, nefazodone, citalopram, 
moclobemide, gabapentin, lamotrigine and topiramate from 79 participating medical 
practices in Grampian during January-March 1997. 
The overall response rates were 44.6% (n=207) for the pilot study and 36.3% (n=837) 
for the main study. The most frequently reported symptoms were: drowsiness for 
carbamazepine, unusual tiredness for sodium valproate, constipation for co-proxamol, 
dry mouth for trazodone, doxepin, tramadol, venlafaxine, nefazodone, moclobemide 
and citalopram, weight gain for gabapentin, loss of memory for lamotrigine, weight loss 
for topiramate and constipation for fentanyl patch. Overall only 22.4% (522/2330) of 
symptoms reported by patients were recorded by GPs in the 310 medical notes 
iii 
accessed. In general, common symptoms were reported more frequently by patients 
than in CSM reports and PEM data. Patients tended to report minor and known ADRs 
which bothered them, while CSM and PEM reports received were of more severe 
ADRs. Respondents were more likely to report symptoms (6040/8630,70%) 
potentially caused by the study drugs than those not to be caused by the study drugs. 
Moderate agreement (Kappa = 0.4-0.5) was found between expert and researcher 
classifications of symptom causality. It is suggested that interpretation by pharmacists 
of patient self-reporting using the checklist questionnaire could result in much higher 
ADR reporting rates, in particular for new drugs. 
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Chapter 1 
Review of Literature 
1.1 Introduction 
A number of patients experience undesirable effects from drugs despite taking them 
as directed (Einarson, 1993). Concern has increased about adverse drug reactions 
(ADRs) since thalidomide-induced phocomelia was first mentioned in the Lancet of 2nd 
December 1961 (Stephen, 1992). This drug had been prescribed as a safe hypnotic 
during pregnancy. Following this tragic event, several countries established agencies 
concerned with drug safety including the Committee on Safety of Drugs in the United 
Kingdom (UK) to identify and prevent illness caused by drugs (Davies, 1991). The 
practolol disaster which caused oculomucocutaneous syndrome in 1975 later 
reinforced this need since it was claimed that side effects of practolol had been 
discovered much earlier in clinical trials (Stephen, 1992). In addition, during the 1970s 
and 1980s there had been a series of major ADRs such as subacute myelo-optic-
neuropathy caused by clioquinol, deaths from liver diseases caused by ticrynafen and 
benoxaprofen, anaphylactoid reactions caused by zomepirac and renal failure caused 
by suprofen. These also had led academic investigators, the pharmaceutical industries 
and the Food and Drug Administration (FDA) of the United States (US) to develop new 
methods for studying drug effects in large populations (Strom, 1994a). 
1.1.1 Limitations of pre-marketing studies 
Clinical trials, required as part of the process of drug approval and labelling, are the 
primary source of information about new drugs. Although these studies confirm that a 
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drug is efficacious and not harmful, they frequently fail to provide the information which 
is necessary in therapeutic decision-making or to identify all ADRs (Ray et al., 1993). 
Generally, clinical trials have limited sample sizes and usually last no longer than three 
years. The numbers of subjects who are exposed to a drug should be between 500 
and 3000 in order to be 95% certain of detecting ADRs that occur in 1-6 persons per 
thousand of exposed individuals (Strom, 1994a). Therefore, ADRs which occur less 
commonly than this are less likely to be found. Thus infrequent or rare serious 
reactions (1 in 10,000 - 1 in 100,000). as well as delayed reactions which result from 
long-term administration, cannot be detected in these pre-marketing studies (0' 
Donnell, 1994). Furthermore, clinical trials generally seek subjects who provide 
homogenous data as much as possible in order to decrease unexplained variability in 
outcome variables and increase the probability of detecting a difference between study 
groups. For these reasons, patients with other illnesses or those taking other drugs 
concomitantly are often excluded (Strom, 1994a). Another limitation is the age of 
patients included in trials e.g., the elderly are often excluded, no children are included, 
despite the finding that susceptibility to ADRs increases in these patients. Moore et al. 
(1998a) reported that overall 51 % of serious ADRs of marketed drugs had not been 
detected prior to approval. 
These limitations have created a need for comprehensive, efficient and cost-effective 
systems to establish post-marketing drug surveillance that confirms or extends the 
data from pre-marketing studies and to determine a wider range of ADRs in the 
general population (Generali et al., 1995; Timm et al., 1995). 
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1.1.2 Morbidity and mortality associated with ADRs 
Several post-marketing surveillance studies have reported that ADRs were either a 
major cause or an important factor leading to hospital admissions. ADRs related to 
hospitalisation have been widely investigated. Seeger et al. (1996) summarised that 
ADRs which were reported to cause admission or occur during admission varied from 
an estimated low of 0.66% to a high of 36.4% of hospital admissions. Studies in 
hospitalised patients, most of which used ADRs as the outcome, also showed that 
injuries due to drugs were common in these patients, although the true incidence was 
controversial and varied considerably from 1.5% to 35% (Walker and Wynne, 1994; 
Bates et al., 1995). Clyne et al. (1992) concluded that the proportion of hospitalised 
patients who had experienced ADRs ranged from 10% to 20%. ADRs which were 
related to hospital admissions accounted for 3-6% and the mortality rates may be up to 
0.1 %. The Boston Collaborative Drug Surveillance Project estimated that 
approximately 30% of hospitalised patients experienced ADRs and that 3 - 28% of all 
hospital admissions were related to ADRs (Classen et al., 1997). In the community the 
incidence of ADRs ranged from 2.6% to 41% (Asscher et al., 1995). The diversity of 
these findings could be attributed to many factors such as differences in methods, 
definitions used to identify ADRs, probability ratings (Le. inclusion or exclusion of 
definite, probable and possible drug reactions), clinical settings, intensity of data 
collection or observation and patterns of prescribing practices (Walker and Wynne, 
1994; Seeger et al., 1996; Nelson et al., 1996; Asscher et al., 1995: Hallas et al., 
1990). 
Lazorou et al. (1998) studied the incidence of serious ADRs from 39 prospective 
studies in US hospitals by retrieVing data from four electronic databases during 1966-
1996. The study found the overall incidence of ADRs was 6.7% and of fatal ADRs was 
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0.32% of hospitalised patients. These could account for up to 140,000 deaths annually 
in the USA, making ADRs the fourth to sixth leading cause of death. A similar study 
retrieving data from databases between 1966 and 1989, with median sample sizes of 
714, was conducted by Einarson (1993). This study showed that the prevalence of 
reported admissions resulting from ADRs was 5.1 %. Of these, 3.7% of patients 
admitted due to ADRs died. A study demonstrated that 4% of the patients hospitalised 
in New York in 1984 suffered an injury associated with medical treatments. The most 
common types of adverse events found were complications related to drugs, 
representing a fifth of all adverse events (Bates et al., 1993; May, 1997). 
McKenney and Harrison (1976) studied 216 patients admitted to a general100-bed 
ward in a large teaching hospital and showed that 11.1 % of patients experienced an 
ADR associated with hospital admissions and ADRs caused hospital admission in 
7.9% of the patients. A prospective study of 452 patients admitted to the intensive care 
unit or internal medicine service of a university-affiliated hospital concluded that 16.2% 
of patients were admitted due to drug-related morbidity, of which 32.9% had an 
adverse reaction (Nelson and Talbert, 1996). In another study, 333 patients in a 
medical ward were monitored for drug events as a cause of hospitalisation. It was 
recognised that drug induced hospitalisation accounted for 10.8% of all admissions. Of 
these, 8.1 % were ADRs and 2.4% were definitely avoidable (Hallas et al., 1990). A 
prospective study in an acute psychiatric ward involving 321 patients over a period of 
17 months found ADRs to be the main cause of hospitalisation in 7.5% of patients 
(Hermesh et al., 1985). 
A recent study carried out by Moore et al. (1998b) in 329 patients admitted to an 
internal medicine ward in France over six months, reported 3% of the admissions were 
related to ADRs and 6.6% of hospitalised patients had significant ADRs. 
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Cunningham et al. (1997) carried out a study in elderly patients admitted to Tayside 
hospitals in the UK over a nine-month period and found 5.9% of admissions were 
secondary to ADRs. A similar, more recent study undertaken in Aberdeen over an 
eight-month period showed that the most common category of drug related problems 
was ADRs and ADR-induced hospitalisation represented 4% of elderly admissions 
(Pongwecharak, 1998). Fenner and Whittington (1994) examined retrospectively the 
record for Coroner's Inquests in a district at Birmingham during 1986-1991 to 
determine the number of deaths due to ADRs. There were 36 deaths related to ADRs 
from the total of 3277 cases which had come to inquest. 
1.1.3 Cost and preventability of ADRs 
Prolonged hospitalisation and increased morbidity and mortality resulting from ADRs 
lead to increased health care expenditures. In the USA, ADRs add billions of dollars to 
annual heath care costs (Mahoney et al., 1991). One seventh of all hospital days were 
reported to be devoted to the care of drug toxicity at an estimated cost of $ 3 billion 
annually (0' Donnell, 1994). 
A matched case-control study revealed that the extra length of hospital stay and the 
excess cost of hospitalisation attributable to an adverse drug event (ADE) were 1.74 
days and $ 2013, respectively. The increased risk of death among patients 
experiencing an ADE was 1.88 (Classen et al., 1997). A study by Bates et al. (1997) 
including 4018 admissions to a 700-bed teaching hospital was performed to assess 
the additional resource utilisation related to ADEs. It was estimated that the post-event 
costs attributable to each individual ADE was $ 2595 for all ADEs and $ 4685 for 
preventable ADEs. The annual costs relevant to all ADEs and preventable ADEs for 
this hospital were $ 5.6 million and $ 2.8 million, respectively. Johnson and Bootman 
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(1995) also evaluated health care costs associated with unresolved or unrecognised 
drug-related problems in the US ambulatory care population and estimated that the 
cost ranged from $ 30.1 billion to $ 136.8 billion. Moore et al. (1998b) assessed the 
frequency and cost of ADRs causing or prolonging hospitalisation in 329 patients 
admitted to an internal medicine ward and concluded that ADR-related excess hospital 
stay was 318 days. This accounted for 8.6% of all hospital days. Between 5% and 9% 
of hospital costs involved ADRs. Seventy seven percent of the ADRs which patients 
experienced were associated with the pharmacological properties of the drugs and 
therefore were presumably avoidable. 
Furthermore, Clyne et al. (1992) in prospective and retrospective studies found that 
community-acquired ADRs represented 42% of the total 541 reported ADRs. The 
majority (87%, $ 482,627) of expense was required to treat ADRs that occurred in the 
community rather than in the hospital. Conversely, hospital-acquired ADRs accounted 
for only 13% of the total costs. 
Most ADRs are dose-dependent, related to the pharmacological characteristics of a 
drug and predictable. Many patients suffer injuries as a result of such occurrences, 
which are frequently preventable. Pearson et al. (1994) concluded that 30-80% of 
ADRs were preventable. A prospective cohort study evaluated preventability of ADEs 
in 2967 patient-days in seven units of an urban tertiary hospital. It was revealed that 
27 incidents were judged ADEs. Of these, 56% were judged definitely or probably 
preventable (Bates et al., 1993). A further prospective cohort study investigated ADEs 
in 4031 adult admissions to 11 units in two hospitals over a six-month period and 
concluded that 42% of the life-threatening and serious ADEs, and 18% of significant 
ADEs were preventable (Bates et al., 1995). 
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Cunningham et al. (1997) also showed that ADRs were the main category of drug-
related problems (DRPs) primarily responsible for patient admissions, accounting for 
64.8% of the admissions related to DRPs. Over 66% of admissions due to ADRs of 
NSAIDs were considered to be definitely preventable and a further 26.7% were 
possibly preventable. Additionally, Pearson et al. (1994) carried out a study in a 
community hospital by reviewing all ADRs reported during a six-month period. Of the 
203 reported ADRs, 19% were identified as preventable. The percentage of the 
preventable ADRs in this study seemed to be low because their ADR definition 
excluded therapeutic failure and data were collected from a concurrent ADR reporting 
system rather than a retrospective chart review method. Nelson and Talbert (1996) 
prospectively reviewed the medical charts of 452 patients admitted consecutively to an 
intensive care unit or internal medicine service. The result was that approximately half 
of drug-related hospital admissions were definitely avoidable. 
These studies show that increasing awareness of ADRs and their early detection could 
result in fewer admissions and reduced costs. 
1.2 Definitions and classification of ADRs 
The World Heath Organisation (WHO) proposed the definition of an Adverse Drug 
Reaction (ADR) as 'any noxious, unintended, and undesired effect of a drug, which 
occurs at doses used in humans for prophylaxis, diagnosis or therapy'. This definition, 
which is one of the most commonly cited, excludes therapeutic failures, intentional and 
accidental poisoning (Le. overdose), and drug abuse. Furthermore, it does not include 
adverse events caused by errors in drug administration or non-compliance (Lazorou et 
Chapter 1: Review of literature 8 
al., 1998). However, other definitions broaden the scope of ADRs by including 
complications caused by misuse (Leape, 1995). 
Another commonly cited definition is that of Karch and Lasagna (1975). They defined 
an ADR as 'any response to a drug which is noxious and unintended, and that occurs 
at doses used in humans for prophylaxis, diagnosis, or therapy, excluding failure to 
accomplish the intended purpose'. 
The European Union also defined ADRs in an article of the Council Directive, one of 
the two texts containing new regulations published in the Official Journal of the 
European Communities. This definition was 'a reaction which is harmful and 
unintended and which occurs at doses normally used in man for the prophylaxis, 
diagnosis or treatment of disease or the modification of physiological function' (Danan, 
1994), thus is similar to the WHO definition. 
Dahlgren (1997) used a definition of ADRs as 'any non-preventable adverse 
experience associated with the use of a drug, including any injury, toxicity, or 
sensitivity'. A much simpler definition of ADR is described as 'unwanted or unintended 
effects of a medicine which occur during its proper use' (Asscher et al., 1995). Some 
include drug interactions to broaden the definition of ADR (May, 1997), while other 
definitions include statements relating to causality. For example, Kramer et al. (1979) 
defined an ADR as 'an undesirable clinical manifestation consequent to and caused by 
the administration of a given drug'. The International Federation of Pharmaceutical 
Manufacturers' Association (IFPMA) also recommends 'an ADR is defined as an 
adverse event which is causally related to the drug'. The United States Food and Drug 
Administration definition however opposes this. It states that an ADR is 'any 
experience associated with the use of a drug whether or not considered drug-related 
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and includes any side effects, injury, toxicity or sensitivity reaction or significant failure 
of expected pharmacological action' (Stephen, 1992). 
Conventionally, ADRs are classified into overdosage, intolerance, side effects, 
secondary effects, idiosyncrasy, hypersensitivity reactions and drug interaction. 
Logically, ADRs can be divided into those that arise from the normal pharmacological 
properties of a drug and those that represent an abnormal and novel response to a 
drug. Such divisions can be classified into two types (A and B) (Rawlins and 
Thompson, 1977). Type A (Augmented) reactions are normal pharmacological effects 
of the drug exaggerated to produce undesirable results. These reactions cause 70% to 
80% of ADRs. Therefore, they are usually predictable and probably preventable. 
Examples of this type of reaction would be postural hypotension from antihypertensive 
drugs, drowsiness induced by diazepam or phenobarbital, warfarin causing bruising, 
dry mouth and other anticholinergic effects due to antihistamines or tricyclic 
antidepressants. Moreover, the reactions are often dose-dependent and the incidence 
of morbidity in the population is fairly high, but their fatal effect is low. Type B (Bizarre) 
reactions are unusual effects that are unrelated to or unexpected from the known 
pharmacological action of the drug. These reactions are unpredictable, unavoidable 
and mayor may not be dose-dependent. They are particularly dangerous. The 
mortality rate is high but the total incidence is significantly low. Examples of this type of 
reaction are agranulocytosis secondary to chloramphenicol, allergic-hypersensitivity 
reactions from antibiotics and anaphylactic reactions, which is one of the most serious 
and potentially life-threatening reactions caused by penicillins. The terms 'idiosyncratic' 
or 'allergic' reactions are used widely as a synonym of type B reactions (May, 1997; 0' 
Donnell,1994). 
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Recently, Wills and Brown (1999) discussed the limitations of the previous 
classification suggesting that it was sometimes difficult to decide whether certain 
reactions were type A or type B, for example, cancers in patients taking 
immunosuppressants, injection site reactions, drug interactions and therapeutic failure. 
Consequently, these workers proposed a new classification of adverse drug reactions 
into 9 categories, i.e. type A (augmented reactions), type B (bugs reactions), type C 
(chemical reactions), type 0 (delivery reactions), type E (exit reactions), type F 
(familial reactions), type G (genetotoxicity reactions), type H (hypersensitivity 
reactions) and type U (unspecified reactions). Lee (1999) however commented that 
this new classification may still have problems in use. This classification is not in 
general use and may not become widespread since it lacks simplicity. 
1.3 Methods for detecting ADRs 
Post-marketing surveillance (PMS) is the study of drug use and drug effects after 
marketing, although it is sometimes applied only to studies undertaken after drug 
marketing which systematically screen for ADRs (Strom, 1994b). IFPMA gave the 
definition of PMS as all methods, including spontaneous reporting, used to define 
more precisely the benefits and risks of drugs under normal prescribing 
circumstances. Inman (1986) defined PMS as a term often used to describe 
techniques to detect or measure the incidence of ADRs, while Stephen (1992) viewed 
PMS as the systematic detection and evaluation of adverse events occurring in 
association with drugs or biologics under customary conditions of use in ordinary 
medical practice. However, the term is commonly used in its wider sense by including 
all kinds of schemes for generating or testing hypotheses about drug events. 
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The aims of PMS are to detect and identify ADRs as early as possible, particularly 
severe and unexpected reactions, to record the frequency and incidence of ADRs as 
well as possible, and to analyse the collected data in order to use it to take any 
regulatory action which might be needed to prevent ADRs in the future (Venulet and 
Ham, 1996; Saine, 1992). 
There are two main types of PMS used to monitor ADRs, descriptive studies and 
analytical studies, based on whether or not a hypothesis is being sought or tested. 
1.3.1 Descriptive studies 
These studies describe events related to ADRs in various populations and do not 
establish any causal relationship. As they do not have a control group, these studies 
are hypothesis-seeking. 
1.3.1.1 Spontaneous reporting 
The spontaneous reporting system (SRS) for ADRs is dependent on voluntary 
collaboration by doctors working in hospital or in medical practice as well as other 
health professionals. Their ADR reports are sent to drug regulatory authorities or 
organisations at the national level to collect, sort and examine serious events 
associated with drugs. The spontaneous reporting serves as an early warning system 
for serious and unexpected ADRs. As this scheme is voluntary, the number of ADRs 
reported are only a small fraction of the actual number occurring in the population, so 
the rate of underreporting is high, up to 85 - 98% of doctors, depending on the country. 
The reporting rates in 14 Melbourne Teaching hospitals during 1991 varied from 
0.02% to 0.72% which were much lower than those reported from an intensive hospital 
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monitoring scheme (Raymond, 1994). Also, a relatively small number of doctors were 
responsible for a disproportionately high number of the total reports (Spencer, 1995; 
Venulet and Ham, 1996). SRS provides the best means of rapidly identifying new and 
rare ADRs. A large amount of data can be collected, numerous drugs can be studied 
and a wide variety of organ systems can be observed at relatively low administrative 
expenditures. However, such schemes are of limited use in quantifying the frequency 
of drug reactions due to the lack of completeness of ADRs reported (the numerator) 
and the total number of patients prescribed the drug (the denominator). Consequently, 
they cannot provide a reliable incidence of ADRs. They may have bias resulting from 
publicity and also have limitations in assessing the relative risk of drugs within the 
same therapeutic group, in identifying delayed ADRs and in the validity of individual 
reports (Anonymous, 1977; Inman, 1986). 
SRS have now been developed around the world, such as the Yellow Card scheme of 
the CSM in the UK and the MedWatch scheme of the FDA in the USA. The national 
reports are subsequently sent to the WHO Collaborating Centre for International Drug 
Monitoring in Uppsala, Sweden, which is now receiving almost 200,000 reports per 
year (Meyboom et al., 1997a). 
In the USA, the MedWatch programme started in June 1993 and is designed to 
promote and facilitate voluntary reporting by health professionals of serious ADRs. It 
was developed because the FDA revealed that as many as 50% of physicians were 
not even aware that the FDA had a reporting system for ADRs. The FDA emphasised 
that it was unnecessary to prove causality, so physicians should submit reports even if 
there was only a suspicion of a serious event related to drugs (Gruchalla, 1995; 
Kennedy et al., 1993). 
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Likewise, there is a European pharmacovigilance system called Rapid Alert Scheme, 
which was introduced in late 1988 to improve communication on important drug safety 
issues. The member states are required to inform other EC members and the 
Commission by fax of any drug safety issue that is likely to lead to significant licensing 
action (Wood, 1992). 
1.3.1.2 Cohort studies without control groups 
This kind of the study aims to identify ADRs as quickly as possible. Several thousand 
patients treated with the drugs studied are monitored by systematic observation under 
normal conditions including assessment of ADRs. In 1977, there were a number of 
studies using this method, for example, Register release and Monitored release. The 
Register release collected data from a predetermined number of patients registered for 
this purpose and analysed this before the product was finally licensed. There were no 
other patients taking the drug during the period of study (Venulet and Ham, 1996). The 
Monitor release scheme studied licensed drugs by asking pharmacists to keep a 
record for a certain period of all patients coming to them and by periodically checking 
back with doctors whether they noticed any ADRs in these patients (Stephen, 1992; 
Wilson, 1977). However, these methods mainly depended on the willingness of 
participating doctors and pharmacists. 
1.3.2 Analytical studies 
These studies determine causal relationships or associations between the study drug 
and the reactions which have occurred. They can be used for hypothesis testing since 
they have a concurrent control group. 
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1.3.2.1 Case-control studies 
Case-control studies are studies that compare cases with a disease or event to 
controls without the disease or event and look for differences in antecedent exposure. 
These studies are frequently used in testing hypothesis about drug-related disease. 
Cases are sought in which a particular adverse event occurred. For these patients, 
those receiving the drug are counted. The control group consists of patients in whom 
the adverse event did not occur. Subsequently, case and control are compared on the 
basis of frequency rate as well as the relative risk. This method can detect uncommon 
or rare ADRs and can be undertaken quickly and easily at relatively low cost. 
However, it may lead to a number of biases and appropriate control groups are 
sometimes difficult to select. Examples of the type of case-control studies include the 
association between venous thromboembolism and oestrogen therapy in 
postmenopausal women and pancreatitis associated with thiazide diuretics (Grasela, 
1996; Lawson and Beard, 1992; Strom, 1994c). 
1.3.2.2 Cohort studies (Controlled) 
Cohort studies are studies which identify subsets of a defined population and follow 
them over time, looking for differences in their outcome. A group of patients taking the 
study drugs are compared with patients who are not taking them or are taking other 
drugs. The studies can be performed either prospectively or retrospectively. Cohort 
studies select subjects on the basis of the presence or absence of an exposure to a 
study drug, while case-control studies select subjects into the study on the basis of the 
presence and absence of a disease or event. This type of study not only requires a 
prolonged period of time, especially for delayed ADRs if undertaken prospectively, but 
is also more expensive than case-control studies. Cohort studies however have major 
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advantages over case-control studies in that control groups are easier to select, bias is 
less likely to occur and more reliable data is obtained. They are particularly useful in 
PMS of newly marketed drugs, even though they need large sample sizes to study 
uncommon ADRs (Morse et al., 1986; Strom, 1994c; Venulet and Ham, 1996). 
Several cohort studies have been conducted. A classic example is the study of a total 
of 10000 patients taking cimetidine in the UK who were followed up for an 18-month 
period in 1981 (Stephen, 1992). Prescription-event monitoring (PEM) is one example 
of drug-based or outpatient cohort studies. It identifies 10,000-20,000 patients from 
photocopies of prescriptions provided by the Prescription Pricing Authority (PPA) 
(Wailer, 1991). (see section 1.4.2) 
1.3.2.3 Population-based studies or Record- linkage studies 
This method is probably the only realistic approach to carrying out screening 
procedures which require very large sample sizes (Carson et al., 1994). The 
availability of computers has led to record-linkage schemes retrieving information from 
many sources including hospitals, general practices, national registers, etc. Studies 
can be limited to hospitalised patients or may cover a relatively large proportion of the 
total population. 
A. Hospital-based population studies 
These studies can also be called Intensive hospital monitoring. This method provides 
standardised information on a database on all patients, therefore, data are not only 
reliable and complete, but also follow up can be easily undertaken to investigate ADRs 
extensively. Therefore incidence rates can be calculated. Data collected can also 
prove causality and the role of additional factors, however, the costs to achieve a 
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satisfactory number of cases are high and the period of observation is limited as this 
method is performed in hospitalised patients. Examples of this method are the Boston 
Collaborative Drug Surveillance Program and the Aberdeen-Dundee System (Inman, 
1986; Venulet and Ham, 1996). Additionally, Bates (1998) proposed that these studies 
using computer surveillance be used to assist in identifying ADRs in hospitals as a 
much more efficient approach than a chart review method. 
An example of this is the use of automatic signals from laboratory data in hospitalised 
patients followed by retrospective chart review of every third patient (Tegeder et al., 
1999). This study found that 18 of 98 patients experienced probable ADRs and only 
one third of these were recognised by the attending physicians. A comparison 
between ADR monitoring involving prospective surveillance and retrospective reviews 
of medical records was undertaken for an entire hospital. The prospective programme 
included chart review for all patients with an order for drugs that might be used to treat 
an ADR and with elevated serum concentrations of selected drugs. The retrospective 
programme was conducted by reviewing all charts with E-codes and diagnosis codes 
that might indicate reactions to a drug for the same period to confirm the occurrence of 
ADRs. It was found that 37% of ADRs were identified by prospective monitoring and 
68% by retrospective reviews while 5% were identified by both methods. This results 
contrasted to a study of Schumock et al. which reported that a medical record-based 
retrospective reporting system was less sensitive than a pharmacy-based prospective 
reporting system (Madsen, 1993). 
B. General population-based studies 
Data from these studies can apply to an identifiable population, all of whose medical 
care is included in a database, regardless of the provider. This allows the 
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determination of incidence rates of ADRs in the light of complete information about 
medical care given to patients. The advantages of these studies are; relatively low 
costs and time involvement for large sample sizes, suitability for uncommon or rare 
ADRs, the possibility of follow up for long-term trends and the ease of obtaining 
sufficient data. However, these studies may not be representative of the population at 
large, there is often no control of confounding factors, and the validity of the data is 
less certain than in hospital-based settings. There are methods of improving the data, 
such as using drugs and procedures as markers of disease and obtaining primary 
medical records. 
Examples of this type of study include COMPASS (Computerised On-line Medicaid 
Pharmaceutical Analysis and Surveillance), MEMO (The Medicine Evaluation and 
Monitoring Unit) in Dundee, Scotland and The Oxford Record-linkage, England (Morse 
et al., 1986; Lawson, 1991; Strom, 1994d; Stephen, 1992). 
1.4 ADR monitoring systems in the UK 
1.4.1 Yellow Card Scheme 
The UK spontaneous reporting system has been operational since 1964 and is known 
as the Yellow Card Scheme. It is organised by the CSM, a committee of the Medicines 
Control Agency (MCA) which has specific responsibilities for promoting the collection 
and investigation of information related to adverse reactions. The MeA is the 
organisation which is responsible for licencing of medicines in the UK, monitoring the 
safety, investigating possible hazards and taking action to minimize the risks to users 
(Wailer et al., 1996; Mann, 1992). It is widely recognised that this scheme plays an 
important role in identifying and assessing drug toxicity. The system depends on the 
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voluntary reporting of suspected drug reactions by health professionals either directly 
to the CSM or indirectly through drug companies (Mann. 1992; Bateman et al.. 1991; 
Rawlins. 1988; Wilson. 1977). The drug manufacturers are required to report all ADRs 
to the MCA. especially serious and unexpected ADRs. within 15 days. The doctors are 
asked to report all events including the minor ones with new drugs marked with a black 
triangle in the data Sheet Compendium and the British National Formulary (BNF). and 
also to report serious reactions. even well-known ADRs. with the older drugs. The 
reports are received by the subcommittee on Safety. Efficacy. and Adverse Reactions. 
which collects and assesses each report. determines epidemiological issues. and 
when warranted disseminates information to doctors and pharmaCists (Scott et al.. 
1988; Anonymous. 1980). 
To date. more than 300.000 UK reports of suspected ADRs have been received. The 
reports are held on a computer database called ADROIT (Adverse Drug Reactions 
On-line Information Tracking). which was introduced in 1991. by combining images 
processing with a relational data base. Approximately 100 ADR reports are received 
daily and entering data into this database is prioritised by the seriousness of reactions 
in order to provide signal generation of previously unrecognised ADRs or new 
information on established ADRs which might need action. Likewise. reaction profiles 
compare the pattern of reactions to a drug in relation to the pattern of reactions 
caused by other therapeutically related drugs. A number of data output programmes 
have been developed on ADROIT. These include alert programmes which allow new 
ADRs or changing patterns of reactions to be picked up more readily and programmes 
screening the database regularly for entirely new reaction associations or evidence of 
new reactions. In addition. there are programmes relating ADRs to drug usage which 
give estimates of changing reporting rates either for individual drugs or therapeutic 
groups of drugs (Wood and Coulson. 1993; Wailer et al., 1996). 
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Since 1975, the CSM has produced a drug safety information bulletin for all doctors, 
dentists, coroners and pharmacists practising in the UK which is known as Current 
Problems. The bulletin, which is issued at approximately 3-monthly intervals, aims 
regularly to inform and alert health professionals about important drug safety issues 
particularly newly-recognised, serious ADRs so that they can use drugs more safely. It 
also provides feedback from the spontaneous reporting system (Lawson and Beard, 
1992; Wailer et al., 1996). 
The UK reporting scheme has successfully provided early warning of a number of 
ADRs, for example, extrapyramidal reactions induced by metoclopramide, blood 
dyscrasia induced by mianserin and gum hyperplasia induced by nifedipine (Rawlins, 
1988). However, the CSM itself estimates that probably only 10% of serious adverse 
reactions are reported to the Committee. Rassaby and Medawar (1992) also 
commented that if patients are treated concomitantly with several similar drugs, it is 
difficult for the Yellow Card Scheme to resolve which drug was responsible for those 
reactions. 
1.4.2 Prescription-event Monitoring (PEM) 
PEM is a system of PMS established by the Drug Safety Research Unit (DSRU) at 
Southampton University which aims to monitor all new drugs used in general practice 
in England, to study a cohort of at least 10,000 patients taking the drug for up to a 
year, to generate hypotheses about adverse reactions, to test specific hypotheses, to 
measure the frequency of adverse events after exposure to a new drug and to 
complement the existing spontaneous reporting system (Wailer, 1991). This enabled 
detection of ADRs by a comparison of the relative incidence of events in groups of 
patients receiving different drugs for similar complaints. It was suggested that the 
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system could feasibly detect ADRs occurring with at a frequency of 0.1 % (Inman, 
1981 ). 
The system involves the retrieval of prescriptions for drugs selected for study from 
Prescription Pricing Authority (PPA). Prescriptions presented to pharmacists for 
dispensing in England are submitted to the PPA in order to reimburse the costs of the 
drugs. Photocopies of selected prescriptions are sent to the DSRU in Southampton in 
order to obtain the patients' name and address, sex, surgery code, unique doctor code 
together with the date of prescription. These are then processed to identify the patient, 
doctor and the fact that drug exposure has occurred. After a short period of time (3, 6 
or 12 months), a standard questionnaire or green form is sent to the prescribers to 
obtain further information including data on any events that may have occurred. The 
green form also requests the following information; age sex, indication, start date of 
study drug (and stop date, if applicable, plus the reason for stopping and drug 
substituted) and an opinion of its efficacy. These data are then entered onto the 
computer and comprise the outcome data (Fleming, 1994; Wailer, 1991). The analysis 
of PEM data is based on the comparison of the incidence of events during the first 
month of treatment with the incidence in subsequent months for all patients prescribed 
that drug. Using ad hoc rules for assessing the relative excess of events associated 
with taking a drug, a rate ratio of more than 3 was regarded as sufficiently large to 
signal a possible ADR. For example, diltiazem induced rash at the rate ratio of 4.6. 
However, this might be affected by various biases, such as underreporting in 
subsequent months and different age and sex pattern of the cohort patients. In 
addition, event rates for the study drug can be compared with an estimate of the 
background level assessed from a range of other drugs and based on patients similar 
to the patients taking the study drug (Andrew et al., 1996; Kubota et al., 1995). 
Chapter 1: Review of literature 21 
PEM is an important development in PMS and now is an alternative national PMS 
system to the yellow card scheme. The strength of PEM is that it provides a means for 
monitoring new drugs early after launch with impeccable exposure data and reliable 
outcome data. Therefore, new ADRs, which represent previously unspecified 
reactions, can be detected. Since it is carried out retrospectively, PEM does not 
influence prescribing practices. However, unlike the yellow card scheme, PEM cannot 
detect rare ADRs except by chance and it is difficult to study ADRs of older drugs 
(Rawson et al., 1990; Mann, 1995; Wailer, 1991). Furthermore, this system solely 
depends on collaboration of the general practitioners to provide essential information. 
During the development of PEM (1980-1984), the response rates from general 
practitioners were at least 70% but since 1984 the rates of returned questionnaires 
has often fallen below 50% (Inman and Pearce, 1993). 
1.4.3 The General Practice Research Database (GPRD) 
The GPRD formerly called VAMP (Value Added Medical Products) is an important 
source of drug usage data from general practice. It has assembled the largest 
database covering a large population (around 4 million patients) in which morbidity 
requiring treatment, referral and prescribing data are gathered routinely in general 
practices. It is the most important record linkage database for monitoring drug safety in 
the UK. Since 1993 the database has been held by the Department of Health and 
managed by the Office of National Statistics (ONS). The MeA can access this 
database for investigation and confirmation signals, monitoring the effects of 
regulatory action and as a source of drug usage information. It is a significantly useful 
database as demographic data, exposure data and outcome data are linked at source 
within the record of each individual patient. Thus, GRPD is capable of conducting 
pharmacoepidemiological studies including case control studies which can explore 
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hypotheses generated by the yellow card scheme and PEM (Fleming, 1994; Wailer et 
al., 1996; Jick, 1995). 
Jick et al. (1991) conducted a study to determine the extent of clinical information 
recorded on the computers of 58 practices covering 2491 patients taking one of three 
NSAIDs. Similar information was studied from manual records of letters received from 
hospital consultants which were kept in the general practitioners' files. It was found 
that 87% of the 1191 patients for whom consultants' letters contained a clinical 
diagnosis was present on the computer record of the general practices. Therefore, this 
indicated that clinical information available on the computer record of general practices 
is satisfactory for many clinical studies using this database. 
1.4.4 The Medicines Evaluation and Monitoring Unit (MEMO) system 
The MEMO Unit set up by the University of Dundee conduct record-linkage PMS 
studies. The facility enables hypotheses testing studies in a population of 400,000 
patients in Tayside, Scotland, using a computer database. The Unit use the 
Community Health Index (CHI), a unique patient identifier, to track all healthcare 
activity in Tayside. These numbers are issued to individual patients in Scotland when 
they register with general practitioners. The CHI number comprises ten digits, the first 
six of which are the date of birth of the patient. There are two main sources of data 
used by MEMO which are linked by the unique CHI including information on all 
prescriptions dispensed and hospital data on all admissions of Tayside residents. The 
prescriptions and the CHI have been obtained from the Prescriptions Pricing Division 
(PPD) since 1989 whereas the hospitalsation data together with the CHI have been 
provided by Tayside Health Board since 1980. When a patient is admitted to a 
hospital, a computerised record known as the Scottish Morbidity Record (SMR) is 
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generated for every consultant episode of care including the ICD9 diagnosis code. 
MEMO also access other data bases indexed by the CHI such as a database of all 
endoscopies, road accidents and other Scottish Morbidity Record data bases. 
Using this information, MEMO can conduct several cohort or case-control studies 
testing hypotheses. For example, a large cohort study to determine the risk profile of 
upper gastrointestinal complications related to approximately 50,000 patients taking 
NSAIDs and a case-control study to investigate whether upper gastrointestinal 
complications were associated with topically applied NSAIDs (MacDonald, 1995). 
One of the strengths of MEMO is that it can validate the computerised data by 
comparing with the original case records in the hospital. It can also calculate the true 
incidence rates based on the relevant population. However, MEMO covers only 
400,000 patients in the population. This sometimes makes it difficult to find proper 
control groups. Also, the indication for the drug prescribed is not known (Stephen, 
1992; Wailer et al., 1996). 
1.4.5 Other monitoring methods 
There are number of individual PMS studies conducted in the UK. For example, drug-
oriented studies are run by an ADR team at Royal Liverpool Hospital (Stephen, 1992). 
A feasibility study undertaken by Drury and Hull (1981) to find out the possibility of 
prospectively monitoring ADRs in general practices, showed that 57% of 103 doctors 
recruited patients into the system and a total of 1771 prescription copies were returned 
by these doctors. Seventy-four percent of the follow up forms inquiring about ADRs in 
the subsequent periods were returned. Thus, it was considered possible to conduct a 
large-scale prospective monitoring for ADRs in general practices in the UK. However, 
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there has been no progress since then. Lumley et al. (1985) also conducted a 
prospective study to determine the incidence of ADRs in 24 general practices. During 
a four week period of study, 638 (1.7%) of 36,500 consultations were recorded as 
involving suspected ADRs by the participating doctors. The doctors considered 70% 
and 28% of these were probable ADRs and possible ADRs, respectively. Only one 
study by Campbell and Howie (1988) has involved patient self-reporting, conducted 
over two two-month periods. Patients prescribed a new drug were given a leaflet by 
the pharmacists in Livingston to encourage them to report any adverse reaction to 
their doctor. The study showed that reports of ADRs increased from six out of 576 in 
the control period to 11 out of 481 in the study period. 
1.5 Causality assessment of ADRs 
The most important problem in monitoring ADRs is whether there is a causal 
relationship between the drug and the unwanted reaction. The estimation of the 
probability that a drug caused an adverse reaction is generally dependent on clinical 
judgment. The lack of established causality criteria for ADRs even in case reports is 
well documented and experts have frequently disagreed in their assessment. Koch-
Weser et al. (1977) found that three clinical pharmacologists who independently 
evaluated 500 ADRs reported by doctors, often disagreed with the doctors and with 
each other. Therefore, attempts to standardise assessment have been created 
through methods based on various criteria. The standardised assessment implies that 
the same operational logiC is always applied. Commonly, the criteria of these methods 
are similar but their weight, gradation, specificity and number of items of information 
considered are different (Benichou and Danan, 1991; Venulet et al., 1980). Usually, 
prefixed numerical scores are attached to the answers of numerous subquestions 
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which then result in a cumulative value, which is interpreted into a causality category, 
i.e. definite, probable, possible or unlikely. The standardised assessment can improve 
communication between users, reproduce and validate the results, and also decrease 
variations in judgements of different experts (Meyboom et ai., 1997b; Venulet, 1992; 
Emanueli and Sacchetti, 1980). 
One of the initial methods established by Karch and Lasagna (1977) relies on five 
criteria: 1) whether the interval between drug and reaction is appropriate 2) whether it 
is a known reaction to the drug 3) whether the reaction is reasonably explained by the 
patients' clinical states or other therapies 4) dechallenge 5) rechallenge. Bergman and 
Wilholm (1981) also applied this method to the study of drug-related problems causing 
admission to a medical clinic. Kramer et al. (1979) developed an algorithm which 
provided a score system for six axes of decision strategy: previous general experience 
with the drug, alternative etiologic candidates, timing of events, drug levels and 
evidence of overdose, dechallenge, and rechallenge. The sum of the scores rated the 
ADR as definite, probable, possible, or unlikely. 
However, Naranjo et al. (1981) and Busto et al. (1981) commented that application of 
the methods of Karch and Lasagna and Kramer et al. to routine clinical practice was 
limited because they were more complex and time consuming. So the authors 
proposed a simple method containing only ten questions as follows: temporal 
sequence, pattern of response, withdrawal, re-exposure, alternative causes, placebo 
response, drug level in body fluids or tissues, dose-response relationship, previous 
patient experience with the suspected drug, and confirmation by objective evidence. 
The total scores categorise probability of ADR into definite (~9), probable (5-8), 
possible (1-4), doubtful (0). Validity testing for this method was undertaken by 
determining the agreement of two physicians and four pharmacists who independentl: 
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assessed 63 randomly selected alleged ADRs. The result showed that the between-
rater reliability which was represented by percent agreement ranged between 83% 
and 92% (Kappa=O.69-0.86). Cooper (1996) also used this probability scoring scale to 
assess the causality of suspected drugs studied in a rural geriatric nursing home 
population. The study found that 444 probable ADRs occurred in 217 of 322 residents 
over a four-year period. Mean probable ADRs experienced by the 217 patients was 
1.9. 
Venulet (1986a, 1986b) developed a checklist and assessment form for the 
standardised assessment of ADRs. It consists of 23 questions divided into three parts 
including history of present adverse reaction, patient's past adverse reaction history 
and monitor's experience. The form also subdivides ADR into dose-related, dose-
unrelated, type I allergic, at the site of application, interaction, drug dependence, 
irreversible, withdrawal symptoms, foetal malformation or unclassified. These 
subsequently translated into five categories of causal relationship between drug and 
the reaction as definite, probable, possible, unlikely, or not related to suspected drug. 
Using this standardised assessment, the results of 1362 cases by comparing the 
judgement of six medical evaluators demonstrated that 62% of total cases were in 
complete agreement. 
WHO also implemented causality assessment of suspected adverse reactions 
according to the presence of laboratory test abnormality, time sequence to 
administration of the drug, attribution by concurrent disease or other drugs, 
dechallenge, predication by pharmacological action, and rechallenge. In this system, 
there are six different degrees of causal relationship which are certain, probable/likely, 
possible, unlikely, conditional! unclassified, or unaccessible/ unclassifiable. This 
method aims to help in routine assessing causality of single case reports or 
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spontaneous reports received by the drug regulators (Meyboom, 1997b; Venulet, 
1992). 
Benechou and Danan (1991) designed aetiological diagnostic schemes adapted to 
specific and defined disorders known to be frequently induced by drugs such as liver 
injury, granulocytopenia, thrombocytopenia, photosensitivity reactions, renal failure, 
etc. These schemes were organised by consensus meetings with university experts 
and specialists in official pharmacovigilance on the basis of disease definition, clinical 
appearance and pathology, signs of severity, aetiology and diagnosis, evidence 
implicating a drug, chronological criteria, and management. The likelihood of a 
relationship for some reactions is defined in a semiquantitative way, using five different 
categories: incompatible, inconclusive, compatible, suggestive, or very suggestive. 
Furthermore, there are computerised systems which help to overcome the complex 
calculations involved in causality assessment, for example, the Bayesian Adverse 
Reactions Diagnostic Instrument (BARDI) using a balance of probability for competing 
explanations which was developed by Naranjo and Lanctot (1991) and a computer 
programme developed for causality assessment using Venulet et al.'s method 
(Anonymous, 1989; Venulet, 1992). 
Although these methods appear to have clear and direct criteria enabling their 
universal use, their application in clinical practice is not always manageable because 
some information such as interactions with other drugs and life style characteristics 
which are not considered by the method may play a decisive role in assessment. In 
addition, some data are often unavailable, i.e. dechallenge, rechallenge or time 
intervals. When the same information is assessed by several methods, the 
conclusions are also different or conflicting (Rogers, 1987; Venulet et al., 1986). In 
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fact, such methods cannot conclude that suspected drugs truly cause the reactions. 
They are still based on subjective decisions and can not eliminate or quantify 
uncertainty but only categorise ADRs into levels of probability (Bastin et aI., 1984; 
Meyboom, 1997b). 
1.6 Problems with ADR reporting systems 
The ADR spontaneous reporting system (SRS) is a significant component of the 
postmarketing surveillance of drugs which is used nation-wide. It remains one of most 
important sources to identify new ADRs once a drug is on the market. The reporting 
system is also designed to generate signals of rare and unexpected ADRs particular in 
serious ADRs and creates hypotheses to be further tested in epidemiological studies. 
Nevertheless, the main problem of the reporting system is underreporting (Walker and 
Lumley, 1986; Rogers et aI., 1988). The overall reporting rate is remarkably less than 
that expected from intensive studies. Fletcher (1995) estimated reporting rates seldom 
account for more than 10% of the actual ADRs that occur. The detection of new and 
unexpected ADRs depends considerably on the attitude, awareness and co-operation 
of doctors to the ADR reporting system (Bateman et aI., 1992). 
1.6.1 Extent of under-reporting in various countries 
In France, seeking to identify the perception of drug safety by young practitioners, it 
was revealed that pharmacovigilance centres are still relatively unknown. The level of 
under-reporting of ADRs was 44%. Moreover, 66% of the residents did not know that 
the spontaneous reporting system was compulsory and 75% of these were unable to 
find the address of the regional pharmacovigilance centre (Graille et al., 1994). 
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In the United States, physicians are an important source for the early warning of 
ADRs. Direct reports from physicians sent to the FDA in 1970 were only 1 % of reports 
received, however these accounted for 24% of all new ADRs (Scott, 1988). In 1983, 
only 57.6 ADRs per 1000 physicians were reported in the US. It was estimated that 
the reporting rates in most institutions were lower than 10-15% (Sweet and Ryan, 
1994). A pilot project to determine the experience of 1167 Rhode Island physicians 
with fatal and severe ADRs found that less than 1 % of suspected serious ADRs were 
reported directly to the FDA (Scott et al., 1987; ScoU, 1988). In addition, a 
questionnaire survey of hospital pharmacy department directors at 444 randomly 
selected hospitals sought information on their institutions' ADR programmes. From 
176 (39.6%) usable respondents, it was found that although approximately 97% of the 
institutions had policies for ADR reporting (there were an average of 70.5 ADRs per 
hospital during 1989), only 6.8 per hospital were reported to the FDA (Tyler and 
Nickman, 1992). Herrera et al. (1992) determined the ADR surveillance system in 61 
hospitals and found larger hospitals (more than 333 beds) tended to have lower rates 
of reported ADRs than small ones (0.034 and 0.064 ADRs per patient days, 
respectively). Also, Rogers et al.(1988) revealed that less than one-fifth of 418 
licensed physicians who had detected ADEs reported them to the US FDA. 
In Australia, the system of ADR reporting and the rate of reporting was examined in 15 
teaching hospitals. The number of reactions reported in 1991 ranged from five to 162 
per hospital, with only three hospitals receiving more than 100 reports. Although all 
hospitals used reports from ward pharmacists, medical and nursing staff, and they had 
alert forms for the patient's history regarding new or previous ADRs, the rates of 
reporting were only 0.02 - 0.72 % (Raymond and Robertson, 1994). 
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In the United Kingdom, a report from the UK Medicines Control Agency suggested that 
underreporting was getting worse, as the number of yellow cards sent in by doctors 
during 1993-1994 had fallen by 17% over the previous year and only 14% of all 
suspected ADRs were reported in general practice (D' Arcy, 1996). Speirs et a!. (1984) 
examined the number of doctors sending in yellow cards during 1972-1980. It was 
shown that of 122,000 doctors eligible to report over the period, only 16% submitted 
reports and a substantially decreased rate of reporting was seen among those 
qualified for less than five years or for more than 40 years. It had also been suggested 
that only 1-10% of serious reactions are reported to the CSM (Walker and Lumley, 
1986). The underreporting of ADRs in 24 general practices involving 100 doctors was 
investigated over a four-week period by Lumley et a!. (1986). There were only 13.5% 
out of a total of 37 ADRs which should have been reported actually submitted to the 
CSM. Additionally, a recent study by Martin et a!. (1998) assessed the degree of 
underreporting of ADRs to new (black triangle) drugs in general practices through the 
PEM system. The results indicated that general practitioners had reported only 275 
(9%) of 3045 events, which were reported as suspected ADRs on the green form of 
PEM, directly to the CSM. Serious unexpected and non-serious unexpected ADRs 
were significantly more likely to be submitted than those non-serious expected ones. 
It was not only the CSM which encountered the under-reporting problem, as response 
rates from general practitioners to supply post-marketing data on new drugs had also 
been falling within the PEM system (Inman and Pearce, 1993). A comparative study 
between spontaneous adverse drug reaction reporting and event monitoring involving 
44,000 patients contributed by 8000 general practices, demonstrated that 
underreporting by the spontaneous reporting system may be as high as 98% for 
several adverse reactions associated with drugs (Fletcher, 1991). Smith et a!. (1996) 
retrospectively analysed data collected by a local ADR reporting scheme over a three-
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year period and found that 1420 ADRs were reported with a rate of 68.7 per 1000 
admission. Following the CSM guidelines for ADR reporting, 477 yellow cards should 
have been submitted, but only 30 (6.3%) were actually sent to the CSM and only 31 
(6.5%) of these involved black triangle drugs. Furthermore, a study conducted in the 
Northern Region showed that up to 73% of junior doctors had never sent a yellow card 
report to the CSM (Bateman et aI., 1992). 
To summarise, the reporting rates from spontaneous reporting systems in many 
countries are still quite low, although the system is very useful for detecting ADRs of 
new drugs and rare ADRs. The reporting system is also able to alert all health 
professionals to be aware of unwanted drug effects. Consequently, various countries, 
realising the benefits, have used different methods to try and improve their reporting 
rates. 
1.6.2 Reasons for under-reporting 
Physicians have played a key role in the reporting systems. Possible reasons for the 
lack of success of the systems were therefore sought by a number of surveys of 
physicians' knowledge, attitude and utilization of the ADR reporting system. Inman and 
Weber (1986) described the "seven deadly sins" which inhibited reporting of ADRs in 
the UK as follows: 1) complacency about the safety of approved drugs 2) fear of 
litigation 3) guilt because of unintentional harm caused to patients 4) ambition to 
publish personally 5) ignorance of reporting mechanisms 6) diffidence in reporting 
mere suspicions, and 7) lethargy resulting in unwillingness to notify the ADRs. 
Attitudes of doctors to the CSM reporting scheme were investigated by postal 
questionnaire sent to 500 randomly selected doctors. Of these, 57% responded to the 
Chapter 1: Review of literature 32 
questionnaire and 63% of the respondents stated that they had previously reported an 
ADR to the CSM or to a pharmaceutical company. Reasons for under-reporting 
included lack of time (21 %), lack of a report form when needed (21 %) and the 
misperception that sending a report required diagnosis of an adverse reaction with 
absolute confidence (8%). Most doctors knew the types of reactions that the CSM 
requests but only one-third knew the precise meaning of the CSM's black triangle 
symbol. Thus, lack of understanding about the reporting scheme may lead to under-
reporting (Belton et al., 1995). 
The attitudes and knowledge of doctors in the North of the UK to the reporting of 
ADRs were assessed by postal questionnaire to which 1181 of 1600 doctors (74%) 
responded. There were few differences in opinion and attitude between general 
practitioners and consultants from high and low reporting districts. General 
practitioners in low reporting areas stated they wrote more prescriptions while 
consultants spent more time in clinical contact and junior doctors did both, all of which 
suggest different workloads may affect the reporting of ADRs. On questions about the 
CSM's black triangle scheme, all doctor groups performed poorly. Difficulty in 
determining the responsible drug, professional obligation, time-consuming reporting of 
ADRs, and complexity of the report method were the main reasons for under-reporting 
(Bateman et al., 1992). Other data from the Drug Safety Research Unit in 
Southampton revealed that there was a consistent inverse relation between the 
number of prescriptions and the response to requests for postmarketing information 
(Inman and Pearce, 1993). 
A further survey was conducted by sending a questionnaire to 60 doctors at the Royal 
Liverpool hospital. Diffidence (39%), ignorance (37%), lethargy (13%), ambition (5%), 
guilt (2%), fear (2%) and complacency (2%) were the reasons of the hospital doctors 
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for not reporting ADRs to the CSM. Of the respondents, 34% stated that it was difficult 
to assess the responsible drug if patients were taking multiple drugs, while there was 
30% felt difficulty in distinguishing the disease state from the reaction caused by the 
suspected drug (Randhawa and Smith, 1987). A retrospective study by Smith et al. 
(1996) analysed data collected by a local ADR reporting scheme in an acute hospital 
medical setting and found well-known reactions to established drugs was the main 
reason for the low proportion of yellow card reporting. Walker and Lumley (1986) also 
designed a questionnaire to obtain information about general practitioners' opinions of 
the yellow card scheme. Of the total of 402 GP respondents, 30% thought the scheme 
was unsatisfactory and 95% thought more feedback from the CSM would improve the 
under-reporting. 
Studies in the USA also found similar reasons for under-reporting. In Rhode Island, 
74% of 1,585 physicians contacted responded to a questionnaire which found that only 
55% of respondents were familiar with the reporting system. They displayed a poor 
knowledge of and underreporting of the ADR reporting system. A lack of report forms, 
uncertainty about the drug which caused the reaction, don't know how to report and 
expectation of the reaction were identified as major impediments to reporting (Scott et 
al., 1987). After implementing various interventions, physicians were resurveyed in the 
next two years. Respondents improved their knowledge and understanding of the ADR 
reporting system, but lack of certainty concerning the suspected drugs was still a 
major problem of non-reporting (Rosenbaum et al., 1990). 
Rogers et al. (1988) surveyed 3000 randomly chosen physicians by mailed 
questionnaire to determine their knowledge, attitudes and behaviour to the US FDA 
reporting system. The response rate was 37%, of which 57% were aware of the FDA 
reporting system. It was indicated that unavailable report forms, events already 
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documented, lack of time and unawareness were the important reasons for the 
physicians not reporting the ADRs. 
Moreover, the lack of co-operation and participation among health professionals 
including physicians, nurses and pharmacists was one of the main reasons for 
underreporting (Pschirer et al., 1990). A recent study by McGovern et al. (1998) 
demonstrated that information concerning ADRs resulting in changes in drug therapy 
was poorly communicated to primary healthcare professionals. 
Pharmacists are one of the health professionals who play an important role in the 
reporting system in the USA. It is however possible that not a" of them pay attention to 
ADR reporting. Therefore, pharmacists' knowledge and perceptions of their role in 
monitoring and reporting suspected drug reactions were determined. Of 235 Rhode 
Island pharmacists, those in retail settings were more likely to be aware of ADRs 
relating to therapeutic inequivalence and to ask patients about ADRs than were 
hospital pharmacists. Seventy five percent of a" pharmacists were familiar with the 
FDA's SRS. However the practice setting, experience in the practice and the number 
of working hours influenced the reporting behaviour. Attitudes which deterred 
pharmacists from reporting ADRs were as follows: unsure which drug caused the 
reaction, do not have form, do not know how to report and reaction was expected 
(Generali et al., 1995). In Hong Kong, a much smaller proportion of pharmacists had 
actually reported ADRs, although they agreed that it is necessary to report them. Most 
pharmacists (87.4%) were not aware of any ADR reporting system. Unlike the 
previous study, there did not appear to be a relationship between ADR reporting 
behaviour and the length or place of practice, workload or patient contact time. The 
pharmacists perceived that severe or unusual ADRs and ADRs to newly marketed 
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drugs were significant enough to report which was similar to that found with Rhode 
Island pharmacists (Lee et aI., 1994). 
Lack of knowledge of an ADR reporting programme and poor attitudes towards the 
scheme have led to non-reporting. Therefore, improvement in knowledge and 
changing attitudes toward the SRS are important means by which to increase the 
reporting rate. 
1.7 Role of pharmacists in ADR reporting systems 
Pharmaceutical services in many countries are increasingly patient-oriented including 
involvement in ADR monitoring schemes. A survey undertaken in 1992 showed that 
46% of pharmacies in National Health Service (NHS) hospitals in the UK operated the 
CSM ADR monitoring scheme and 13% also operated an additional ADR monitoring 
scheme (Cotter et al., 1994, 1996). In the USA, more than 95% of 248 federal 
hospitals participated in ADR programmes in 1993 and in approximately 70% of 
pharmacist interventions were documented in the medical records (Crawford and 
Santell, 1993). Thus, UK hospital pharmacists appear to provide less ADR monitoring 
services than those in the USA. However, USA pharmacists have been able to submit 
ADR reports to the FDA directly since 1962 which contrasts with UK pharmacists who 
have only been allowed to send yellow cards to the CSM since April 1997. Spencer 
(1985) suggested that the role of UK hospital pharmacists in ADR reporting systems 
had been neglected, although they were encouraged to participate in initiatives 
designed to increase awareness and improve the reporting rate. 
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Other countries such as Australia, Belgium, France, Germany, Ireland, New Zealand 
have also permitted pharmacists to directly contribute to the reporting system as a 
potential source of ADR reports, while pharmacists in Denmark, Finland, the 
Netherlands and Sweden, like UK pharmacists, have been excluded from supplying 
ADR reports to the national ADR reporting schemes (Roberts et al., 1994). 
1.7.1 Role of UK pharmacists in ADR reporting 
Previously, the yellow card system only accepted ADR reports from doctors, dentists, 
coroners and pharmaceutical companies (Committee on Safety of Medicines, 1997). 
Pharmacists in the UK were not given this opportunity despite ADRs presumably being 
drawn to their attention during the course of their work (Anonymous, 1993). As the 
yellow card scheme had been limited by gross underreporting, Veitch and Talbot 
(1985) and D' Arcy (1996) suggested that a possible way of increasing the reporting 
rate was to make reporting by doctors compulsory as in Sweden, however, this could 
be opposed by the doctors. Another feasible way was that pharmacists should be 
involved in the reporting process by encouraging doctors to report ADRs together with 
occasionally identifying reactions and taking responsibility for reporting themselves. 
Although a working party did not recommend direct reporting by pharmacists to the 
CSM, it acknowledged that pharmacists participating with doctors in ADR reporting 
should be introduced and further developed (Edwards et al., 1989). Randhawa et al. 
(1987) surveyed hospital doctors' opinions on whether pharmacists should be involved 
in the reporting scheme of the CSM. Of 60 doctors, 70% thought that pharmacists 
should report in conjunction with doctors while 20% thought pharmacists should report 
ADRs directly. In addition, several researchers demonstrated that both hospital and 
community pharmaCists play a potential role in ADR reporting and monitoring (Roberts 
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et al., 1993; Whittlesea and Walker, 1996a,1996b; Bussey et al., 1985; Davis et al., 
1999; Lee et al., 1997). 
Eventually, all hospital pharmacists in the UK were allowed an official role in the 
national reporting scheme from 1 April 1997. However, community pharmacists in only 
four regional centres (Cardiff, Birmingham, Liverpool and Newcastle) are able to join in 
ADR demonstration schemes. These regional schemes will be evaluated before 
considering any further extension to pharmacist reporting (Anomymous, 1997; 
Anonymous, 1996). 
1.7.1.1 The role of hospital pharmacists 
A working party led by Grahame-Smith in 1986 provided advice to the CSM that the 
CSM should ask health authorities to encourage the participation of pharmaCists in 
work on ADRs in hospital. However, they did not support direct reporting by 
pharmacists to the CSM. In contrast, the Nuffield report of 1986 supported the belief 
that there was a strong case for recognising the role of hospital pharmacists in ADR 
reporting (Nuffield Foundation, 1986). 
There were several ADR monitoring schemes developed involving pharmacists to 
improve the ADR reporting rate. A pharmacy-based ADR reporting scheme (green 
card scheme) was established at the Royal Liverpool Hospital in 1984 which 
encouraged pharmaCists, nurses and doctors to initiate reports. Subsequently, the 
reports were assessed weekly by a pharmacist and a clinical pharmacologist and 
forwarded to the CSM if the ADRs were considered to be serious or involved black 
triangle drugs. The rate of reporting increased nearly eight-fold after the beginning of 
the scheme (Winstanley et al., 1989). A similar scheme was developed for all medical 
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wards in the John Radcliffe hospital, Oxford. It provided a simple alert method using a 
locally designed yellow form at the end of the bed, with subsequent follow up, 
monitoring and validation of the reports by an ADR team consisting of a pharmacist 
and a clinical pharmacologist. The results also demonstrated a marked increase in the 
number of reported ADRs, with the incidence of 6% of patients possibly experiencing 
ADRs (Booth et al., 1988). In addition, Bussey et al. (1985) conducted a study to 
demonstrate that clinical pharmacists could improve the reporting of ADRs by working 
closely with clinicians. All suspected ADRs detected by the clinicians were passed to 
the clinical pharmacist for further investigation from medical notes, biomedical prOfiles, 
patient interviews and discussions with the clinicians. Over the 21 month period, a total 
of 79 suspected ADRs were observed and 44 reports were forwarded to the CSM, 
compared with two reports from the same setting in the 12 months prior to the study. 
Some hospital pharmacists in the UK have been involved in setting up regional ADR 
reporting schemes which were operated in conjunction with the CSM, i.e. the West 
Midlands, Northern region and Wales. In 1990 a trial scheme to allow hospital 
pharmacists to sign the yellow cards and submit them to the CSM was announced 
(Anonymous, 1990). There was considerable evidence that the regional groups had 
increased the number of ADRs reported as described below. 
In the Northern region, a pilot scheme was established to evaluate the contribution of 
hospital pharmacists in ADR reporting. In the early stage, three general hospitals were 
chosen to participate in the scheme and compared with four control hospitals. 
Reporting cards (green card) were placed on all wards, outpatient clinics and 
X-Ray departments. Health professionals were asked to record brief details of any 
suspected ADRs on green cards which were forwarded to the pharmacy department 
for further assessment and follow up by a pharmacist if necessary. Yellow cards were 
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completed by the clinician in collaboration with the pharmacist. It was revealed that the 
green card scheme tended to increase the number of yellow cards in one hospital and 
the quality of yellow cards originating from green cards was equivalent to those from 
control hospitals (Edwards et al., 1989). During 1992-1993, all hospital pharmacists 
within the region were asked to report any suspected ADRs by using the special report 
form which was similar to the yellow card. Subsequently, the ADR reports were sent to 
the Northern Regional Monitoring Centre for analysis. The results showed the 
reporting of ADRs in the region markedly increased by 45%, with a 54% increase in 
the reporting of serious reactions. Significantly more reports from hospital pharmacists 
concerned serious ADRs and new drugs than those from hospital medical staff. 
Pharmacists also generated 30% of all hospital reports in this region in 1992 and their 
report quality with regard to causality, appropriateness and completeness was 
comparable to those of doctors (Lee et al., 1997; Lee, 1993). 
In Wales, the ADR scheme was established in 1983. All yellow cards issued were 
addressed to the medical assessor for the scheme and received in the department of 
pharmacology and therapeutics. The replacement card was subsequently forwarded to 
the reporting doctor, with a preliminary letter from the medical assessor. Also, an ADR 
bulletin was produced and distributed to all doctors every six months. It was concluded 
that not only was feedback to reporters on their contribution to this scheme recognised 
as useful, but also collaboration with doctors would prepare pharmacists for a future 
role in ADR reporting (Spencer, 1985). 
In West Midlands region, drug information pharmacists played a key role in a devolved 
reporting system. Requests to drug information pharmacists about ADRs led to 
reporting to the CSM. Yellow cards were completed for approximately 10% of the 1824 
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ADR inquiries to the drug information centre during 1976-1981 at Good Hope Hospital 
in the West Midlands (Veitch and Talbot, 1985). 
After the recent announcement from the CSM that hospital pharmacists are allowed to 
report the yellow card directly, Green et al. (1997) surveyed 200 hospitals in the UK by 
sending questionnaires to investigate the activity of hospital pharmacists involving 
ADR reporting. Of 172 respondents, local ADR reporting schemes were in operation in 
26 (15%) pharmacy departments. Only 2.3% and 1.7% documented ADR details were 
in patients' notes and communicated to the patients' GPs, respectively. Time factors 
and lack of perceived need to operate a scheme were the main reasons for lack of a 
local ADR scheme. However, 80% of the settings without local schemes would 
consider implementing a scheme in the future. The authors suggested that local ADR 
schemes could encourage pharmacists to take a key role in this area. Recently, a 
survey to assess the role of hospital pharmaCists in national ADR reporting after one 
year after of being allowed to report ADRs directly to the CSM showed that 64% of a 
total 185 pharmacy departments had submitted only five or fewer ADR reports to the 
CSM during this year, while 62% of the departments claimed to promote pharmacist 
reporting and education of pharmacists on ADR reporting was provided by 69% of 
pharmacies, the level of ADR reporting activity by pharmacy departments varied 
remarkably and in most cases was insufficiently developed (Ferguson and Dhillon, 
1999). 
A recent study undertaken by Davis et al. (1999) evaluated the suspected ADR reports 
submitted by hospital pharmacists to the CSM in the first year of their official role. 
During 1 April 1997 - 31 March 1998,645 (3.1%) of a total 17,769 spontaneous 
reports were received directly from the UK hospital pharmacists. Hospital pharmacists 
sent a higher proportion of serious ADR reports but a lower proportion of reactions 
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related to black triangle drugs, compared with hospital doctors. This data suggested 
that hospital pharmacists made a valuable contribution to the yellow card scheme 
apart form the doctors, however, there was variability in levels of reporting from 
hospital pharmacists which needed continuing education to raise their role profile. A 
recent training programme for hospital pharmacists in ADR reporting was set up by 
Mersey regional monitoring centre in June 1998. It was shown that the number of 
ADRs reported in the month following the study day increased from an average of six 
to fourteen. Nevertheless, constant reminders were needed to alert the pharmacists to 
maintain the number of reports (Randall, 1999). 
1.7.1.2 The role of community pharmacists 
In 1992, the Department of Health and the Royal Pharmaceutical Society jointly 
published recommendations for an extended role for community pharmacists (Royal 
Pharmaceutical Society, 1992). Therefore, a study was performed to examine the 
views of community pharmacists and the Family Health Services Authorities (FHSAs) 
on those recommendations. Both community pharmacists (72%) and FHSAs (84%) 
agreed that pharmacists should report ADRs to the CSM directly and the Royal 
College of General Practitioners (RCGP) also accepted this suggestion (Sheppard et 
al., 1995). A similar study by Sutters and Nathan (1993a, 1993b) was undertaken to 
explore community pharmacists and general practitioners' attitudes towards extended 
pharmacy roles. The results showed 78% of community pharmacists and 85% of 
general practitioners supported community pharmacists' involvement in ADR 
monitoring, with no significant difference between professions. Both professions also 
agreed that the pharmaceutical industry should promote the role of community 
pharmacists in ADR monitoring. Bond et al. (1995) also found that 74% of a total of 
266 general practitioners agreed on the extended role of community pharmacists in 
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formal ADR reporting system. A report of a meeting between the Royal 
Pharmaceutical Society and the RCGP also noted that the RCGP supported the 
reporting of ADRs by community pharmacists and their formal role in the ADR 
reporting system (Whittlesea and Walker, 1996a; Anonymous, 1992). 
While the importance of over-the counter (OTC) drugs and self medication has 
increased markedly over the past decade in the UK, ADRs from these medicines are 
less likely to be recognised by doctors. It has been suggested that the potential role of 
community pharmacists should be developed by collecting and reporting ADRs to OTC 
drugs (Roberts et al., 1993). 
A number of studies have emphasised the contribution made by community 
pharmacists in ADR reporting. Khan and Archer (1994) carried out a study over a six-
week period to confirm the role of community pharmacists in ADR reporting. Ten 
randomly selected community pharmacies in Manchester participated in the study. 
There were 96 completed reports received, of which 70% were identified by the 
pharmacists, although the severity of most cases was mild. All the pharmacists 
believed they should submit ADR reports for OTC drugs and 90% wanted to submit 
reports on black triangle drugs to the CSM. 
Whittlesea and Walker (1996a, 1996b) developed an ADR reporting scheme using the 
CSM criteria for community pharmacists holding patient medicine records (PMRs) in 
Wales and determined whether the pharmacists had appropriate knowledge and 
access to sufficient information to complete ADR reports. Of the 196 community 
pharmacies invited, 100 agreed to participate in the study. During the study period, 21 
out of these participants sent 49 ADR reports, of which 12 reports related to black 
triangle drugs. A panel consisting of six pharmacists evaluated the ADR reports. One-
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third of the reports were agreed by all the panel to be ADRs, while a further one-third 
of reports were considered to be ADRs by all except one member of panel. The 
number of complete fields for the reports ranged from 15 to 30 of the total 31 fields of 
information contained in the ADR report form. The researchers also evaluated the 
scheme by sending questionnaires to the participating pharmacists. The response rate 
was 70%. Of these, 87% and 75% indicated the preferred route was both to the eSM 
and the patient's GP for submitting the ADR reports of new drugs and prescription only 
medicines (POM), respectively. Fifty nine percent agreed with direct submission to the 
eSM solely for the OTe drugs. The results suggested that community pharmacists 
had the potential to report ADRs, with appropriate knowledge and were willing to 
commit the time to complete the reports (Whittlesea et al., 1993). 
Wolfson et al. (1993) investigated the role of the UK community pharmacists in ADR 
reporting by conducting four linked studies. The first study determined the perception 
of the pharmacists about their role in ADR reporting by sending questionnaires to all 
116 pharmacies in Bradford. The results showed 95% of the 61 respondents admitted 
that patients had presented to them with a symptom thought by the patient to be an 
ADR. Eighty two percent and 89% felt they should be involved in reporting ADRs to 
black triangle drugs and OTe drugs respectively, while 69% of them thought 
involvement in ADR reporting would require further education. The second study 
sought to determine whether any symptom described by patients presenting in 
pharmacies could be due to an ADR. The community pharmacists were asked to 
complete the form for all patients complaining of symptoms. A total of 342 completed 
forms were returned from 14 pharmacies. It was found that 22% of all patients 
presenting with symptoms were taking drugs before the onset of the symptom. Of 28 
possible ADRs identified by the researchers, four were suitable to report to the eSM. 
The researchers estimated that approximately 20,000 yellow cards would result if this 
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pharmacy network applied across the UK. Study 3 aimed to investigate an ADR 
reporting scheme being established for pharmacists to report ADRs to a limited 
number of drugs and assess if their reports would be of value to the CSM. Of 75 
pharmacists participating in the scheme, 26 forms were returned from 14 different 
pharmacies. The results suggested that ten reports would be of benefit to the CSM. 
Study 4 assessed the reasons for the low reporting rate in study 3 using a 
questionnaire survey. The results demonstrated that 63% of respondents did not 
complete the forms due to no ADRs being identified. After evaluating the four pilot 
areas, the authors recommended that reporting of ADRs by community pharmacists 
was feasible and of benefit to the CSM, however, further education should be 
arranged. Pharmacists should report ADRs directly to the CSM as well as to the GP. 
Also, patient medical records were suggested as a useful tool in identification and 
reporting of ADRs. 
A more recent study by Green et al. (1999) investigated pharmacists' attitudes and 
knowledge of ADR reporting and the Yellow Card scheme in 40 randomly selected 
community pharmacies within one demonstration scheme area. It was found that 
almost all of the pharmacists (93%) were aware that they were able to report ADRs 
but only one had done so. The main reasons for not submitting reports were lack of 
time and the reactions identified were well-recognised. Few pharmacists knew the 
reporting criteria for' black triangle' drugs. Although reporting on OTC drugs is a 
potential role of community pharmacists, 70% of them agreed that they would be 
unlikely to report an ADR related to the OTC drugs. However, most agreed that ADR 
reporting is important area in which pharmacists should be involved. 
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1.7.2 Role of pharmacists outside the UK 
Pharmacists in several countries are able to participate in national ADR reporting 
systems. Hospital-based pharmacists more often get involved in ADR schemes than 
those in community. In Canada, one in every six hospitalised patients has experienced 
an ADR (Taras-Zosowski and Einarson, 1989), therefore, pharmaCists' contribution to 
the ADR programme helps to reduce the financial burden of ADRs. In the Netherlands, 
a regional pharmacy-based ADR surveillance scheme showed that the contributions of 
doctors and pharmacists prevented iatrogenic damage. Community pharmaCists also 
played a key role in drug monitoring (Roberts et al., 1994). Additionally, in 1984 a 
regional spontaneous reporting system was set up to collect and evaluate suspected 
ADRs. ADRs reported by doctors were collected and passed to a pharmacist for 
additional information as well as an assessment of the causal relationship between the 
reaction and the suspected drug. The complete report was then sent to a centre 
known as the Netherlands Pharmacovigilance Foundation (LARES). A total of 22,000 
ADR reports were received by LARES at the end of 1995 and about 15% of these 
were previously unknown ADRs (de Koning et al., 1997). 
In the USA, in 1985 90% of ADR reports were submitted by drug companies, while 
health professionals reported the remaining 10%, of which one-third was from 
pharmacists. Pharmacists had been significantly involved in the setting up of ADR 
reporting programmes within institutional settings due to the requirements mandated 
by the US Joint Commission of the Accreditation of Healthcare Organizations 
(JCAHO). These ADR schemes varied from hospital to hospital but satisfied JCAHO 
requirements (Fincham, 1989). According to American Society of Health-system 
Pharmacists (ASHP) guidelines, a comprehensive ADR monitoring and reporting 
programme should be an integral part of an organisation's drug use system and 
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pharmacists should exert leadership in the development, maintenance, and ongoing 
evaluation of ADR programmes (American Society of Health-system Pharmacists, 
1995). Tyler and Nickman (1992) surveyed 444 randomly selected hospitals by 
sending questionnaires to directors of pharmacy and revealed 90% of 176 
respondents met all of the JCAHO standard and 28% complied with all of the ASHP 
guidelines. Ninety seven percent of the hospitals had policies for ADR reporting. A 
study of Herrera et al. (1992) found 96% of 61 responding hospitals collected 
information on ADRs, with 22% indicating their surveillance system as active. The 
professionals most often cited as responsible for the systems included pharmacists, 
assurance personnel and nurses. 
Close interaction between doctors and pharmacists was listed as one of the key 
features of a hospital ADR surveillance system described by Gilroy et al. (1990) which 
could contribute to a substantial increase in reporting. There are many other examples 
of schemes involving pharmacists which have also resulted in higher frequencies of 
ADR reports (Ma honey et aI., 1991; Shuban, 1991; Saltiel et al., 1995; Wu et al., 1992; 
Zoka et al., 1994; Upchurch et al., 1991; Wessenberg et al., 1993). 
Since ADRs are one of the commonest drug-related problems resulting in clinical 
intervention (Alderman, 1997) and as already noted, many ADRs are preventable (see 
Section 1.1.3) the use of systematic surveillance schemes has provided an opportunity 
for pharmacists to reduce morbidity associated with ADRs (Evans et al., 1994). The 
involvement of pharmacists in both formal and informal ADR reporting can thus 
contribute significantly to improvements in patient care. 
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1.8 Patient-self reporting of ADRs 
None of the formal PMS systems fare very well in detecting new ADRs because of 
lack of appropriate control groups (Solovitz et al., 1987). They also have problems in 
validating the causality of reported symptoms and require a great deal of additional 
information to rule out non-drug causes. Another method which could be useful is 
patient-self reporting of symptoms related to drugs. ADR reports direct from patients 
are included in the national ADR registers in the USA and Germany (Roberts et al., 
1993). Most suspected ADRs in outpatient populations were initiated by patients' 
reports to their doctors, but there is little published literature regarding the 
development of formal patient-initiated surveillance approaches (Fisher and Bryant, 
1992). 
1.8.1 Community pharmacist involvement in patient-self reporting of 
ADRs 
There are a limited number of studies in the area of patient self-reporting of ADRs with 
which pharmacists have been involved. Those studies are described below. 
Campbell and Howie (1988) initiated a method for increasing the reporting rate of 
ADRs by using patient-self reporting of ADRs. A total of 896 patients prescribed one of 
77 black triangle drugs were given a leaflet by the community pharmacists and 
encouraged to report any adverse reaction to their doctors. The doctors were also 
asked to review the case notes to assess whether the adverse reaction reported could 
be attributed to the suspected drug. The results showed that reports of ADRs 
increased from ten per 1000 in the two-month control period to 23 per 1000 in the two-
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month intervention period. Surprisingly however, only one yellow card was sent to the 
CSM during the study period. 
Fisher et al. (1987a, 1995) and Fisher and Bryant (1992) conducted a patient-initiated, 
pharmacy-based PMS study at the University of Texas Medical Branch. Initially 2705 
randomly selected outpatients prescribed antibiotics and tricyclic antidepressants as 
an experimental group had a printed notice attached to their medication bags. The 
patients were requested to report any new or unusual symptoms during the next two 
weeks by calling a toll-free telephone number to a trained ADR interviewer. Another 
sample of 1109 patients acted as a control group and did not receive the information 
but were interviewed by telephone two weeks later. The results demonstrated both 
experimental and control groups reported predictably high relative frequencies for the 
most commonly known ADRs to these drugs. These researchers concluded that 
patient-self monitoring could be a promising complement to existing doctor-based 
reporting systems as well as a possible early alert mechanism for detecting ADRs to 
new drugs. The researchers also performed a pilot study offering different levels of 
compensation for study participants. It was revealed that the percentage of 
acceptance for the full sample of volunteers was related to the amount of 
compensation given with $25 resulting in a 59% increase and $10 resulting in a 34% 
increase in acceptance (Bryant et al., 1990). Fisher et al. (1995) also used the same 
method via a free-phone interview to compare ADRs reported by a large sample of 
outpatients prescribed f1uoxetine and sertraline. Data were collected on 1577 
f1uoxetine-treated and 1209 sertraline-treated patients who filled their prescriptions at 
596 different pharmacies nationwide. The data indicated 34% of patients on sertraline 
called at least once to report one or more ADRs compared with 20% of patients on 
f1uoxetine. Most of the reported symptoms were expected ADRs. A further study by 
the same authors planned to involve 700 Texas pharmacies with a goal to monitor at 
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least 10,000 patients treated with a particular target drug in order to detect relatively 
rare ADRs over a five-year period. Nevertheless, there has been a lack of support for 
this method from both the US FDA and the pharmaceutical industry (Fisher et aI., 
1987b; Fisher, 1995). A similar study (Fisher et al., 1993) compared incidence 
estimates and relative risk for a number of ADRs experienced by 815 trazodone-
treated and 2487 fluoxetine-treated patients. 
Mitchell et al. (1988,1989,1994) suggested event reporting was reliable and had 
greater sensitivity than reaction reporting for detecting true ADRs. A subsequent study 
was carried out to investigate the potential of patient reports of ADRs in a region of 
Australia. Eighty community pharmacists were asked to distribute event report forms 
consisting of 35 questions to consecutive patients presenting prescriptions for either 
diclofenac or piroxicam. Patients were asked to complete the form one month after it 
was received. Drug-free subjects and spontaneous reports submitted by health 
professionals to the national reporting system were also recruited to compare with the 
study group. Of the 1559 report forms distributed, 39% were returned. Patient-self 
reporting identified established ADRs compared with the drug-free subjects, while 
reports from health professionals tended to report more severe but rarer reactions 
than patient-self reports. The authors suggested that the system based on patient-self 
reporting could increase sources of information on ADRs that were important to 
patients and might generate early warning of symptomatic reactions to new drugs. 
In addition, a prospective observational study based on telephone interviews with 1475 
patients presenting prescriptions for NSAIDs at five community pharmacies was 
conducted in a region of Canada. Of the patients approached, 51 % participated and 
83% of these provided completed interviews. It was found that 19% of recruited 
patients reported a new health problem or unusual symptoms at the initial interview. Of 
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the total 183 reported health problems, 86% affected the GI system (Willison et al., 
1995). 
Egberts et al. (1996) compared the time to reporting of ADRs by patients and by 
health professionals for a newly introduced antidepressant, paroxetine. Data from 
patients who consulted a pharmacist via a free telephone medicine information service 
during 1992-1994 were searched for those indicating an ADR related to paroxetine. 
The results showed the mean lag time for all suspected reactions to paroxetine by 
patient self-reporting was 229 days less than for reports submitted by health 
professionals to the Pharmacovigilance Foundation in the Netherlands. The proportion 
of new ADRs was comparable for both systems. These workers suggested that, 
although the patient reporting might generate false alarms, it may play an additional 
role in pharmacovigilance as it enabled earlier detection of ADRs. A recent study by 
van den Bemt et al. (1999) evaluated the relative value of ADRs reported by doctors, 
nurses and by patients on four wards of two hospitals in the Netherlands over a two-
month period. The ADRs were collected by spontaneous reporting from doctors and 
nurses and by patient reporting via an interview with a hospital pharmacist. The 
pharmacist asked the patients whether they experienced any ADRs on the previous 
day. If so, the patients were asked further information about the time relationship. Of a 
total 620 patients, ADRs were reported in 29%. It was revealed that doctors reported a 
statistically significant higher number of serious and unknown ADRs than those 
reported by patients and nurses. Interestingly, adverse reactions to newly marketed 
drugs were only reported by patients which accounted for 8% of all daily ward visit 
reports. Therefore, pharmacist-assisted patient-self reporting might be useful for 
detecting adverse reactions caused by newly marketed drugs. 
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It has also been suggested that patients' drug related concerns can be identified using 
a brief medication questionnaire with a mixture of closed and open-ended questions 
and indirect and direct questions which could easily be incorporated by pharmacists 
into their normal routine (Svarstad, 1998). A study using the questionnaire to screen 
drug related concerns in asthma patients in pharmacy practice found 50% of the 
patients had experienced bothersome effects of drugs (Anonymous, 1998). 
1.8.2 Patient-reported adverse effects to specific drugs 
Several studies have been described in which patients have been asked to record the 
presence and/or severity of side effects resulting from a specific drug group. In 
general, these consist of lists of potential adverse effects and patients conSistently 
identify well-recognised symptoms as well as other, perhaps unanticipated, effects. 
Alopecia, fatigue, and taste change were among the most common side effects 
identified by patients receiving chemotherapy with the well known CHOP regime 
(Sitzia et al., 1997), while fatigue was both the most common and the most 
troublesome side effect of carboplatin (Buckingham et al., 1997). Patients receiving 
antiepileptic drugs identified mood changes and irritability, general cognitive difficulties 
and fatigue, although the latter was the only symptom which was more common in 
drug-treated patients than in controls (Brown and Tomlinson, 1982). Scottish patients 
treated with lithium for affective disorders selected symptoms known to be adverse 
effects of the drug significantly more frequently than 'dummy' symptoms (Nicol, 1998), 
while Hong Kong Chinese patients also selected symptoms known to be adverse 
effects to lithium from checklists (Lee, 1993). Rickels and Downing (1970), using 
checklists in patients treated with tranquilizers or antidepressants and controls, 
showed that four of the six most commonly cited symptoms corresponding to known 
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adverse effects were significantly more frequent in drug-treated respondents than in 
controls. 
The use of checklists which include a range of selected potential adverse effects, 
mostly known already to be associated with the drugs under study, are clearly not 
appropriate for the detection of previously unknown adverse effects or for general use. 
Such checklists therefore have limited application, although they do show that patients 
are capable of identifying adverse effects. 
1.8.3 Attribution of events to drug therapy by patients 
There are further studies which suggest that patients are capable of correctly 
attributing adverse events to drug therapy. A study by Sorovitz et al. (1987) involved 
the development of a complete listing of possible ADRs selected from Long (1977) and 
the US Pharmacopoeia 1983. Using interviews, these workers showed that patients 
correctly attributed possible ADRs to the target drug (antidepressant or antibiotic) 
more frequently (69%) than other symptoms (43%). Nevertheless, Fisher and Bryant 
(1990) suggested that attribution accuracy depended both on the surveillance method 
and on how reports were obtained. Discrimination was better when patients reported 
adverse events spontaneously than when through systematic enquiry by an 
interviewer. The use of a systematic enquiry following a patient-initiated telephone call 
by patients who have experienced possible side effects following use of a drug has 
been shown to identify different effects with different antidepressants (Fisher et al., 
1993, 1994). These authors suggested that by asking patients to attribute symptoms 
to a particular drug they are less likely to accrue false positives than using methods 
which document all health changes after initiation of medication, such as PEM. 
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Specific questioning using checklists was found by Rickels and Downing (1970) not to 
increase the number of drug-related symptoms identified through suggestion, since 
symptoms not known to be related to drugs did not differ in frequency between drug-
treated patients and untreated controls. 
It is therefore possible that patient self-reporting could identify previously unknown 
adverse effects, provided sufficiently large numbers of patients are studied. These 
methods could also be used to identify problems more rapidly than health 
professional-initiated reporting systems (Egberts et al., 1996). In addition these 
methods could be used to obtain more realistic estimates of the incidence of minor 
adverse effects, since these are more likely to be reported by patients (Mitchell et aI., 
1994) 
1.8.4 Factors affecting patient self-reporting of ADRs 
Older patients are more likely to experience ADRs than younger patients because the 
ageing process is associated with both physiological and pathological decline in most 
body systems (Beard, 1992). However the elderly may under-report symptoms, 
possibly because of the perception that many symptoms may be regarded as part of 
the natural process of ageing, rather than being drug-related (Morgan et al., 1997). 
Indeed, increasing age appeared in one study of those over 65 to be associated with a 
decreased tendency to report symptoms using an open questionnaire (Chrischilles et 
al., 1992). This could include a reduced ability to detect and report ADRs in the very 
elderly. Conversely, Bryant et al. (1991, 1992) found that those aged 50 or over were 
possibly better at discriminating probable ADRs from other types of adverse events 
than were younger patients. 
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Hospitalised patients were reported to be more likely to report ADRs than those 
attending outpatient clinics or in the community in one study (Mannesse et al., 1997). 
These patients, however, were less likely to recognise severe reactions than mild ones 
and the frequency of reactions reported was related to the number of drugs being 
taken, rather than to the number of disease states present. 
1.8.5 Comparison of methods used in patient self-reporting 
The three methods commonly used to detect ADRs by patient self-reporting are open 
questions, systematic assessment using a symptom checklist and spontaneous 
reporting (Corso et al., 1992). A systematic enquiry combined with spontaneous 
reporting appears to more than double detection rates compared to spontaneous 
reporting alone (Fisher et al., 1987c). However the latter appears to be most reliable 
for unexpected ADRs, although the actual incidences may be underestimated (Barber 
and Santanello, 1995). While an open-ended questionnaire has the advantage of not 
suggesting adverse effects to patients, the symptom checklist can encourage reporting 
of symptoms which patients may otherwise fail to report. In a comparison of these two 
methods in 515 patients treated with bacampicillin, a greater frequency of ADRs was 
reported using the checklist, although the events reported in response to the open 
questions were in general more serious (Wallin and Sjovall, 1981). As a result these 
authors suggested that a combination of the two methods was optimal in detecting 
ADRs. Downing et al. (1970) also found a higher frequency of reported adverse effects 
using a structured checklist than an open question. As mentioned in section 1.8.3, the 
checklist did not suggest adverse effects to the untreated control group included in this 
work. Spontaneous reporting was found by Rosenthal et al. (1996) to result in a lower 
overall prevalence of adverse events than when identified by a standard questionnaire. 
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These studies confirm other work showing that open questioning of healthy individuals 
and those on medication results in fewer symptoms being reported than the use of 
checklists (Ciccolunghi and Chaudri, 1975). These workers however also found that 
more severe symptoms were reported using open questions, which is in line with the 
more serious nature of spontaneously reported events found by Wallin and Sjovall 
(1981). This was also confirmed by the findings of Barber and Santanello (1995) in 
that more bothersome effects were reported spontaneously, although most patients 
who completed a checklist in their study had experienced some adverse effects. 
Open questions and checklists were also compared with doctors' reports by Borghi et 
al. (1984). These workers found that open questions provided more information about 
the symptoms of disease than the unwanted effects of drugs. The checklist seemed to 
suggest mild signs and symptoms to the patients. They concluded that conventional 
reporting by doctors appeared to provide more reliable information about adverse 
effects. The view that questionnaire-obtained reports of side effects are relatively poor 
was also held by Curb et al. (1985), since they found that many fewer patients had 
their drug discontinued because of the reported side effects than for other reasons. 
While acknowledging that patients may not be qualified to decide on the attribution of 
symptoms, may only spontaneously report those adverse effects which are most 
bothersome and may be prompted by checklists to report symptoms with high 
frequency, the fact remains that patient perceived adverse effects are a common 
cause of failure to comply with medication regimens (Stockwell and Schulz, 1992). It is 
therefore important to obtain information about patients' perceptions of adverse 
effects. 
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Corso et al. (1992) developed a questionnaire containing a comprehensive list of 
symptoms in lay terminology categorised by body system in order to overcome the 
overestimation of ADR incidence which is common with checklists. This was used as 
part of a computer-assisted interview to obtain information from patients regarding 
their medication regimens and the presence of complaints. The list of symptoms was 
extracted from the United Sates Pharmacopoeia Dispensing Information (USPDI) 
computerised database. This comprehensive list was deliberately designed to 
eliminate the bias and false positive responses, since patients were asked about all 
potential ADRs, not just those known to be associated with the specific drugs. It was 
suggested that this list may also improve patients' ability to identify and report 
symptoms experienced. 
1.9 Reasons for undertaking this study 
Pharmacists in many countries are changing their roles, particularly in primary care. 
Many projects have identified areas in which the involvement of pharmacists can 
improve patient care and the recent involvement of pharmacists in ADR reporting has 
similarly shown they can enhance the existing system. Many patients suffer from 
ADRs (see Section 1.1.2), many are caused by physician prescribing decisions (Bates 
et al., 1993), yet many are preventable (see Section 1.1.3). As pharmacists increase 
their contact with patients the opportunities for prevention of ADRs also increases. 
The majority of work on ADR reporting has not however involved patients directly, yet 
the main methods of detecting ADRs currently in use in the UK rely on the patient 
spontaneously reporting symptoms to prescribers. The actual incidence of ADRs could 
be considerably higher (Gill et aI., 1995) and could contribute to patients not taking 
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medicines. Patients' involvement in treatment decisions is increasing (The Royal 
Pharmaceutical Society of Great Britain, 1997), yet their experiences of using drugs 
are not routinely sought. A questionnaire which enables patients to report their 
perceptions of adverse drug effects could thus be of value in different situations, for 
example to assist in identifying ADRs to new drugs or to identify problems during 
routine monitoring of therapy. 
Therefore, the purpose of this study was to develop and validate such a questionnaire 
and to evaluate its use in identifying ADRs to new, black triangle drugs. 
1.10 Objectives of the present study 
The present study was divided into two phases. 
Phase I: Pilot study 
1. To develop and validate a questionnaire for patients to complete to enable 
detection of potential ADRs. 
2. To determine the frequency of potential ADRs reported by patients using this 
questionnaire to five established central nervous system (eNS) drugs. 
3. To compare patients' reports of potential ADRs to those reported in their GP 
medical records. 
4. To evaluate the potential accuracy of patients' attribution of symptoms to the five 
drugs by classification of the symptoms using causality assessment. 
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Phase 11: Main study 
1. To identify a sufficiently large population of patients prescribed one of nine new 
drugs to enable the generation of meaningful data on their perceptions of potential 
ADRs to these drugs. 
2. To identify the frequency and rate of self-reported ADRs to these drugs. 
3. To compare patients' reports to the documentation of these reactions by GPs for a 
sample of the reports. 
4. To compare patients' and GPs' reports to those received by the CSM for the same 
period. 
5. To evaluate the potential accuracy of patients' attribution of symptoms to the new 
drugs by classification of the symptoms using causality assessment. 
6. To obtain an external comparison of whether the individual symptom 
classifications are appropriate or agreed. 
7. To compare the rates of ADRs reported by patients to the nine new drugs with 
nation-wide data from the CSM, data from PEM, published data and the five 
established drugs from the pilot study. 
Chapter 2 
Methods 
2.1 General 
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Prior to commencing research, permission to undertake the study was obtained from 
the Joint Ethical Committee of Grampian Health Board and the University of Aberdeen 
(Appendix A) and permission to access prescriptions was obtained from the Pharmacy 
Practice Division (PPD). The MeA was also approached to ensure that data from 
yellow card reports was available. 
2.2 Questionnaire design 
The questionnaire for detecting potential adverse drug reactions designed by Corso et 
al. (1992) and the standardised interview used to identify, describe and quantify 
symptoms by Fisher et al. (1987a) were used as a basis for the questionnaire. Two 
different types of questionnaire were designed, one involving closed questions and 
one open questions (Appendix B). The closed questions comprised a list of potential 
symptoms in all body systems. This questionnaire also provided an opportunity to add 
other symptoms or complaints for each body system using an open question. The 
open questionnaire provided spaces for patients to fill in the symptoms from which 
they considered to be caused by the study drug in each body system. Both 
questionnaires also requested information about the dose and frequency of the study 
drug, its indication and the start and stop dates of any other concomitant drugs. Both 
questionnaires were designed to ensure that all potential symptoms which 
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respondents considered could be due to the study drug could be included, by covering 
all body systems. 
Lists of patients prescribed one of four eNS drugs were obtained from the repeat 
prescriptions of one general medical practice in Aberdeen. These drugs were two 
established drugs namely trazodone, amitriptyline and two new drugs namely tramadol 
and moclobemide. A small sample of 14 patients whom the GPs thought would 
willingly help with the study were sent both questionnaires by mail. Subsequently all 
those who agreed were visited at home in order to ask their views on the two types of 
questionnaire and to determine their ability to complete the questionnaires and 
whether they were worried by any aspect of them. 
The patients views were summarised, the results from the two questionnaires 
compared and this data reviewed by the study team. The list of symptoms was found 
to be easier to complete than the open-ended questions by all patients and neither 
caused concern in any patient. Therefore this approach was used in further 
development. Some questions were also modified following the interviews (see 
Section 3.3.1). 
The questionnaire developed from the pre-pilot study was divided into three parts. 
• Part I concerned basic demographic information about patients and their 
medicines including the patient's sex, age, dose and frequency of study drug 
taken, start date and indication for the study drug. It asked patients to list other 
concomitant drugs along with whether they were started before or after the study 
drug and whether they had been stopped or not, other medical conditions, and 
requested information on any hospital admissions since starting the study drug as 
well as reasons for admission. 
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• Part 2 asked patients about their experiences of possible side effects. The 
symptoms listed were categorised into 19 body systems or anatomic regions. 
There was also a sub-question included in each body system which asked whether 
patients had experienced any other symptoms not listed and if so, to specify the 
symptoms. In addition, part 2 contained questions asking patients to identify the 
most bothersome symptoms, rate the severity of the most bothersome symptoms 
and state whether they had informed their doctors about all, some or none of them. 
• Part 3 was only for completion by patients who had stopped taking the study drug. 
It requested the stop date of the study drug, reasons for stopping the drug, which, 
if any, symptoms had disappeared and whether any other symptoms had started 
after discontinuing the drug. 
The final questionnaire included a covering letter which confirmed to patients that all 
information collected would be treated in the strictest confidence and there would be 
no effect on their future medical care if they declined to take part. Reassurance was 
also given that their medicine did not cause all the effects or symptoms listed in the 
questionnaire. Care was taken in the design of the questionnaire to take account of 
previous research on colour and layout (Oppenheim, 1992) and to emphasise on each 
page that patients should identify only symptoms which they thought could be side 
effects of the study drug (see Appendix C). 
2.3 Definition of ADR 
The definition of ADR used in the present study was derived from that of the World 
Health Organisation (WHO). Thus any patient who identified a symptom which they 
perceived to be the result of an ADR defined as experiencing 'a noxious, unintended 
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effect of a drug that occurs at a dose normally used in humans for therapy, 
prophylaxis, or diagnosis'. This included unwanted pharmacological actions of a drug, 
excessive effects of the intended pharmacological action of a drug and idiosyncratic or 
allergic reactions. Intentional and accidental overdose, drug abuse and drug 
interaction were excluded from this definition. 
2.4 Criteria for assessment causal relationship 
The information available for assessment of causal relationship was that from self-
reports completed by patients and patient medical records in some cases. 
Consequently, none of the classification systems described in Chapter 1 could be 
used. New criteria for classifying each symptom reported by patients were therefore 
devised. The logical categories developed accounted for the probability of a causal 
relationship between symptoms reported and study drugs, concomitant drugs or 
disease states. These criteria allowed symptoms to be classified into eight categories 
as follows: 
1. Symptom caused by the study drug 
- known or previously reported reaction to study drug and 
- could not reasonably be explained by the effects of concomitant drug(s) and 
- could not reasonably be explained by the known characteristics of the 
patient's clinical condition 
2. Symptom caused by the study drug and concomitant drug(s) 
- known or previously reported reaction to study drug and 
- could reasonably be explained by the effects of concomitant drug(s) and 
- could not reasonably be explained by the known characteristics of the 
patient's clinical condition 
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3. Symptom caused by the study drug and disease(s) 
- known or previously reported reaction to study drug and 
- could not reasonably be explained by the effects of concomitant drug(s) and 
- could reasonably be explained by the known characteristics of the patient's 
clinical condition 
4. Symptom caused by the study drug, concomitant drug(s) and disease(s) 
- known or previously reported reaction to study drug and 
- could reasonably be explained by the effects of concomitant drug(s) and 
- could reasonably be explained by the known characteristics of the patient's 
clinical condition 
5. Symptom caused by only concomitant drug(s) 
not known or not previously reported reaction to study drug and 
could reasonably be explained by the effects of concomitant drug(s) and 
could not reasonably be explained by the known characteristics of the 
patient's clinical condition 
6. Symptom caused by only disease(s) 
- not known or not previously reported reaction to study drug and 
- could not reasonably be explained by the effects of concomitant drug(s) and 
- could reasonably be explained by the known characteristics of the patient's 
clinical condition 
7. Symptom caused by concomitant drug(s) and disease(s) 
- not known or previously reported reaction to study drug and 
- could reasonably be explained by the effects of concomitant drug(s) and 
- could reasonably be explained by the known characteristics of the patient's 
clinical condition 
8. Unclassified 
- not known or not previously reported reaction to study drug and 
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- could not reasonably be explained by the effects of concomitant drug(s) and 
- could not reasonably be explained by the known characteristics of the 
patient's clinical condition 
These eight categories were then grouped into four categories according to the 
probability of the causal relationship. The presence of an ADR was classified as 
probable, possible, unlikely, or unattributable depending on which criteria were 
satisfied. 
Criteria 1 = Probable: symptom probably caused by the study drug 
Criteria 2-4 = Possible: symptom possibly caused by the study drug 
Criteria 5-7 = Unlikely: symptom unlikely to be caused by the study drug 
Criteria 8 = Unattributable: potential previously unreported symptom to 
study drug and unattributable to other drugs or disease states 
Furthermore, the criteria on which the four categories were based were adapted for 
ease of use in classifying the reported symptoms. These criteria were used to provide 
an external comparison of whether the individual symptom classifications were 
appropriate or agreed. The modified criteria used for expert validation are listed below: 
1. Symptom caused by the study drug 
- known or previously reported reaction to study drug and 
- could not reasonably be explained by the effects of concomitant drug(s) and 
- could not reasonably be explained by the known characteristics of the 
patient's clinical condition 
2. Symptom caused by the study drug and concomitant drug(s), andl or by 
disease(s) 
- known or previously reported reaction to study drug and 
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- could reasonably be explained by the effects of concomitant drug(s) and! or 
by the known characteristics of the patient's clinical condition 
3. Symptom caused by only concomitant drug(s) and! or disease(s) 
- not known or not previously reported reaction to study drug and 
- could reasonably be explained by the effects of concomitant drug(s) and! or 
by the known characteristics of the patient's clinical condition 
4. Unclassified 
- not known or not previously reported reaction to study drug and 
- could not reasonably be explained by the effects of concomitant drug(s) and 
- could not reasonably be explained by the known characteristics of the 
patient's clinical condition 
These classifications were graded into the same four probabilities of causal 
relationship as the previous eight criteria. 
Criteria 1 = Probable: the symptom probably caused by the study drug 
Criteria 2 = Possible: the symptom possibly caused by the study drug 
Criteria 3 = Unlikely: the symptom unlikely to be caused by the study drug 
Criteria 4 = Unattributable: potential previously unreported symptom to study 
drug and unattributable to other drugs or disease states 
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2.5 Pilot study 
The purpose of the pilot study was to validate the questionnaire by using well-
established drugs with known side effect profiles and using information from medical 
records to assess the completeness and accuracy of patient responses. It also 
enabled the researcher to gain practice in identifying adverse reactions to known 
drugs and provided further experience with the questionnaire prior to studying new 
drugs with less well-established side effect profiles. It was estimated that 50 patients 
taking each drug would provide sufficient data to validate the questionnaire. 
Three medical practices with which links had already been established were asked to 
allow patients from their lists to be included in the pilot study. 
2.5.1 Patient selection 
2.5.1.1 Inclusion criteria 
1. Patients prescribed one of five established CNS drugs; trazodone (Molipaxin®), 
doxepin (Sinequan®), sodium valproate (Epilim®, Convulex®), carbamazepine 
(Tegretofll» or co-proxamol via the repeat prescribing system. 
2. Age 16 and over. 
2.5.1.2 Exclusion criteria 
1. Patients aged less than 16. 
2. Patients resident in nursing homes. 
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2.5.2 Questionnaire distribution 
Postal, pre-paid enveloped questionnaires (Appendix C) were sent to all patients 
prescribed carbamazepine, sodium valproate and trazodone from the three 
participating general practices. The questionnaires were sent to all patients prescribed 
doxepin and co-proxamol from two general practices and a random selection from 
another practice in order to achieve the aim of approximately 50 questionnaires 
returned from patients prescribed each study drug. If responses were not received 
within one month, reminder letters (Appendix D) and further questionnaires were sent 
to non-respondents. No follow up beyond the second mailing was attempted. 
2.5.3 Data validation and evaluation 
The responses to all questionnaires returned in which patients who reported a 
symptom were compared to information obtained by examination of the patients' 
medical notes. The aims of this process were to validate and clarify the information 
which patients had provided in the questionnaires and to obtain additional information 
such as strength of study drugs, other drugs taken or other disease states, where this 
had not been completed in the questionnaire. A data collecting form was designed for 
recording relevant information from the medical notes (see Appendix E). The details of 
information retrieved from the medical notes were as follows: 
• Study drug: drug strength and dosage regimen, indication for use, start 
date, stop date (if patients had stopped taking the drug), whether 
symptoms reported by patients were recorded in medical notes and 
whether they were recorded as symptoms or side effects, date of recording 
in the medical notes for individual symptoms 
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• Concomitant drugs: name of other drugs taken concomitantly, start date, 
stop date 
• Disease states with the year of diagnosis, whether the disease states were 
active problems (if available) 
• Other relevant data (if available) such as laboratory results which may be 
related to the symptoms reported, drug allergy, alcohol intake, cigarette 
smoking, patient's weight. 
After collecting data from medical notes, each symptom reported in Part 2 of the 
questionnaire was evaluated and categorised into one of the eight criteria for causality 
described in Section 2.4 using data from Part 1 and further information obtained from 
the medical notes. Information sources of known ADRs for the study drugs and the 
concomitant drugs were British National Formulary (British Medical Association and 
the Royal Pharmaceutical Society of Great Britain, 1998), ABPI Compendium of Data 
Sheets and Summaries of Product Characteristics (The Association of the British 
Pharmaceutical Industry, 1998), Drugdex Drug Evaluation Monograph (1998), Meyler's 
Side Effects of Drugs: an encyclopedia of adverse reactions and interactions (Dukes 
et al., 1996) and common ADRs reported in the CSM data. Reference sources of 
symptoms related to the disease states included Davidson's Principles and Practice of 
Medicine (Edwards et al., 1995), Textbook of Therapeutics: Drug and Disease 
Management (Herfindal and Gourley, 1996), Manual of Medical Therapeutics 
(Woodley and Whelen, 1992) and Harrison's Principles of Internal Medicine: 
Companion Handbook (Isselbacher et ai, 1994). 
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2.6 Main study 
The main study involved distribution of the questionnaire to patients throughout 
Grampian who had been prescribed one of nine 'black triangle' drugs, validation of a 
sample of these by review of medical notes, evaluation and comparison to other 
reports of ADRs from CSM, PEM and other sources and external validation of the 
classification. 
The questionnaire was modified in minor details after being used in the pilot study to 
ensure its appropriateness (Appendix F). Presently, doctors and hospital pharmacists 
are asked to report all suspected reactions, i.e. any adverse or any unexpected event, 
however minor, which could conceivably be attributed to newly marketed drugs 
indicated by the inverse black triangle symbol. Despite uncertainty about the causal 
relationship, reports to the CSM should be made regardless of whether the reaction is 
well recognised, and even if other drugs have been given concurrently. Therefore, 
symptoms reported by patients which were considered to be probable, possible or 
previously unknown reactions could be regarded as complementary to the existing 
reporting system. Estimation of the number of cases in which such symptoms were 
identified could thus be used to evaluate the usefulness of the questionnaire for 
identifying ADRs to new drugs. 
2.6.1 Patient selection 
All general practices in Grampian were approached by sending a letter to the senior 
partner in each practice (Appendix G) asking their permission for questionnaires to be 
sent to their patients. Of the total of 97 medical practices, 79 were willing to participate 
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in the study. The participating general practices were sent a reminder letter (Appendix 
H) and a sample of the final questionnaire before the questionnaires were sent to their 
patients. 
2.6.1.1 Inclusion criteria 
1. Patients taking one of nine black triangle drugs which were four antidepressants 
[venlafaxine (Efexorl!li). nefazodone (Dutoninl!li). citalopram (CipramW~) 
moclobemide (Manerixl!li)]. three anticonvulsants [gabapentin (Neurotinl!li). 
lamotrigine (Lamictall!li). topiramate (Topamaxl!li)] and two analgesics [tramadol 
(Zydoll!li). fentanyl patch (Durogesicl!li)]. All these drugs were given a black triangle 
symbol by the CSM issued in the British National Formulary (BNF), Data Sheet 
Compendium and Monthly index of Medical Specialists (MIMS) at the time of the 
study. 
2. Each prescription dispensed for the study drugs which had been issued by the 79 
participating practices in Grampian over the study period (January to March 1997) 
was identified by the Pharmacy Practice Division (PPD) in Edinburgh, using a 
search for the drug names listed above. The identification provided was in the form 
of a unique number with which all prescriptions are issued during the computerised 
pricing process. Patients' names and addresses were not captured as part of this 
process, therefore the actual prescription forms had to be accessed to obtain this 
information. The numbers provided were used to search manually through the 
prescription forms (GP10s) held at the PPD office in Aberdeen and the patients' 
names and addresses were copied from the prescription. 
3. Patients who were prescribed a study drug at least once during the study period. 
Patients who were prescribed more than one individual drug studied were sent all 
relevant questionnaires. 
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4. Age 16 and over. 
2.6.1.2 Exclusion criteria 
1. Patients who had been prescribed the same study drug(s) more than once during 
January-March 1997 were excluded from a second mailing by using a computer 
programme set up for this purpose. 
2. Patients aged under 16. 
3. Those patients who lived in nursing homes. 
2.6.2 Questionnaire distribution 
Postal questionnaires with pre-paid envelopes were sent to the patients to determine 
their perceived ADRs to the new drugs. The questionnaires sent to patients receiving 
the antidepressants venlafaxine, nefazodone and citalopram, the analgesic drugs 
tramadol and fentanyl patch and the anticonvulsants gabapentin, lamotrigine and 
topiramate. There were no reminders sent to the non-respondents as it was felt that 
this may upset patients who had serious illness and were not willing to participate in 
the study. 
2.6.3 Data validation and evaluation 
A sample of the questionnaires received were validated using a similar method to that 
used in the pilot study. Since the largest number of questionnaires concerned 
tramadol and venlafaxine, these were selected for the validation process. Permission 
was sought from eleven practices to access the medical records of their patients who 
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had responded to the questionnaire. The practices were selected on the basis that a) 
a substantial number of questionnaires relating to these drugs had been returned and 
b) there was already a working relationship with a pharmacist to enable access to be 
obtained easily. The data obtained from the medical records was as described in 
Section 2.5.3. A total of 53 questionnaires concerning tramadol and 50 venlafaxine 
questionnaires were validated in this way. All symptoms reported by all respondents 
were evaluated and categorised for causality using the criteria described in Section 
2.4. 
The 103 cases for which additional data had been obtained from medical notes were 
further evaluated by asking an expert on adverse drug reactions, who was formerly a 
senior pharmacist at the CSM Regional Reporting Unit, Newcastle-upon-Tyne, to 
independently categorise the symptoms reported by these patients for causality, using 
the criteria described in Section 2.4. The classifications made were compared to those 
made by the researcher for the same cases. 
2.6.4 Comparison to yellow card reports 
Information was obtained on yellow card reports submitted to the CSM for the study 
drugs from the 79 participating practices during the study period in the form of 
anonymised individual patient prints. The reports were compared to the questionnaire 
responses. 
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2.7 Data analysis and statistical methods 
Databases were set up for both the pilot study and the main study on SPSS for 
windows version 6.0 and version 9.0. After analysis of the pilot study data, some 
details of the database established were adjusted in order to improve its use for the 
main study. While SPSS was used for most data analysis, where this was not 
possible, Minitab for windows version 7 and version 12 were used. 
The following analyses were carried out: 
1. Patients' demographic details and general data on the medicines they were taking 
were studied using descriptive statistics. The Mann-Whitney U test was used for 
comparing median age or concomitant drugs between gender. 
2. The number of reported symptoms and the number of concomitant drugs were 
further sub-grouped to enable relationships between these and other variables to 
be investigated. 
3. The number of respondents using other drugs for the same indication as the study 
drugs and also those using other CNS drugs were calculated and relationships to 
other variables studied. 
4. Relationships between the number of reported symptoms, age and number of 
concomitant drugs taken were investigated using Spearman's rank correlation. 
5. All other relationships between variables obtained from the questionnaire were 
investigated using chi-square tests for association. Some data were regrouped, if 
necessary, for statistical analysis, e.g. age group, severity of symptoms, number of 
reported symptoms and number of concomitant drugs. 
6. The ten most frequently reported symptoms for each drug in the questionnaires 
were compared to similar data for the study drugs obtained from the CSM, data 
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from PEM studies and symptoms recorded in medical notes, where available. The 
Z-test for two proportions was used for comparisons of the frequency of each 
individual symptom reported where sample sizes were sufficiently large. 
7. The ten most frequently reported symptoms for each drug were compared within 
therapeutic categories using data from both the pilot and the main study. These 
symptoms were also compared to those obtained in published data. Comparisons 
were evaluated using the Z-test for two proportions for each individual symptom 
reported where sample sizes were sufficiently large. 
8. Comparison of the classifications for causality for each individual symptom in 103 
cases (53 tramadol and 50 venlafaxine) made by the research pharmacist and by 
an expert were investigated using the Kappa statistic. 
9. An assessment of the ability of patients to accurately attribute symptoms to the 
drugs being studied was made by comparing the percentage of symptoms 
considered by the researcher to be probable or possible ADRs with those 
considered unlikely or not to be ADRs, using chi-square tests. 
The 95% confidence interval or P-value at 0.05 was chosen to accept or reject the null 
hypotheses. 
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Chapter 3 
Results and Discussion: 
Pre-pilot and pilot study 
3.1 Pre-pilot study 
The pre-pilot study was carried out in July 1996. The purpose of the pre-pilot study 
was to develop a suitable questionnaire to be used in the pilot and main study. Both 
the closed and open questionnaires designed were sent to 14 patients by mail. One 
week after the questionnaires were sent, patients were contacted to arrange a home 
visit in order to ask their views on both questionnaires. There were five, five, three and 
one patients who had taken amitriptyline, trazodone, tramadol and moclobemide, 
respectively. Of these, 11 (79%) patients agreed to a home visit and nine (82%) 
reported at least one symptom since starting the drug. The patients' views on both 
types of questionnaire and their ability to complete the questionnaires are shown in 
Table 3.1. Based on this summary of patients' views, the closed questionnaire was 
chosen and questions relating to information about concomitant drugs and symptom 
severity were amended. In addition minor changes to the wording and layout of the 
questionnaire were made. 
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Table 3.1 Patients' views on and ability to complete the two different types of 
questionnaire 
Patients' Views No. of Patients ( %) 
1. Found no difficulty to fill in 11 (100%) 
2. Closed questions were easier than 9 ( 82%) 
open questions 
3. Open questions were easier than 1 ( 9%) 
closed questions 
4. Both closed and opened questions 1 ( 9%) 
were easy 
5. Questionnaire was quite long 1 9%) 
6. Unable to remember or difficult 7 64%) 
to remember start date 
7. Able to remember start date 4 ( 36%) 
8. Gave more details in closed questions 9 (100%)* 
9. Ticked a lot of boxes 3 ( 33%)* 
10. Did not finish the open questions 2 ( 18%) 
11. Did not tick" None" in the closed questions 3 ( 33%)* 
* N = 9 (number of patients who reported at least one symptom) 
3.2 Pilot study 
Data collection for the pilot study was undertaken between October 1996 and 
September 1997. The developed questionnaire was customised for five established 
drugs; carbamazepine, sodium valproate, trazodone, doxepin and co-proxamol. 
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Patients who had been prescribed one of these drugs from three general practices in 
Aberdeen were sent the appropriate questionnaire. 
3.2.1 Response rates and demographic data 
There were 464 questionnaires sent to patients taking the five drugs which accounted 
for 173, 79 and 212 questionnaires sent to patients registered at the three practices. 
Of these, 207 questionnaires were returned (44.6%). The number of questionnaires 
sent and response rates for each drug are shown in Table 3.2. Of the total 
respondents, 35.3% were male and 64.7% were female (Table 3.3). The mean age ± 
SD of respondents was 54.5 ± 21.1 years, but the majority of patients were aged 60-
79 years (35.3%) and 40-59 years (25.6%). The males had a median age of 58.0 
years and the females 59.0 with no Significant difference between males and females 
(Mann-Whitney U = 4599.5, P = 0.533). The number of respondents in each age group 
are presented in Figure 3.1. 
Table 3.2 Number of questionnaires distributed and response rates for each drug 
Number of questionnaires Number of respondents 
Drug Sent (%) 
Carbamazepine 81 44 (54.3%) 
Sodium valproate 52 25 (48.1%) 
Trazodone 115 41 (35.7%) 
Doxepin 105 52 (49.5%) 
Co-proxamol 111 45 (40.5%) 
Total 464 207 (44.6%) 
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Table 3.3 Number of respondents accord ing to sex for each drug 
Number of respondents ( %) 
Car Val Tra Dox Cop Total 
Sex 
Male 21 7 15 14 16 73 
(47.7%) (28.0%) (36.6%) (26.9%) (35.6%) (35.3%) 
Female 23 18 26 38 29 134 
(52.3%) (72.0%) (63.4%) (73.1 %) (64.4%) (64.7%) 
Car = carbamazepine, Val = sodium valproate , Tra = trazodone, Oox = doxepin, Cop = 
co-proxamol 
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Figure 3.1 Age groups of respondents for each study drug 
Of the tota l respondents, 50.2% and 23.2% were prescribed 1-3 and 4-6 concomitant 
drugs, respectively. The mean ± SO of number of concomitant drugs was 3.1 ± 2.6. 
There was no strong relationship between increasing age and number of concomitant 
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drugs (Spearman r = 0.289, P< 0.001). The number of concomitant drugs being taken 
by the respondents for each study drug are shown in Table 3.4. There were no 
significant differences between drugs in gender of respondents (X2 = 5.189, df = 4, P = 
0.268) or in the numbers taking concomitant drugs ( 0-2 vs 3-4 vs 5-6 vs >6); (x2 = 
17.039, df = 12, P = 0.148). Age group was however statistically different between 
drugs (l = 72.050, df = 12, P < 0.001). Respondents taking antiepileptics were 
younger, while those taking co-proxamol were the oldest. 
Table 3.4 Number of concomitant drugs used by respondents taking study drugs 
Number of respondents (%) 
Drug Number of concomitant drugs Total 
0 1-3 4-6 7-9 ~10 
Carbamazepine 7 27 5 4 1 44 
(15.9%) (61.4%) (11.4%) ( 9.1%) ( 2.3%) (100%) 
Sodium valproate 6 14 5 - - 25 
(24.0%) (56.0%) (20.0%) (100%) 
Trazodone 4 17 13 5 2 41 
( 4.9%) (41.5%) (31.7%) (12.2%) ( 4.9%) (100%) 
Doxepin 10 24 13 5 - 52 
(19.2%) (46.2%) (25.0%) ( 9.6%) (100%) 
Co-proxamol 4 22 12 5 2 45 
( 8.9%) (48.9%) (26.7%) (11.1%) ( 4.4%) (100%) 
Total 31 104 48 19 5 207 
(15.0%) (50.2%) (23.2%) ( 9.2%) ( 2.4%) (100%) 
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Of the total respondents prescribed carbamazepine, the most frequent indication for 
use was epilepsy (n=33, 75%), followed by manic depression (n=4, 11 %), trigeminal 
neuralgia (n=5, 11 %) and other neurological disorders (n=1, 2%), while almost all 
respondents were taking sodium valproate for epilepsy (n=24, 94%). Two 
respondents, one on each drug did not give the indication. For patients prescribed 
antidepressants, the indications for use of trazodone were depression (n= 28, 68%), 
anxiety (n=7,17%), sleeplessness (n=4,1 0%) and panic attack (n=1, 2%), while those 
for doxepin were depression (n= 31,60%), anxiety (n=3, 6%), sleeplessness (n=13, 
25%) and panic attack (n=1, 2%). The remaining four patients did not specify the 
indication. The most frequent indication for the use of co-proxamol was osteoarthritis 
(n= 17,38%), followed by back pain (n= 7,16%), unspecific pain (n= 6,13%), other 
bone or muscle diseases (n= 5,11%), rheumatoid arthritis (n=4, 9%) and spondylosis 
(n=4, 9%), headache (n=1, 2%) and degenerative bone or jOint disease (n=1, 2%). 
Although 92 patients (44.4%) reported that they had been in hospital after starting the 
study drugs, none of them indicated that the admissions had been caused by these 
drugs. 
3.2.2 Symptoms reported 
The total number and frequency of symptoms reported for each drug are shown in 
Table 3.5. There was no strong relationship between number of reported symptoms 
and increasing age (Spearman r = -0.158, P = 0.024) or increasing number of 
concomitant drugs (Spearman r = 0.275, P < 0.001). The number of reported 
symptoms for each drug are presented in Figure 3.2 grouped for ease of interpretation 
(0-5 vs 6-10 vs 11-15 vs >15). There were no significant differences in the number of 
reported symptoms between drugs (x2 = 18.162, df = 12, P-value = 0.111). However, 
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males reported significantly more symptoms than females (x2 = 15.024, df = 3, P = 
0.002). 
Table 3.5 Total number and frequency of symptoms reported for each drug 
No. of different Total number of symptoms 
Drug (n) symptoms reported reported (median, range) 
Carbamazepine (44) 73 283 (4.5,0-22) 
Sodium valproate (25) 79 269 (9.0, 0-41) 
Doxepin (52) 79 310 (4.0,0-24) 
Trazodone (41) 87 452 (10.0,0-34) 
Co-proxamol (45) 77 300 (3.0, 0-51) 
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Figure 3.2 Grouped number of reported symptoms for each drug 
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Drowsiness, unusual tiredness! weakness, dry mouth, dry mouth and constipation 
were the most frequently symptoms reported by patients prescribed carbamazepine, 
sodium valproate, trazodone, doxepin and co-proxamol, respectively. Appendix I 
shows frequency of each individual reported symptom categorised by body systems 
for each study drug. The ten most frequently reported symptoms for each drug along 
with the frequency with which these were recorded in the medical notes are shown in 
Tables 3.6, 3.7 and 3.8. Overall only 360 (22.3%) of total 1614 symptoms reported by 
patients were recorded by GPs. Sixty five (31.4%) and 17 (8.2%) of the total 207 
respondents reported complete information in the questionnaire about concomitant 
drugs and disease states, respectively, compared with the records in their medical 
notes. 
Table 3.6 The ten most frequently reported symptoms from the anticonvulsants by 
patient questionnaire (bold) and in medical notes ( ) 
Rank Number of symptoms 
Carbamazepine (n=44) Sodium valproate (n=25) 
1 Drowsiness 15 (2) Unusual tiredness! weakness 14 (5) 
2 Unusual tiredness! weakness 12 (4) Tremor 11 (3) 
3 Difficulty concentrating 10 (0) Difficulty concentrating 9 (2) 
4 Reduced vision 10 (4) Loss of memory 9 (1) 
5 Tremor 9 (1) Drowsiness 8 (4) 
6 Light-headedness 9 (1) Hair loss 7 (3) 
7 Dizziness 8 (3) Headache 6 (3) 
8 Loss of memory 8 (0) Indigestion 6 (1) 
9 Headache 7 (4) Change in mood 6 (2) 
10 Double vision 7 (1) Passing water more often 6 (2) 
Anxiety 6 (2) 
Weight gain 6 (4) 
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Table 3.7 The ten most frequently reported symptoms from the antidepressants by 
patient questionnaire (bold) and in medical notes ( ) 
Rank Number of symptoms 
Trazodone (n=41) Doxepin (n=52) 
1 Dry mouth 20 (2) Dry mouth 26 (2) 
2 Anxiety 19 (12) Indigestion 11 (3) 
3 Drowsiness 17 (7) Drowsiness 10 (2) 
4 Light-headedness 16 (2) Constipation 9 (2) 
5 Unsteadiness on feet 14 (2) Light-headedness 9 (2) 
6 Unusual tiredness/ weakness 14(5) Excessive thirst 9 (0) 
7 Difficulty concentrating 13 (3) Unusual tiredness/ weakness 9 (1) 
8 Constipation 13 (4) Weight gain 9 (2) 
9 Itching skin 12 (1) Palpitations 9 (3) 
10 Excessive thirst 12 (0) Ringing in ears 9 (1) 
Table 3.8 The ten most frequently reported symptoms from the analgesic by patient 
questionnaire (bold) and in medical notes ( ) 
Rank Number of symptoms 
Co-proxamol (n=45) 
1 Constipation 11 (1) 
2 Itchy eyes 10 (2) 
3 Dry mouth 10 (0) 
4 Flushing 10 (2) 
5 Itching skin 9 (3) 
6 Change in finger nails 9 (0) 
7 Increased sensitivity to cold 9 (0) 
8 Dizziness 8 (1) 
9 Excessive thirst 7 (0) 
10 Unusual tiredness/ weakness 7 (2) 
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The most bothersome symptoms reported by patients taking carbamazepine were 
increased sleep (n = 4,9%), loss of memory (n= 3, 7%), increased sweating (n= 2, 
5%), dizziness (n=2, 5%), runny or stuffy nose (n=2, 5%), reduced vision (n=2, 5%) 
and tremor (n=2, 5%), while those taking sodium valproate were weight gain (n=4, 
16%), loss of memory (n= 3,12%), unusual tiredness! weakness (n=3, 12%) and 
difficulty concentrating (n= 2, 8%). Regarding patients taking the antidepressants, the 
most bothersome reported symptom for trazodone was unusual tiredness! weakness 
(n=9, 22%), followed by increased sensitivity to cold (n=3, 7%), excessive thirst (n=3, 
7%), difficulty concentrating (n=2, 5%) and weight gain (n=2, 5%), respectively, while 
the most bothersome reported symptom for doxepin was increased sleep (n=4, 8%), 
followed by increased sweating (n=3, 6%), reduction in sleep (n=2, 4%), change in 
mood (n=2, 4%), unusual tiredness! weakness (n=2, 4%), diarrhoea (n=2, 4%), 
palpitations (n=2, 4%) and dry mouth (n=2, 4%), respectively. For patients taking the 
analgesic (co-proxamol), the five most bothersome symptoms reported included 
increased sweating (n=4, 9%), dry mouth (n=3, 7%), bone or joint pain (n=3, 7%), 
itching of skin (n=2, 4%) and difficulty concentrating (n=2, 4%). 
There were 101 (48.8%) respondents who indicated they had reported some or all of 
these symptoms to their doctors. Respondents who reported more symptoms on the 
questionnaire were significantly more likely to have informed their doctors about the 
symptoms than those who reported less symptoms (x2 = 23.027, df = 3, P < 0.001) as 
detailed in Table 3.9. 
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Table 3.9 Number of reported symptoms in relation to whether or not patients 
reported their symptoms to their doctors 
Number of reported Number of patients (%) 
symptoms Whether patients informed their 
doctors of symptoms Total* 
Yes No 
::;;5 28 (45.9%) 33 (54.1%) 61 (100%) 
6-10 27 (87.1%) 4 (12.9%) 31 (100%) 
11-15 25 (80.6%) 6 (19.4%) 31 (100%) 
>15 21 (80.8%) 5 (19.2%) 26 (100%) 
* Total number of valid cases =149 
3.2.3 Severity of symptoms reported 
Most respondents who rated the severity of their most bothersome symptoms rated 
them as moderate (28.0%) or severe (15.9%) (Table 3.10). There were no statistically 
significant associations between the severity of the reported symptoms in relation to 
the frequency of taking the drugs (l = 5.456, df = 4, P = 0.244) or whether patients 
had informed their doctors about the symptoms (x,2= 5.815, df = 2, P = 0.055) (see 
Table 3.11 and 3.12). In contrast, there was an association between symptom severity 
and the number of symptoms reported (Table 3.13). Patients rating their symptoms as 
severe were likely to report more symptoms than those who reported only mild 
symptoms (x,2 = 23.459, df = 6, P < 0.001). Severity of symptoms reported did not 
significantly associate with number of concomitant drugs (l = 4.426, df = 6, P = 0.619) 
as presented in Figure 3.3. 
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Table 3.10 Severity ratings of the most bothersome symptoms reported by patients 
Severity of symptoms No. of respondents % 
Minimally 6 2.9 
Mildly 19 9.2 
Moderately 58 28.0 
Severely 33 15.9 
Very severely 15 7.2 
Does not apply 46 22.2 
Unspecified 30 14.5 
Table 3.11 Severity of reported symptoms in relation to frequency of taking study 
drugs 
Severity of Number of patients (%) 
symptoms 
Frequency of taking drugs [times/day) Total· 
1 2 ~3 
Mild 11 7 6 24 
(45.8%) (29.2%) (25.0%) (100%) 
Moderate 21 16 19 56 
(37.5%) (28.6%) (33.9%) (100%) 
Severe 10 17 20 47 
(21.3%) (36.2%) (42.6%) (100%) 
• Total number of valid cases = 127 
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Table 3.12 Severity of reported symptoms in relation to whether or not patients 
reported symptoms to their doctors 
Severity of Number of patients (% 
symptoms 
Whether patients informed Total* 
their doctors of symptoms 
Yes No 
Mild 13 10 23 
(56.5%) (43.5%) (100%) 
Moderate 38 13 51 
(74.5%) (25.5%) (100%) 
Severe 36 7 43 
(83.7%) (16.3%) (100%) 
* Total number of valid cases = 117 
Table 3.13 Severity of symptoms reported in relation to number of reported 
symptoms 
Severity of Number of patients (%) 
symptoms 
Number of reported symptoms Total* 
~5 6·10 11·15 >15 
Mild 14 5 3 3 25 
(56.0%) (20.0%) (12.0%) (12.0%) (100%) 
Moderate 19 20 11 8 58 
(32.8%) (34.5%) (19.0%) (13.8%) (100%) 
Severe 8 7 17 16 48 
(16.7%) (14.6%) (35.4%) (33.3%) (100%) 
* Total number of valid cases = 131 
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Figure 3.3 Severity of symptoms in relation to number of concomitant drugs 
3.2.4 Patient attribution of symptoms to drugs 
Approximately half of the symptoms reported by patients were classified by the 
researcher as being possibly caused by study drugs (n = 861), with a further 197 
probably caused by study drugs. Three hundred and ninety three were classed as 
unlikely to be an ADR, and 163 were unattributable (Figure 3.4). The basis of the 
causal relationship was the classification of each reported symptom using eight 
criteria, the results of which are shown in Table 3.14. The classification was used to 
assess the accuracy of patient attribution of the side effects they reported (Table 
3.15). Respondents were significantly more likely to report symptoms potentially 
caused by the study drug (probable/ possible) than those not likely to be caused by 
the study drug (unlikely/ unattributable) for each drug (X2 = 121.1, df = 4, P <0.001). 
unlikely 
24.3% 
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unattributable 
10.1% 
Figure 3.4 Classification of causal relationship of reported symptoms into four criteria 
Table 3.14 Classification of reported symptoms classified into eight criteria for 
assessment of causal relationship 
Total frequency of 
Causal relationship Criteria reported symptoms 
No. % 
Probable ADRs 1 197 12.2 
Possible ADRs 2 245 15.2 
3 198 12.3 
4 418 25.9 
Subtotal 861 53.4 
Unlikely ADRs 5 102 6.3 
6 181 11 .2 
7 110 6.8 
subtotal 393 24.3 
Unattributable ADRs 8 163 10.1 
Total 1614 100 
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Table 3.15 Patient attribution accuracy of symptoms as side effects of drugs 
Drug Frequency of yes Frequency of no Total 
criteria*(%) criteria **(%) 
Carbamazepine 253 (89.4%) 30 (10.6%) 283 
Sodium valproate 166 (61.7%) 103 (38.3%) 269 
Trazodone 255 (56.4%) 197 (43.6%) 452 
Doxepin 227 (73.2%) 83 (26.8%) 310 
Co-proxamol 157 (52.3%) 143 (47.7%) 300 
Total 1058 (65.6%) 556 (34.4%) 1614 
* yes criteria = reported symptoms potentially caused by study drugs 
(possible! probable) 
** no criteria = reported symptoms not likely to be caused by study drugs 
(unlikely! unattributable) 
As the number of reported symptoms increased, there was an increase in the 
proportion of patients reporting symptoms less likely to be caused by drugs and which 
were either classified as unlikely to be an ADR or unattributable (Table 3.16). 
Table 3.16 Number of reported symptoms in relation to number of patients reporting 
at least one symptom classified as unlikely ADRs and unattributable 
Number of N No. of patients No. of patients 
reported reporting ~1 reporting ~1 
symptoms unlikely ADR (%) unattributable 
symptoms (%) 
~5 110 26 (23.6%) 17 (15.5%) 
6-10 35 23 (65.7%) 15 (42.9%) 
11-15 33 26 (78.8%) 23 (67.9%) 
>15 29 29 (100%) 27 (93.1%) 
3.3 Discussion 
3.3.1 Pre-pilot study 
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After asking patients' views on the two types of questionnaires and their ability to 
complete them, it was found that all eleven patients found them not difficult to fill in 
and neither caused any concern. Only one of the patients commented that the 
questionnaires were quite long. Nine felt that the list of symptoms was easier to 
complete than the open-ended questions. Also, patients gave more symptoms which 
they considered to be caused by their drugs using the closed questionnaire than the 
open-ended questionnaire. This finding is consistent with the work of Fisher et al. 
(1987c), Wallin and Sjovall (1981), Downing et al. (1970) and Ciccolunghi and 
Chaudrui (1975). They suggested that a checklist of symptoms could increase the 
reporting of symptoms which patients otherwise failed to recognise and the use of 
checklists appeared to detect a higher frequency of ADRs than spontaneous reporting. 
Rosenthal et al. (1996) also found that a standard questionnaire resulted in a higher 
prevalence of adverse effects than spontaneous reporting. 
Furthermore, two patients did not finish completing the open questions. Therefore, the 
questionnaire containing the list of symptoms was selected for further development in 
this study. Rickels and Downing (1970) confirmed that specific questioning using 
checklists did not increase the number of drug-related symptoms through suggestion, 
although Borghi et al. (1984) found that a checklist seemed to suggest mild signs and 
symptoms to patients. However, the present study used a comprehensive list of 
symptoms for each body system to ask patients about all potential ADRs, not just 
those known to be related to the specific drugs in order to lessen the chance of bias 
and false positive responses. 
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Although open questions appeared to be more reliable for unexpected ADRs and to 
detect more serious ADRs than closed ones (Barber and Santanello, 1995; Wallin and 
Sjovall, 1981), the pilot study aimed to detect ADRs to well established drugs which 
have been available for a long period of time. It was considered unlikely that 
unexpected or rare ADRs would be detected within the small number of patients in the 
pilot study. Also, the main study for which the questionnaire was developed aimed to 
identify ADRs to black triangle drugs for which reports are requested of any ADRs 
related to the drugs, even known and minor ADRs. It was therefore considered likely 
that the checklist would help patients to report any symptoms which they had 
experienced. 
Seven patients in the pre-pilot study were unable to remember the start date (month! 
year) of all drugs taken exactly. Therefore some amendments were made to only ask 
about the start date of the study drug because this was considered important 
information which was required. As patients might have difficulty in recalling all of the 
start dates of the concomitant drugs taken, the modified questionnaire asked instead 
about the time relationship of the concomitant drugs with the study drug. The question 
thus asked whether the other drugs were started before or after the study drug and 
whether they had already stopped taking them or not. These questions were also 
emphasised by a sentence explaining that it was important for the researchers to 
know, therefore patients were requested to try to remember and fill in these questions. 
This question was also changed from the original which asked respondents to list all 
other drugs taken during the past month, to ask about drugs taken since starting the 
study drug. More details about the purpose of the questionnaire and repeated 
assurance that their medicine did not cause all the effects listed in the questionnaire 
were added in Part 2. Unlike the open-ended questionnaire, the checklist did not ask 
about the severity of symptoms in each body system, since this made it too long to fill 
Chapter 3: Pilot study 93 
in. Instead, a question was asked about the severity of the most bothersome 
symptoms only. In each question in Part 2, the word 'complaints' was changed to the 
more specific 'side effects' in order to emphasise that patients should not tick other 
symptoms not caused by the study drug. Options for responses to the question 
concerning whether patients had told their doctors about their symptoms was modified 
from yes! no to all! some! none in order to be applicable to all reported symptoms. 
Questions concerning symptoms appearing after stopping the study drug were also 
moved to become Part 3 and patients were asked to complete this part only if they had 
stopped taking the drug. This would reduce the time taken to complete the 
questionnaire for those who were still taking the drug. 
3.3.2 Pilot study 
Patients aged less than 16 were excluded from the present study as they were 
considered too young to complete the questionnaire and judge which symptoms may 
have been caused by study drug. Patients who lived in nursing homes were also 
excluded because they were presumed to be too ill to complete the questionnaire. The 
overall response rate of the pilot study was 44.6%. This appeared to be rather low 
despite sending a reminder to nonrespondents. However, a similar response rate 
(47.8%) was found by Ciccolunghi and Chaudri (1975) who studied patient-self 
reporting of symptoms via two types of questionnaire, open and closed questions. 
Bryant et al. (1990) found that the percentage of acceptance for the full sample of 
volunteers into a patient self-monitoring study was related to the amount of 
compensation given. Furthermore, a study to investigate effects of incentives on 
recruitment and response rate in community-based pharmacy practice research by 
Kennedy et al. (1999) found that Significantly more customers who were provided free 
medicines from the participating pharmacies returned their questionnaires, compared 
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with those who were not provided with free medicines. It is possible, therefore, that 
compensation could have increased the response rate from patients in the present 
study. In relation to the types of drugs, the response rates from patients prescribed 
anticonvulsants (carbamazepine and sodium valproate) (51.9%) were slightly higher 
than from those taking antidepressants (trazodone and doxepin) (42.3%). This may be 
explained by patients with psychological problems being reluctant to complete the 
questionnaire. Another possible reason is that respondents taking antidepressants 
(majority were in the age group 60-79) were likely to be older than those taking 
anticonvulsants (majority were in the age group 20-39). However, when considering 
the overall response rate, patients aged 60-79 provided the highest response rate 
(35.3%). This may be because the respondents in this age group were less likely to be 
working and so have more time to complete the questionnaires. The present study 
found no relationship between increasing age and number of concomitant drugs. This 
finding is comparable to a study to monitor medication problems in the elderly by 
pongwecharak (1998). On the contrary, Stewart et al. (1991) and Simons et al. (1992) 
found that older age was associated with the use of more prescribed medicines. 
There was no statistical difference between the proportion of male and female 
respondents between study drugs. As a whole, two third of the respondents were 
female. This is in accordance with a study of patient self-monitoring by Fisher et 
al.(1993) in which approximately 75% of volunteer patients were female. On 
considering each drug separately, carbamazepine seemed to have a little higher 
proportion of male respondents (48%) than other drugs but there was no significant 
difference. 
Half of the respondents were taking one to three concomitant drugs and around one 
quarter of them were taking four to six other drugs. The number of concomitant drugs 
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taken did not differ significantly between the study drugs, however slightly more 
respondents on carbamazepine (61%) took one to three concomitant drugs than was 
the case for other respondents. 
Most patients were taking sodium valproate and carbamazepine for epilepsy, although 
a limited number of patients were taking carbamazepine for manic depression and 
trigeminal neuralgia. Also, most patients took co-proxamol for musculo-skeletal 
diseases. As would be expected, the majority of patients took antidepressants for 
depression (59, 63%) with a further 27 (29%) taking them for sleep difficulty and 
anxiety. This is consistent with a study by Fisher et al. (1993) in which it was found 
that 62% and 17% of patients had taken trazodone for depression and sleep difficulty, 
respectively. However, the present study had a higher proportion of patients taking 
trazodone for sleepless and anxiety (27%) than the study by Fisher et al. (1993) which 
may be due to differences in diagnosis or drug use between the USA and UK. 
Males reported significantly more symptoms than females despite there being fewer 
male respondents. The present study did not find any positive relationship between 
increasing age and number of reported symptoms. This is in agreement with a study of 
the elderly over 65 using a questionnaire to report symptoms (Chrischilles et al., 
1992), which found that increasing age appeared to be associated with a decreased 
tendency to report symptoms. It may be that the elderly under-report symptoms 
because of their perception that those symptoms were from the ageing process rather 
than being drug-related, although they may be more likely to experience ADRs than 
younger patients. However, a study which retrieved data from MEDLlNE followed by 
selective reviews of all pertinent articles, indicated there was no relation between 
advancing patient age and the risk of adverse drug reactions (Gurwitz and Avorn, 
1991). This is another possible reason for increasing age not being related to the 
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number of reported symptoms in this study. Alternatively, it could be due to alteration 
of ADR detection and reporting capacities of the elderly. In contrast, Bryant et al. 
(1991, 1992) found that those aged 50 or over were possibly better at discriminating 
probable ADRs from other types of adverse events than were younger patients. There 
was also no relationship between number of reported symptoms and number of 
concomitant drugs. This is in line with studies by Hallas et al. (1991), Pongwecharak 
(1998) and Fisher et al. (1993) which found no association between the number of 
prescribed drugs and the incidence of medication-related problems including ADRs. 
The majority of respondents (over 50%) reported between one and five symptoms. 
However some reported very high numbers, up to 51. It is reasonable to assume that 
such respondents did experience a wide range of symptoms, however the possibility is 
high that many of these would be related to concomitant drugs or diseases, rather 
than to the study drug. Respondents taking trazodone reported the greatest number of 
different symptoms (87) and also the highest median per patient (10). A total of 79 
different symptoms were reported to both sodium valproate and doxepin, despite there 
being more than twice as many doxepin-treated respondents than those receiving 
sodium valproate. A high median number of symptoms per patient was also found with 
sodium valproate (9). Carbamazepine on the other hand had the lowest number of 
different symptoms (73) and a much lower median per patient (4.5) than sodium 
valproate. This may suggest that carbamazepine is better tolerated than sodium 
valproate and doxepin better tolerated than trazodone. While respondents taking co-
proxamol reported the lowest median number of symptoms (3), the highest number 
were also reported by a patient taking co-proxamol (51). 
Some of the top ten symptoms reported may have been associated with patients' 
illness rather than the drugs taken, for example, anxiety and difficulty concentrating for 
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trazodone, unusual tiredness! weakness and decrease in sexual desire for doxepin, 
loss of memory for carbamazepine and sodium valproate. However, no patients taking 
the antidepressants who cited anxiety as a symptom also gave it as the indication. It is 
possible that some patients tended to report symptoms which were due to their illness 
as these symptoms were likely to interfere their lifestyle or be particularly bothersome, 
which led patients to report these symptoms in high percentages. Also, patients may 
have found it was difficult to judge whether these symptoms were caused by their 
illness or the study drug. 
The ten symptoms most frequently reported by patients for each drug were as 
expected except indigestion for doxepin, anxiety for trazodone, and itchy or irritated 
eyes and change in finger nails for co-proxamol. These symptoms could have been 
caused by patients' disease states or be ADRs of concomitant drugs. For doxepin, of 
the total 11 symptoms reported as indigestion, five (45%) were attributable to only 
concomitant drugs, two (18%) were attributable to only patients' illness and four (36%) 
were attributable to both illness and concomitant drugs. For trazodone, of the total 19 
symptoms reported as anxiety, seven (37%) were attributable to only patients' illness 
and 11 (58%) were attributable to both illness and concomitant drugs taken. For co-
proxamol, of the total ten symptoms reported as itchy or irritated eyes, four (40%) 
were attributable to only concomitant drugs taken, two (20%) were attributable to only 
patients' illness and four (40%) were unattributable, while all nine of the symptoms 
reported as change in finger nails were unattributable. 
Many of the symptoms cited as being most bothersome by respondents were also 
among those most frequently reported. This was particularly evident in the case of 
carbamazepine, for which five of the ten most frequently reported symptoms were also 
stated to be most bothersome, particularly drowsiness and memory loss. Three of the 
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four most often cited bothersome symptoms for sodium valproate were also among 
the top four most frequently reported, including unusual tiredness! weakness. Weight 
gain with sodium valproate was the most frequently cited bothersome symptom, by 
four (16%) respondents, which suggests that most patients who do gain weight are 
concerned by it. Three of the top ten symptoms for trazodone were among those 
stated to be most bothersome, with unusual tiredness being cited most frequently. 
However this was the only one of the top ten symptoms reported with doxepin which 
was regarded as bothersome. Dry mouth and itchy skin were the only two symptoms 
reported frequently to co-proxamol which were cited as bothersome. Unusual 
tiredness! weakness and drowsiness were therefore both reported frequently and were 
considered bothersome by many respondents taking anticonvulsants and 
antidepressants. While these could be symptoms of the disease states present in the 
patients, rather than adverse effects, they are nonetheless likely to interfere with 
lifestyle and it is perhaps not surprising that they were cited frequently. 
Data from Drugdex Drug Evaluation Monographs (1998), ABPI Compendium of 
Datasheets and Summaries of Product Characteristics (The Association of the British 
Pharmaceutical Industry, 1998) and Handbook of Clinical Drug Data (Knoben and 
Anderson, 1994) showed that vertigo, ataxia, drowsiness, unsteadiness on feet and 
dizziness are relatively common side effects of carbamazepine which were also found 
in the ten most frequently reported symptoms of this study. However, the commonest 
side effects of sodium valproate are nausea, diarrhoea, abdominal cramp and 
indigestion of which only indigestion appeared in the top ten, most likely because 
these symptoms often occur during the initiation of therapy. This study asked patients 
to report any symptoms experienced during the previous 12 months at the time that 
they received the questionnaire, so those gastrointestinal symptoms may have already 
disappeared by the time of the study. For trazodone, the common side effects include 
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drowsiness, fatigue, dizziness, hypotension, nausea and vomiting. Most of these were 
also found to be the top ten symptoms reported in the present study, except nausea, 
vomiting and dizziness. Again nausea and vomiting tend to disappear on continued 
treatment. Dizziness was presumably difficult to differentiate from light-headedness 
and unsteadiness on feet which were also two of the top ten symptoms reported in this 
study. For doxepin, drowsiness, anticholinergic side effects, especially dry mouth and 
constipation, and hypotension are relatively common side effects. All were included in 
the top ten symptoms reported. For co-proxamol, the common side effects were 
dizziness, sedation and nausea and vomiting, but only dizziness was one of the ten 
most frequently reported symptoms in this study. Again it is possible that tolerance 
had developed to nausea, vomiting and sedation or that these symptoms already 
disappeared at the time of the study. Constipation was the commonest symptom 
reported in this study. This may be because tolerance does not develop to 
constipation and there are probably actually a large of number of patients taking co-
proxamol in the community who suffer from this symptom. Therefore, despite it being a 
minor symptom, it was consequently reported frequently in the questionnaires. 
For trazodone, the five most frequently reported symptoms including dry mouth, 
anxiety, drowsiness, light-headedness and unsteadiness on feet were the same as a 
previous study by patient self-monitoring using telephone interviews (Fisher et al., 
1993), although the frequency found in the present study was higher. Using 
questionnaires to identify possible ADRs as opposed to telephone interviews after 
spontaneous patient-reporting may pick up more potential ADRs. 
Respondents were asked to rate the severity of their most bothersome symptoms into 
one of six categories. The results showed that subjective severity ratings for these 
symptoms tended to be more than merely minimal or mild, which is compatible with 
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the study by Fisher et al. (1993). The most frequent severity reported was moderately 
(28%) followed by severely (16%), while minimal severity was cited least often (3%). A 
number of patients did not report any side effects at all and they ticked all lists of side 
effects in each body system as none. Also some who did report symptoms may not 
have felt the symptoms bothered them and either did not provide a severity rating or 
selected 'does not apply'. There thus appeared to be a clear division between those 
who reported no or minimal symptoms and those who identified many symptoms, at 
least some of which they regarded as bothersome to a moderate or severe degree. 
This is supported by the strong association found between severity rating and number 
of symptoms reported. 
This shows that patients were much more likely to report in questionnaires adverse 
effects that were particularly more subjectively severe and bothersome to them which 
is in agreement with studies by Fisher et al., (1995) and Fisher (1995). However the 
lack of a statistically significant relationship between severity and informing their doctor 
is surprising, this may be due to small numbers, since in fact 84% of patients rating 
symptoms as severe did report these to their doctor. Conversely there were similar 
numbers of patients reporting mild symptoms to their doctor as did not do so. There 
was however a strong tendency for patients identifying more than five symptoms to 
report these to their doctor. A few patients, despite claiming to experience symptoms 
which were severe or moderately severe, clearly did not view them as being 
sufficiently important to inform the doctor about them. Perhaps this is due to the 
opportunity presented by the questionnaire in contrast to the need to be pro-active in 
informing a doctor. 
The failure of many patients to report all symptoms to their GP could have contributed 
to most of these not being recorded in medical notes. When the symptoms reported by 
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patient questionnaire were compared with those recorded in the medical notes of the 
same patient, it was revealed that the frequency with which symptoms reported by 
patients were recorded in the medical notes was extremely low. Overall only 22% of 
total symptoms reported were recorded, even for symptoms well known to be caused 
by drugs which patients were prescribed. This finding supports the under-reporting of 
ADRs by doctors to the CSM. Further explanations for infrequent records in the 
medical notes could include doctors not being concerned about any minor and well-
established side effects reported by patients or having limited time to record those 
reported symptoms. In many cases the symptoms may not have been related to the 
study drugs, instead being caused by patients' disease states or concomitant drugs. 
The doctors may also feel unsure about attributing reported symptoms definitely to a 
particular drug. There have been several studies investigating the reasons for under-
reporting of ADRs to authorities (Inman and Weber, 1986; Belton et al., 1995; 
Bateman et al., 1992; Inman and Pearce 1993; Randhawa et al., 1987; Smith et al., 
1996; Scott et al., 1987; Rosenbaum et al., 1990; Rogers et al., 1988; Generali et al., 
1995). Those reasons included uncertainty about whether the drug caused the 
reaction, lack of time, lethargy resulting in unwillingness to notify the ADRs, guilt 
because of unintentional harm caused to patients, complacency about the safety of 
approved drugs, poor knowledge and attitudes, well-known reactions to established 
drugs and unawareness of ADRs. Thus similar reasons could explain lack of recording 
as well. 
The causal relationships produced by classifying the reported symptoms into eight 
criteria showed that by far the greatest proportion (26%) fell into category 4, which 
stated that the symptom could be caused by the study drug, concomitant drugs and 
diseases. A further 27% of symptoms could have been caused by the study drug and 
either concomitant drugs (category 2) or diseases (category 3). Therefore for over half 
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the symptoms reported the possibility existed that the study drug could have been the 
cause, but there was no way of ascertaining this any more clearly. Symptoms falling 
into these three categories were grouped together as possibly being caused by the 
study drug. This illustrates the difficulties associated with patients' self-reporting, since 
it becomes impossible to attribute symptoms to particular drugs without details of time 
relationships. However there are similar difficulties in attribution in any situation, as 
evidenced by this being cited as a reason for under-reporting to regulatory authorities 
(Bateman et al., 1992; Randhawa et al., 1987; Scott et al., 1987; Generali et al., 
1995). 
In 12% of reported symptoms which were known to have been previously reported to 
the study drugs, there were no other obvious causes among concomitant drugs or 
diseases (category 1), therefore these were classed as probable ADRs. Combining 
both possible and probable ADRs gave a total of 65% of reported symptoms which 
could have been due to the study drugs. This suggests that patients were reporting 
with a useful degree of accuracy. Indeed for all five drugs in this pilot study, patients 
were more likely to report probable or possible ADRs than other symptoms which were 
unlikely to be ADRs (categories 5,6 and 7) or were unknown to be associated with any 
drugs being taken or disease states (category 8). This degree of attribution by patients 
is similar to that found by Fisher et al. (1994). These workers also found that 
discrimination was better when patients reported adverse events spontaneously rather 
than through systematic enquiry by interview. A further study using an interview to 
determine patients' ability to accurately discriminate possible ADRs from other 
symptoms also found similar attribution rates (almost 70%) (Solovitz et al. 1987). The 
comparable degree of attribution found in the present study using a systematic 
questionnaire could therefore be considered to be better than may have been 
expected. 
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A surprisingly high number of symptoms reported (10%) could not be attributed to any 
of the patients' drugs or disease states. This does suggest that patients may have 
over-reported, as was found from the results of the study by Borghi et al. (1984). 
There is also a strong possibility of bias arising from the likely higher probability of 
those who returned questionnaires having symptoms to report. The over-reporting 
may have been by only a proportion of respondents, as those reporting more 
symptoms were more likely to report symptoms not known to be caused by the study 
drugs. This suggests that patients who reported more symptoms seemed to be worse 
discriminators than those who reported less symptoms. 
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Chapter 4 
Results and Discussion: 
Main study 
General practices in Grampian were approached to ask for their co-operation with this 
study. Eighty one percent of the total of 97 medical practices agreed to allow their 
patients to be included in the study. A total of 2307 postal questionnaires with pre-paid 
envelopes were distributed to patients who were prescribed one of nine black triangle 
drugs during January - March 1997. 
4.1 Results 
4.1.1 Response rates and demographic data 
There was a total of 924 questionnaires returned which accounted for an overall 
response rate of 40.1 %. However, the number of respondents who returned valid 
questionnaires was 837, 36.3% of the total questionnaires sent to patients. Table 4.1 
lists the number of questionnaires sent to patients and response rates for each study 
drug. The highest response rates (59.1 %) were found in patients taking gabapentin, 
topiramate (56.5%) and lamotrigine (45.0%) although the numbers were small. The 
greatest number of questionnaires were issued and returned from patients prescribed 
tramadol and venlafaxine, since these drugs were prescribed most frequently. Of the 
total respondents, 33.2% were male, 66.2% were female, 0.6% did not specify. The 
greatest proportion of females were found in those prescribed antidepressants (n = 
269,69.7%), followed by those prescribed analgesics (n = 232, 65.9%) and those 
prescribed anticonvulsants (n = 53, 53.5%). The mean ± SD age of the respondents 
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was 50.5 ± 17.2 years, with the majority of respondents falling into the 40-59 (38.0%) 
and 20-39 (28.2%) age groups. Characteristics of the respondents are presented in 
Table 4.2. The males had a median age of 49.0 years and the females 48.0 years with 
no significant difference between males and females (Mann-Whitney U = 74261.5, P = 
0.800). 
Of the total respondents, 50.2% and 25.7% were prescribed 1-3 and 4-6 concomitant 
drugs, respectively. The mean ± SD of number of concomitant drugs was 3.0 ± 2.2. 
The number of respondents taking concomitant drugs is shown in Table 4.3. Females 
were taking significantly more concomitant drugs (median 3.0, range 0-16) than males 
(median 2.0, range 0-16); (Mann-Whitney U = 53583.5, P = 0.008), however the 
relationship between increasing age and number of concomitant drugs was not strong 
(Spearman r = 0.307, P < 0.001). 
Table 4.1 Number of respondents and response rates 
Drug No. of No. of valid Response rate 
questionnaires sent respondents (%) 
Citalopram 132 43 32.6 
Fentanyl patch 64 8 12.5 
Gabapentin 115 68 59.1 
Lamotrigine 40 18 45.0 
Moclobemide 48 16 33.3 
Nefazodone 204 64 31.4 
Topiramate 23 13 56.5 
Tramadol 1048 344 32.8 
Venlafaxine 633 263 41.5 
Total 2307 837 36.3 
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Table 4.2 Number of respondents according to sex and age groups 
Number of % 
respondents 
Sex 
Male 278 33.2 
Female 554 66.2 
not specified 5 0.6 
Age group 
< 20 9 1.1 
20-39 236 28.2 
40-59 318 38.0 
60-79 212 25.3 
~80 47 5.6 
not specified 15 1.8 
Total 837 100 
Table 4.3 Number of respondents according to number of concomitant drugs 
Number of Number of % 
concomitant drugs respondents 
0 53 6.3 
1-3 420 50.2 
4-6 215 25.7 
7-9 48 5.7 
~10 8 1.0 
not specified 93 11.1 
Total 837 100 
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4.1.2 Symptoms reported 
Of the total 837 respondents, 742 (88.6%) reported at least one symptom. The total 
number of symptoms reported was 7016 and the median per patient was 6.0 (range 0-
71). Patients prescribed tramadol and venlafaxine reported more different symptoms 
and a higher number of symptoms than those prescribed other drugs, while those 
prescribed fentanyl patch had the greatest median of number of symptoms reported, 
followed by nefazodone, venlafaxine and moclobemide, respectively (Table 4.4). The 
number of reported symptoms were grouped into five categories (:~5, 6-10,11-15,16-
20 and ~20). Both males and females reported less than six symptoms with the 
highest frequency. The number of symptoms reported showed no relationship to sex 
(X2 = 2.722, df = 4, P = 0.605), age (Spearman r = -0.089, P = 0.2152 for grouped 
data) or the number of concomitant drugs being taken (Spearman r = 0.026, P = 0.414 
for grouped data) (Table 4.5, Table 4.6 and Table 4.7). The greatest proportion of 
respondents had been taking one of the drugs under study for between 181 to 360 
days as shown in Table 4.8. Duration of therapy did not appear to influence the 
number of reported symptoms (X2 = 20.583, df = 16, P = 0.195). 
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Table 4.4 Total number and frequency of symptoms reported for each drug 
Drug (n) No. of different Total number of symptoms 
symptoms reported reported ( median, range) 
Citalopram (43) 78 358 (5.0,0-37) 
Fentanyl patch (8) 47 94 (12.5, 2-24) 
Gabapentin (68) 77 575 (5.5,0-37) 
Lamotrigine (18) 46 117 (5.0, 0-17) 
Moclobemide (16) 52 103 (6.5,0-16) 
Nefazodone (64) 85 677 (8.5,0-39) 
Topiramate (13) 41 59 (3.0,0-12) 
Tramadol (344) 92 2333 (4.5,0-51 ) 
Venlafaxine (263) 97 2700 (7.0, 0-71) 
Table 4.5 Number of reported symptoms compared to sex of respondents 
Sex Number of patients (%) 
Number of reported symptoms Total 
::;5 6-10 11-15 16-20 >20 
Male 133 64 35 24 22 278 
(47.8%) (23.0%) (12.6%) (8.6%) (7.9%) (100%) 
Female 273 105 75 45 56 554 
(49.3%) (19.0%) (13.5%) (8.1%) (10.1%) (100%) 
Not 2 2 - - 1 5 
specified (40.0%) (40.0%) (20.0%) (100%) 
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Table 4.6 Number of reported symptoms compared to age group 
Age Number of patients (%) 
group 
Number of reported symptoms Total* 
~5 6-10 11-15 16-20 >20 
~25 26 10 6 6 6 54 
(48.1%) (18.5%) (11.1%) (11.1%) (11.1%) (100%) 
26-50 178 84 57 36 38 393 
(45.3%) (21.4%) (14.5%) (9.2%) (9.7%) (100%) 
51-75 143 62 40 22 27 294 
(48.6%) (21.1%) (13.6%) (7.5%) (9.2%) (100%) 
-c.75 55 10 6 4 6 81 
(67.9%) (12.3%) (7.4%) (4.9%) (7.4%) (100%) 
* Total number of valid cases = 822 
Table 4.7 Number of reported symptoms compared to number of concomitant drugs 
Number of Number of patients (%) 
concomitant 
drugs Number of reported symptoms Total* 
~5 6-10 11-15 16-20 >20 
0-2 174 84 50 24 32 364 
(47.8%) (23.1%) (13.7%) (6.6%) (8.8%) (100%) 
2-4 92 40 31 18 18 199 
(46.2%) (20.1%) (15.6%) (9.0%) (9.0%) (100%) 
4-6 67 18 15 12 13 125 
(53.6%) (14.4%) (12.0%) (9.6%) (10.4%) (100%) 
>6 26 9 5 7 9 56 
(46.4%) (16.1%) (8.9%) (12.5%) (16.1%) (100%) 
* Total number of valid cases = 744 
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Table 4.8 Number of reported symptoms compared to duration of therapy 
Duration Number of patients (%) 
of therapy 
(days) Number of reported symptoms Total· 
~5 6-10 11-15 16-20 >20 
1-180 81 24 21 8 9 143 
(56.6%) (16.8%) (14.7%) (5.6%) (6.3%) (100%) 
181-360 106 51 28 17 14 216 
(49.1%) (23.6%) (13.0%) (7.9%) (6.5%) (100%) 
361-540 61 38 25 13 20 157 
(38.9%) (24.2%) (15.9%) (8.3%) (12.7%) (100%) 
541-720 41 16 15 6 10 88 
(46.6%) (18.2%) (17.0%) (6.8%) (11.4%) (100%) 
>720 38 19 10 10 13 90 
(42.2%) (21.1%) (11.1%) (11.1%) (14.4%) (100%) 
• Total number of valid cases = 694 
The majority of the respondents had taken the study drugs once a day (57.0%). There 
was no significant relationship between the frequency of dosing and the number of 
reported symptoms (x2 = 5.109, df = 8, P = 0.746) as presented in Table 4.9. Thirty 
nine percent of the respondents were taking other drugs with the same indication as 
the study drug and 48.7% of respondents were taking other CNS drugs. Concomitant 
use of further drugs for the same indication as the study drug did not appear to affect 
the number of reported symptoms (X2 = 2.036, df = 4, P = 0.729) (Table 4.10). 
However, patients taking any other CNS drug were likely to report significantly more 
symptoms than those not taking other eNS drugs as shown in Table 4.11 (X2 = 
20.069, df = 4, P < 0.001). Appendix J lists frequency of each individual reported 
symptom categorised by body systems for each study drug. 
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Table 4.9 Number of reported symptoms compared to frequency of drug use 
Frequency of Number of patients (%) 
taking drugs 
(times/day) Number of reported symptoms Total* 
~5 6-10 11-15 16-20 >20 
1 40 100 57 37 43 477 
(50.3%) (21.0%) (11.9%) (7.8%) (9.0%) (100%) 
2 117 50 37 21 24 249 
(47.0%) (20.1%) (14.9%) (8.4%) (9.6%) (100%) 
~3 16 11 8 2 3 40 
(40.0%) (27.5%) (20.0%) (5.0%) (7.5%) (100%) 
* Total number of valid cases = 766 
Table 4.10 Presence of other drugs with the same indication in relation to number of 
reported symptoms 
Presence of Number of patients (%) 
other drugs 
with the same Number of reported symptoms Total* 
indication ~5 6-10 11·15 16·20 >20 
No 149 68 43 28 38 326 
(45.7%) (20.9%) (13.2%) (8.6%) (11.7%) (100%) 
Yes 183 73 52 30 33 371 
(49.3%) (19.7%) (14.0%) (8.1%) (8.9%) (100%) 
* Total number of valid cases = 697 
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Table 4.11 Presence of other eNS drugs in relation to number of reported 
symptoms 
Presence of Number of patients (%) 
other eNS 
drugs Number of reported symptoms Total* 
~5 6-10 11-15 16-20 >20 
No 208 86 60 28 26 408 
(51.0%) (21.1%) (14.7%) (6.9%) (6.4%) (100%) 
Yes 124 55 35 30 45 289 
(42.9%) (19.0%) (12.1%) (10.4%) (15.6%) (100%) 
* Total number of valid cases = 697 
4.1.3 Severity of symptoms reported 
The majority of respondents rated the severity of their most bothersome symptoms 
reported as moderate (27.6%) and severe (21.5%) (Figure 4.1). Although no 
significant association was found between the total number of concomitant drugs and 
symptom severity (X2 = 12.776, df = 8, P = 0.120), it can be seen from Figure 4.2 that 
all respondents taking ten or more concomitant drugs rated their symptoms as 
moderate or severe, while the majority of those taking between four and nine other 
drugs rated symptoms as severe. 
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Minimally moderately very severely not specified 
mildly severely does not apply 
Severity of symptoms reported 
Figure 4.1 Classification of severity of most bothersome symptoms reported 
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Figure 4.2 Severity of most bothersome symptoms in relation to number of 
concomitant drugs 
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There were no significant associations found in those who gave a rating between the 
severity ratings and duration of therapy (x2 = 1.112, df = 8, P = 0.367) (Table 4.12), 
frequency of dosing (X2 = 8.695, df = 4, P = 0.892) (Table 4.13), presence of other 
drugs with the same indication as the study drug (x2 = 0.232, df = 2, P = 0.891) (Table 
4.14), and presence ofotherCNSdrugs (l = 1.561, df = 2, P = 0.458) (Table 4.15). 
On the contrary, the number of reported symptoms was Significantly associated with 
symptom severity (l = 75.765, df = 8, P < 0.001) (see Figure 4.3). For those 
respondents who completed both questions, patients who rated their most bothersome 
symptoms as severe were more likely to have informed their doctors about these 
symptoms than those rating the severity as mild (x2 = 43.926, df = 2, P < 0.001) (Table 
4.16). 
Table 4.12 Severity of symptoms in relation to duration of therapy 
Severity of Number of patients (%l 
symptoms 
Duration of therapy (days Total* 
1·180 181·360 361·540 541·720 >720 
Mild 15 27 25 8 10 85 
(17.6%) (31.8%) (29.4%) (9.4%) (11.8%) (100%) 
Moderate 31 68 40 30 32 201 
(15.4%) (33.8%) (19.9%) (14.9%) (15.9%) (100%) 
Severe 43 58 52 34 25 212 
(20.3%) (27.4%) (24.5%) (16.0%) (11.8%) (42.6%) 
* Total number of valid cases = 498 
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Table 4.13 Severity of symptoms in relation to frequency of taking study drugs 
Severity of Number of patients (%) 
symptoms 
Frequency of taking drugs times/day) Total* 
1 2 ~3 
Mild 61 (62.2%) 31 (31.6%) 6 (6.1%) 98 (100%) 
Moderate 134 (63.5%) 68 (32.2%) 9 (4.3%) 211 (100%) 
Severe 138 (60.3%) 77 (33.6%) 14(6.1%) 229 (100%) 
* Total number of valid cases = 538 
Table 4.14 Severity of symptoms in relation to whether presence of other drugs 
with the same indication 
Severity of Number of patients (%) 
symptoms Presence of other drugs with 
the same indication Total* 
No Yes 
Mild 35 (46.1%) 41 (53.9%) 76 (100%) 
Moderate 96 (49.2%) 99 (50.8%) 195 (100%) 
Severe 103 (48.8%) 108(51.2%) 211 (100%) 
* Total number of valid cases = 482 
Table 4.15 Severity of symptoms in relation to whether presence of other eNS 
drugs 
Severity of Number of patients (%) 
symptoms Presence of other eNS drugs 
Total* 
No Yes 
Mild 48 (63.2%) 28 (36.8%) 76 (100%) 
Moderate 113 (57.9%) 82 (42.1%) 195 (40.5%) 
Severe 116 (55.0%) 95 (45.0%) 211 (100%) 
* Total number of valid cases = 482 
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Figure 4.3 Severity of most bothersome symptoms in relation to number of 
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Table 4.16 Severity of reported symptoms in relation to whether or not patients 
reported symptoms to their doctors 
Severity of Number of patients (%) 
symptoms 
Whether patients informed their Total* 
doctors of symptoms 
Yes No 
Mild 31 (52.5%) 28 (47.5%) 59 (100%) 
Moderate 151 (76.3%) 47 (23.7%) 198 (100%) 
Severe 186 (87.7%) 26 (12.2%) 212(100%) 
* Total number of va lid cases = 469 
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4.1.4 Patient attribution of symptoms to drugs 
Fifty five percent (n=3848) of the total number of perceived symptoms reported were 
classified by the researcher as being possibly caused by the study drugs, with a 
further 1134 (16%) classed as probably caused by study drugs. Seventeen percent 
(n= 1226) were classed as unlikely to be an ADR and 12% (n=808) were 
unattributable (see Figure 4.4). Table 4.17 shows the results of the classification for 
causal relationship of the perceived symptoms according to the eight criteria used. 
The highest frequency was of those symptoms which could be caused by the study 
drug and concomitant drugs (criteria 2). There were also a large number which could 
have been caused by concurrent disease states in addition to drugs being taken 
(criteria 4). 
unlikely 
17.5% 
unattributable 
11 .5% 
Figure 4.4 Classification of causal relationship of reported symptoms into four 
criteria 
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Table 4.17 Number of total frequency of reported symptoms classified into eight 
criteria according to causal relationship 
Total frequency of 
Causal relationship Criteria reported symptoms 
No. % 
probable ADRs 1 1134 16.2 
possible ADRs 2 1619 23.1 
3 706 10.0 
4 1523 21.7 
Subtotal 3848 54.8 
unlikely ADRs 5 438 6.3 
6 399 5.7 
7 389 5.5 
Subtotal 1226 17.5 
unattributable ADRs 8 808 11.5 
Total 7016 100.0 
Respondents were significantly more likely to report symptoms potentially caused by 
the study drug (probable/ possible) than those not likely to be caused by the study 
drug (unlikely/ unattributable) for each drug (l = 148.632, df = 8, P < 0.001) which is 
presented in Table 4.18. Patients who reported more symptoms were likely to report 
more symptoms not known to be caused by the study drugs and which were either 
classified as unlikely to be an ADR or unattributable (Table 4.19). 
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Table 4.18 Patient attribution accuracy of symptoms as side effects of drugs 
Drug Frequency of Frequency of Total (%) 
yes criteria* (0/0) no criteria **(%) 
citalopram 303 (84.6%) 55 (15.4%) 358 (100%) 
fentanyl patch 68 (72.3%) 26 (27.7%) 94 (100%) 
gabapentin 387 (67.3%) 188 (32.7%) 575 (100%) 
lamotrigine 70 (59.8%) 47 (40.2%) 117 (100%) 
moclobemide 80 (77.7%) 23 (22.3%) 103 (100%) 
nefazodone 408 (60.3%) 269 (39.7%) 677 (100%) 
topiramate 32 (54.2%) 27 (45.8%) 59 (100%) 
tramadol 1567 (67.2%) 766 (32.8%) 2333 (100%) 
venlafaxine 2067 (76.6%) 633 (23.4%) 2700 (100%) 
Total 4982 (71.0%) 2034 (29.0%) 7016 (100%) 
* yes criteria = reported symptoms potentially caused by study drugs 
(probable! possible) 
** no criteria = reported symptoms not likely to be caused by study drugs 
(unlikely! unattributable) 
Table 4.19 Number of reported symptoms in relation to number of patients reporting 
at least one symptom classified as unlikely ADRs and unattributable 
Number of N No. of patients No. of patients reporting 
reported reporting ~1 ~1 unattributable 
symptoms unlikely ADR (%) symptoms (%) 
:5:5 408 79 (19.4%) 107 (26.2%) 
6-10 171 78 (45.6%) 119 (69.6%) 
11-15 110 79 (71.8%) 94 (85.5%) 
>15 148 131 (88.5%) 137 (92.6%) 
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4.2 Discussion 
The overall response rate of the main study (40.1 %) was lower than that from the pilot 
study (44.6%) which may have been due to not sending a reminder to 
nonrespondents. The reason for this was it was felt this may upset patients who had 
serious illness and were not willing to participate in this study. There were 87 invalid 
questionnaires returned, resulting in a final response rate of 36.3%. These invalid 
questionnaires included those which were returned but not completed (n= 10), those 
returned from patients who were unable to complete the questionnaire either because 
of their disease state(s) or illiteracy (n=11), those who had deceased (n=21), those 
who could not remember taking the study drug and those who had not taken the study 
drug (n=24). A higher response rate (51%) was found in a prospective observational 
study based on telephone interviews to identify new health problems associated with a 
NSAID by patient self-reporting (Willison et al., 1995). This study recruited patients by 
direct contact from individuals who went to the participating pharmacies to fill new or 
repeat prescriptions for NSAIDs, while the present study recruited patients by mailing 
a questionnaire. Pharmacist recruitment could therefore be a potential means of 
increasing response rates. 
The majority of the respondents were prescribed tramadol and venlafaxine which 
represented 41 % and 31 % of the total respondents, respectively. The remaining seven 
drugs represented both 27% of questionnaires issued and 27% of respondents. The 
highest response rate was found in patients prescribed topiramate, while the lowest 
was in those prescribed fentanyl patch. Considering the different types of study drugs, 
the average response rates for anticonvulsants (gabapentin, lamotrigine and 
topiramate) (55.6%) were higher than for antidepressants (citalopram, moclobemide, 
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nefazodone and venlafaxine) (38.0%) and analgesics (fentanyl patches and tramadol) 
(31.6%). It is possible that patients prescribed either tramadol or fentanyl patch as a 
pain killer had serious illness, Le. cancer, therefore were unable to respond to the 
questionnaires sent or they had already deceased. This is supported by the finding 
that nine (43%) and seven (33%) out of a total of 21 invalid questionnaires returned 
because patients had deceased, were from those prescribed tramadol and fentanyl 
patch respectively. Additionally, most of the 23 invalid questionnaires returned 
because patients did not remember taking the study drugs or actually did not take 
them, 18 (78%) were from patients prescribed tramadol. This may have contributed to 
lower response rate for tramadol. As was found in the pilot study, patients with 
depression may have been less willing to participate than those with epilepsy. 
Approximately two-thirds of the respondents were female which concords with the pilot 
study, a patient self-monitoring study by Fisher et al. (1993) and a patient self-
reporting study in patients prescribed ophthalmic medications by Barber and 
Santanello (1995). The greater number of female respondents on antidepressants 
(70% of all respondents on antidepressants) was probably related to the higher 
prevalence of depression in females (Lloyd, 1995). The respondents in the main study 
(mean age = 50.5, majority aged 40-59) seemed to be younger than those in the pilot 
study (mean age = 54.5, majority aged 60-79) but older than those in the study by 
Fisher et al. (1993) (mean age = 45.3 for fluoxetine-treated patients). Also, as in the 
pilot study, no significant differences were found between the sexes in the age 
distribution. However the number of concomitant drugs being taken was greater in 
females. About half of the respondents were taking 1-3 concomitant drugs and one 
quarter were taking 4-6 drugs, the same proportions found in the pilot study. In 
addition, the analysis again indicated no relationship between increasing age and 
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number of concomitant drugs. This is in agreement with a study to monitor medication 
problems in the elderly by Pongwecharak (1998). 
A study involving factors influencing the reporting of symptoms by Ciccolunghi and 
Chaudri (1975) revealed that 63 (97%) out of a total of 65 drug-treated subjects 
reported at least one symptom through a 38-item checklist questionnaire. However, 
the present study found a lower proportion (88.6%) of the respondents reported at 
least one symptom. This is most likely to be related to the small numbers involved in 
the study by Ciccolunghu and Chaudri, compared to the present study, which 
consequently had a higher possibility of finding patients who reported no side effects. 
The fact that the questionnaire designed for the present study was generic, listing 
potential side effects related to any drug, not only for the study drug and therefore had 
many more symptoms listed than the 38-item checklist used by Ciccolunghi and 
Chaudri could also have resulted in a lower number of patients reporting at least one 
symptom. This may indicate that increasing the number of symptoms listed in the 
questionnaire appears to diminish over-reporting which could occur through 
suggestion using specific short checklist questionnaires. Furthermore, a patient self-
reporting study to find out new health problems related to NSAIDs using telephone 
interviews found a much lower percentage of patients (19%) reported at least one new 
health problem (Willison et al., 1995), compared with the present study. A study by 
Fisher et al. (1995) also found that only 31.4% and 19.7% of sertraline-treated and 
f1uoxetine-treated patients, respectively, called at least once to report one or more 
adverse events, while a study to determine patient-perceived side effects to 
antihypertensive drugs using a closed questionnaire at each clinic visit found that 
75.4% of patients reported at least one symptom (Curb et al., 1985). These 
differences may indicate that using checklist questionnaires as a tool could result in 
more symptoms reported and probably detects more symptoms related to drugs than 
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the interview methods (Ciccolunghi and Chaudri, 1975). However, the use of 
questionnaires may also lead to respondents reporting a large number of symptoms 
which are unattributable to the study drugs. In the present study, 10.1 % and 11.5% of 
reported symptoms in the pilot and main studies respectively could not be attributed to 
any known cause. As the drugs involved in the main study were relatively new and 
subject to 'black triangle' reporting to the CSM, it is possible that some of these 
symptoms were previously unrecognised ADRs. However the similarity in the 
frequency with which unattributable symptoms were reported between the main study 
and the pilot study suggests it is more likely that the type of questionnaire used may 
have resulted in these high numbers of reports. This is supported by the finding that 
the number of unattributable symptoms increased with the total number of symptoms 
reported. Consequently, patients who reported more symptoms seemed to be worse 
discriminators since they reported more unattributable symptoms. 
Patients prescribed anticonvulsants appeared to report fewer different symptoms than 
those prescribed antidepressants. This may indicate that antidepressants caused 
more different side effects than anticonvulsants. However, it is much more likely that 
this was due to the difference in sample size, since patients taking anticonvulsants 
(n=99) were much lower in number than patients taking antidepressants (n=386). 
Patients prescribed fentanyl patches reported the highest median of different 
symptoms, although they were fewest in number. This is most likely due to biases 
from some patients within such a small group prescribed this drug who reported high 
numbers of symptoms. The lowest number of different symptoms were reported by 
patients taking topiramate (41) and lamotrigine (46), while the highest ranges were 
reported by patients taking tramadol (97) and venlafaxine (92). This again may 
indicate that increasing the number of respondents was likely to increase the number 
of different symptoms reported since those taking tramadol and venlafaxine accounted 
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for 74.3% of the total respondents. Combining the results from both the pilot and main 
studies suggests that the number of different symptoms reported is low with numbers 
of respondents below 25, but that large increases in the number of respondents above 
25 does not result in a large increase in the number of different symptoms reported. 
This supports the use of such questionnaires as a tool for reporting of potential 
adverse effects, since it suggests that the symptoms reported do conform to a pattern, 
rather than being randomly distributed. 
The results suggest that patients receiving the new CNS drugs studied experienced a 
wide range of side effects. While it may be that in fact patients taking these drugs had 
truly experienced those side effects, it may be that patients took a broad view of the 
term 'side effect' used in the questionnaire. For example, some of the symptoms 
reported appeared to be unrelated to the information obtained on either the disease 
states or its treatment. These could be attributed to other medication being taken or 
other conditions not listed on the questionnaires by respondents. Despite the fact that 
the questionnaire included various statements in an attempt to focus patients' thinking 
(namely: 'please be assured this does not mean your medicine can cause all of the 
side effects listed here', 'Only indicate the problems which were not present before 
you started taking study drug name' and 'Have you had any of the following symptoms 
which you think may be due to side effects from this medicine'), the respondents may 
nonetheless have had the impression that they were expected to experience many of 
the effects listed. They may also have experienced an increase in side effects due to 
suggestion from the symptoms listed in the questionnaires, particularly mild signs and 
symptoms. Indeed, many of the unattributable symptoms reported could have been 
due to suggestion as was mentioned by Borghi et al. (1984). However, evidence from 
other contexts suggests that informing patients of potential side effects does not lead 
to an increased incidence of those side effects (Rickels and Downing, 1970; Lamb, 
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1994; Howland et al., 1990). The questionnaire design was an attempt to reduce bias 
caused by suggestion. It listed many potential ADRs applicable to any drug, not just 
the study drugs as previously mentioned in Chapter 2. Also, as these problems were 
anticipated, the classification of causal relationship was established to provide an 
interpretation of how accurately patients attributed the symptoms to the study drugs. 
As found in the pilot study, the main study found no positive relationship between 
increasing age and number of reported symptoms for all study drugs. In fact, some 
studies have found an association between increasing age and incidence of ADRs 
experienced (Walker and Wynne, 1994; 0' Donnell, 1994; Cuningham et al., 1997) 
although others have not found this association (Nelson and Talbert, 1996; Moore et 
aI., 1998). The present study revealed no relationship between increasing age and the 
number of concomitant drugs being taken, therefore if polypharmacy is related to the 
number of experienced ADRs, this may account for the lack of relationship between 
increase in age and number of reported symptoms in this study. Unlike the pilot study, 
the main study found no difference in number of symptoms reported between males 
and females, despite females having been reported to suffer more ADRs than males 
(0' Donnell, 1994; Cunningham et al., 1997). 
The study also showed no relationship between increasing number of concomitant 
drugs and number of reported symptoms. Studies by Hallas et al. (1991), 
Pongwecharak (1998) and Fisher et al. (1993) found no association between the 
number of prescribed drugs and the incidence of medication-related problems which 
included ADRs. Conversely, other studies have reported polypharmacy to be a 
predictor of ADRs among several groups of hospitalised patients including the elderly, 
critical care patients, patients undergoing complicated surgical procedures and 
patients admitted to general medical wards (May, 1997; Moore et al., 1998; 
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Cunning ham et aI., 1997; Classen et aI., 1997; Nelson and Talbert, 1996; Lee, 1993). 
However the present study suggests that increasing the number of concomitant drugs 
does not affect the incidence of ADRs. Possible reasons for this may be that any 
association between concomitant drugs taken and number of ADRs experienced may 
have been masked by patients not reporting all ADRs which they experienced and not 
having the opportunity for discussion with a researcher. This study was undertaken in 
out-patients, while most of the studies in which a relationship was found were carried 
out in in-patient populations. Thus, patients who participated in this study were less 
seriously ill and more likely not to report any ADR which had disappeared before they 
completed the questionnaires. Furthermore, patients may have become accustomed 
to those ADRs whose onset was several months ago and consequently not bothered 
to report them. These latter points may also explain why in the present study patients 
who had been taking the study drugs for longer did not report significantly more 
symptoms than those with a shorter duration of therapy. This finding is different from 
the work of Fisher et al. (1993,1995) which took duration of exposure to the study 
drugs into account statistically as a confounding factor affecting adverse clinical events 
reported. However, another reason for this difference may be that the main study 
involved patients taking only newly marketed drugs which have less widespread use 
and total exposure time than older drugs. This point resulted in the majority of 
respondents having a drug exposure time in this study of less than one and a half 
years (61.6%), so there were too few patients who had a longer exposure time to the 
study drugs to demonstrate whether or not an increase in duration of therapy could 
increase the number of ADRs experienced and reported. In addition, there was no 
evidence from this study of increasing frequency of drug taking leading to an increase 
in the number of symptoms reported. As expected, the vast majority (87%) of patients 
had taken one of the nine study drugs in the recommended dosage regimen with the 
frequency of one or two times a day. Of those patients who had taken study drugs 
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more frequently, the doses were still in the normal ranges recommended. It is 
therefore unlikely that more ADRs would be experienced and reported. The data from 
the present study also suggests that patients who were taking other drugs with the 
same indication as the study drugs had no significant increase in the number of 
reported symptoms, compared with the rest. However, patients taking any other CNS 
drugs reported more symptoms than those not taking other CNS drugs. This could be 
because taking other CNS drugs would increase in number of different side effects 
experienced and lead to an increase in number of symptoms reported, while the same 
side effects would be caused by drugs of the same class. 
Severity of the most bothersome symptoms reported was graded into five levels as 
minimally, mildly, moderately, severely and very severely by 70% of respondents. The 
result showed that patients tended to rate the severity of their most bothersome 
symptoms more than minimally or mildly with the majority selecting moderately and 
severely (49.1 %). This finding is in line with the pilot study and the studies by Fisher et 
al. (1993), Fisher (1995) and Buckingham et al. (1997). As in the pilot study, 15% of 
total respondents rated the severity as 'does not apply'. The severity was regrouped 
into three levels as mild, moderate and severe for statistical analysis. There were no 
statistical differences among these three degrees of severity with regard to duration of 
therapy, frequency of drug taken, whether patients were taking other CNS drugs or 
other drugs for the same indication as the study drugs. Conversely, a greater 
proportion of patients who rated the most bothersome symptoms as severe were 
found to inform their doctors about these symptoms than those who rated the severity 
as mild. This suggests that patients with more severe symptoms were concerned 
about these symptoms, which led them to report them to their doctors. In the pilot 
study there was a trend towards a similar relationship between the severity of 
symptoms and whether patients reported the symptoms to their doctors. It is possible 
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that patients taking the newer drugs in the main study may have been more concerned 
about any effect they perceived to be related to these drugs than those who were 
taking the older drugs in the pilot study. Nevertheless, Fisher (1995) found many more 
patients taking an older drug (trazodone) reporting well known ADRs, when compared 
with a newer drug (f1uoxetine). The relationship between severity of symptoms 
reported and number of drugs being taken concomitantly was not statistically 
significant, although there were higher percentages of patients who reported the most 
bothersome symptoms as severe who were taking four or more other drugs, compared 
with those who reported the symptoms as moderate and mild. Mannesse et al. (1997) 
also found the use of three of more drugs was a significant factor in patients with 
severe adverse reactions. The results showed a significant relationship between the 
severity of symptoms reported and number of reported symptoms. This suggests that 
patients were much more likely to report symptoms in the questionnaires that were 
particularly subjectively severe and bothersome to them which is similar to the findings 
of the pilot study and studies by Fisher et al. (1995) and Fisher (1995). 
With regard to the accuracy of patients' attribution of symptoms to study drugs, the 
majority of symptoms were classified as possibly (54.3%) or probably (16.2%) caused 
by the study drugs. Therefore, a large number of symptoms reported could also be 
attributed to concomitant drugs or patients' disease states (possible ADRs), while only 
16.2% of symptoms reported could be attributed to only the study drugs (probable 
ADR). One of the limitations of any patient self-reporting is that data are mainly 
obtained from patient perceptions and recollections, although in this study further data 
were also obtained from the medical records in some cases. Nonetheless, it is difficult 
for patients and even health professionals to judge which symptoms were caused by 
drugs with certainty. This view is broadly in agreement with other studies in that one of 
the main reasons for doctors not reporting an ADR was uncertainty about whether the 
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reaction was caused by the suspected drug (Scott et al., 1987; Bateman et al., 1992; 
Inman and Weber, 1986; Randhawa et al., 1987). Although there have been many 
attempts to reduce the uncertainty by creating various criteria to assess the causality 
of ADRs (Karch and Lasagna, 1977; Kramer et aI., 1979; Naranjo et aI., 1981; 
Venulet, 1986a), such methods are still unable to conclude that the suspected drugs 
truly caused the reactions or eliminate the uncertainty. They only categorise ADRs into 
levels of probability. The need to develop a new classification system, based on 
different criteria, arose because of the lack of additional data available to enable any 
of these standard criteria to be used. It must also be emphasised that in most cases, 
information on concurrent drugs and disease states was only obtained from patients, 
and therefore may be incomplete or unreliable. However, using this classification in 
this large cohort of patients, as with the pilot study, it was found that patients appeared 
to be capable of correctly identifying possible ADRs caused by the study drugs, 
accounting for 71.0% of reported symptoms. This again is in line with the estimate of 
Fisher et al. {1994}. 
The results showed a relationship between increasing number of reported symptoms 
and the proportion of patients reporting symptoms not known to be caused by the 
study drugs. This finding is in agreement with the pilot study and again suggests that 
patients who reported more symptoms seemed to be representative of worse 
discriminators since they tended to report more symptoms classed as either unlikely 
ADRs or unattributable. This could also have led to bias due to over-reporting by those 
patients. 
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Chapter 5 
Results and Discussion: 
Main study: Tramadol 
5.1 Results 
5.1.1 Response rate and demographic data 
There was a total of 1048 postal questionnaires sent to patients prescribed tramadol. 
Of these, 344 patients valid responses were obtained, representing a response rate of 
32.8%. Of the total respondents, 115 (33.4%) were male and 227 (66.0%) were 
female, two (0.6%) did not specify. The mean ± SD age of the respondents was 57.4 ± 
17.0 of which the majority were in age groups were 60-79 (38.9%) and 40-59 (33.4%). 
Table 5.1 lists number of respondents in different age groups. 
Table 5.1 Number of respondents prescribed tramadol according to age groups 
Age group Number of % 
respondents 
< 20 1 0.3 
20-39 58 16.9 
40-59 115 33.4 
60-79 134 38.9 
~80 31 9.0 
not specified 5 1.5 
Total 344 100 
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5.1.2 Drug therapy 
Table 5.2 shows concomitant drugs being taken by number of respondents. The 
majority of the respondents (81 %) were taking between one and six concomitant 
drugs. The mean ± SO number of concomitant drugs was 3.7 ± 2.3 (range 0-16). 
There was no strong relationship between increasing age and number of concomitant 
drugs (Spearman r = 0.19743, P < 0.001). The average duration of taking tramadol 
was 324.8 days (SO = ± 348.1) with approximately one-third of the respondents 
(31.7%) taking it for between 1-180 days. Of the total respondents, 32.6%,25.9% and 
20.6% had taken tramadol two, three and four times daily, respectively. The most 
frequent indication for taking tramadol was back pain (25.3%) which was followed by 
other bone or muscle pains (17.7%), unspecified pain (17.2%) and osteoarthritis 
(15.4%) as shown in Table 5.3. Two hundred and twenty three respondents (64.8%) 
reported that they also had other medical conditions. Although 137 respondents 
(39.8%) reported that they had been in hospital after starting tramadol, none of them 
indicated that the admissions had been caused by tramadol. Twenty seven percent of 
the 126 respondents who had stopped taking tramadol did so because they felt that 
they did not need the drug any longer and a further 20% felt the drug was not helping 
them (Table 5.4). Thirty-eight respondents (11.0% of the total 344 respondents) 
claimed to have stopped taking it because either they or their doctor identified a 
problem with it. 
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Table 5.2 Number of respondents prescribed tramadol according to number of 
concomitant drugs 
Number of Number of % 
concomitant drugs respondents 
0 12 3.5 
1-3 149 43.3 
4-6 129 37.5 
7-9 29 8.4 
~10 5 1.5 
Not specified 20 5.8 
Total 344 100 
Table 5.3 Number of respondents prescribed tramadol according to indication for use 
Indication Number of % 
respondents 
Osteoarthritis 53 15.4 
Rheumatoid arthritis 8 2.3 
Spondylosis 3 0.9 
Degenerative bones or joints 16 4.7 
Other bone or muscle pains 61 17.7 
Trigeminal neuralgia 1 0.3 
Back pain 87 25.3 
Cancer pain 3 0.9 
Colic pain 24 7.0 
Headache 10 2.9 
Unspecified pain 59 17.2 
No indication given 19 5.5 
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Table 5.4 Reasons for stopping tramadol cited by 126 respondents 
Reason Number of % 
respondents 
I felt I didn't need it any longer. 34 27.0 
The doctor said I didn't need it any 17 13.5 
longer. 
The doctor told me to stop as I was 19 15.1 
having problems with it. 
I decided to stop as I was having 19 15.1 
problem with it. 
I felt it wasn't helping me 25 19.8 
Others 10 7.9 
Not specified 2 1.6 
Total 126 100 
5.1.3 Symptoms reported 
Of the total 344 respondents prescribed tramadol, 289 (84.0%) reported at least one 
symptom, while 55 (16.0%) reported no side effects experienced. There were 92 
different symptoms and 2333 total symptoms reported (median = 4.5, range = 
0-51). No significant relationship between the number of reported symptoms and age 
(Spearman r = 0.027), number of concomitant drugs (Spearman r = 0.071) or duration 
of therapy (Spearman r = 0.209) was found in the respondents prescribed tramadol. 
Two hundred and three (59.0%) and 120 (34.9%) of the 344 respondents were taking 
other analgesics and other eNS drugs, respectively. Patients who were taking other 
analgesics reported similar numbers of symptoms to those who were not taking other 
analgesics in addition to tramadol (X2 = 0.766, df = 3, P-value = 0.858). On the other 
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hand, patients taking any other eNS drugs together with tramadol were likely to report 
more symptoms than those not taking other eNS drugs (X2 = 9.567, df = 3, P = 0.023) 
as demonstrated in Table 5.5. 
Table 5.5 Presence of other eNS drugs concomitant with tramadol in relation to 
number of reported symptoms 
Presence of Number of patients (%) 
other eNS 
drugs Number of reported symptoms Total· 
:s:5 6·10 11·15 >15 (%) 
No 115 36 29 15 195 
(59.0%) (18.5%) (14.9%) (7.7%) (100%) 
Yes 64 20 13 23 120 
(53.3%) (16.7%) (10.8%) (19.2%) (100%) 
• Total number of valid cases = 315 
Of the total 344 respondents, 93 (27.0%) and 48 (13.9%) perceived the severity of 
their most bothersome symptoms as moderate and severe, respectively. 
Approximately one-fifth of the respondents claimed they had informed their doctors 
about all symptoms reported in the questionnaires and a similar proportion had told 
their doctors about some of the symptoms they reported (Table 5.6). Patients who 
perceived the most bothersome symptoms as severe were significantly more likely to 
inform their doctors about symptoms reported in the questionnaires, compared with 
those who perceived the symptoms as mild (X2 = 11.052, df = 2, P = 0.004) which is 
shown in Figure 5.1. There was also a significant association between the number of 
reported symptoms and severity rating of the most bothersome symptoms (X2 = 
14.585, df = 6, P = 0.024) as presented in Figure 5.2. 
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Table 5.6 Number of respondents prescribed tramadol according to severity of most 
bothersome symptoms and whether they informed their doctors. 
No. of respondents % 
Severity 
minimally 15 4.4 
mildly 25 7.3 
moderately 93 27.0 
severely 48 13.9 
very severely 24 7.0 
does not apply 71 20.6 
not specified 68 19.8 
Inform doctors 
all of symptoms 77 22.4 
some of symptoms 70 20.3 
none of symptoms 72 20.9 
not sure 23 6.7 
does not apply 57 16.6 
not specified 45 13.1 
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Figure 5.1 Severity of most bothersome symptoms reported by patients prescribed 
tramadol in relation to whether patients reported symptoms to their doctor 
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Figure 5.2 Severity of most bothersome symptoms in relation to number of symptoms 
reported by patients prescribed tramadol 
Dry mouth, light-headedness and constipation were the three most commonly reported 
symptoms by patients prescribed tramadol. Table 5.7 shows the ten most commonly 
reported symptoms of tramadol expressed as percentages using different 
denominators , i.e. number of respondents, number of patients prescribed tramadol 
during the study period , total number of reported symptoms. Unusual tiredness or 
weakness was most often reported as the most bothersome effect of tramadol, 
accounting for 7% of the total respondents. The ten symptoms reported as most 
bothersome with the highest frequency are summarised in Table 5.8. Only one of the 
ten reported symptoms which started after stopping tramadol was a known withdrawal 
symptom. (see Table 5.9) 
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Table 5.7 The ten most frequently reported symptoms in 344 respondents taking 
tramadol 
Frequency 
Rank of reported 
Symptoms 
1. dry mouth 112 
2. light-headedness 85 
3. constipation 84 
4. increased sleep 70 
5 increased sweating 69 
6. flushing 67 
7. nausea! vomiting 66 
8. unusual tiredness! 65 
weakness 
9. itching of skin 65 
10. dizziness! vertigo 56 
* number of total respondents 
** number of total questionnaires sent 
*** total number of reported symptoms 
% 
N = 344* N = 1048** N = 2333*** 
32.6 10.7 4.8 
24.7 8.1 3.6 
24.4 8.0 3.6 
20.3 6.7 3.0 
20.1 6.6 2.9 
19.5 6.4 2.9 
19.2 6.3 2.8 
18.9 6.2 2.8 
18.9 6.2 2.8 
16.3 5.3 2.4 
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Table 5.8 The ten most frequent symptoms reported as most bothersome by patients 
prescribed tramadol 
Rank No. of patients* % 
( n=344 ) 
1. unusual tiredness! weakness 24 7.0 
2. increased sweating 23 6.7 
3 reduction in sleeping 14 4.1 
4. change in mood 13 3.8 
5. constipation 11 3.2 
6 excessive thirst 11 3.2 
7. itching of skin 10 2.9 
8. bone or joint pain 10 2.9 
9. nausea! vomiting 10 2.9 
10. light-headedness 10 2.9 
* total frequency of most bothersome symptoms = 314 
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Table 5.9 Frequency of reported symptoms which started after stopping tramadol 
Symptoms Frequency of reported symptoms· (%) 
(n=344) 
1. muscle weakness 
2. unsteadiness on feet 
3. itchy or irritated eyes 
4. tinnitus 
5. dry mouth 
6. decreased in sexual desire 
7. decreased in sexual ability 
8. increased sleep 
9. reduction in sleeping @ 
10. not specified 
Total 
• number of patients reporting these symptoms = 10 
@ known withdrawal symptoms 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
10 (3.0%) 
5.1.4 Comparison between symptoms reported in the questionnaire 
and in medical notes 
Data was obtained from the medical records of 50 of the respondents prescribed 
tramadol. Of the total 315 symptoms reported by the 50 patients in the questionnaires, 
only 66 (20.9%) were recorded by GPs in the medical notes. Of these, 59 (89.4%) 
were recorded in the medical notes as symptoms, three (4.5%) were recorded as side 
effects of tramadol and four (6.1 %) were recorded as side effects of other drugs taken. 
There were seven reports describing a total of 17 symptoms related to tramadol from 
the Grampian region sent to the CSM over the same period (1 July 1996 - 31 August 
1997). Ten (20%) and six (12%) of the total 50 respondents reported complete 
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information in the questionnaire about concomitant drugs and disease states, 
respectively, compared with the records in their medical notes. The ten most 
commonly reported symptoms in the questionnaire and the frequency with which these 
were recorded in the medical notes are compared in Table 5.10. 
Table 5.10 Comparison of the ten most frequently symptoms of tramadol reported by 
patients in questionnaires with those recorded by doctors in medical notes 
Frequency of reported symptoms % 
Rank ( n= 50) availabi I ity 
Questionnaires Medical notes in medical 
notes 
1. dry mouth 9 0 0 
2. light-headedness 10 0 0 
3. constipation 10 2 20 
4. increased sleep 11 1 9 
5 increased sweating 9 1 11 
6. flushing 10 3 30 
7. nausea! vomiting 12 5 42 
8. unusual tiredness! 16 4 25 
weakness 
9. itching of skin 7 1 14 
10. dizziness! vertigo 7 1 14 
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5.1.5 Comparison between symptoms reported in the present study 
with CSM data 
Of the ten most common symptoms reported by patients prescribed tramadol in the 
present study, five were also one of the ten most commonly reported symptoms from 
CSM data. These were increased sleep, increased sweating, nausea! vomiting, itching 
of skin and dizziness! vertigo. Table 5.11 compares the frequency of the ten most 
frequently reported symptoms in the present study with CSM data together with a 
frequency ranking for CSM reports. The study data was compared with the CSM data 
using total frequency of reported symptoms as a denominator. Considering each 
individual symptom, nine of the ten most commonly reported symptoms in the present 
study were reported in significantly different proportions from those in CSM data. Only 
increased sweating was reported with similar frequency (Z = -0.97,95% Cl = -1.49-
0.51 %, P = 0.333). Headache, rashes, hallucinations, convulsions, confusion and 
nausea! vomiting and dizziness! vertigo, which were the top ten symptoms reported 
from CSM data, were all reported with higher frequency to the CSM by prescribers 
than by patients in the current study (Table 5.12). Many patients reported dry mouth, 
light-headedness, constipation, flushing and unusual tiredness! weakness. These 
symptoms were infrequently reported to the CSM. 
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Table 5.11 Comparison of the ten most frequently reported symptoms to tramadol in 
the present study with CSM data 
Frequency of reported 
Rank symptoms (%) p-
Own study* CSM data** value*** 
1. dry mouth 112(4.8%) 24 (1.0%) < 0.001 
2. lig ht-headed ness 85 (3.6%) 19 (0.8%) < 0.001 
3. constipation 84 (3.6%) 19 (0.8%) < 0.001 
4. increased sleep@ 70 (3.0%) 48 (2.0%) 0.027 
5 increased 69 (2.9%) 83 (3.5%) 0.333 
sweating@ 
6. flushing 67 (2.9%) 18 (0.7%) < 0.001 
7. nausea/ vomiting@ 66 (2.8%) 366 (15.2%) < 0.001 
8. unusual tiredness/ 65 (2.8%) 42 (1.7%) 0.016 
weakness 
9. itching of skin@ 65 (2.8%) 96 (4.0%) 0.021 
10. dizziness/ vertigo@ 56 (2.4%) 176 (7.3%) < 0.001 
* denominator = total frequency of reported symptoms = 2333 (n = 344) 
** denominator = total frequency of reported symptoms = 2404 (n= 1185) 
*** Z-test 
@ one of the ten most frequently reported symptoms from CSM data 
CSM 
ranking 
No. 
20 
25 
25 
10 
6 
27 
1 
13 
5 
2 
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Table 5.12 Comparison of the ten most frequently reported symptoms to tramadol in 
CSM data with the present study 
Frequency of reported 
Rank symptoms (%) P-value*** 
CSM data* Own study** 
1. nausea! vomiting@ 366 (15.2%) 66 (2.8%) < 0.001 
2. dizziness! vertigo@ 176 (7.3%) 56 (2.4%) < 0.001 
3. headache 123 (5.1%) 40 (1.7%) < 0.001 
4. rashes 119 (4.9%) 20 (0.9%) < 0.001 
5. pruritus@ 96 (4.1%) 65 (2.8%) 0.021 
6. increased sweating@ 83 (3.5%) 69 (3.0%) 0.333 
7. hallucinations 80 (3.3%) 8 (0.3%) < 0.001 
8. convulsions 54 (2.2%) 4 (0.2%) < 0.001 
9. confusion 53 (2.2%) 13 (0.6%) < 0.001 
10. increased sleep@ 48 (2.0%) 70 (3.0%) 0.027 
* denominator = total frequency of reported symptoms = 2404 ( n=344) 
** denominator = total frequency of reported symptoms = 2333 (n =1185) 
*** Z-test 
@ one of the ten most frequently reported symptoms of the present study 
Chapter 5: Tramadol 144 
5.1.6 Comparison between symptoms reported in the present study 
and PEM data 
The number of patient-months of treatment was calculated, where data was available, 
to provide a comparative denominator to a PEM study. Higher proportions were found 
for eight of the ten most commonly reported symptoms in the present study, while only 
nausea! vomiting had lower proportions, compared with PEM data (Z = -4.68, 95% Cl 
= -1.81 - -0.74%, P = <0.001). Only dizziness! vertigo was found to have no 
statistically significant difference in the proportions of reports between the present 
study and PEM study (Z= 0.23,95% Cl = -0.38 -0.49%, P = 0.814). However, it was 
revealed that three of the ten most frequently reported symptoms in the present study 
were also found to be among the ten most frequently reported events from PEM data. 
These were nausea! vomiting, dizziness and fatigue or weakness. In addition, six of 
the ten most frequently reported symptoms in this study were among the 20 most 
frequently reported events of PEM data (Table 5.13). 
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Table 5.13 Comparison of the ten most frequently reported symptoms to tramadol in 
the present study with PEM data 
Frequency of reported 
Rank Symptoms (%) P-value*** 
Own study* PEM data** 
1. dry mouth 89 (2.88%) 27 (0.12%) < 0.001 
2. light-headedness 74 (2.40%) 42(0.19%) < 0.001 
3. constipation@ 63 (2.04%) 133 (0.59%) < 0.001 
4. increased sleep@ 62 (2.01%) 165 (0.73%) < 0.001 
5 increased sweating@ 54 (1.75%) 47 (0.21%) < 0.001 
6. flushing 56 (1.81%) 13 (0.06%) < 0.001 
7. nausea/ vomiting@ 59(1.91%) 719 (3.19%) < 0.001 
8. unusual tiredness! 
weakness@ 56 (1.81 %) 147 (0.65%) < 0.001 
9. itching of skin 50 (1.62%) 52 (0.23%) < 0.001 
10. dizziness/ vertigo@ 42 (1.36%) 295 (1.31%) 0.814 
* denominator = total number of patient-months of treatment = 3086 (number of 
valid patients = 285) 
** denominator = total number of patient-months of treatment = 22539 
*** Z-test 
@ one of the 20 most frequently reported events from PEM data 
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5.1.7 Comparison between symptoms reported in the main study and 
the pilot study 
Co-proxamol was the analgesic in the pilot study to which tramadol was compared. Six 
of the ten most frequently reported symptoms to tramadol were also among the top 
ten reported with co-proxamol. The frequencies of many of the symptoms reported 
with both drugs were similar (Table 5.14). However light-headedness, increased sleep 
and nausea! vomiting were reported significantly more frequently with tramadol. 
Table 5.14 Comparison of the ten most frequently reported symptoms of tramadol 
with co-proxamol 
Rank Frequency of reported symptoms 
(%) 
Tramadol* 
(n= 344) 
1. dry mouth@ 112 (32.6%) 
2. light-headedness 85 (24.7%) 
3. constipation@ 84 (24.4%) 
4. increased sleep 70 (20.3%) 
5 increased sweating 69(20.1%) 
6. flushing@ 67 (19.5%) 
7. nausea! vomiting 66 (19.2%) 
8. unusual tiredness! 65 (18.9%) 
weakness@ 
9. itching of skin@ 65 (18.9%) 
10. dizziness! vertigo@ 56(16.3%) 
* denominator = number of total respondents 
•• Z-test 
Co-proxamol* 
(n= 45) 
10 (22.2%) 
6 (13.3%) 
11 (24.4%) 
4 (8.9%) 
5(11.1%) 
10 (22.2%) 
1 (2.2%) 
7 (15.6%) 
9 (20.0%) 
8 (17.8%) 
P-value** 
0.123 
0.041 
0.997 
0.016 
0.083 
0.675 
< 0.001 
0.565 
0.861 
0.804 
@ one of the top ten most frequently reported symptoms of co-proxamol 
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5.1.8 Patient attribution of symptoms to drugs 
Of the total number of perceived symptoms reported, 1246 (53.4%) were classified by 
the researcher as being possibly caused by the study drugs, with a further 321 
(13.8%) classed as probably caused by study drugs. Four hundred and fifty six 
symptoms (19.5%) were classed as unlikely to be an ADR and 310 were unattributable 
(13.3%). Table 5.15 lists the result of the classification for causal relationship of the 
perceived symptoms according to the eight criteria. The highest frequency was of 
those symptoms which could be caused by the study drug and concomitant drugs 
(criteria 2). Also, there were a large number which could have been caused by 
concurrent disease states in addition to drugs being taken (criteria 4). A greater 
proportion of respondents (67.2%) reported symptoms potentially caused by tramadol 
(probable! possible) than those (32.8%) not likely to be caused by tramadol (unlikely! 
unattributable ). 
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Table 5.15 Classification of symptoms reported by patients prescribed tramadol into 
eight criteria for assessment of causal relationship 
Total frequency of 
Causal relationship Criteria reported symptoms 
No. % 
probable ADRs 1 321 13.8 
possible ADRs 2 790 33.9 
3 79 3.4 
4 377 16.2 
Subtotal 1246 53.4 
unlikely ADRs 5 222 9.5 
6 105 4.5 
7 129 5.5 
Subtotal 456 19.5 
Unattributable ADRs 8 310 13.3 
Total 2333 100 
5.1.9 Comparison between expert and researcher opinion on the 
classification for causal relationship 
Of a total 315 symptoms reported by 50 patients whose medical notes were accessed 
and evaluated, 219 symptoms (69.5%) were jointly agreed and 96 symptoms (30 .5%) 
were disagreed between the expert and the researcher using the four categories of 
causal relationship . Considering each criteria of the causal relationship, 0 (0%), 169 
(53 .7%),40 (12.7%) and 10 (3.2%) of the symptoms reported were mutually agreed 
with the classifications as probable, possible, unlikely and unattributable, respectively 
(Table 5.16). Kappa value for agreement between the expert and the researcher was 
0.43 indicating moderate agreement (Altman, 1992). 
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Table 5.16 Comparison of expert and researcher classifications of symptoms 
reported from tramadol into four criteria according to causal relationship 
Number of reported symptoms by 
Researcher expert classifications (%) Total 
Classifications Probable Possible Unlikely Unattribut-
able 
Probable 0 20 5 2 27 
(0%) (6.3%) (1.6%) (0.6%) (8.6%) 
Possible 0 169 25 5 199 
(0%) (53.7%) (7.9%) (1.6%) (63.2%) 
Unlikely 0 9 40 7 56 
(0%) (2.9%) (12.7%) (2.2%) (17.8%) 
Unattributable 0 7 16 10 33 
(0%) (2.2%) (5.1 %) (3.2%) (10.5%) 
Total 0 205 86 24 315 
(0%) (65.1 %) (27.3%) (7.6%) (100%) 
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5.2 Discussion 
The response rate for patients prescribed tramadol (32.8%) was lower than that for the 
remaining drugs in the main study (39.2%), although the number of respondents was 
largest (n= 344). The majority of respondents prescribed tramadol were elderly (60-
79). This is most likely due to the majority of respondents being prescribed tramadol 
for musculoskeletal problems (n=228, 66.3%) which presumably occur more frequently 
in the older age group. Again, there was no evidence of a relationship between 
increasing age and number of concomitant drugs in respondents taking tramadol 
which was in accordance with the pilot study. Approximately one-third of the 
respondents had taken tramadol for less than six months, however the mean duration 
of therapy was 325 days. This suggests that the majority of respondents suffered from 
chronic pain which related to their disease states, particularly musculoskeletal 
problems which are frequently chronic in nature. 
The number of respondents taking tramadol for cancer pain was low (n=3). This may 
not necessarily suggest that tramadol was not frequently prescribed for cancer pain. It 
may indicate that cancer patients were less able to respond to the questionnaires sent 
due to severity of illness, compared with those suffering from musculoskeletal 
diseases. The response rate to fentanyl patches, which are most frequently prescribed 
for cancer pain was also low. Not surprisingly, tramadol was also prescribed in only a 
small number of respondents for minor pains, such as headache, as its indication is for 
moderate and severe pain. 
Interestingly, the data show that 51 (14.8%) of the respondents had stopped taking 
tramadol since their medical condition had improved. This suggests that tramadol was 
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also being used for acute conditions. Thirty-eight respondents (11.0%) perceived that 
problems had caused them to discontinue tramadol, with or without their doctor's 
recommendation. The percentage of the respondents who discontinued tramadol was 
lower than that of a more recent study to examine the effect of three titration 
schedules on the tolerability of tramadol by Ruoff (1999) which found 15.2-30.8% of 
patients discontinued tramadol during day 1- day 10 of the titration schedule because 
of adverse events. This difference is probably because patients in the present study 
had already passed the titration period which is normally at the beginning of therapy. 
Twenty five (7.3%) of the respondents who had discontinued the drug had done so 
because they felt tramadol was not helping them. This suggests that although 
tramadol is used for moderate or severe pain, it may not be effective enough for 
relieving pain in some patients. 
Eighty-four percent of the respondents taking tramadol reported at least one symptom 
which was slightly lower than for the rest of the main study (92.3%). However, this 
result is slightly higher than the 77.8% found by Crighton et al. (1997) in a prospective 
double-blinded study involving 18 women who received tramadol during laparoscopic 
sterilisation. The respondents reported a wide range of symptoms (0 - 51) and a high 
number of different symptoms (95), although the median number of symptoms 
reported was only 4.5. Some patients may have over-reported symptoms which they 
suffered regardless of whether the symptoms were caused by tramadol or not, leading 
to bias. Within this group of respondents there was no positive relationship between 
increasing age, number of concomitant drugs or duration of therapy with number of 
symptoms reported. 
The severity of the most bothersome symptoms reported was rated into one of five 
levels as minimally, mildly, moderately, severely and very severely by 60% of the 
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respondents taking tramadol. Fewer of this group of respondents completed this rating 
than those taking other drugs (77.1 %) while a higher percentage ticked 'does not 
apply' and 'unspecified'. This is clearly related to the finding that more respondents 
prescribed tramadol reported they had experienced no side effects than for the 
remaining drugs (16% vs 7.7%). 
Interestingly, only half of the respondents (147!289) who reported symptoms which 
they thought to be side effects from tramadol had informed their doctors about these. 
It is likely that the symptoms which they did not inform their doctor were minor side 
effects and did not bother them. This may also lead doctors to under-detect and 
under-report ADRs occurring in out-patient populations. This is particularly important 
for symptoms relating to black triangle drugs which require the reporting of any type of 
ADR, even minor or known side effects. 
As the range of reported symptoms was large, this discussion will concentrate on 
those which occurred most frequently. Six of the symptoms cited as being most 
bothersome by the respondents taking tramadol were also among the top ten most 
frequently reported. These were light-headedness, constipation, increased sweating, 
nausea! vomiting, unusual tiredness! weakness and itching of skin. All of the ten most 
frequently reported symptoms and nine of the ten most bothersome symptoms 
reported, except bone or joint pain reported by ten respondents, are known side 
effects of tramadol. This suggests that the respondents seemed to report mainly 
symptoms potentially caused by tramadol. However, bone or joint pain which was 
most likely attributable to patients' disease states was also cited as one of the ten 
most bothersome symptoms. This suggests that a few patients also appeared to report 
the symptoms which bothered them a lot even though those symptoms did not relate 
to the study drug. The large number of respondents reporting potential ADRs however 
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meant that bone or joint pain was not one of the top ten most frequent symptoms 
reported. 
By taking into account only the number of respondents (n=344) as the denominator, 
these percentages of symptoms reported could form an estimate of the highest likely 
incidence of individual side effects, particularly as patients experiencing side effects 
may be more likely to respond. The lowest likely incidence could be estimated by 
using the total number of questionnaires sent to patients prescribed tramadol including 
nonrespondents (n=1048) as the denominator and assuming that nonrespondents did 
not experience any side effects. Thus, an incidence estimate of dry mouth could range 
from 10.7% to 32.6%, light-headedness from 8.1 % to 24.7% and constipation from 
8.0% to 24.4%. These interval estimates could therefore diminish the bias from 
representative patients who may have had ADRs but did not respond to the 
questionnaire or those who may have ignored side effects that they were familiar with. 
However, the method used in this study, involving questionnaire distribution at a Single 
point in time, meant that any patients who had stopped tramadol or were switched to 
some other drug did not receive the questionnaire. Therefore, while it is a sample of all 
patients prescribed the drug at a given time, the sample may comprise mainly the 
'survivor' patients as described in studies by Fisher et al. (1993, 1995) and Fisher 
(1995). It is important to note however that since the questionnaire was distributed six 
months after the prescription was dispensed, 11% of respondents had stopped taking 
the drug. Therefore the method should have resulted in the inclusion of a more 
representative sample of those who tolerated tramadol than those who did not. 
Ten (2.9%) out of a total 344 respondents reported symptoms which started after 
stopping tramadol, however only one of these was a known withdrawal symptom of 
tramadol, reduction in sleep. This confirms a finding reviewed by Budd (1994) from 
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clinical studies, PMS studies and clinical experience over 15 years that the 
development of dependence during long term therapy use was uncommon, therefore it 
was not surprising that few withdrawal symptoms were associated with tramadol in the 
present study. The other nine symptoms reported such as muscle weakness, 
unsteadiness on feet, itchy or irritated eyes, tinnitus and dry mouth, may have been 
related to patients' disease states or concomitant drugs which patients were still taking 
after discontinuing tramadol. 
When compared with symptoms reported by patients taking tramadol in the 
questionnaires, it was found that the frequency with which symptoms reported by 
patients recorded in the medical notes was low. Only 20.9% of the 315 symptoms 
reported by 50 respondents were recorded by GPs in the medical notes which is 
comparable to the 22% in the pilot study. Of these, only 4.5% were recorded as side 
effects from tramadol, the rest were recorded as symptoms (89.4%) and side effects 
from other drugs taken (6.1 %). Of the 50 patients whose case notes were studied, 26 
(52%) said they had informed their doctors about the symptoms reported. Of these, 18 
(69%) had at least one symptom recorded in the case notes. This may suggest that 
the reporting by patients seems to be reliable. Alternatively, although doctors tended 
to record symptoms reported to them, only a limited number of those symptoms were 
recorded in the case notes for each individual patient. This may contribute to the 
finding that only 21 % of total symptoms reported were recorded in case notes. As well 
as doctors not recording all the symptoms, almost half the patients claimed not to have 
reported any of the symptoms they identified by questionnaire to their doctors. The 
symptoms which were most frequently reported in the medical notes were nausea! 
vomiting (42%), flushing (30%), unusual tiredness/ weakness (25%) and constipation 
(20%). Three of these symptoms were among those identified by patients as most 
bothersome, which may have led them to report the symptoms to their doctors. 
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Data obtained from the CSM showed that only seven yellow cards including 17 
adverse effects to tramadol originated from the Grampian region during the period that 
patients were asked to report their experiences of ADRs in the questionnaire (Le. the 
12 months prior to completing the questionnaires). These included reports both sent 
directly to CSM as well as indirectly via the pharmaceutical industry or from the 
scientific literature. While patients may have perceived symptoms as being related to 
tramadol, their doctors were not recording most of the symptoms reported to them as 
side effects. This must have contributed to the low rate of yellow card submissions to 
the CSM. However given that the majority of symptoms reported by questionnaire 
were known side effects of tramadol, the results suggest there was significant under-
reporting. This is despite the requirement for minor or known ADRs to black triangle 
drugs to be reported to the CSM. 
When the top ten most frequently reported symptoms in the present study were 
compared with the CSM data using total number of reports as the denominator, higher 
reporting frequencies were found for six of the top ten symptoms reported in the 
present study, while lower frequencies were found for three others which were 
nonetheless among the top ten symptoms reported in CSM data. This may suggest 
that the patient self-reporting study tended to detect more minor and known side 
effects as well as background symptoms, i.e. dry mouth, constipation, increased sleep, 
flushing and unusual tiredness! weakness, whereas the CSM tended to detect more 
serious side effects, i.e. nausea! vomiting, itching of skin, rash, hallucinations, 
confusion and convulsions. This finding is in agreement with studies by Mitchell et al. 
(1989,1994) and van den Bemt et al. (1999) which concluded that patient-self 
reporting tended to identify established ADRs particularly to new drugs, while reports 
from health professionals tended to describe rarer and more severe reactions than 
patient-self reports. A similar finding was found by Cossmann et al. (1997) in that the 
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most frequently documented adverse effects of tramadol in clinical and PMS studies, 
i.e. drowsiness, tiredness and dry mouth were noted very infrequently in spontaneous 
reports since these side effects are normally known and were described in the product 
information. For established drugs, the CSM requests reports for all serious suspected 
reactions, including those that are fatal, life-threatening, disabling, incapacitating or 
which result in or prolong hospitalisation, even if the reactions are well recognised 
(British Medical Association and the Royal Pharmaceutical SOciety of Great Britain, 
1998; Denman et al., 1988; Anonymous, 1980). However, tramadol is a newer drug 
with the black triangle symbol for which any reactions should be reported, even those 
which are minor or well-known. While it may be that doctors did not know the precise 
meaning of the CSM's black triangle, as was found in a study by Belton et al. (1995), it 
is most likely that for the patients who did report symptoms, their GPs viewed these as 
symptoms of disease states, not ADRs. This is confirmed by the documentation of the 
vast majority of symptoms which were recorded in notes as disease-related. Another 
reason may be that doctors placed less significance on less serious reactions, 
resulting in failure to report those reactions to the CSM. As the Yellow Card system 
(organised by the CSM) is known to suffer from under-reporting (D'Arcy, 1996; Speirs 
et al., 1994; Walker and Lumley, 1986; Martin et al., 1998), it is not surprising that the 
present study found greater percentages of overall symptoms reported than those 
from CSM data. 
This study shows that a large number of patients in the community actually suffer from 
minor side effects, i.e. dry mouth and constipation (32.6% and 24.4% of the total 
respondents) which were often ignored by health professionals. The results also 
support the suggestion that an ADR monitoring system based on reports from patients 
would be cheap and might lead to quicker identification of symptomatic reactions to 
some new drugs (Mitchell et al., 1988). However, clearly not all symptoms reported by 
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the patients were likely to be true adverse reactions of tramadol since many symptoms 
may have related to their disease states or other drugs taken, while 310 were 
unattributable, suggesting some over-reporting by patients. 
It was only possible to compare results to a PEM study by using patient-months during 
the whole treatment period as a denominator, the same as PEM method, therefore 
only respondents providing information about duration of therapy were included in this 
comparison (285 patients). This method of calculation reduced the frequency of the 
top ten commonly reported symptoms, however all except nausea! vomiting were 
reported more frequently than from the PEM data. This may indicate that patient self-
reporting tended to detect more known side effects than the PEM method which 
depends on the willingness of doctors to report events. This method has also 
encountered an under-reporting problem similar to that seen with the Yellow Card 
system (Inman and Pearce, 1993). Six of the top ten reported symptoms in the 
present study were cited among the top 20 events reported of the PEM data. The 
comparison to PEM data thus supports the suggestion that patient-self reporting did 
appear to identify potential side effects caused by tramadol. Most of the top 20 
reported events of tramadol from PEM data were expected and minor side effects, 
such as nausea! vomiting, headache, dizziness, lassitude, insomnia, drowsiness and 
anxiety which were similar to the findings of the present study. Campbell and Howie 
(1988) have also commented that the PEM method seemed to fail to detect serious 
reactions. 
Interestingly, the frequency of increased sweating and dizziness! vertigo reported in 
the present study were comparable to the CSM data and PEM data, respectively. It is 
possible that these symptoms bothered patients and were easily identified by patients 
as side effects of tramadol, thus leading to reports about these side effects to doctors. 
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Tolerance may have developed to other symptoms. such as nausea! vomiting, which 
were found with lower frequency in the present study. compared with the CSM and 
PEM data. This is especially likely in comparisons to data from PEM reports which 
concentrate on events occurring in the early months of therapy (Freemantle et al., 
1997). Therefore, acute reactions, such as nausea! vomiting, are more likely to be 
detected by this method than that used in the present study which asked patients to 
report any symptoms experienced during the previous 12 months prior to receiving the 
questionnaire. 
Six of the ten most commonly reported symptoms from tramadol in the main study 
were also among the top ten symptoms reported from co-proxamol in the pilot study. 
These were dry mouth, constipation, flushing, unusual tiredness! weakness, itching of 
skin and dizziness! vertigo. All are known side effects to both drugs. Although the 
numbers taking co-proxamol may be too small for accurate comparisons, light-
headed ness, increased sleep and nausea! vomiting were found in significantly higher 
proportions in patients taking tramadol than in those taking co-proxamol. The 
remaining seven of the top ten commonly reported symptoms were comparable in 
both drugs. This finding is in line with a meta-analysis of 3453 postoperative patients 
from 18 studies by Moore and McQuay (1997) which showed that incidence of nausea 
and vomiting was higher in patients taking an oral single dose of tramadol 50, 75 and 
100 mg than in those taking paracetamol 650 mg combined with propoxyphene 100 
mg for dental pain. Tramadol was also shown to cause more drowsiness. nausea! 
vomiting and dizziness than the combination of paracetamol and propoxyphene for 
postoperative pain but only at a dose of 100mg. Sunshine (1994) reviewed oral single 
dose studies of tramadol and found that tramadol at 50, 75 or 100 mg resulted in a 
higher incidence of nausea! vomiting, dizziness and headache than the combination of 
paracetamol (650 mg) and dextropropoxyphene (100 mg) for both dental extraction 
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and postoperative pain. While the dose of dextropropoxyphene HCI studied here is 
lower than that studied by those workers and the present study involves chronic 
therapy, the similar findings are interesting. However, a comparative study of the 
analgesic efficacy and safety profiles between tramadol and co-proxamol was 
conducted by Crighton et al. (1997) which demonstrated that the incidence of nausea/ 
vomiting were comparable which contrasts with the present finding. These researchers 
did however present a similar trend towards a lower incidence of CNS side effects in 
co-proxamol group, i.e. drowsiness, dizziness, headache, but no statistical differences 
were proved. 
Data from Drugdex Drug Evaluation Monographs (1998), Moore and McQuay (1997) 
and Dayer et al. (1994) demonstrated that nausea, vomiting, constipation, dry mouth, 
fatigue, dizziness, somnolence, headache and sweating are relatively commonly 
reported adverse effects of tramadol. All except headache were also found in the top 
ten reported symptoms of the present study. Although headache was not among the 
top ten symptoms reported, it was reported by a high percentage (n=40, 11.6%) of the 
respondents. Cossmann et al. (1997) summarised the safety data of tramadol from 
phase 11 to IV clinical studies, including postmarketing surveillance studies covering 
more than 21,000 patients, as well as the spontaneous reporting system. These 
workers found that the most frequently documented ADRs in clinical and PMS studies 
were nausea/ vomiting, dizziness, drowsiness, tiredness, sweating and dry mouth 
which were all found in the top ten reported symptoms of the present study. These 
comparisons may indicate that patient-self reporting seems to be an effective method 
for detecting ADRs to new drugs. 
Summarising data from clinical trials and postmarketing studies using Drugdex Drug 
Evaluation Monographs (1998), Sunshine (1994), Cossmann et al. (1997), Budd 
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(1994), Moore and McQuay (1997), Crighton et al. (1997), Hopkins et al. (1998) and 
Ruoff (1999) results in an incidence of dry mouth ranging from 3-18%, light-
headedness 0.3-1.3%, constipation 1.9-35%, increased sleep 0.3-50%, increased 
sweating 1.1-20%, nausea! vomiting 3.1-65%, unusual tiredness! weakness 5.9-35%, 
itching of skin 0.1-25% and dizziness! vertigo 1-25%. By calculating interval incidence 
estimates for the present study as previously described and comparing these with the 
incidences from those studies, it was found that the incidence of seven of the top ten 
symptoms were similar in range to published studies. These were constipation (8.0-
24.4%), increased sleep (6.7-20.3%), increased sweating (6.6-20.1 %), nausea! 
vomiting (6.3-19.2%), unusual tiredness! weakness (6.2-18.9%) and dizziness! vertigo 
(5.3-16.3%) and itching of skin (6.2-18.9%). Two of the top ten symptoms were found 
in higher incidences in the present study to published data. These were dry mouth 
(10.7-32.6%) and light-headedness (8.1-24.7%). This again may suggest that patient-
self reporting of ADRs is potentially useful and is comparable to other drug monitoring 
studies. However, it is important to take into consideration the different conditions 
between studies. For instance, PMS studies were performed in outpatients, whereas 
most clinical trials are carried out in hospitals. Different methods were also used to 
detect ADRs, i.e. checklist questionnaire, open questionnaire, interview or observation 
and also different sample sizes could affect the occurrence of the side effects 
identified. Light-headedness was found at a higher percentage in this study, possibly 
because it was carried out in out-patients who are more likely to suffer from 
hypotension than those in hospitals who were confined to bed. Another explanation is 
that patients may find it difficult to differentiate light-headedness from dizziness, which 
could result in a higher incidence of light-headedness and a lower incidence of 
dizziness. The latter symptom was in fact found in much higher incidence in other 
studies (up to 35%). Interestingly, dry mouth was the most commonly reported 
symptom found in the present study, much higher than reported elsewhere. This may 
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suggest that minor and known ADRs could be detected more often by patient self-
reporting, or that symptoms reported with higher frequencies were likely to be caused 
by concomitant drugs taken or patients' disease states, i.e. there was over-reporting. 
The researcher classified the majority of symptoms reported by patients as possibly 
caused by tramadol (53.4%), with a further 13.8% probably caused by tramadol. Thus, 
the results showed that greater proportion of the respondents reported symptoms 
potentially caused by tramadol (67.2%) than those not likely to be caused by tramadol 
(32.8%). More symptoms reported by respondents prescribed tramadol were classified 
as 'unlikely' (19.5%) than was found in the remaining drugs (16.4%). One possible 
reason is that there are fewer known side effects to tramadol than other drugs studied, 
thus a larger number of symptoms were classified as not being caused by tramadol. 
Incomplete data provided by respondents may however have affected these 
classifications. 
When the classifications of symptoms reported by 50 patients, whose medical notes 
were accessed, into four criteria of causal relationship were compared between the 
expert and the researcher, there was agreement for 69.5% of the total 315 symptoms 
which indicated a moderate agreement (Kappa = 0.43). Similar levels of agreement 
have been found in other studies. Using conventional four categories, i.e. definite, 
probable, possible and doubtful, between-rater agreement for two physicians and four 
pharmacists who independently assessed 63 selected ADRs was 38-63% (Kappa 
0.21-0.4) (Naranjo et al., 1981). Similarly, using the standardised assessment created 
by Venulet et al. (1980), 391 (61%) of a total 640 ADR reports were identical in the 
judgement of four evaluators. However, the development of a probability category for 
assessment resulted in an 83-92% agreement and Kappa = 0.69-0.86 (Naranjo et al., 
1981). There is thus broad agreement between several studies that evaluators 
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frequently disagree in their assessment of ADR reports using their subjective 
judgement (Koch-Weser et al., 1977; Kramer et al., 1979; Meyboom et al., 1997; 
Venulet et al., 1980; Naranjo et al., 1981), Venulet (1992) has also suggested that 'the 
true causality of a single case of ADR is not known and, working retrospectively with a 
finite amount of data, will never be known', 
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Chapter 6 
Results and Discussion: 
Main study: Venlafaxine 
6.1 Results 
6.1.1 Response rate and demographic data 
There was a total of 633 postal questionnaires sent to patients prescribed venlafaxine. 
Of these, 263 patients returned valid responses giving a response rate of 41.5%. Of 
the total respondents, 78 (29.7%) were male and 184 (70.0%) were female, one 
(0.4%) did not specify. The mean ± SD age of the respondents was 46.6 ± 15.7 years 
but the majority of patients were aged 40-59 (41.8%) and 20-39 (36.5%). Table 6.1 
lists number of the respondents in different age groups. 
Table 6.1 Number of respondents prescribed venlafaxine according to age groups 
Age group Number of % 
respondents 
< 20 1 0.4 
20-39 96 36.5 
40-59 110 41.8 
60-79 40 15.2 
~ 80 10 3.8 
not specified 6 2.3 
Total 263 100 
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6.1.2 Drug therapy 
The majority of the respondents were taking 1-3 (50.6%) and 4-6 (14.8%) concomitant 
drugs. The mean ± SO of number of concomitant drugs was 2.4 ± 2.0 (range 0-10) 
(see Table 6.2). There was not a strong relationship between increasing age and 
number of concomitant drugs (Spearman r = 0.280, P < 0.001). The average duration 
of taking venlafaxine was 381.5 days (SO = ± 215.1). The majority of the respondents 
had been taking venlafaxine for 361-540 days (n=81, 33.9%) and 181-360 days (n=76, 
31.8%), followed by 541-720 days (n=34, 14.2%), 1-180 days (n=31, 13.0%) and >720 
days (n=17, 7.1%), respectively. Of the total respondents, 99 (11.8%), 411 (49.1%), 
198 (23.7%) and 77 (9.2%) were taking venlafaxine one, two, three and four times 
daily, respectively. The most frequent indication for taking venlafaxine was depression 
(n=232) with relatively few respondents citing other indications (Table 6.3). One 
hundred and fifteen respondents (43.7%) reported that they also had other medical 
conditions. Although 65 respondents (24.7%) reported that they had been in hospital 
after starting venlafaxine, none of them indicated that the admissions had been 
caused by venlafaxine. Of the total 86 respondents who had stopped taking 
venlafaxine, the most frequently cited reasons were that patients felt they did not need 
the drug any longer 22 (25.6%) and their doctors said they did not need it any longer 
19 (22.1%) (Table 6.4). There was a total of 26 respondents (9.9%) who had stopped 
venlafaxine because either they or their doctors had identified problems with it. 
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Table 6.2 Number of respondents prescribed venlafaxine according to number of 
concomitant drugs 
Number of Number of % 
concomitant drugs respondents 
0 28 10.6 
1-3 133 50.6 
4-6 39 14.8 
7-9 10 3.8 
~10 2 0.8 
not specified 51 19.4 
Total 263 100 
Table 6.3 Number of respondents prescribed venlafaxine according to indication for 
use 
Indication 
Number of % 
respondents 
depression 232 88.2 
anxiety 5 1.9 
panic attack 1 0.4 
stress 6 2.3 
other psychotic disorder 5 1.9 
myalgic encephalomyelitis 2 0.8 
not specified 12 4.6 
Total 263 100 
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Table 6.4 Reasons for stopping venlafaxine cited by 86 respondents 
Reason Number of % 
respondents 
I felt I didn't need it any longer. 22 25.6 
The doctor said I didn't need it 19 22.1 
any longer. 
The doctor told me to stop as I 16 18.6 
was having problems with it. 
I decided to stop as I was having 10 11.6 
problem with it. 
I felt it wasn't helping me 8 9.3 
others 11 12.8 
Total 86 100 
6.1.3 Symptoms reported 
Of the total 263 respondents prescribed venlafaxine, 249 (94.7%) reported at least 
one symptom, while only 14 (5.3%) reported no side effects experienced. There were 
97 different symptoms and 2700 total symptoms reported (median = 7, range = 0-71). 
There was no relationship between increasing age and number of reported symptoms 
in the respondents prescribed venlafaxine (Spearman r = -0.124, P = 0.047). The 
number of reported symptoms by respondents in different age groups of the 
respondents is presented in Figure 6.1. Again, there were no relationships between 
the number of reported symptoms and increasing number of concomitant drugs 
(Spearman r = 0.121, P = 0.079) or duration of therapy (Spearman r = 0.088, P = 
0.169) (Figure 6.2). Forty nine (18.6%) and 99 (37.6%) of the 263 respondents were 
taking other antidepressants and other eNS drugs, respectively. There was also no 
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significant association between the number of symptoms reported and whether 
patients were taking other antidepressants (X2 = 6.139, df = 3, P = 0.105) or other 
eNS drugs (X2 = 1.047, df = 3, P = 0.790). 
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Figure 6.1 Number of reported symptoms by respondents taking venlafaxine in 
relation to age group 
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Figure 6.2 Number of reported symptoms by respondents taking venlafaxine in 
relation to duration of therapy 
Chapter 6: Venlafaxine 168 
The majority of respondents perceived the severity of the most bothersome symptoms 
as moderately (n =78. 29.7%) and severely (n = 77, 29.3%). Thirty five percent of the 
respondents had informed their doctors of all symptoms reported in the questionnaires 
and 27.8% had reported some of them (Table 6.5). Patents who perceived the most 
bothersome symptoms as severe were significantly more likely to have informed their 
doctors about their symptoms. compared with those who perceived the symptoms as 
mild (X2 = 14.851. df = 2. P = 0.006) as shown in Figure 6.3. There was also a 
significant relationship between the number of reported symptoms and the severity of 
the most bothersome symptoms perceived (X2 = 33.866, df = 6. P < 0.001) ( Figure 
6.4). 
Table 6.5 Number of respondents prescribed venlafaxine according to severity of 
most bothersome symptoms and whether they informed their doctors 
Number of 
respondents % 
Severity 
minimally 11 4.2 
mildly 18 6.8 
moderately 78 29.7 
severely 77 29.3 
very severely 26 9.9 
does not apply 25 9.5 
not specified 28 10.6 
Inform doctors 
all of symptoms 93 35.4 
some of symptoms 73 27.8 
none of symptoms 41 15.6 
not sure 19 7.2 
does not apply 19 7.2 
not specified 18 6.8 
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Figure 6.3 Severity of most bothersome symptoms reported by patients prescribed 
venlafaxine in relation to whether patients reported symptoms to their doctors 
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Figure 6.4 Severity of most bothersome symptoms in relation to number of 
symptoms reported by patients prescribed venlafaxine 
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Dry mouth. increased sweating and light-headedness were the three most commonly 
reported symptoms by patients prescribed venlafaxine. The ten most frequently 
reported symptoms of venlafaxine are shown in Table 6.6 using variety of 
denominators. These were used to provide incidence estimates in ranges. The most 
bothersome symptoms reported from venlafaxine were increased sweating (n=41. 
15.6%), unusual tiredness or weakness (n=23. 8.7%) and weight gain (n=23. 8.7%). 
The ten most bothersome symptoms reported are summarised in Table 6.7. 
Table 6.6 The ten most frequently reported symptoms from venlafaxine 
Frequency 
Rank of reported 
Symptoms 
1. dry mouth 121 
2. increased sweating 107 
3. light-headedness 91 
4. J.. sexual desire 89 
5. unusual tiredness! 88 
weakness 
6. flushing 78 
7. constipation 71 
8. weight gain 70 
9. excessive thirst 68 
10.change in mood 66 
* number of total respondents 
** number of total questionnaires sent 
*** number of total reported symptoms 
% 
N = 263* N = 633** 
46.0 19.1 
40.7 16.9 
34.6 14.4 
33.8 14.1 
33.5 13.9 
29.7 12.3 
27.0 11.2 
26.6 11.1 
25.9 10.7 
25.1 10.4 
N = 2700*** 
4.5 
4.0 
3.4 
3.3 
3.3 
2.9 
2.6 
2.6 
2.5 
2.4 
.. 
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Table 6.7 The ten most bothersome symptoms reported by patients prescribed 
venlafaxine 
Rank Number % 
of patients* 
( n= 263 ) 
1. increased sweating 41 15.6 
2. unusual tiredness/ 23 8.7 
weakness 
3. weight gain 23 8.7 
3. decrease in sexual 16 6.1 
desire 
5. difficulty concentrating 15 5.7 
6. reduction in sleeping 12 4.6 
7. anxiety/ agitation 12 4.6 
8. constipation 11 4.2 
9. nausea/ vomiting 10 3.8 
10. dry mouth 10 3.8 
* total frequency of most bothersome symptoms = 366 
Of the total 86 respondents who discontinued venlafaxine, ten (11.6%) reported a total 
of 49 symptoms which started after stopping venlafaxine, the most frequent being 
change in mood (10), dizziness/ vertigo (5) and unusual tiredness! weakness (5) 
(Table 6.8). Eight out of the total 17 different symptoms reported were known 
withdrawal symptoms . 
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Table 6.8 Frequency of reported symptoms which started after stopping venlafaxine 
Symptoms Frequency of reported 
symptoms* ( %) 
( n = 86 )** 
1. unsteadiness on feet 2 (2.3%) 
2. headache@ 4 (4.6%) 
3. decrease in appetite 1 (1.2%) 
4. nausea/ vomiting@ 4 (4.6%) 
5. confusion@ 1 (1.2%) 
6 light-headedness 2 (2.3%) 
7. dizziness/ vertigo@ 5 (5.8%) 
8. anxiety/ agitation@ 4 (4.6%) 
9. change in mood 10(11.6%) 
10. anger/ aggression 3 (3.5%) 
11. reduction in sleeping@ 3 (3.5%) 
12. unusual tiredness/ weakness~ 5 (5.8%) 
13. increased sleep 1 (1.2%) 
14. increased sweating@ 1 (1.2%) 
15. weight loss 1 (1.2%) 
16. palpitations 1 (1.2%) 
17. flu-like symptoms 1 (1.2%) 
Total 49 (57.0%) 
* number of patients reporting these symptoms = 10 
** number of patients who stopped taking venlafaxine = 86 
@ known withdrawal symptoms ( total frequency = 27, 31.4% ) 
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6.1.4 Comparison between symptoms reported in the questionnaire 
and in medical notes 
Of the total 401 symptoms reported by 53 patients whose medical notes were studied, 
only 96 (23.9%) were recorded by GPs in the notes. Of these, 69 (72%) were 
recorded as symptoms, 24 (25.0%) were recorded as side effects of venlafaxine and 
three (3%) were recorded as side effects of other drugs taken. Seventeen (32.1 %) and 
13 (24.5%) of the total 53 respondents reported complete information in the 
questionnaire about concomitant drugs and disease states, respectively, compared 
with the records in their medical notes. The ten most commonly reported symptoms in 
the questionnaire and the frequency with which these were recorded in the medical 
notes are compared in Table 6.9. 
Table 6.9 Comparison of the ten most frequent symptoms of venlafaxine reported by 
patients in questionnaires with those recorded by doctors in medical notes 
Frequency of reported % 
Symptom and Rank symptoms (n= 53) availability 
Questionnaires Medical notes in medical 
notes 
1. dry mouth 23 3 13 
2. increased sweating 20 11 55 
3. light-headedness 14 0 0 
4. decrease in sexual desire 21 2 10 
5. unusual tirednessl weakness 11 6 54 
6. flushing 14 6 43 
7. constipation 14 6 43 
8. weight gain 13 8 62 
9. excessive thirst 11 0 0 
10. change in mood 12 11 92 
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6.1.5 Comparison between symptoms reported in the present study 
with CSM data 
Of the ten most common symptoms reported by patients prescribed venlafaxine in the 
present study, only increased sweating was among the ten most commonly reported 
symptoms in CSM data. Table 6.10 compares the frequency of the ten most frequently 
reported symptoms in the present study with CSM data together with ranking in 
number of the most frequently symptoms reported in CSM data. The study data was 
compared with the CSM data using total frequency of reported symptoms as a 
denominator. Considering each individual symptom, nine of the ten most commonly 
reported symptoms in the present study had significantly different proportions from 
those in CSM data, with only increased sweating being similar (Z = 0.27, 95% Cl = 
-0.87-1.14%, P = 0.785). Increased sweating was in fact the only one of the top ten 
symptoms in CSM data which was among the top ten reported symptoms in the 
present study, although unusual tiredness! weakness and change in mood were within 
the top 20 CSM symptoms. Similarly, five of the top ten reported symptoms of CSM 
data had significantly higher frequency than those in the present study. Five symptoms 
(increased sweating, anxiety! agitation, tremor, palpitations and paraesthesia) however 
were reported with similar proportions to the present study (Table 6.11). 
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Table 6.10 Comparison of the ten most frequently reported symptoms of venlafaxine 
in the present study with CSM data 
Frequency of reported 
Rank Symptoms (%) p-
value*** 
Own study* CSM data** 
1. dry mouth 121 (4.5%) 25 (0.8%) 
2. increased sweating@ 107 (4.0%) 113(3.8%) 
3. light-headedness 91 (3.4%) 60 (2.0%) 
4. ..l. sexual desire 89 (3.3%) 12 (0.4%) 
5. unusual tiredness! 88 (3.3%) 34 (1.2%) 
weakness 
6. flushing 78 (2.9%) 19 (0.6%) 
7. constipation 71 (2.6%) 28 (0.9%) 
8. weight gain 70 (2.6%) 11 (0.4%) 
9. excessive thirst 68 (2.4%) 5 (0.2%) 
10. change in mood 66 (2.4%) 35 (1.2%) 
* denominator = total frequency of reported symptoms = 2700 
** denominator = total frequency of reported symptoms = 2956 
*** Z-test 
<0.001 
0.785 
0.002 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
@ one of the ten most frequently reported symptoms from CSM data 
CSM 
ranking 
No. 
23 
5 
12 
>30 
19 
>30 
21 
>30 
>30 
18 
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Table 6.11 Comparison of the ten most frequently reported symptoms of venlafaxine 
in CSM data with the present study 
Frequency of reported 
symptoms (%) 
Rank 
CSM data* Own study** 
1. nausea! vomiting 334 (11.6%) 64 (2.4%) 
2. dizziness! vertigo 173 (5.9%) 48 (1.8%) 
3. headache 150 (5.1%) 50 (1.9%) 
4. rashes 145 (4.9%) 15 (0.6%) 
5. increased sweating@ 113 (3.8%) 107 (4.0%) 
6. unsteadiness on feet 91 (3.1%) 41 (1.5%) 
7. anxietyl agitation 83 (2.8%) 59 (2.2%) 
8. tremor 79 (2.7%) 56 (2.1%) 
9. palpitations 66 (2.2%) 58 (2.1%) 
10. paraesthesia 65 (2.2%) 46 (1.7%) 
* denominator = total frequency of reported symptoms = 2956 
** denominator = total frequency of reported symptoms = 2700 
*** Z-test 
P-value*** 
<0.001 
<0.001 
<0.001 
<0.001 
0.785 
<0.001 
0.133 
0.139 
0.828 
0.177 
@ one of the ten most frequently reported symptoms of the present study 
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6.1.6 Comparison between symptoms reported in the present study 
and PEM data 
Using patient-months as a denominator to facilitate comparison to a PEM study, there 
were significantly higher proportions of the top ten symptoms reported in the present 
study, compared with PEM data (Table 6.12). Only unusual tiredness/ weakness was 
among the top ten reported events of PEM data, however, four of the top ten reported 
symptoms in this study were cited among the 20 most frequently reported events of 
PEM data. These were increased sweating, unusual tiredness/ weakness, constipation 
and change in mood. 
Table 6.12 Comparison of the ten most frequently reported symptoms of venlafaxine 
in the present study with PEM data 
Frequency of reported 
Rank Symptoms (%) P-value*** 
Own study* PEM data** 
1. dry mouth 111 (3.58%) 94 (0.17%) <0.001 
2. increased sweating@ 99 (3.19%) 185 (0.32%) <0.001 
3. light-headedness 87 (2.80%) 94 (0.17%) <0.001 
4. J.. sexual desire 85 (2.74%) 26 (0.05%) <0.001 
6 unusual tiredness/ 84 (2.71%) 355 (0.62%) <0.001 
weakness@ 
6. flushing 72 (2.32%) 34 (0.06%) <0.001 
7. constipation@ 66 (2.13%) 182 (0.32%) <0.001 
8. weight gain 65 (2.09%) 99 (0.18%) <0.001 
9. excessive thirst 62 (2.00%) 7 (0.01%) <0.001 
10. change in mood@ 60 (1.93%) 416 (0.74%) <0.001 
* denominator = total number of patient-months of treatment = 3102 ( number of 
valid patients = 244) 
** denominator = total number of patient-months of treatment = 56516 
*** Z-test @ one of the 20 most frequently reported events from PEM data 
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6.1.7 Comparison between symptoms reported in the main study and 
the pilot study 
Symptoms reported to venlafaxine were compared with those reported to the older 
antidepressants in the pilot study, trazodone and doxepin. Many of the symptoms 
reported were the same for all three drugs and occurred with similar frequency. 
However, increased sweating (Z=6.58, 95% CI= 23.43-43.31 %, P <0.001) and flushing 
(Z=3.67, 95% Cl = 9.27-30.53%, P <0.001) were reported less frequently with both 
trazodone and doxepin (Tables 6.13 and 6.14). Four further symptoms were also 
reported less frequently with doxepin than with venlafaxine. These were light-
headed ness, reduced sexual desire, unusual tiredness! weakness and change in 
mood (Table 6.14). 
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Table 6.13 Comparison of the ten most frequently reported symptoms of venlafaxine 
with trazodone 
Frequency of reported 
Rank Symptoms (%) 
Venlafaxine Trazodone* 
(n=263) (n=41 ) 
1. dry mouth@ 121 (46.0%) 20 (48.8%) 
2. increased sweating 107 (40.7%) 3 (7.3%) 
3. light-headedness@ 91 (34.6%) 16 (39.0%) 
4. '" sexual desire 89 (33.8%) 9 (22.0%) 
5. unusual tiredness/ 88 (33.5%) 14(34.1%) 
weakness@ 
6. flushing 78 (29.7%) 4 (9.8%) 
7. constipation@ 71 (27.0%) 13 (31.7%) 
8. weight gain 70 (26.6%) 11 (26.8%) 
9. excessive thirst@ 68 (25.9%) 12 (29.3%) 
10. change in mood 66 (25.1%) 12 (29.3%) 
* denominator = number of total respondents 
** Z-test 
P-value** 
0.741 
<0.001 
0.588 
0.094 
0.931 
<0.001 
0.544 
0.977 
0.653 
0.583 
@ one of the top ten most frequently reported symptoms of trazodone 
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Table 6.14 Comparison of the ten most frequently reported symptoms of venlafaxine 
with doxepin 
Frequency of reported 
Rank 
Symptoms (%) 
Venlafaxine 
(n=263) 
1. dry mouth@ 121 (46.0%) 
2. increased sweating 107 (40.7%) 
3. light-headedness@ 91 (34.6%) 
4. ,I, sexual desire 89 (33.8%) 
5. unusual tiredness/ 88 (33.5%) 
weakness@ 
6. flushing 78 (29.7%) 
7. constipation@ 71 (27.0%) 
8. weight gain@ 70 (26.6%) 
9. excessive thirst@ 68 (25.9%) 
10. change in mood 66 (25.1%) 
* denominator = number of total respondents 
** Z-test 
Doxepin* 
(n=52) 
26 (50.0%) 
4 (7.7%) 
9 (17.3%) 
7 (13.5%) 
9 (17.3%) 
6(11.5%) 
9 (17.3%) 
9 (17.3%) 
9 (17.3%) 
4 (7.7%) 
@ one of the top ten most frequently reported symptoms of doxepin 
P-value** 
0.599 
<0.001 
0.004 
<0.001 
0.007 
0.001 
0.102 
0.115 
0.147 
<0.001 
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6.1.8 Patient attribution of symptoms to drugs 
Of the total number of perceived symptoms reported, 1518 (56.2%) were classified by 
the researcher as being possibly caused by the study drugs, with a further 549 
(20.3%) classed as probably caused by study drugs. Three hundred and fifty four 
symptoms (13.1 %) were classed as unlikely to be an ADR and 279 were unattributable 
(10.3%). Table 6.15 lists the result of the classification for causal relationship of the 
perceived symptoms according to the eight criteria . The highest frequency was of 
those symptoms which could be caused by the study drug and concomitant drugs as 
well as patients' disease states (criteria 4). A higher percentage (76 .5%) of the 
reported symptoms were therefore potentially caused by venlafaxine (probable/ 
possible) than those (23.5%) not likely to be caused by venlafaxine (unlikely/ 
unattributable ). 
Table 6.15 Classification of symptoms reported of venlafaxine classified into eight 
criteria for assessment of causal relationship 
Total frequency of 
Causal relationship Criteria reported symptoms 
No. % 
Probable ADRs 1 549 20.3 
Possible ADRs 2 502 18.6 
3 411 15.2 
4 605 22.4 
Subtotal 1518 56.2 
Unlikely ADRs 5 72 2.7 
6 161 6.0 
7 121 4.5 
subtotal 354 13.2 
unattributable ADRs 8 279 10.3 
Total 2700 100 
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6.1.9 Comparison between expert and the researcher opinion on the 
classification for causal relationship 
Of a total 401 symptoms reported by 53 patients whose medical notes were accessed 
and evaluated, there was agreement for 320 symptoms (79.8%) on the causal 
relationship, while there was disagreement for 81 symptoms (20.2%) between the 
expert and the researcher. Considering each criteria of the causal relationship, 1 
(0.2%), 274 (68.3%), 32 (8.0%) and 13 (3.3%) of the symptoms reported were 
mutually agreed with the classifications as probable, possible, unlikely and 
unattributable, respectively (Table 6.16). Kappa value for agreement between the 
expert and the researcher was 0.51 indicating moderate agreement (Altman, 1992). 
Table 6.16 Comparison of expert and researcher classifications of symptoms 
reported from venlafaxine into four criteria according to causal relationship 
Number of reported symptoms by 
Researcher expert classifications (0/0) 
Classifications Probable Possible Unlikely Unattributable 
Probable 1 18 10 2 
(0.2%) (4.5%) (2.5%) (0.5%) 
Possible 0 274 21 4 
(0%) (68.3%) (5.2%) (1.0%) 
Unlikely 0 8 32 5 
(0%) (2.0%) (8.0%) (1.2%) 
Unattributable 0 5 8 13 
(O%) (1.2%) (2.0%) (3.3%) 
Total 1 305 71 24 
(0.2%) (76.1%) (17.7%) (6.0%) 
Total 
31 
(7.7%) 
299 
(74.6%) 
45 
(11.2%) 
26 
(6.5%) 
401 
(100%) 
Chapter 6: Venlafaxine 183 
6.2 Discussion 
The response rate from patients prescribed venlafaxine (41.5%) was higher than the 
overall response rate of the main study (36.3%) and for tramadol (32.8%). The 
proportion of female respondents taking venlafaxine was higher than for tramadol and 
the overall results of the main study. probably because depression occurs more often 
in females than males (Uoyd. 1995). The majority of respondents prescribed 
venlafaxine were younger than those prescribed tramadol. Again this probably reflects 
the wide age range over which depression is found. The mean number of concomitant 
drugs was also found to be lower in those taking venlafaxine (2.4. maximum =10 
drugs) than the overall results (3.0) and those taking tramadol (3.7. maximum = 16 
drugs). however the majority of respondents as with the overall study were taking 1-3 
concomitant drugs. This supports the suggestion that older patients. which made up 
the majority of the tramadol group. may take more medicines than younger patients. 
as in the venlafaxine group (Cunningham et al.. 1997; Classen et al.. 1997; Lee. 1993; 
May. 1997). However. as in the pilot study. the relationship between increasing age 
and number of concomitant drugs in respondents taking venlafaxine was not strong. 
About 34% of the respondents had taken venlafaxine for 361-540 days with the mean 
duration of therapy being 381.5 days which was slightly longer than those taking 
tramadol (majority = 1-180 days. mean = 324.8 days). This is probably a reflection of 
the need for prolonged therapy for depression. Nearly ten percent of respondents 
were taking venlafaxine more than three times a day which is in excess of the dose 
recommendation of two to three times a day (Feighner. 1994). However. the licensed 
dose regimen in the UK is 75-150 mg daily in 2 divided doses (British Medical 
Association and the Royal Pharmaceutical Society of Great Britain. 1998). It is 
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possible that some patients could not remember the exact dosage regimen of the 
medicines taken or may have confused venlafaxine with concomitant drugs taken. 
As anticipated, most of the respondents were taking venlafaxine for depressive illness 
(88.2%), but only 4.2% were taking venlafaxine for anxiety and stress. This differs 
from the pilot study in which fewer respondents were taking trazodone (68%) and 
doxepin (60%) for depression and more were taking trazodone (29%) and doxepin 
(33%) for other indications, such as anxiety, sleeplessness or panic attack. Thus older 
drugs, for which more information and experience are available, appeared to be used 
in more diverse indications than newer drugs. Less than 50% of the respondents 
stated that they had other medical conditions. This again may be a consequence of 
the majority of patients being aged less than 60 years, therefore they were less likely 
to have other diseases than the elderly, although it is possible that some patients were 
not aware of or concerned about other health problems. There were no patients 
admitted to hospital as a result of adverse reactions to venlafaxine. This may suggest 
that venlafaxine seemed to cause few serious ADRs likely to require hospitalisation in 
an out-patient sample. Danjou and Hackett (1995) also found that severe or serious 
events occurred at a relatively low rate in venlafaxine-treated patients, in particular, 
the rates of deaths, seizures, severe rash and elevated liver function test were low. 
This is also supported by Ellingrod and Perry (1994), who showed that venlafaxine had 
a very low rate of occurrence of serious, rare effects, compared with other 
antidepressants. However, venlafaxine is a newly marketed drug, thus more 
information on its safety profile must be provided from further PMS stUdies before 
making this assumption. The sample size of the present study may not be sufficient for 
detecting serious ADRs, particularly rare ones. In pre-marketing studies, about 500-
3000 patients are required for detecting ADRs which occur in 1-6 persons per 
thousand of exposed individuals (0' Donnell, 1994). 
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Forty one (15.6%) respondents had stopped taking the drug because their disease 
had improved whereas 26 (9.9%) perceived problems which caused them to 
discontinue the drug with or without their doctor's recommendation. This is, 
comparable to the discontinuation rate (8-10%) found in long term treatment (up to 
one year) in controlled studies as summarised by Oanjou and Hackett (1995). On the 
other hand, these workers found that short term treatment (six weeks) with venlafaxine 
resulted in a higher rate of discontinuation due to its adverse effects, representing 
16%, while a greater incidence (19-20%) of discontinuing treatment due to side effects 
was found in clinical trial studies reported by Ellingrod and Perry (1994) and in the 
analysis of pooled studies by Feighner (1994). However, the data from the present 
study showed that the average duration of taking venlafaxine was 382 days, thus it is 
comparable to long term treatment. The percentage of the respondents who had 
discontinued venlafaxine was higher than in similar studies by Fisher et al. (1995) 
which found 5.1 % of patients stopped sertraline and 2.1 % of patients stopped 
f1uoxetine because of their side effects. This may be due to the slightly different 
methodological approach, although both methods detected ADRs by patient self-
reporting. However it could suggest that venlafaxine caused more serious side effects 
which patients were unable to tolerate than sertraline and f1uoxetine. Only eight 
respondents (3%) indicated that they stopped venlafaxine as it was not helping them. 
This is a very low figure compared to that found by Danjou and Hackett (1995) who 
showed that 7-11% of venlafaxine-treated patients discontinued the drug due to 
unsatisfactory response. While this may be an indicator that venlafaxine is an effective 
antidepressant, the study was not designed to assess efficacy. 
Nearly 95% of the respondents taking venlafaxine reported at least one symptom 
which was higher than those in the overall results (88.6%) and those taking tramadol 
(84.0%). The respondents also reported a wide ranger of symptoms (0 - 71) and 
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higher number of different symptoms (97) compared to tramadol, with the median of 
number of symptoms reported being seven. This may due to biases from some 
patients who over-reported symptoms which they suffered regardless of whether the 
symptoms were caused by venlafaxine or not. It may also suggest that patients taking 
antidepressants tended to experience more different side effects than those taking 
analgesics. As was found in the tramadol group, there was no positive relationship 
between increasing age, number of concomitant drugs or duration of therapy with the 
number of symptoms reported by respondents taking venlafaxine. The lack of a clear 
relationship between increasing age and number of reported symptoms was confirmed 
by an analysis of a clinical trial database by Rudolph and Derivan (1996), indicating 
there was no significant difference in the risk of occurrence of the most common ADRs 
was revealed between those over and under 65 years. Likewise, the number of 
reported symptoms did not differ depending on whether patients were taking other 
antidepressants or other CNS drugs. The lack of an effect of other CNS drugs differs 
from that found in the tramadol group which may be due to a lower average number of 
concomitant drugs being taken by respondents on venlafaxine. 
Severity ratings for the most bothersome symptoms reported were provided by 80% of 
the respondents on venlafaxine, which was higher than the average of the remaining 
study drugs (65%). This is probably associated with the finding that a smaller number 
of respondents on venlafaxine (5%) reported no side effects experienced than the rest 
study drugs (14%), therefore this led fewer patients on venlafaxine to tick less 'does 
not apply' and 'unspecified'. A greater proportion of venlafaxine respondents perceived 
the most bothersome symptoms as moderately and severely than was found for 
tramadol respondents. This could be due to the longer duration of therapy in 
venlafaxine respondents, which would consequently increase exposure time to the 
drug and the possibility of perceiving more severe side effects. As with the pilot study 
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and the tramadol respondents, increased severity of the most bothersome symptoms 
was associated with an increase in the number of reported symptoms and increased 
tendency to inform their doctors about the symptoms reported. Interestingly, 63% of 
respondents informed their doctors about the symptoms reported in the questionnaires 
which they thought to be side effects from venlafaxine. This was more than those on 
tramadol, which could also be related to the greater number reporting severe 
symptoms. 
Six of the symptoms cited as being most bothersome by the respondents taking 
venlafaxine were also among the top ten most frequently reported. These were dry 
mouth, constipation, increased sweating, unusual tiredness or weakness, decrease in 
sexual desire and weight gain. This showed that patients tended to report symptoms, 
even minor side effects, which more bothered or interfered with their lifestyle. All of the 
ten most bothersome symptoms reported and nine of the ten most frequently 
symptoms reported, except change in mood, are known side effects of venlafaxine. 
Therefore the respondents seemed to report mostly symptoms potentially caused by 
venlafaxine, as was found with tramadol. However, change in mood, which could be 
attributed to patient illness, was also cited as one of the top ten symptoms reported 
and also featured among symptoms reported after stopping the drug. Such reports are 
probably similar to the inclusion of bone and joint pain among symptoms reported with 
tramadol. This suggests that, while the majority of symptoms reported by patients are 
perceived side effects of medicines, the questionnaire may also have prompted the 
reporting of disease-related symptoms. There were in total 6.0% of the symptoms 
reported which were classed as explainable only by disease states present and many 
more (42.1 %) could have been related to either disease states or drug therapy. Fewer 
respondents prescribed tramadol reported symptoms of disease states (4.5% plus 
25.1 % related to disease states or drugs), which may reflect the ease with which 
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symptoms can be distinguished from potential ADRs to analgesics. However it must 
be taken into consideration that incomplete data was provided by those respondents 
whose medical records were examined, which therefore leads to the assumption that 
most of the remaining respondents did not provide all information about concomitant 
drugs and disease states. This would have an effect on the classification of symptoms 
reported. 
Twelve percent of the 86 respondents who stopped venlafaxine reported symptoms 
which started after stopping the drug. Nearly 50 percent of the total 17 different 
symptoms reported were known withdrawal symptoms caused by venlafaxine, such as 
headache, nausea! vomiting, confusion and dizziness. This is in line with reports of 
withdrawal symptoms occurring on abrupt cessation, dose reduction or tapering of 
venlafaxine which were more frequent at daily doses of 150 mg or more (Sinclair et aI., 
1998). The symptoms are in agreement with a review by Sinclair et al. (1998) which 
summarised that the common withdrawal symptoms were headache, nausea, 
vomiting, dizziness, insomnia, nervousness and asthenia. Interestingly, the most 
frequently reported symptom after discontinuing venlafaxine was change in mood, 
which is not a known withdrawal reaction and is more likely to relate to patients' 
depressive illness, which recurred after discontinuing their treatment. This explanation 
could also apply to the other symptoms reported which are not known withdrawal 
symptoms, such as decrease in appetite, anger! aggression, increased sleep, weight 
loss and palpitations. It is also possible that these and other symptoms, i.e. light-
headedness, unsteadiness on feet and flu-like symptoms may be related to other 
disease states or concomitant drugs which patients were still taking after discontinuing 
venlafaxine. 
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Similarly low recording in medical notes of symptoms reported by patients taking 
venlafaxine in the questionnaires (23.9%) was found to the tramadol group and the 
pilot study. However a larger proportion of these (25%) were recorded as side effects 
than was found in the tramadol group. This may be due to doctors' greater awareness 
of venlafaxine side effects or the greater severity of the symptoms. as was found in 
patient reports. It is of interest that for 11 of the 12 patients who reported change in 
mood, this symptom which was recorded in medical notes, although as a symptom 
related to depressive illness. Many patients had clearly identified this effect in their 
questionnaires. Increased sweating and weight gain were also documented in more 
than half the cases who reported these symptoms by questionnaire. It appears that 
these were bothersome to the patients, leading them to report the symptoms to their 
doctors. This is supported by frequent citation of these among the most bothersome 
symptoms reported (rank 1 and 3). 
The comparison of patient-reported symptoms to data from CSM reports suggest that 
patient self-reporting tended to detect more minor and known side effects such as dry 
mouth, constipation, flushing, unusual tiredness/ weakness and excessive thirst, 
whereas the CSM method tended to detect more serious and acute side effects such 
as nausea! vomiting, rashes, unsteadiness on feet and dizziness! vertigo. This was 
also found in the tramadol group and is in agreement with other work (Mitchell et al., 
1989, 1994; van den Bemt et al., 1999). While the symptoms reported most frequently 
differed, five of the top ten CSM reports were found with similar frequency in the 
present study. Also there may have been difficulty in distinguishing light-headedness, 
reported in the questionnaire, from dizziness, vertigo or unsteadiness on feet, which 
were frequent among CSM reports. 
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Surprisingly, change in mood, which was frequently reported in the present study and 
would appear unlikely to be attributed to an adverse reaction of venlafaxine was 
ranked 18 among CSM reports. Change in mood was also among the top 20 reported 
events in PEM data. This may suggest that even health professionals may report 
symptoms associated with patients' illness rather than the suspected drug. This could 
be due to difficulty in distinguishing the disease states from the reaction caused by the 
suspected drug cited as one of the main reasons for AOR under-reporting (Randhawa 
and Smith, 1987; Scott et al., 1987; Generali et al., 1995; Bateman et al., 1992). It is 
also possible that mood changes bothered patients, thus led them to report it to their 
doctors. Alternatively, it is possible that these could represent side effects of 
venlafaxine, since the drug can cause mania! hypomania or suicidal ideation (Stoner 
et al., 1999), although thought of suicide was also included in the questionnaire. 
However in a study of 2258 venlafaxine-treated patients, the incidence of both of these 
side effects was remarkably low (0.4% each) (Oanjou and Hackett, 1995), while there 
were 25.1 % of patients in the current study reporting mood change. Thus, it would 
seem most likely that the majority of patient reports would have been related to 
depressive illness. 
In total four of the top ten reported symptoms in the present study were also among 
the top 20 events reported from PEM data, many of which were known side effects of 
venlafaxine. PEM data generally identified less severe side effects than CSM data, 
such as increased sweating, unusual tiredness, insomnia, drowsiness and constipation 
which is similar to the findings of the present study. 
Nausea! vomiting, dizziness and headache were found less frequently in the present 
study, compared with the CSM and PEM data. This is likely to be due to tolerance 
developing among the respondents (Oanjou and Hackett, 1995; Sinclair et al., 1998; 
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Feighner, 1994; Preskorn. 1995) which is also demonstrated by PEM data showing 
that 69.6% of all nausea! vomiting events were reported during the first month of 
therapy. falling rapidly over the subsequent weeks. PEM studies are more likely to 
detect acute reactions than the present method. since they concentrate on events in 
the early months of therapy (Freemantle et al.. 1997). Preskorn (1995) also 
commented that the incidence of side effects did not reflect their severity as some 
adverse effects were either intolerable or so serious that treatment must be 
discontinued. This is in line with the finding of the present study that nausea! vomiting 
was one of top ten most bothersome symptoms but not one of the ten most common 
reported symptoms. 
Excessive thirst and decrease in sexual desire were found in considerably higher 
frequencies in the present study. compared with CSM and PEM data. This may be 
because the patients in the present study who ticked dry mouth often ticked excessive 
thirst as well. while the reports from health professionals may have been more likely to 
cite only dry mouth. It is also likely that side effects concerning confidential issues. 
such as sexual life are much more likely to be detected by a patient-self reporting 
method since reports to doctors are likely to be infrequent. 
Many of the ten most commonly reported symptoms from venlafaxine were also 
among the top ten symptoms reported from trazodone and doxepin. all of which were 
previously known side effects to both drugs. Although numbers of respondents on the 
older drugs were low. therefore comparisons should be undertaken cautiously. there 
were no significant differences in the incidences of anticholinergic side effects between 
the three drugs. This supports the findings of Holliday and Benfield (1995). Ellingrod 
and Perry (1994) and Oanjou and Hackett (1995). who compared venlafaxine and 
trazodone. However it differs from the conclusions of Sinclair et al. (1998) and 
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Augustin et al. (1997), who suggested that venlafaxine caused much fewer 
anticholinergic side effects than tricyclic antidepressants, of which doxepin is an 
example. Dry mouth was, in fact, the most commonly reported symptom from 
venlafaxine. It is possible that this could be due to a lack of tolerance developing, as 
suggested by Feighner (1994). Increased sweating was found with much higher 
frequency in patients receiving venlafaxine and was also among common symptoms 
reported in clinical studies (Sinclair et al., 1998; Danjou and Hackett, 1995), although 
the latter workers did not identify this as being more frequent with venlafaxine than 
trazodone. Unusual tiredness was found in similar proportions between venlafaxine 
and trazodone, which has also been found elsewhere (Ellingrod and Perry, 1994; 
Danjou and Hackett, 1995). 
Many of the symptoms reported in the present study with high frequencies (see 
Appendix J) were among those identified from other sources (Drugdex Drug 
Evaluation Monographs, Holliday and Benfield, Feighner, Danjou and Hackett, 
Preskorn, Augustin et al., Ellingrod and Perry, Sinclair et al.) as commonly reported 
adverse effects of venlafaxine. While the frequencies of these reported symptoms 
were high in the present study, the estimates of lowest likely incidence obtained using 
number of questionnaires issued as a denominator correlate well with the incidences 
reported in these studies for five common symptoms. It may thus be that the method, 
while identifying mainly potential adverse events, does result in over-estimates of their 
incidence. The majority of the symptoms reported were classed as potentially caused 
by venlafaxine (76.5%), which was slightly higher than those reported from tramadol 
(67.2%). Thus although there were more symptoms reported in total from venlafaxine 
and also a wider range of symptoms, this is likely to be due to there being more 
potential side effects with this drug than is the case with tramadol. Most of the 
classification of 401 symptoms reported by a sample of 53 patients were agreed by an 
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independent expert (320,80%), of which 275 (86%) were judged to be probable or 
possible ADRs. If it is assumed that the classification was therefore generally 
appropriate, the questionnaire appears to have demonstrated a reasonable specificity 
for adverse effects to venlafaxine. This is further supported by the general finding that 
patients who reported few symptoms were less likely to report those classed as 
unlikely or unattributable ADRs. 
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Chapter 7 
Results and Discussion: 
Main study: Other drugs 
7.1 Results of anticonvulsants 
7.1.1 Response rates and demographic data 
There were total 115, 40 and 23 postal questionnaires sent to patients prescribed 
gabapentin, lamotrigine and topiramate, respectively. Of these, 68, 18 and 13 patients 
responded giving response rates of 59%, 45% and 56% for gabapentin, lamotrigine 
and topiramate, respectively. Of the total respondents prescribed these three 
anticonvulsants, 45 (45%) were male and 43 (54%) were female, one (1.0%) did not 
specify. The mean ± SO age of the total respondents was 38.1 ± 14.1 years with the 
majority of patients in the age groups 20-39 (50%) and 40-59 (31 %). Regarding each 
individual drug, patients taking gabapentin had mean age ± SO = 39.8 ± 15.0, 
lamotrigine had mean age ± SO = 30.8 ± 9.5 and topiramate had mean age ± SD = 
39.2 ± 12.6. Table 7.1 lists number of the respondent characteristics according to sex 
and age groups. 
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Table 7.1 Number of respondents prescribed gabapentin, lamotrigine and 
topiramate according to sex and age groups 
Number of respondents (%) 
Gab* Lam* Top* Total 
(n=68) (n=18) (n=13) (n=99) 
Sex 
Male 33 (49%) 6 (33%) 6 (46%) 45 (45%) 
Female 34 (50%) 12(67%) 7 (54%) 53 (54%) 
not specified 1 ( 1 %) - - 1 ( 1%) 
Age group * 
<20 5 ( 7%) 2 (11%) - 7 ( 7%) 
20-39 29 (44%) 13 (72%) 7 (54%) 49 (50%) 
40-59 22 (32%) 3 (17%) 6 (46%) 31 (31 %) 
60-79 9 (13%) - - 9 ( 9%) 
~80 1 ( 1%) - - 1 ( 1 %) 
not specified 2 ( 3%) - - 2 ( 2%) 
* Gab = Gabapentin, Lam = Lamotrigine, Top = Topiramate 
7.1.2 Drug therapy 
The majority of the respondents were taking 1-3 (75%) and 4-6 (14%) concomitant 
drugs. The overall mean ± SO of number of concomitant drugs was 2.7 ± 1.6 (range 
1-8) with no differences between the patient groups (Table 7.2). The average duration 
of taking the anticonvulsants was 720.1 days (SO = ± 574.5). The majority of the 
respondents had been taking anticonvulsants for more than 720 days (n=32, 40%). 
Figure 7.1 shows duration of therapy for each drug. Of the total respondents 
prescribed anticonvulsants, 29 (37%),36 (46%) and 13 (17%) were taking these one, 
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two, three or more times daily, respectively. Indications for use reported in the 
questionnaires are listed in Table 7.3. There were 46 (46%) respondents who reported 
having other medical conditions. Although 42 respondents (42%) reported that they 
had been in hospital since starting the study anticonvulsants, none of them indicated 
that the admissions were caused by those drugs. Five respondents had stopped 
taking their study anticonvulsants, but only one of these, taking topiramate, had done 
50 because they were having a problem with it. 
Table 7.2 Number of respondents prescribed gabapentin, lamotrigine and 
topiramate according to number of concomitant drugs 
Number of Number of respondents (%) 
concomitant Gab* Lam* Top* Total 
drugs (n=68) (n=18) (n=13) (n=99) 
0 - - - -
1-3 51 (75%) 12 (67%) 11 (84%) 74 (75%) 
4-6 11 (16%) 2 (11 %) 1 ( 8%) 14 (14%) 
7-9 3 ( 4%) 2(11%) 1 ( 8%) 6 ( 6%) 
~10 - - - -
not specified 3 ( 4%) 2(11%) - 5 ( 5%) 
mean ± SO 2.7 ± 1.5 2.9 ± 2.2 2.6 ± 1.6 2.7±1.6 
* Gab = Gabapentin, Lam = Lamotrigine, Top = Topiramate 
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Figure 7.1 Duration of therapy for each anticonvulsant 
Table 7.3 Number of respondents prescribed gabapentin . lamotrigine and 
topiramate according to indication for use 
Number of respondents (%) 
Indication 
Gab* Lam* Top* Total 
(n=68) (n=18) (n=13) (n=99) 
unspecified epilepsy 61 (90%) 15 (83%) 13 (100%) 89 (90%) 
grand mal epilepsy 1 ( 1%) - - 1 ( 1%) 
partial seizure 4 ( 6%) 2 (11 %) - 6 ( 6%) 
not specified 2 ( 3%) 1 ( 6%) - 3 ( 3%) 
*Gab = Gabapentin. Lam = Lamotrigine. Top = Topiramate 
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7.1.3 Symptoms reported and comparison to CSM data and pilot study 
Of the total 99 respondents prescribed anticonvulsants, 84 (85%) reported at least one 
symptom, while only 15 (15%) reported no side effects experienced. Considering each 
individual drug, 59 (87%), 14 (78%) and 11 (85%) of the respondents taking 
gabapentin, lamotrigine and topiramate, respectively, reported at least one symptom. 
There were 77, 46 and 41 different symptoms and 575 (median = 5.5, range 0-37), 
117 (median = 5.0, range 0-17) and 59 (median =3, range 0-12) total symptoms 
reported by respondents taking gabapentin, lamotrigine and topiramate, respectively 
(Figure 7.2). Eighty eight (89%) and 21 (21 %) of respondents taking the 
anticonvulsants were also taking other anticonvulsants and other CNS drugs, 
respectively. There were no strong relationships between number of reported 
symptoms and increasing number of concomitant drugs (Spearman r = 0.061, P = 
0.557), duration of therapy (Spearman r = 0.103, P = 0.360) or age (Spearman r = 
0.215, P = 0.034). While no Significant association was found between number of 
symptoms reported and the presence of other anticonvulsants (P = 0.482, Fisher's 
exact test), patients taking other CNS drugs were more likely to report more than ten 
symptoms (x2 = 14.412, df= 1, P <0.001) (Table 7.4). 
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Figure 7.2 Number of reported symptoms for each anticonvulsant 
Table 7.4 Presence of other eNS drugs in relation to number of patients reporting 
symptoms 
Presence of Number of patients (%) 
other eNS drugs 
Number of reported symptoms Total* 
~10 >10 
No 61 12 73 
(83.6%) (16.4%) (100%) 
Yes 9 12 21 
(42.9%) (57.1 %) (100%) 
* Total number of valid cases = 94 
The majority of respondents perceived the severity of the most bothersome symptoms 
as moderately {n =21 , 21 %} and severely (n = 24, 24%). Thirty six percent of the 
respondents had informed their doctors about all symptoms reported in the 
questionnaires and a further 24 % about some of these symptoms (Table 7.5). 
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Table 7.5 Number of respondents prescribed each anticonvulsant according to 
severity of most bothersome symptoms and whether they informed their doctors 
No. of respondents (%) 
Gab* Lam* Top* Total 
(n=68) (n=18) (n=13) (n=99) 
Severity 
Minimally 3 ( 4%) - 1 ( 8%) 4 ( 4%) 
Mildly 4 ( 6%) - - 4 ( 4%) 
Moderately 16(24%) 3 (17%) 2 (15%) 21 (21%) 
Severely 15 (22%) 8 (445) 1 ( 8%) 24 (24%) 
very severely 7 (10%) - 2 (15%) 9 ( 9%) 
does not apply 9(13%) 2(11%) 3 (23%) 14 (14%) 
not specified 14 (21%) 5 (28%) 4 (31%) 23 (23%) 
Inform doctors 
all of symptoms 26 (38%) 4 (22%) 6 (46%) 36 (36%) 
some of symptoms 18 (26%) 5 (28%) 1 ( 8%) 24 (24%) 
none of symptoms 4 ( 6%) 2 (11 %) 3 (23%) 9 ( 9%) 
not sure 2 ( 3%) 1 ( 6%) - 3 ( 3%) 
does not apply 11 (16%) 2 (11 %) 1 ( 8%) 14 (14%) 
not specified 7 (10%) 4 (22%) 2 (15%) 13 (13%) 
*Gab = Gabapentin, Lam = Lamotrigine, Top = Topiramate 
Weight gain, loss of memory and anxiety! agitation were the most commonly reported 
symptoms from gabapentin (Table 7.6) while loss of memory (8 patients), difficulty in 
concentrating (6) and light-headedness (5) were those from lamotrigine. The most 
frequently reported symptoms from topiramate were weight loss, bloated feeling and 
unsteadiness on feet (3 patients each). The most common bothersome symptom 
reported for gabapentin was weight gain (11), for lamotrigine was loss of memory (5) 
and for topiramate was unusual tiredness! weakness (2). Carbamazepine and sodium 
valproate, the anticonvulsants involved in the pilot study, were compared with the 
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three in the main study (Table 7.6). Many symptoms were common to all the drugs. 
While the numbers of respondents in all groups are relatively low, the data do suggest 
that weight gain may be more of a problem with gabapentin than with the other drugs 
and that difficulty concentrating, loss of memory, increased sleep or unusual tiredness! 
weakness are common side effects with all five anticonvulsants. 
Table 7.6 Frequently reported symptoms of the anticonvulsants in main study and 
pilot study 
Frequency of reported Symptoms (%) 
Symptom Gab* Lam* Top* Car* Val* 
(n=68) (n=18) (n=13) (n=44) (n=25) 
1. weight gain 24 (35%) 4 (22%) 1 (7.7%) 5 (11%) 6 (24%) 
2. loss of memory 21 (31%) 8 (44%) 2 (15%) 8 (18%) 9 (36%) 
3. anxiety/ agitation 17 (25%) 1 (6%) 1 (8%) 4 (9%) 6 (24%) 
4. change in mood 17 (25%) 4 (22%) 1 (8%) 4 (9%) 6 (24%) 
5. difficulty concentrating 17 (25%) 6 (33%) 3 (23%) 10 (23%) 9 (36%) 
6. increased sleep 16 (24%) 3 (17%) 2 (15%) 15 (34%) 8 (32%) 
7. headache 16 (24%) 2(11%) 2 (15%) 7 (16%) 6 (24%) 
8. unsteadiness on feet 14(21%) 4 (22%) 3 (23%) 6 (14%) 5 (20%) 
9. dry mouth 14(21%) 1 (6%) 1 (8%) 7 (16%) 4 (16%) 
10. light-headedness 14 (21%) 5 (28%) 1 (8%) 9 (20%) 4 (16%) 
11. dizziness! vertigo 14 (21 %) 4 (22%) 2 (15%) 8 (18%) 3 (12%) 
12. unusual tiredness! 13 (19%) 3 (17%) 2 (15%) 12 (27%) 14 (56%) 
weakness 
13. tremor 13 (19%) 4 (22%) 1 (8%) 9 (20%) 11 (44%) 
14. reduction in sleeping 8 (12%) 4 (22%) - 6 (14%) 4 (16%) 
*Gab = Gabapentin, Lam = Lamotrigine, Top = Topiramate, Car = Carbamazepine, 
Val = Sodium valproate 
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Of the ten most commonly symptoms reported by patients taking gabapentin in the 
present study, five were cited as the ten most commonly reported symptoms in CSM 
data. These were anxiety! agitation, change in mood, increased sleep, headache and 
unsteadiness on feet (Table 7.7). However, only unsteadiness on feet and dizziness! 
vertigo from lamotrigine, both reported by four patients in the present study, were 
among the top ten symptoms of CSM data. Weight loss and unsteadiness on feet, the 
commonest symptoms from topiramate were cited in 22 and 12 out of 203 CSM 
reports, respectively. 
Table 7.7 Comparison of the ten most frequently reported symptoms of gabapentin in 
the present study with CSM data 
Frequency of reported symptoms (%) 
Rank 
Own study CSM data 
( n= 575 )* ( n= 583 )* 
1. weight gain 24 (4.2%) 11 (1.9%) 
2. loss of memory 21 (3.7%) 4 (0.7%) 
3. anxiety! agitation@ 17 (3.0%) 15 (2.6%) 
4. change in mood@ 17 (3.0%) 15 (2.6%) 
5. difficulty concentrating 17 (3.0%) 1 (0.2%) 
6. increased sleep@ 16 (2.8%) 32 (5.5%) 
7. headache@ 16 (2.8%) 23 (3.9%) 
8. unsteadiness on feet@ 14 (2.4%) 29 (5.0%) 
9. dry mouth 14 (2.4%) 1 (0.2%) 
10. light-headedness 14 (2.4%) --
* total frequency of reported symptoms 
@ one of the 10 most frequently reported symptoms of CSM data 
7.2 Results of other antidepressants 
7.2.1 Response rates and demographic data 
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There were in total 204, 132 and 48 postal questionnaires sent to patients prescribed 
nefazodone, citalopram and moclobemide, respectively. The response rates were 
31.4% (n=64), 32.6% (n=43) and 33.3% (n=16) for nefazodone, citalopram and 
moclobemide, respectively. Of the total respondents prescribed these three 
antidepressants, 37 (30.1%) were male and 85 (69.1%) were female, one (0.8%) did 
not specify. The mean ± SO age of the total respondents was 49.0 ± 14.9 years with 
the majority of patients in the age groups 40-49 (48.0%) and 20-39 (26.0%). 
Regarding each individual drug, respondents prescribed nefazodone had mean age ± 
SO = 46.2 ± 11.8, citalopram had mean age ± SO = 55.0 ± 18.2 and moclobemide 
had mean age ± SO = 44.1 ± 11.3. Table 7.8 shows the respondent characteristics 
according to sex and age groups. 
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Table 7.8 Number of respondents prescribed nefazodone. citalopram and 
moclobemide according to sex and age groups 
Number of respondents (%) 
Nef* Cit* Moc* Total 
(n=64) (n=43) (n=16) (n=123) 
Sex 
Male 25 (39.1) 9 (20.9) 3 (18.8) 37 (30.1) 
Female 39 (60.9) 33 (76.7) 13 (81.2) 85 (69.1) 
not specified - 1 ( 2.3) - 1 ( 0.8) 
Age group * 
< 20 - - - -
20-39 18 (28.1) 7 (16.3) 7 (43.8) 32 (26.0) 
40-59 36 (56.2) 16 (37.2) 7 (43.8) 59 (48.0) 
60-79 9 (14.1) 14 (32.6) 2 (12.5) 25 (20.3) 
~ 80 - 5 (11.6) - 5 ( 4.1) 
not specified 1 ( 1.6) 1 ( 2.3) - 2 ( 1.6) 
* Nef = Nefazodone • Cit = Citalopram. Moc = Moclobemide 
7.2.2 Drug therapy 
The majority of the respondents were taking 1-3 (51.2%) and 4-6 (22.0%) concomitant 
drugs. The overall mean ± SD of number of concomitant drugs was 2.4 ± 2.0 (range 
1-10) (Table 7.9). The average duration of taking the antidepressants was 353.5 days 
(SD = ± 300.2). The majority of the respondents were taking the three antidepressants 
180-360 days (n=42, 38.9%) and 1-180 days (n=27, 25.0%). followed by 361-540 days 
(n=17. 15.7%). 541-720 days (n=11. 10.2%) and more than 720 days (n=11, 10.2%), 
respectively. Figure 7.3 presents duration of therapy for each drug. Of the total 123 
respondents prescribed the three antidepressants, 40 (32.5%). 74 (60.2%) and 7 
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(5.7%) were taking them one, two, three or more times daily, respectively. Indications 
for use reported in the questionnaires are listed in Table 7.10. 
Table 7.9 Number of respondents prescribed nefazodone, citalopram and 
moclobemide accord ing to number of concomitant drugs 
Number of Number of respondents (%) 
concomitant Nef* Cit* Moc* Total 
drugs (n=64) (n=43) (n=16) (n=123) 
0 7 (10.9) 4 ( 9.3) 2 (12.5) 13 (10.6) 
1-3 34 (53.1) 22 (51 .2) 7 (43.8) 63 (51.2) 
4-6 10 (15.6) 11 (25.6) 6 (37.5) 27 (22.0) 
7-9 1 ( 1.6) 1 ( 0.8) - 2 ( 1.6) 
~10 - 1 ( 0.8) - 1 ( 0.8) 
not specified 12 (18.8) 4 ( 3.2) 1 ( 6.2) 17 (13.8) 
mean ± SD 1.9 ± 1.7 2.7 ± 2.2 2.9 ± 1.9 2.4 ± 2.0 
* Nef = Nefazodone, Cit = Citalopram, Mac = Moclobemide 
50~------------------------------' 
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Figure 7.3 Duration of therapy for each antidepressant 
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Table 7.10 Number of respondents prescribed nefazodone, citalopram and 
moclobemide according to indication for use 
Number of respondents (%) 
Indication 
Nef* Cit* Moc* Total 
(n=64) (n=43) (n=16) (n=123) 
depression 53 (83%) 36 (84%) 14 (88%) 103 (84%) 
anxiety 4 ( 6%) 2 ( 5%) - 6 ( 5%) 
panic attack 1 ( 2%) - - 1 ( 1 %) 
stress 4 ( 6%) 1 ( 2%) - 5 ( 4%) 
other psychotic disorders 1 ( 2%) 1 ( 2%) - 2 ( 2%) 
other bone or muscle 1 ( 2%) - - 1 ( 1%) 
diseases 
not specified - 3 ( 7%) 2 (12%) 5 ( 4%) 
* Nef = Nefazodone, Cit = Citalopram, Moc = Moclobemide 
There were 67 (54%) respondents who reported having other medical conditions. 
None of the 28 respondents (23%) who reported a hospital admission after starting the 
antidepressants indicated that the admissions were related to these drugs. Of the total 
123 respondents taking the three antidepressants, 42 (34%) had stopped taking the 
drugs. The reasons for discontinuing the drugs are described in Table 7.11. In total 14 
had stopped because of perceived problems with their drug. 
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Table 7.11 Number of respondents according to reasons for stopping nefazodone, 
citalopram and moclobemide 
Reason Number of respondents (%) 
Nef* Cit* Moc* Total 
(n=24) (n=13) (n=5) (n=42) 
I felt I didn't need it any 5(21%) 4 (31%) 2 (40%) 11 (26%) 
longer. 
The doctor said I didn't 3 (12%) 1 ( 8%) - 4 (10%) 
need it any longer. 
The doctor told me to stop 5(21%) 3 (23%) - 8 (19%) 
as I was having problems 
with it. 
I decided to stop as I was 4(17%) 1 ( 8%) 1 (20%) 6 (14%) 
having problem with it. 
I felt it wasn't helping me 3 (12%) 3 (23%) 2 (40%) 8 (19%) 
Others 4 (17%) 1 ( 8%) - 5 (12%) 
* Nef = Nefazodone, Cit = Citalopram, Moc = Moclobemide 
7.2.3 Symptoms reported and comparison to CSM data and other 
antidepressants 
Of a total 123 respondents prescribed the antidepressants, 114 (92.7%) reported at 
least one symptom, while only nine (7.3%) reported no side effects experienced. 
Considering each individual drug, 62 (97%),37 (86%) and 15 (94%) out of a total 
respondents taking nefazodone, citalopram and moclobemide, respectively, reported 
at least one symptom. There were 85, 78 and 52 different symptoms and 677 (median 
= 8.5, range 0-39), 358 (median = 5.0, range 0-37) and 103 (median = 6.5, range 0-
16) total symptoms reported by respondents taking nefazodone, citalopram and 
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moclobemide, respectively (Figure 7.4). Twenty four (20%) and 43 (35%) of the 123 
respondents were taking other antidepressants and other CNS drugs, respectively. 
There was no relationship between number of reported symptoms and age (Spearman 
r = -0.132, P = 0.150), number of concomitant drugs (Spearman r = 0.018, P = 0.885) 
or duration of therapy (Spearman r = -0.011, P = 0.909). Respondents taking other 
antidepressants were more likely to report more than ten symptoms (/ = 4.140, df = 
1, P = 0.042) (Table 7.1 2), while there was no similar effect of taking other CNS drugs 
(/ = 0.107, df= 1, P = 0.743). 
60 ~---------------------------------' 
50 
40 
30 
20 Drug name 
citalopram 
10 
-c 
a> o moclobemide (.) 
L..-
a> 0 a.. ~ nefazodone 
:s5 6-10 11-15 >15 
Number of reported symptoms 
Figure 7.4 Number of reported symptoms for each antidepressant 
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Table 7.12 Presence of other antidepressants in relation to number of patients 
reporting symptoms 
Presence of other Number of patients (%) 
antidepressants 
Number of reported symptoms Total* 
s;10 >10 
No 43 27 70 
(61%) (39%) (100%) 
Yes 9 15 24 
(38%) (62%) (100%) 
* Total number of valid cases = 94 
The majority of respondents perceived the severity of most bothersome symptoms as 
moderate (n =38,30.9%) and severe (n = 28, 22.8%). Twenty eight percent of the 
respondents had informed their doctors about all symptoms reported in the 
questionnaires and 30 % about some symptoms reported (Table 7.13). 
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Table 7.13 Number of respondents prescribed each antidepressant according to 
severity of most bothersome symptoms and whether they informed their doctors 
Number of respondents (%) 
Nef* Cit* Moc* Total 
(n=64) (n=43) (n=16) (n=123) 
Severity 
minimally 3 ( 5%) 2 ( 5%) 3 (19%) 8 ( 6%) 
mildly 9 (14%) 7 (16%) 2 (12%) 18(15%) 
moderately 19 (30%) 15 (35%) 4 (25%) 38 (31%) 
severely 21 (33%) 5 (12%) 2 (12%) 28 (23%) 
very severely 6 ( 9%) 4 ( 9%) 1 ( 6%) 11 ( 9%) 
does not apply 5 ( 8%) 6 (14%) 4 (25%) 15(12%) 
not specified 1 ( 2%) 4 ( 9%) - 5 ( 4%) 
I nform doctors 
all of symptoms 21 (33%) 9 (21%) 4 (25%) 34 (28%) 
some of symptoms 22 (34%) 10 (23%) 5 (31%) 37 (30%) 
none of symptoms 10 (16%) 10 (23%) 3 (19%) 23 (19%) 
not sure 5 ( 8%) 5 (12%) 2 (12%) 12 (10%) 
does not apply 4 ( 6%) 7 (16%) 2 (12%) 13(11%) 
not specified 2 ( 3%) 2 ( 5%) - 4 ( 3%) 
* Nef = Nefazodone, Cit = Citalopram, Moc = Moclobemide 
Dry mouth was clearly the most common symptom for all drugs and constipation and 
light-headedness were also frequently reported by all respondents except those on 
moclobemide (Table 7.14). Unusual tiredness! weakness and increased sleep were 
also commonly reported to all drugs. Although the number of respondents taking 
moclobemide was very small, this drug did appear to show a different adverse effect 
profile, indicated by the proportionately high number of patients reporting headache. 
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Paraesthesia was a particularly frequent report from respondents on nefazodone and 
decreased sexual desire was more common in those taking nefazodone and 
venlafaxine. 
Three of the top ten symptoms reported to the CSM for nefazodone were among the 
top ten in this study (Table 7.15). Nausea/ vomiting was the most frequent symptom 
reported to the CSM from moclobemide, comprising 80 reports, followed by headache 
with 63 reports. These symptoms were reported by three and five patients respectively 
in the present study. Headache, tremor, increased sweating and anxiety/ agitation 
were found with citalopram in both the present study and reports to the CSM (Table 
7.16), although nausea/ vomiting, the commonest symptom among CSM reports was 
only cited by eight respondents. Unusual tiredness! weakness, paraesthesia and 
anxiety/ agitation were also reported frequently in this study to nefazodone, as in CSM 
data. Difficulty concentrating was reported by 20 patients on nefazodone and was also 
cited by nine as being most bothersome. Anxiety! agitation was similarly cited 
frequently as most bothersome (8 patients) and in general (16 patients). Increased 
sweating (5) and unusual tiredness! weakness (5) were cited most frequently as 
bothersome symptoms with citalopram, while decrease in sexual desire (2) was only 
the most bothersome symptom reported by patients taking moclobemide. 
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Table 7.14 Frequency of reported symptoms to the antidepressants in main study 
and pilot study 
Frequency of reported Symptoms % 
Symptom 
Nef Cit Moc Ven Tra 
(n=64) (n=43) (n=16) (n=263) (n=41 ) 
1. dry mouth 29 (45%) 16 (37%) 6 (38%) 121 (46%) 20 (49%) 
2. unusual 
tiredness 24 (38%) 14 (33%) 3 (19%) 88 (34%) 14 (34%) 
3. light-
headedness 22 (34%) 15 (35%) 1 (6%) 91 (35%) 16 (39%) 
4. difficulty 
concentrating 20 (31%) 3 (7%) 3 (19%) 59 (22%) 13 (32%) 
5. J. sleep 19 (30%) 7 (16%) 4 (25%) 64 (24%) 8 (20%) 
6. paraesthesia 19 (30%) 7 (16%) 1 (6%) 46 (18%) 7 (17%) 
6. J. sexual 
desire 17 (27%) 10 (23%) 3 (19%) 89 (34%) 9 (22%) 
8. dizziness! 
vertigo 17 (27%) 6 (14%) 4 (25%) 48 (18%) 10 (24%) 
9. tremor 16 (25%) 13 (30%) 1 (6%) 56 (21%) 10 (24%) 
10. anxiety! 
agitation 16 (25%) 9 (21%) 2 (12%) 59 (22%) 19 (46%) 
11. i sleep 12 (19%) 14 (33%) 2 (12%) 45 (17%) 17 (42%) 
12. i sweating 10 (16%) 12 (28%) 2 (12%) 107 (41%) 3 (7%) 
13. headache 15 (23%) 11 (25%) 5 (31 %) 50 (19%) 2 (5%) 
14. flushing 10(16%) 10 (23%) - 78 (30%) 4 (10%) 
15. constipation 11 (17%) 8 (19%) 1 (6%) 71 (27%) 13 (32%) 
16. nausea! 14 (22%) 8 (19%) 3 (19%) 64 (24%) 1 (2%) 
vomiting 
Nef = Nefazodone, Cit = Citalopram, Moc = Moclobemide, Ven = Venlafaxine, 
Tra = Trazodone, Dox = Doxepin 
Dox 
(n=52) 
26 (50%) 
9 (17%) 
9 (17%) 
7 (14%) 
4 (8%) 
7 (14%) 
6 (12%) 
6 (12%) 
4 (8%) 
4 (8%) 
10 (19%) 
4 (8%) 
5 (10%) 
6 (12%) 
9 (17%) 
1 (2%) 
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Table 7.15 Comparison of the ten most frequently reported symptoms of nefazodone 
in the present study with CSM data 
Frequency of reported symptoms (%) 
Rank 
Own study CSM data 
( n= 677 )* ( n= 1941 )* 
1. dry mouth 29 (4.3%) 20 (1.0%) 
2. unusual tiredness/ 24 (3.5%) 56 (2.9%) 
weakness@ 
3. light-headedness 22 (3.2%) 20 (1.0%) 
4. difficulty concentrating 20 (3.0%) 9 (0.5%) 
5. reduction in sleeping 19 (2.8%) 20 (1.0%) 
6. paraesthesia@ 19 (2.8%) 76 (3.9%) 
7. J, sexual desire 17 (2.5%) 3 (0.2%) 
8. dizzinessl vertigo@ 17 (2.5%) 193 (9.9%) 
9. tremor 16 (2.4%) 22 (1.1%) 
10. anxietyl agitation 16 (2.4%) 40 (2.1 %) 
* total frequency of reported symptoms 
@ one of the ten most frequently reported symptoms from CSM data 
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Table 7.16 Comparison of the ten most frequently reported symptoms of citalopram 
in the present study with CSM data 
Frequency of reported symptoms (%) 
Rank 
Own study CSM data 
( n= 358 )* ( n= 731 )* 
1. dry mouth 16 (4.5%) 13(1.8%) 
2. light-headedness 15 (4.2%) 9 (1.2%) 
3 increased sleep 14 (3.9%) 8 (1.1%) 
4. unusual tiredness/ 14 (3.9%) 15 (2.0%) 
weakness@ 
5. tremo~ 13 (3.6%) 30(4.1%) 
6. increased sweating@ 12 (3.4%) 24 (3.3%) 
7. headache@ 11(3.1%) 34 (4.6%) 
8. flushing 10 (2.8%) 1 (0.1%) 
9 J.. sexual desire 10 (2.8%) 6 (0.8%) 
10. anxiety/ agitation@ 9 (2.5%) 26 (3.6%) 
* total frequency of reported symptoms 
@ one of the ten most frequently reported symptoms from CSM data 
7.3 Results of fentanyl patch 
Only eight of the 64 patients (13%) prescribed fentanyl patch who were sent 
questionnaires returned them. None of these cited cancer pain as the indication for 
use, although seven described pain in varying types. All eight respondents reported 
symptoms, giving a total of 94 symptoms, with a median of 12.5 (range 2-24). In total 
47 different symptoms were reported, with constipation being the most common (5), 
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followed by nausea/ vomiting (4), decreased appetite (4) and weight loss (4). Nausea/ 
vomiting was also among the top ten symptoms reported to the CSM for fentanyl patch 
(11 out of 327 reports), although constipation was reported only once. Bronchospasm 
was more frequently reported to the CSM (15 reports) and difficulty in breathing was 
reported by three of the eight patients in the present study. Despite the very small 
number of respondents on fentanyl patch, the incidence of reports of constipation and 
nausea/ vomiting appears to be higher than with tramadol and co-proxamol. 
7.4 Patient attribution of symptoms to drugs 
Of a total 1303, 4600 and 2727 symptoms reported, 788 (60.5%), 2496 (54.3%) and 
1425 (52.3%) were classified by the researchers as being possibly caused by the 
study drugs, with a further 120 (9.2%), 844 (18.3%) and 367 (13.5%) classed as 
probably caused by all anticonvulsants, antidepressants and analgesics, respectively, 
in both main study and pilot study. Two hundred and eighty nine symptoms (17.8%), 
755 (16.4%) and 575 (21.0%) were classed as unlikely to be an ADR and 106 (8.1%), 
505 (11.0%) and 360 (13.2%) were classed as unattributable from all anticonvulsants, 
antidepressants and analgesics, respectively. Table 7.17 shows the results of the 
classification for causal relationship of the perceived symptoms according to the eight 
criteria for the three different therapeutic groups of drugs including pilot study. The 
highest frequency was of those symptoms which could have been caused by the study 
drug and concomitant drugs as well as patients' disease states (criteria 4) for the 
anticonvulsants (35.8%) and the antidepressants (22.2%), while for analgesics, more 
symptoms were reported which could have been caused by the study drug and 
concomitant drugs (criteria 2) (32.2%). Higher percentages of reported symptoms 
were found to be potentially caused by the study drugs (probable/ possible) in all 
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therapeutic classes than those not likely to be caused by the study drugs (unlikely/ 
unattributable) (Table 7.17). Overall, symptoms reported by patients taking 
antidepressants were more often classed as potentially caused by study drugs, while 
symptoms reported by patients taking analgesics were more likely to be classed as 
unlikely to be caused by study drugs and unattributable. 
Table 7.17 The overall distribution of symptom class for the three different 
therapeutic groups of drugs included in the pilot study 
Total frequency of reported 
Causal Criteria symptoms (%) 
relationship 
Anticonvulsants Antidepressants 
probable ADRs 1 120 (9.2%) 844 (18.3%) 
possible ADRs 2 198 (15.2%) 789 (17.2%) 
3 124 (9.5%) 685 (14.9%) 
4 466 (35.8%) 1022 (22.2%) 
Subtotal 788 (60.5%) 2496 (54.3%) 
unlikely ADRs 5 121 (9.3%) 159 (3.5%) 
6 68 (5.2%) 355 (7 .7%) 
7 100 (7.7%) 241 (5.2%) 
Subtotal 289 (22.2%) 755 (16.4%) 
unattributable ADRs 8 106 (8.1 %) 505 (11.0%) 
Total 1303 (100%) 4600 (100%) 
Analgesics 
367 (13.5%) 
878 (32.2%) 
95 (3.5%) 
452 (16 .6%) 
1425 (52.3%) 
260 (9.5%) 
157 (5.7%) 
158 (5.8%) 
575 (21.0%) 
360 (13.2%) 
2727 (100%) 
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7.5 Discussion 
The overall response rate for patients prescribed anticonvulsants (55.6%) was 
comparable to the response rate of the anticonvulsants in the pilot study (51.9%). 
Proportions of female respondents were slightly higher overall than males, however 
this was mainly due to a larger number of female respondents taking lamotrigine. 
Similar to the pilot study, the majority of the respondents taking anticonvulsants were 
aged 20-39 and 40-49. The mean number of concomitant drugs being taken was also 
similar to the anticonvulsants in the pilot study (2.7 vs 2.4). Nearly 40% of the 
respondents had taken the anticonvulsants for more than 720 days with the mean 
duration of therapy of 720 days which was longer than those taking the 
antidepressants (273 days) and the analgesics (329 days). This is most likely due to 
the need for continuing long term therapy in patients with epilepsy. Those on 
anticonvulsants were also more likely to be taking other drugs as the same indication 
with study drugs (89%) than was the case in patients taking antidepressants (19%) 
and analgesics (60%). 
Almost all respondents were taking anticonvulsants in the main study for epilepsy 
(97%) as was found in those taking sodium valproate, while a number of patients were 
taking carbamazepine (in the pilot study) for other conditions (13%) including manic 
depression and trigeminal neuralgia. Less than 50% of the respondents stated that 
they had other medical conditions, which could be related to their relatively young age. 
Only 5 (5%) respondents had stopped taking the anticonvulsants in the main study. Of 
these, only one patient had stopped topiramate because of its side effects, which 
represented 7.7% (1 in 13) of the total respondents taking topiramate. In double-blind, 
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placebo-controlled trials involving more than 500 patients taking topiramate, the 
withdrawal rate due to adverse effects was found to be 11-14% (Privitera, 1997; 
Jones, 1998). The lower rate found in the present study is most likely due to small 
sample numbers and the likelihood of not the method identifying those who withdrew 
within the first few months of therapy, which was the most likely period for withdrawal 
(Privitera, 1997). The very small number who discontinued drugs because of problems 
may suggest that anticonvulsants seemed to be well-tolerated. Handforth and Treiman 
(1994) and Ramsay (1994) both found that adverse effects related to gabapentin were 
not severe and seldom caused drug discontinuation. A recent review by Jones (1998) 
also found that to date, no evidence was found of serious systematic side effects, such 
as rash, hepatotoxicity or cardio-toxicity in patients taking topiramate. Nevertheless, 
Goa and Sorkin (1993) summarised that around 3-11.5% gabapentin-treated patients 
withdrew from premarketing trials and placebo-controlled trials due to its side effects. 
Also, Fitton and Goa (1995) suggested that approximately 4-15 % of patients on 
lamotrigine withdrew from therapy due to its side effects. Other findings have also 
showed 7-9% withdrawal rates due to adverse effects from lamotrigine (Patsalos and 
Sander, 1994; Kalviainen, 1993; Messenheimer, 1995; Richens, 1994). 
Approximately 85% of the respondents taking the three black triangle anticonvulsants 
reported at least one symptom, which is lower than the 93% in the pilot study. More 
patients on gabapentin reported at least one symptom (87%) than for other 
anticonvulsants and also reported the greatest number of different symptoms (77). A 
summary of data from long-term studies of gabapentin by Ramsay (1994) found that 
81.4% of patients reported at least one symptom. In addition, the US Gabapentin 
Study Group (1994) concluded that adverse reactions were reported by 88% of 
patients on gabapentin. 
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As was found for all study drugs, the respondents tended to rate the most bothersome 
symptoms as moderate or severe which may be due to the questionnaire design 
requesting ratings only for the most bothersome symptoms. Messenheimer (1995) and 
Goa and Sorkin (1993) demonstrated that most ADRs to gabapentin and lamotrigine 
were of mild to moderate severity. Patients taking other centrally acting drugs were 
more likely to report more symptoms, in contrast to those taking venlafaxine and other 
antidepressants. This may be due to a different range of side effects occurring with 
anticonvulsants compared to other eNS drugs. 
Nine of the ten most frequently reported symptoms of gabapentin were expected side 
effects, except light-headedness, which may not have been distinguished from 
dizziness, a known side effect. Three of the top ten symptoms from lamotrigine, light-
headedness, change or difficulty in hearing and decrease in sexual desire, were not 
established side effects. It is possible that change in hearing may relate to epilepsy, 
while decrease in sexual desire could be related to depression which is an established 
side effect, although the small numbers make interpretation difficult. Overall, patients 
appeared to report mostly known side effects from the anticonvulsants which is in 
agreement with the findings from the rest of the study. 
There were a number of symptoms reported in the present study which were also cited 
in eSM data. Six of the top ten symptoms of gabapentin in the present study were 
among the top ten from eSM data, while only two of the top ten symptoms reported 
from lamotrigine and three from topiramate were among the top ten symptoms from 
eSM data. However the small number of sample sizes for the latter two drugs 
(Iamotrigine =18, topiramate =13) mean the results are not representative. 
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There were also many common side effects with the older anticonvulsants, 
carbamazepine and sodium valproate, and most reports were of previously known side 
effects. While the majority of symptoms were reported in patients taking gabapentin, 
weight gain was particularly frequent. This may suggest that gabapentin was not better 
tolerated than carbamazepine, which supports the suggestion by Mattson (1995a) that 
carbamazepine usually produced minimal adverse effects with long term therapy. 
However, a study comparing the neuropsychological performance of patients taking 
gabapentin and carbamazepine showed that the effects of both drugs did not differ to 
a statistically significant degree (Kalviainen et al., 1993) and in the present study 
similar frequencies were found in difficulty concentrating. In contrast to a review by 
McLean (1995) which suggested central side effects of gabapentin began within the 
first few weeks of therapy and lasted for approximately two weeks, in the present 
study, with the majority of patients (about 75%) taking gabapentin for more than 720 
days, there were still a large number of reports of CNS side effects. Patsalos and 
Sander (1994) and Handforth and Treiman (1994) also demonstrated that weight gain 
had been reported in some patients, particularly in long term treatment. 
A review by Mattson (1995b) found that the overall success rate based on continuation 
on drugs was better for lamotrigine monotherapy than carbamazepine monotherapy 
due to its improved tolerability. The numbers in the present study were unfortunately 
too small to allow comparisons. In addition, the majority of the respondents (89%) 
were also taking other anticonvulsants in present study which could have affected the 
reports. 
The same problem occurred with topiramate. However, the three reports of weight loss 
with this drug concord with the high number of reports to the CSM and represented a 
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higher frequency than that with carbamazepine and sodium valproate. This is in 
agreement with a review by Privitera (1997). 
Data from Drugdex Drug Evaluation Monographs (1998), Kalviainen et al. (1993), 
Patsolos and Sander (1994), McLean (1995), Ramsay (1994), The US Gabapentin 
Study Group (1994) and Handforth and Treiman (1994) demonstrated that dizziness, 
somnolence, ataxia, headache, fatigue, weight gain, nystagmus, tremor, diplopia, 
nausea! vomiting and rhinitis are relatively common reported adverse effects of 
gabapentin. Some of these symptoms were also found in the top ten reported 
symptoms of the present study. Incidence estimates obtained using different 
denominators as in Chapters 5 and 6 of increased sleep, unsteadiness on feet, dry 
mouth and dizziness in the present study were comparable with data from PMS 
studies and clinical trials, but weight gain, anxiety! agitation and headache were found 
in higher percentages. This again supports the suggestion that patient-reporting 
seems to be a good method for detecting ADRs, although there may be over-reporting 
of symptoms which are of more concern to patients, such as weight gain, anxiety! 
agitation. Interestingly, data from Drugdex database showed that jitteriness and loss of 
memory led patients to discontinue gabapentin. The number of respondents taking 
lamotrigine and topiramate were too small to enable useful comparisons to the 
literature to be made. 
The overall response rate for patients prescribed the three antidepressants (43.3%) 
was comparable to response rate of those in the pilot study (42.3%) with the 
proportion of female respondents twice that of males and a preponderance of 
relatively young respondents, as with venlafaxine. Respondents were taking other 
drugs with the similar frequency to venlafaxine (2.4, range 0-10) though the mean 
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duration of therapy was less. As with venlafaxine, the indications were limited in 
comparison to the older drugs. 
A high proportion (34%) of respondents on these newer antidepressants had stopped 
taking the drugs, as was found with venlafaxine. Similar proportions had stopped 
because of problems either with or without their doctors' suggestion. For nefazodone, 
this rate (14%) was similar to a comparative trial which included 2496 nefazodone-
treated patients and found that about 16% of patients discontinued therapy due to 
adverse effects (Cyr and Brown, 1996). A multicentre double-blind comparison study 
in 105 out-patients receiving nefazodone also found a withdrawal rate of 14% (Baldwin 
et aI., 1996), while Robinson et al. (1996) summarised that 12% of 1310 patients 
taking nefazodone in short-term, placebo-controlled trials worldwide stopped treatment 
because of adverse experiences. While a slightly higher withdrawal rate (19%) was 
found by Feiger et al. (1996), no withdrawals (0%) were found by Feighner et al. 
(1989). The withdrawal rate from citalopram adverse effects in the present study was 
9%, which is slightly higher than the 5% found in a meta-analysis of 325 patients 
(Milne and Goa, 1991). Data from respondents treated with moclobemide was 
insufficient to draw any conclusions, however studies have found that few patients 
discontinued the drug due to adverse effects (Fitton et aI., 1992; Larsen et aI., 1984). 
The high proportion (93%) of respondents taking nefazodone, citalopram and 
moclobemide who reported at least one symptom is similar to that found in patients 
taking venlafaxine (95%). The frequency for nefazodone (97%) concords with a study 
by Feiger et al. (1996) which found 96% of a total 78 patients taking nefazodone 
reported an adverse event during the study period, although fewer patients reported 
adverse events (84%) in a comparison study by Baldwin et al.(1996). Ninety four 
Chapter 7: Other drugs 223 
percent of the respondents taking moclobemide in the present study reported at least 
one symptom, compared to 57% found in a long term study (Moll et aI., 1994,. 
Although similar proportions of patients on all the newer antidepressants were also 
taking other antidepressants, for venlafaxine, there was no increase in symptoms 
reported. while there was an increase in symptoms reported by those patients who 
were prescribed nefazodone, citalopram and moclobemide. This may be an effect of 
sample size. 
Most of the ten most frequently reported symptoms were expected side effects, 
although some could be attributable to depressive illness as well, such as unusual 
tiredness, headache, reduction in sleeping and anxiety/ agitation which is in 
agreement with a review by Milne and Goa (1991). This was also found with the 
venlafaxine group, suggesting that these patients appeared to report symptoms in the 
questionnaires which interfered with their lifestyle, including those which were 
attributable to their illness, such as decrease in sexual desire and difficulty 
concentrating. This is endorsed by the finding that almost all of the most bothersome 
symptoms reported for antidepressants were among the ten most frequently reported 
symptoms. 
Although the patient numbers were small, there were some interesting reports which 
compared well with CSM data including the identification of paraesthesia with 
nefazodone and nausea/ vomiting and headache with moclobemide. Dry mouth, 
unusual tiredness and increased sleep were frequently reported to all antidepressants, 
although dry mouth was less frequently reported in the nefazodone group compared 
with trazodone, which concords with a review by Cyr and Brown (1996). Insomnia was 
also higher from nefazodone, as was found by these workers. In contrast however with 
the data from Cyr and Brown (1996), in the present study, dizziness was found with 
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higher frequency, while anxiety! agitation were found in lower frequency in the 
nefazodone group, compared to the trazodone group. No direct comparisons were 
found in the literature between nefazodone and doxepin, although Robinson et al. 
(1996), Preskorn (1995) and Fontaine (1993) showed that patients receiving 
nefazodone experienced a lower frequency of fatigue, postural hypotension, dry 
mouth, tremor and dizziness than those with imipramine, but a higher frequency of 
light-headedness. Similar incidences of dry mouth, increased sleep and constipation 
were found with nefazodone and doxepin in the present study, while the remainders 
were found in higher percentages in the nefazodone group. This may be related to 
different tolerability profiles of doxepin and imipramine. 
While patients taking citalopram reported a lower frequency of dry mouth than those 
taking trazodone and doxepin, it was still the most common symptom. However, a 
meta-analysis of double-blind studies comparing citalopram with tricyclic 
antidepressants concluded that citalopram appeared to cause relatively fewer 
anticholinergic side effects (Milne and Goa, 1991). Tremor, increased sweating and 
headache were found more frequently in patients on citalopram than in those on 
doxepin. This finding contrasts with a meta-analysis of controlled clinical trials by 8ech 
and Cialdella (1992) which found those three symptoms in higher rates in patients on 
amitriptyline than those on citalopram. Again this may reflect a different side effect 
profile of doxepin from other tricyclic antidepressants. In addition, a possible reason 
for the high incidence of increased sweating is that perspiration did not diminish in 
frequency after the first few weeks of therapy, as suggested by Milne and Goa (1991). 
Other effects, light-headedness, increased sleep and anxiety! agitation, were found 
less frequently in patients taking citalopram compared to trazodone. However, these 
three symptoms were reported more frequently in the citalopram group, compared with 
the doxepin group. 
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The number of respondents taking moclobemide was low, however some symptoms 
were common to other antidepressants. Dry mouth was reported with lower frequency 
by patients taking moclobemide than those taking other drugs, except citalopram, 
although it was still most frequent. However headache and nausea/ vomiting, 
symptoms frequently reported to the CSM, were also common. Other workers (Amrein 
et al., 1997; Stabl et al., 1989; Hilton et al., 1995; Fitton et al., 1992; Chen and Ruch, 
1993) have compared moclobemide with tricyclic antidepressants and found 
headache, reduction in sleep, dry mouth and unusual tiredness to be higher in 
frequency with moclobemide. However, those workers found nausea and palpitations 
with a similar frequency in both groups and dizziness in lower frequency or at least 
comparable frequency in moclobemide group. Nightmares also reported by these 
workers could not be compared with other drugs in pilot study as it was not available in 
the pilot study questionnaires. 
Many of the symptoms reported to nefazodone were cited in other studies (Drugdex 
Drug Evaluation Monographs, 1998; Robinson et aI., 1996; Baldwin et aI., 1996; 
Feiger et al., 1996; Augustin et al., 1997; Fontaine, 1993; Preskorn, 1995; Cyr and 
Brown, 1996). While many of the interval estimates compare well with the incidences 
from those studies, other symptoms namely paraesthesia, decrease in sexual desire, 
tremor and anxietyl agitation were found in higher percentages in the present study. 
Similarly, common side effects from citalopram, i.e. nausea! vomiting, increased 
perspiration, headache, dry mouth, tremor, insomnia, sedation, dizziness and 
constipation (Milne and Goa, 1991) were among the top ten symptoms reported in this 
study. Also, the incidence estimates of dry mouth, unusual tiredness! weakness, 
increased sweating and anxiety/ agitation in the present study were among those 
ranges identified (Drugdex Drug Evaluation Monograph, 1998; Milne and Goa, 1991; 
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Bech and Cialdella, 1992). while increased sleep. tremor. headache and decrease in 
sexual desire were found in higher proportions. 
Interestingly more of the frequencies of reports from moclobemide treated patients 
were comparable to incidence estimates obtained from Drugdex Drug Evaluation 
Monographs (1998). Fitton et al. (1992), Amrein et al. (1997), Hilton et al. (1995). 
Chen and Ruch (1993), Stabl et al (1989), Larsen et al. (1984) and Moll et al. (1994). 
despite the relatively small sample size for moclobemide (16) in the present study. 
The very low response rate for return of questionnaires to fentanyl patch (13%) was 
probably due to its use for severe pain, in particular cancer pain. Thus many patients 
were probably too ill to complete the questionnaires and a number of patients sent 
questionnaires had in fact already deceased (7 out of 64). Other research has shown 
that 9-17% of patients withdrew from clinical trials due to intolerable adverse effects 
from fentanyl patch (Calis et al.,1992; Sloan et al.. 1998). The present study found that 
a high percentage of respondents using fentanyl patch perceived the most 
bothersome symptoms reported as severe (38%). which was greater than in those on 
tramadol (14%). This may suggest that fentanyl patch tended to produce more severe 
side effects than tramadol. 
Almost all of the top ten symptoms reported and the most bothersome symptoms from 
fentanyl patch were established ADRs. with the exception of weight loss. The higher 
frequencies found with fentanyl patch for the common symptoms to fentanyl patch, 
tramadol and co-proxamol were probably due to the small number of respondents 
using fentanyl patch. However the incidence of bronchospasm was interesting. 
particularly when compared to CSM data and bearing in mind that many patients 
claimed to be suffering from abdominal pain. The potency of fentanyl patch may also 
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have been a factor in the increased frequency of symptoms, although with the 
exception of constipation and abdominal pain, estimated incidence rages were in line 
with those found in other studies (Drugdex Drug Evaluation Monograph, 1998; Sloan 
et al., 1998; Sandler, 1992; Grond et al., 1997; Calis et al., 1992; Miguel et al., 1995). 
The classification of symptoms reported using the eight criteria for the three different 
therapeutic groups of drugs including pilot study showed that a lower percentage of 
probable ADRs were found for anticonvulsants, compared to antidepressants and 
analgesics. This may be an effect from higher proportions of respondents taking other 
drugs with the same indication in the anticonvulsant group (89%) than other groups 
(antidepressants 19%, analgesics 60%). Thus, it is less likely that symptoms would be 
classed as being caused only by the anticonvulsants. Fewer symptoms were classed 
as being caused by disease states in those reported to analgesics (31.6%) than to 
anticonvulsants (58.2%) and antidepressants (50.0%). This is probably because 
disease-related symptoms in patients with pain were very different from symptoms 
likely to be related to the study drugs. The higher overall proportion of symptoms 
reported from antidepressants which were potentially caused by study drugs suggests 
that the questionnaire may be particularly suitable for this class of drugs. 
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Chapter 8 
Overall discussion and conclusion 
8.1 Overall discussion 
The questionnaire developed for this study comprised lists of symptoms in all body 
systems to enable the detection of a wide range of potential ADRs. Although the drugs 
studied were from only three therapeutic classes, the questionnaire was designed to 
be usable for any class of drug. It was hoped by this means to reduce bias and 
minimise false positive responses. The questionnaire was distributed directly to 
patients known to have been prescribed the drugs being studied, not via health 
professionals and relied solely on patient co-operation. The overall response rate for 
the pilot and main study together was approximately 40%. This is similar to a 39% 
response rate found in a study of patient self-reporting via forms distributed by 
community pharmacists in Australia (Mitchell et al., 1994). It is possible to obtain much 
higher response rates to questionnaires from patients if these are distributed by 
doctors, however there are major problems in ensuring adequate distribution (Stewart, 
1999). While there were relatively few respondents for some drugs, such as fentanyl 
patch, moclobemide and topiramate, with the exception of fentanyl patch, this was due 
to the small number of questionnaires distributed. This was also the case in the pilot 
study. Data obtained from these questionnaires is therefore less representative of the 
population receiving these drugs. A large number of questionnaires were issued to 
most of the Grampian population who had been prescribed tramadol and venlafaxine 
over a three-month period. This resulted in a large number of questionnaires being 
returned from these patients (tramadol=344, venlafaxine=263), which enabled 
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comparison of the results with published information on the safety profiles of both 
drugs, since these were more likely to be representative. 
There were a relatively high number of non-respondents, some of whom may have 
experienced adverse effects from the study drugs. It is possible that patients who did 
experience symptoms they felt to be drug-related would be more likely to return 
questionnaires. Based on this possibility, an assumption was made that non-
respondents had no symptoms, to enable estimates of the lowest incidence of potential 
ADRs to be made. Using the number of respondents as a denominator resulted in 
estimates of highest incidence, therefore it was possible to obtain a range of incidence 
estimates, which could be compared to published studies. It was recognised that the 
results obtained are point prevalences and that method thus excludes any patients 
who may have had ADRs and either stopped the study drugs or switched to some 
other drugs before the questionnaires were distributed. 
The method involved manual retrieval of patient names and addresses from the 
patients' prescriptions at the PPD in Aberdeen, which was very time-consuming. A 
surprisingly large number of prescriptions were in doctors own hand-writing of which 
some were illegible. This resulted in a number of questionnaires being returned 
unopened because of wrong addresses or wrong names, which contributed to the low 
response rates. In future, prescriptions will include CHI numbers, which would reduce 
the problems encountered in identifying patient details. However there are also ethical 
considerations in using prescription details to identify patients, which have been 
highlighted since the study was undertaken (Anonymous, 1999). In fact there were 
complaints from a small number of patients receiving the questionnaires respecting 
confidentiality. Additional information explaining how their details had been obtained 
was provided to all patients and the questionnaires stated that all information collected 
would be treated in the strictest confidence. However there were queries about these 
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points from some patients, who nonetheless returned questionnaires and also a few 
concerns expressed about the safety of the drugs they were taking. Anxiety generated 
by being invited to take part in research has been identified (Jones et al., 1995) and 
these workers suggested that an explanation of the data held by the researchers could 
overcome some problems. Reminder letters may undermine patients' confidence in the 
assurances given by researchers of confidentiality and the lack of effect of not 
participating on future care (Jones et al., 1995). The decision not to issue them on 
these grounds also affected the response rate. While there was an attempt to 
determine whether the questionnaires caused anxiety in the pre-pilot phase, only a 
small number of patients were interviewed. Although the questionnaires emphasised 
that all symptoms listed were not entirely the side effects from the study drug, 
misunderstanding may have remained about the drug safety which resulted in patients 
seeking advice from their doctors. In fact there was a study by De Wit et al. (1996) 
which demonstrated that 94% of respondents had no objection to the reporting of 
ADRs by their doctors or pharmacists and 77% did not object to the use of their 
medical data, even if these data were not anonymous, as long as the data were kept 
strictly confidential. Nonetheless it may have been preferable, in view of the potential 
for anxiety, to use alternative distribution methods. 
The method relied on information supplied by patients, therefore the pilot study was 
designed to obtain access to all respondents' medical notes to check the accuracy of 
the data. Similarly, information from a sample of respondents receiving the two drugs 
for which most questionnaires were returned was also validated by accessing their 
medical records. While data was not inaccurate, details of concomitant drugs and 
disease states was frequently incomplete. This is a limitation of any study relying on 
patients as an information source. In the present study, it undoubtedly had an effect on 
the classification of symptoms in those whose notes were not examined. 
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The vast majority of the respondents (89%) reported at least one symptom and the 
symptoms covered a wide range. This is lower than that found by Ciccolunghi and 
Chaudri (1975) in a study of factors influencing the reporting of symptoms in which 
97% of patients reported at least one symptom. The latter study used a 38-item 
checklist, which was shorter than the generic questionnaire used here. It had been 
found by Fisher et al. (1995) and Willison et al. (1995) that checklist questionnaires 
result in a higher frequency of reported symptoms than interview methods. This 
suggests that questionnaires may detect more drug-related symptoms, but may also 
result in reports of symptoms which are unattributable to the study drugs, as was found 
in the present study. Some of these unattributable symptoms could have been 
previously unrecognised ADRs to the newer drugs, although the similar frequency of 
unattributable symptoms to established drugs suggests otherwise. The method may 
also have caused patients to experience an increase in side effects due to suggestion 
from the symptoms listed in the questionnaires, especially mild symptoms as proposed 
by Borghi et al. (1984). 
About two third of respondents in both the main and pilot study were female which may 
have been related to the high numbers receiving antidepressants. However a majority 
of females were also found in other patient self-monitoring studies by Fisher et al. 
(1993), Barber and Santanello (1995) and Mitchell et al. (1994). The finding that the 
response rates were however lower in patients taking antidepressants than in patients 
with neurological problems suggests that those with psychological problems were less 
willing to participate in the study. 
Age was not related to the number of reported symptoms and there was no association 
between number of reported symptoms and number of concomitant drugs which is 
similar to the findings of Fisher et al. (1993) and Hallas et al. (1991). There was, 
however, an association between the number of symptoms reported and symptom 
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severity. In addition, patients who perceived most bothersome symptoms as severe 
were more likely to have informed their doctors about the symptoms reported in the 
questionnaires. These results provide evidence that self-reporting patients tend to 
report symptoms that were especially bothersome to them, as was also found by 
Fisher (1995). This is confirmed by the finding that patients often rated the severity of 
their symptoms more than merely minimally and moderately, which is in concordance 
with the studies by Fisher et al. (1993) and Buckingham et al. (1997). Many of the most 
frequently reported symptoms were also cited as the most bothersome symptoms. 
Although over-reporting and inaccurate attribution will undoubtedly be a problem with 
such a system, the importance of patients' perceptions is increasingly being 
recognised (The Royal Pharmaceutical Society of Great Britain, 1997). Data from the 
medical records of over 300 patients found that only 22.4% (5221 2330) of the 
symptoms patients claimed to experience were recorded by their GPs. While most of 
symptoms reported in the questionnaire were minor, they could have an effect on 
medicine-taking. In the majority of cases, when symptoms were recorded in medical 
notes, they were not described as drug side effects but as symptoms. It is of course 
probable that some were likely to be symptoms of existing disease states. However it 
is possible that doctors are not considering the possibility of adverse reactions when 
patients do report new symptoms. This could lead to further inappropriate prescribing 
to relieve the symptoms, but may also be a factor contributing to under-reporting. 
Interestingly, only seven reports were submitted from Grampian to the CSM relating to 
tramadol and sixteen to venlafaxine over the 14-month period which patients were 
reporting on. 
Where numbers were sufficient to allow comparisons to be made with data from the 
CSM, it was found that many of the most frequently reported symptoms occurred with 
higher frequency in the present study. Symptoms reported by patients were also more 
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minor and known ADRs, while the Yellow Card method tended to detect more 
prominent and serious ADRs. This finding is comparable to studies by Mitchell et al. 
(1989,1994) and van den Bemt et al. (1999) which concluded that patient-self 
reporting appeared to identify established ADRs particularly to new drugs, while 
reports from health professionals tended to report more rarer and more severe 
reactions. While it should be feasible to detect rare and serious reactions using patient 
questionnaires, larger sample sizes than that of the present study would be required. 
Other evidence suggests that the most frequently documented ADRs in clinical trials 
and other PMS studies were noted very infrequently in spontaneous reports 
(Cossmann et al., 1997). It is also known that the Yellow Card system suffers from 
under-reporting (D' Arcy, 1996; Speirs et al., 1994; Martin et al., 1998; Walker and 
Lumley, 1986). Therefore it is not surprising that the present study found greater 
percentages for many symptoms and detected different symptoms than data from the 
CSM. Higher frequencies for many symptoms were also found in the present study 
when data were compared with those from PEM studies. The latter method seemed to 
detect symptoms which occurred more frequently in the early stages of treatment, 
reflecting the fact that PEM studies are concerned with events during the first six 
months of therapy (Freemantle et al., 1997). Respondents in the present study had 
been taking the study drugs for longer periods, therefore symptoms which disappeared 
on continuing treatment or to which tolerance developed were less likely to be detected 
by this method, although patients were asked to report any suspected symptoms 
related to the study drugs in the 12 months previous to receiving the questionnaire. 
Over-reporting and the need to use lay terminology for the questionnaire, which 
resulted in the need to adapt or combine terms from CSM data, could also have 
contributed to the differences found. Both the Yellow Card system and PEM stUdies 
rely on the willingness of health professionals to report symptoms, but are also 
dependent on patients reporting symptoms to them. It is perhaps not surprising that 
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symptoms such as decreased sexual desire were detected more frequently by the 
present method. The findings indicate that a large number of patients in the community 
actually suffer from minor and known ADRs. This supports the suggestion that an ADR 
monitoring system based on reports from patients would be inexpensive and might 
lead to faster identification of symptomatic reactions to some new drugs (Mitchell et aI., 
1988). 
Although the numbers in the pilot study were small, some comparisons of the 
symptoms reported to different drugs within therapeutic classes were in line with other 
published data. For example, there were more frequent reports of drowsiness, nausea! 
vomiting and dizziness to tramadol than to co-proxamol, the anticholinergic effect dry 
mouth was found more frequently with doxepin, a tricyclic antidepressant, than with the 
newer antidepressants venlafaxine and nefazodone. Insomnia was more prevalent 
with lamotrigine than carbamazepine and weight loss was more frequent with 
topiramate than carbamazepine and sodium valproate. However, other comparisons 
did not concord with existing data, for instance, the present study found that increased 
sweating occurred more often with venlafaxine than with trazodone, loss of memory, 
dizziness and reduction in sleep were reported in greater percentages in those taking 
lamotrigine than in those taking carbamazepine and dizziness was found in higher 
frequency with nefazodone than trazodone. These differences may be related to 
duration of therapy, small numbers in some cases or to the presence of concomitant 
drugs with similar side effect profiles. The vast majority of patients taking the 
anticonvulsants studied, for example, were also taking other anticonvulsants. Overall, 
patients taking other centrally acting drugs tended to report more symptoms. Given the 
method used, neither this nor other confounding factors such as other disease states, 
dosage regimen, duration of therapy and patient characteristics could be controlled. 
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The estimates of incidence range for many of the symptoms reported in the present 
study were comparable with incidences found in other published data which included 
both premarketing and postmarketing studies. These comparisons are possibly more 
useful than the CSM or PEM data, since pre-marketing studies and clinical trials 
involve systematic enquiries of all patients taking the drugs studied and consequently 
do not have the problem of under-reporting. Disappointingly, although the researchers 
contacted the manufacturers of tramadol and venlafaxine to request any data on file 
involving drug tolerability, only one published paper, which we already had, was 
provided for venlafaxine, and none for tramadol. Many of the frequently reported 
symptoms in this study were cited as common ADRs from published data. These 
findings may suggest that patient self-reporting appeared to be an effective method for 
detecting ADRs, especially for new drugs. However, for a number of symptoms, higher 
reporting rates were found in the present study. Duration of therapy may again be a 
factor contributing to these differences since there were a limited number of studies of 
long term therapy, while the majority of respondents in the present study (54%) had 
been taking the study drugs for more than six months. Over-reporting by some patients 
of symptoms associated with concomitant drugs or disease states and the small 
sample sizes for some study drugs are also likely to affect the comparability with 
published work. 
The pre-pilot study showed that patients had difficulty in remembering start and stop 
dates of both study drugs and concomitant drugs. As a result, the questionnaire was 
modified to maximise response rates which could have been affected by inability to 
complete questions. This resulted in minimal data being available to enable symptom 
causality to be estimated and the consequent need for a classification system to be 
developed which did not require such detailed information as those in common use 
(Kramer et al., 1979; Naranjo et al., 1981; Venulet et al., 1986a, 1986b; Benechou and 
Danan, 1991). The system involved simple categories designed to enable 
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classification of symptoms reported into different probability levels of a causal 
relationship. It used information on known ADRs and symptoms of disease states, but 
did not require exact time relationships. Hence, none of symptoms reported in this 
study could be classified as definitely caused by the study drugs. The classification 
system was used by an independent expert (a pharmacist specialising in ADRs) to 
categorise 716 of the 5033 total symptoms reported. This provided an estimate of 
accuracy of the researcher classifications. There was agreement for 70-80% of 
reported symptoms (Kappa = 0.4-0.5). This is in line with that using conventional 
categories (Naranjo et al., 1981) and that using standardised assessment (Venulet et 
al., 1980). While there were 20-30% of symptoms over which there was disagreement, 
many studies have found similar disagreements, since these are subjective decisions 
based on experience and knowledge (Koch-Weser et aI., 1977; Kramer et aI., 1979; 
Meyboom et al., 1997; Venulet et al., 1980; Naranjo et aI., 1981). Attempts to lessen 
disagreement by establishing various criteria to assess the causality of ADRs have not 
obviously improved level of agreement. 
Using the eight criteria, which were developed into four categories of attribution, it was 
found that patients were likely to report symptoms which could have been attributed to 
the study drugs rather than those not attributed to the study drugs. This suggests that 
patients were reporting with a useful degree of accuracy, similar to that found by Fisher 
et al. (1994), Solovitz et al. (1987) and Mellinger et al. (1988). However, only 12% and 
16% of symptoms reported in the pilot study and main study, respectively, were known 
to have been previously reported to the study drugs and no other obvious causes 
among concomitant drugs or diseases and could therefore be classed as probable 
ADRs. This illustrates the difficulties associated with patients' self-reporting, since it 
becomes impossible to attribute symptoms to particular drugs without details of time 
relationships. Again, it must emphasised that in most cases, the only information on 
concurrent drugs and disease states was obtained from patients, thus was often 
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incomplete or may also be unreliable. The majority of symptoms fell into the category 
of possible ADR, since they could also have been caused by concomitant drugs and/ 
or diseases. In addition, some patients also seemed to report symptoms which 
bothered them a lot even though they were unlikely to be caused by the study drugs, 
such as patients taking tramadol who reported bone and jOint pain. Mitchell et al. 
(1988) also found that many of the events reported by patients taking amoxycillin or 
co-trimoxazole were related to their illness. It is difficult for patients to judge which 
symptoms were caused by the drugs with any degree of certainty. The disagreement 
over some classifications found here and in other studies suggest health professionals 
also have difficulty. Several studies have found that one of the main reasons for 
doctors not reporting an ADR was uncertainty about whether the reaction was caused 
by the suspected drugs (Scott et al., 1987; Bateman et al., 1992; Inman and Weber, 
1986; Smith, 1987). A surprisingly high number of symptoms reported (10% in pilot 
study and 12% in main study) could not be attributed to any of patients' drugs or 
disease states. This suggest that some patients may have over-reported, as was found 
in a study by Borghi et al. (1984). Patients who reported few symptoms were less likely 
to report both unattributable symptoms and unlikely ADRs. 
There are important limitations in the present study on patient self-reporting which 
should be noted. This study was performed retrospectively and relied mainly on 
information provided by patients, which could be incomplete and unreliable. Also data 
concerning dechallenge and rechallenge were unavailable. Other relevant information, 
such as exact time-relationships between the reactions and the drugs taken and 
laboratory data were also missing. Even though in some cases further information was 
obtained from medical records, some important data, such as start date and stop date 
of drugs taken were sometimes not recorded. This problem is a common one in 
general practice, as illustrated by the finding that only 23% of a total 155 sets of 
medical notes had a complete repeat medication record (Mansfield, 1986). The 
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method is unlikely to detect ADRs which need laboratory information or physiological 
measurements, such as blood disorders, cardiovascular, hepatic or renal dysfunction. 
Delayed ADRs, e.g. interstitial nephritis, cancer, are also unlikely to be detected by this 
method. Although patients also reported reasons for hospital admission after starting 
the study drugs, the method did not detect any serious ADRs which caused 
hospitalisation. It is not certain whether this is in fact feasible using the questionnaire, 
although large sample sizes would almost certainly be required. One postmarketing 
study in a very large number of patients taking antibacterial agents (15172) using 
questionnaires via a pharmacy-based approach found that only 13 patients were 
admitted to hospitals with 14 events which were possibly related to the target drugs 
and only one event was identified as due to the target antibacterial (Borden and Lee, 
1982). Most patients tended to report symptoms they perceived as relatively severe 
possible ADRs, however some serious real ADRs may be unreported because patients 
may not have perceived them to be important or related to their drug, such as bruising 
or passing dark brown urine. The extent of under-reporting is unknown. On the other 
hand, a number of patients tended to over-report symptoms which were probably 
related to their disease states rather than the study drugs. They were also likely to 
report more symptoms which bothered them a lot or interfered with their lifestyle, but 
would be regarded as minor side effects, such as dry mouth, increased sweating, 
weight changes and reduction in sleeping. It is also possible that information about 
which ADRs to expect during treatment provided on patient information leaflets by 
community pharmacists could have improved the quality of their reporting. 
Unlike controlled clinical trials, the total number of patients on each study drug was not 
available to provide an appropriate comparison and the number of patients who had 
stopped the study drugs because of adverse effects, particularly at the beginning of 
therapy, may have been underestimated by the method used. The actual number of 
patients were not provided from CSM and PEM, therefore, the data had to be adapted 
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to enable comparisons using similar denominators. This lead to the loss of some data 
and may also have contributed to bias in the comparisons, since there were many 
more reported symptoms per patient than those per CSM report. The inability of the 
method to identify definite ADRs and to use standard classification systems for 
causality is also a drawback. 
Nonetheless, as no single method is without limitations, the present study suggests 
that this patient self-reporting questionnaire would be a valuable addition to systems 
for screening ADRs associated with drug use in the community. It is suggested that the 
method could provide meaningful information which is complementary to that obtained 
using other PMS methods. While it is expensive to follow cohorts of patients, especially 
considering the large sample sizes required to detect ADRs with low incidence, patient 
self-reporting is an extremely cost-effective method. The method can obtain early 
patient reports about possible ADRs of newly marketed drugs and is particularly useful 
for monitoring CNS drugs which necessarily require information from patients about 
behavioral and subjective symptoms. Such a method may also help the early 
identification of ADRs which could be further investigated using the other existing PMS 
methods including voluntary reports from health professionals or pharmaco-
epidemiological studies. It is likely that this method based on patient self-reporting 
might also have a capacity to generate early signals of previously unknown 
symptomatic reactions with new drugs, if sample sizes are adequate as was found by 
Coulter (1988) for eye pain associated with nifedipine. Furthermore, the present study 
suggests that the interpretation of patient self-reports by pharmacists which could be 
followed where necessary by interview could assist in increasing ADR reporting rates. 
This could be particularly useful for newer drugs. There is considerable evidence to 
suggest that both hospital and community pharmacists in the UK have a potential role 
in detecting and monitoring ADRs and could increase the ADR reporting rates (Booth 
et al., 1988; Bussy et al., 1985; Edwards et al., 1989; Lee et al., 1997, 1993; Veitch 
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and Talbot 1985; Khan and Archer, 1994; Davis et al., 1999; Whittlesea and Walker 
1996a, 1996b; Wolfson et al., 1993). Their contribution in the area of ADR reporting 
has also been accepted or encouraged by doctors, the CSM, the Royal 
Pharmaceutical Society of Great Britain, Family Health Services Authorities as well as 
the Royal College of General Practitioners (Sheppard et aI., 1995; Nuffield Foundation, 
1986; The Royal Pharmaceutical Society of Great Britain, 1992; Sutters and Nathan, 
1993a, 1993b). The use of a questionnaire such as the one developed for this study 
could be valuable in enabling pharmacists, in particular those in the community, to 
extend their involvement in patient care to ADR monitoring and reporting. Pharmacists 
are uniquely placed to influence medication use at both prescriber and patient levels 
and their role in minimising ADRs occurring in the community is likely to increase in the 
future. 
Pharmacists are increasingly working in medical practices (Weir et aI., 1997; Martin et 
al., 1998) and undertaking medication reviews. It would be useful to evaluate the 
patient self-completion questionnaire and the pharmacists' screening of it in this 
situation, perhaps prior to interview. Another option could be to develop a short form of 
the postal questionnaire for patients arriving at the surgery for appointments or to 
collect repeat prescriptions to complete, which pharmacists could screen for problems 
which should be reported to the patient's GP. Here again pharmacists could 
subsequently be involved in taking more extensive drug histories as appropriate and in 
completing ADR reporting forms, enabling suitable cases to be submitted to the CSM 
with GP approval. Alternatively, the questionnaires could be distributed to patients who 
present their prescriptions for a particular drug class via community pharmacists. 
Patients could be encouraged to report any adverse reaction by some kind of 
incentive, such as gift vouchers, prize draws, while the questionnaires could be 
returned to a central point in pre-paid envelopes provided as in the present study. 
Further research into the use of open-ended questionnaires, such as that developed 
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for the pilot study would be useful, as it may identify any bias caused by suggestion 
through the checklist questionnaires. In addition, research is needed into the use of the 
checklist questionnaire in the present study for other drug classes which have fewer 
known ADR, differing from those in the present study, such as drugs for treating 
gastrointestinal disorders, antibiotics, NSAIDs. This could also help in validating the 
questionnaire and estimating the accuracy of patients' attribution of reported 
symptoms. Studying drugs with fewer adverse effects and diseases with fewer 
symptoms may result in increased chances of reporting known ADRs using checklist 
questionnaires. Further work is also needed into methods of enhancing the reliability of 
information provided by patients. Studies would ideally involve accessing all medical 
records or patient interview in a sample. The comparisons of patients' judgement of 
symptoms related to drugs with those of an expert panel would also be interesting. 
Applying the same type of questionnaire to healthy subjects who have not received 
any drug would also be valuable to identify the frequency of any general background 
symptoms. In order to obtain more representative results, further studies should recruit 
a high number of patients, in particular new drugs. This would improve the reliability of 
the data obtained enabling better comparisons. Multi-centre or nation-wide studies 
would be required for this. 
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8.2 Overall conclusion 
The study demonstrated the feasibility of obtaining symptom reports from patients 
using a novel checklist, which were mainly classed as possible or probable ADRs. The 
symptoms reported were mostly known side effects to the drugs studied, although 
reported with higher frequency than in CSM or PEM data. Although serious and novel 
ADRs are less likely to be detected using this method, it shows that ADRs are common 
in the community. The data is of value, since patient involvement in treatment 
decisions is increasingly recognised as important. The questionnaire has a number of 
potential applications which should be further investigated. 
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Glossary 
Adverse drug events (AD E) - any unfavourable occurrence that occurs during or 
following clinical use of a drug, but which does not necessarily have a causal 
relationship with this treatment. 
Adverse drug reaction (ADR) - any noxious, unintended and undesired effect of a 
drug, which occurs at doses used in humans for prophylaxis, diagnosis or therapy. 
Alternatively, ADR is an adverse drug event which is judged to be caused by the drug. 
Adverse Drug Reactions On-line Information Tracking (ADROIT) - a computer 
database which holds ADR reports submitted to the CSM in the UK by combining 
images processing with a relational data base, organised by the MCA. 
Causality assessment - an assessment of the likelihood in an individual case that the 
suspected drug caused the adverse reaction. 
Committee on Safety of Medicines (CSM) - a committee which has specific 
responsibilities for promoting the collection and investigation of information related to 
adverse drug reactions in the UK. 
Community Health Index (CHI) - a unique patient identifier which is issued to 
individual patients in Scotland when they register with general practitioners. 
Drug monitoring - any procedure which aims at providing systematic inferences on 
likely chains of causation linking drugs and adverse reactions within a population. 
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Ethical Committee - an independent body who considers clinical research studies in 
the context of safety, integrity and human rights. 
Incidence rate of a reaction - a measure of a how frequently the reaction occurs. 
Specifically, it is the number of new cases of the reaction which develop over a defined 
time period in a defined population at risk, divided by the number of the people in that 
population at risk. 
Medicines Control Agency (MCA) - an organisation which is responsible for licencing 
of medicines in the UK, monitoring the safety, investigating possible hazards and 
taking action to minimise the risks to users. 
Pharmacoepidemiology - the study of drug use and its effects, both beneficial and 
adverse, in large populations. 
Pharmacy Practice Division (PPD) - an organisation of the Common Services 
Agency which is responsible for a number of activities including examination, checking, 
investigation and pricing of prescriptions for drugs, medicines and listed appliances 
supplied as pharmaceutical services under the National Health Service in Scotland. 
postmarketing surveillance (PMS) - the study of drug use and drug effects after 
marketing. 
Prescription- Event Monitoring (PEM) - a system of postmarketing surveillance 
established by the Drug Safety Research Unit at Southampton University which aims 
to monitor all drugs used in general practice in England. 
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Prevalence rate of a reaction - a measurement of how common the reaction is. 
Specifically, it is the number of existing cases of the reaction in a defined population at 
a given point in time, divided by the number of people in that population. 
Prospective studies - studies performed simultaneously with the events under study. 
Retrospective studies - studies conducted after the events under study. 
Side effect - any unintended effect of a pharmaceutical product occurring at doses 
normally used in man, which is related to the pharmacological properties of the drug. 
Spontaneous reporting system (SRS) - a postmarketing surveillance method which 
is dependent on voluntary collaboration by doctors and other health professionals 
submitting ADR reports to drug regulatory authorities at the national level. 
Type A adverse reaction - a reaction which is the result of an exaggerated but 
otherwise predictable pharmacological effect of a drug. They tend to be common, 
dose-related, and less serious than Type B reactions. 
Type B adverse reaction - a reaction which is an aberrant effect of the drug. They 
tend to be uncommon, not dose-related, and unpredictable. 
Yellow Card Scheme - the spontaneous reporting system in the UK which is 
organised by the CSM. 
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.......................................................................................................................................................................... 
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Appendix B1 
2 September 1996 
Dear 
We are writing to ask for your help with a study we are carrying out about side effects from 
medicines. At the moment we are trying to find a questionnaire that patients will be able to fill in, to 
tell us about any experiences they have had since taking their medicines. 
We have enclosed a questionnaire which we would like you to fill in. We will then contact you to 
arrange a visit so that you can tell us how easy or difficult you found it. This will help us to choose 
the best type of questions to use for other patients to fill in. 
We hope you will be able to help us with this study. Please do not worry if you find any questions 
difficult. We want to find out what you think about our questionnaire. One of us will contact you in 
the next week to arrange a time to come and see you about this study. 
With many thanks 
Yours sincerely 
Dr P R S Duffus and Dr Janet Krska ( Practice Pharmacist) 
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CONFIDENTIAL 
Please tick (.I) and fill in where appropriate 
PART 1 : GENERAL INFORMATION ABOUT YOU AND YOUR MEDICINE 
1. YourName: ________________________________________________ __ 
2: 
3. 
4. 
Sex: 1 0 Male 2 0 Female 
Age: ___ years old 
When did you start taking your ? (-_/_-) 
month / year (Please try to fill this in, because it is important 
that we know this) 
5. What condition did your doctor prescribe this medicine for? _________ _ 
6. How many times a day are/were you taking this medicine? 
1- Once a day 
2 0 Twice a day 
3 :::; Three times a day 
4 n Four times a day 
5 0 Other (please indicate) 
7. How many tablets are/were you taking each time? 
1 ~ One 
2 ~ Two 
3 ~ Three 
4 = Four 
5 0 Other (please indicate) ____ _ 
8. Please list all other medicines that you have taken regularly since starting and 
approximately when you started and stopped taking each. Please leave "Stop Date" blank 
for any medicines you are still taking. Again it is important that you try to remember. 
Name of Medicine Start Date (month/year) Stop Date (month/year) 
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9. Do you have any other medical conditions? 
1 0 Yes 2 0 No 
If yes, please list them _____________________ _ 
10. Since you started takin9 ____ , have you been in hospital for any reason? 
1 0 Yes 2 0 No 
If yes, what was the reason? ___________________ _ 
PART 2 : EXPERIENCES OF POSSIBLE SIDE EFFECTS 
Please try to complete all of this part, even though you may feel questions are repeated. 
This is to help us find out which way of asking the questions you find easiest. 
part 2A 
Since starting , have you had any symptoms? Please only describe symptoms which 
e not present before. wer 
11. 
Do you have any symptoms/complaints related to your skin, hair or nails? 
1 0 Yes 2 0 No 
If yes, please describe _____________________ _ 
12. 
Do you have any symptoms/complaints related to your muscles, bones or jOints? 
1 0 Yes 2 0 No 
If yes, please describe _____________________ _ 
Do you have any symptoms/complaints related to your head? 
1 0 Yes 2 0 No 
If yes, please describe _____________________ _ 
Appendix B4 
Remember, only describe symptoms you have had since starting, ______ _ 
14. Do you have any symptoms/complaints related to your eyes or vision? 
1 eYes 2 =: No 
If yes, please describe _________________ -----
15. Do you have any symptoms/complaints related to your ears or hearing? 
1 :::' Yes 2 :::: No 
If yes, please describe ___________________ ---
16. Do you have any symptoms/complaints related to your mouth, gums , nose, throat, neck 
or voice? 
1 DYes 2 Cl No 
If yes, please describe _________________ -----
17. Do you have any symptoms/complaints related to your breathing or lungs? 
1 :::: Yes 2 :::: No 
If yes, please describe _________________ -----
18. Do you have any of the following symptoms/complaints related to your heart or circulation? 
1 CJ Yes 2 Cl No 
If yes, please describe ___________________ ----
19. Do you have any symptoms/complaints related to your stomach or bowel movements? 
1 :::: Yes 2 :::: No 
If yes, please describe ___________________ ----
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Remember, only describe symptoms you have had since starting, ______ _ 
20. Do you have any symptoms/complaints related to your kidneys, bladder or urinary system? 
1 0 Yes 2 0 No 
If yes, please describe _____________________ _ 
21. Do you have any symptoms/complaints related to your sexual function (ability) or your sex 
organ? 
1 0 Yes 2 0 No 
If yes, please describe ______________________ _ 
2 Do you have any symptoms/complaints related to your body movement or balance? 2 . 
23. 
24. 
1 0 Yes 2 0 No 
If yes, please describe ______________________ _ 
Do you have any symptoms/complaints related to your mental health? 
1 0 Yes 2 0 No 
If yes, please describe ______________________ _ 
Do you have any other symptoms/complaints that you have not described in the above 
questions? 
1 0 Yes 2 0 No 
If yes, please describe _____________________ _ 
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Part 28 
Since starting , have you had any of the following symptoms? Please tick (./) 
all the boxes which apply ,and only indicate the problems which were not present before. 
25. Do you have any of the following symptoms/complaints related to your skin? 
1 0 bleeding 
2 0 bruising 
3 D burning sensation 
4 0 flushing of skin 
5 0 increased sensitivity 
of skin to light 
6 _ itching of skin 
7 0 pale skin 
8 C puffy skin 
9 ~ pins and needles sensation 
10 0 skin rash 
11 C yellowing of skin 
12 ~ Other (please indicate) 
13 =: None 
26. Do you have any of the following symptoms/complaints related to your hair or nails? 
1 0 change in fingernails 
2 0 hair loss 
3 [I Other (please indicate) 
4 [j None 
27. Do you have any of the following symptoms/complaints related to your muscles, bones or 
joints? 
1 [I bone or joint pain 
2 0 muscle pain or weakness 
3 0 trembling & shaking of 
fingers & hands 
4 0 unsteadiness on feet 
5 [I unusual or uncontrolled body movement 
6 0 Other (please indicate) 
7 -.-: None 
28. Do you have any of the following symptoms/complaints related to your head? 
1 [I headache 3 [I Other (please indicate) 
2 D migraine headache 
4 :J None 
29. Do you have any of the following symptoms/complaints related to your vision? 
1 0 reduced vision 
2 0 double vision 
3 [I Other (please indicate) 
4 0 None 
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Remember, only tick the boxes that represent symptoms you have had since starting, ____ _ 
30. Do you have any of the following symptoms/complaints related to your eyes? 
1 0 itchy or irritated or inflamed 
eyes or eyelids 
2 0 inability to move eyes 
3 0 unusual movement of the eyes 
4 0 Other (please indicate) 
5 0 None 
31. Do you have any of the following symptoms/complaints related to your hearing or ears? 
1 0 change or difficulty in hearing 
2 0 feeling of fullness in the ears 
3 0 ringing, buzzing or noises in ears 
4 0 Other (please indicate) 
5 [1 None 
2 Do you have any of the following symptoms/complaints related to your mouth or gums? 3 . 
33. 
34. 
35. 
1 0 bleeding from gums 
2 0 dry mouth or throat 
3 0 Other (please indicate) 
4 0 None 
Do you have any of the following symptoms/complaints related to your nose, throat, 
neck or voice? 
1 0 difficulty talking 
2 0 slurred speech 
3 0 runny or stuffy nose 
4 0 sore throat 
5 0 Other (please indicate) 
6 C None 
Do you have any of the following symptoms/complaints related to your breathing or lungs? 
1 iJ cough 
2 [J difficulty breathing 
3 0 fast breathing 
4 u slow breathing 
5 0 Other (please indicate) 
6 0 None 
Do you have any of the following symptoms/complaints related to your heart or circulation? 
1 0 palpitations/ racing heart 
2 0 missed heart beat 
3 0 Other (please indicate) 
4 0 None 
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Remember, only tick the boxes that represent symptoms you have had since startlng, ____ _ 
36. Do you have any of the following symptoms/complaints related to your stomach or 
digestive system? 
1 --' ' 
2 -, L..., 
3 -
-' 
4 -~ 
5 CJ 
bloated feeling or gas 
decrease in appetite 
indigestion 
increase in appetite 
stomach pain or cramps 
6 - vomiting 
7 vomiting blood or material that looks like 
coffee grounds 
9 [J Other (please indicate) 
10 0 None 
37. Do you have any of the following symptoms/complaints related to your rectum or bowel 
movements? 
1 LJ black tarry stool 
2 c constipation 
3 0 diarrhoea 
4 0 Other (please indicate) 
5 [] None 
38. Do you have any of the following symptoms/complaints related to your kidneys, bladder or 
urinary system? 
1 !.-- burning, discomfort or pain 5 - passing water more often w 
while passing water 6 [] bloody urine 
2 LJ dark brown urine 7 -, Other (please indicate) cJ 
3 [j difficulty in passing water 
4 0 passing water less often 
8 0 None 
39. Do you have any of the following symptoms/complaints related to your sexual function 
(ability)? 
1 [] decrease in sexual desire 
2 0 decrease in sexual ability 
3 0 increase in sexual desire 
4 [] Other (please indicate) 
5 [] None 
40. Do you have any of the following symptoms/complaints related to your reproductive (sex) 
organ? 
1 [] abnormal or change in 
vaginal bleeding 
2 ~ burning or irritated penis 
3 [] Other (please indicate) 
4 C None 
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Remember, only tick the boxes that represent symptoms you have had since starting, ____ _ 
41. Do you have any of the following symptoms/complaints related to your nervous system? 
42. 
43. 
44. 
1 ~ confusion or delirium 
2 0 light-headed when getting up 
from a lying or sitting position 
or feeling faint 
3 J dizziness or staggering (vertigo) 
4 0 increase in convulsions (seizures) 
5 J Other (please indicate) 
6 0 None 
Do you have any of the following symptoms/complaints related to your mental health? 
1 0 anxiety (nervousness) or 5 0 anger 
agitation 6 0 loss of memory 
2 0 change in mood 7 0 thought of suicide 
3 0 difficulty concentrating or 8 0 reduction in sleeping 
learning 9 0 increase sleep or drowsiness 
4 0 hallucinations (seeing, 10 C Other (please indicate) 
hearing or feeling things 
that are not there) 
11 0 None 
Do you have any of the following symptoms/complaints? 
1 0 increased sensitivity to cold 7 0 unusual tiredness or weakness 
2 
,.., excessive thirst 8 ,.., weight gain 
....J u 
3 ' , fever '--' 9 C weight loss 
4 0 flu-like symptoms 10 n Other (please indicate) w 
5 0 hot flushes 
6 0 increase sweating 
11 " None w 
Which of the symptoms have bothered you most? 
and how much has it ( have they) bothered you at worst? 
1 0 minimally 
2 0 mildly 
3 0 moderately 
4 0 severely 
5 0 very severely 
DO you think any of the above symptom(s) you have described may possibly be caused by 
? 
-----------------
1 0 Yes 2 0 No 3 0 Don't know 
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46. Have you told your doctor about this/these symptom(s)? 
1 0 Yes 2 0 No 
PART 3 :Only complete this section if you have stopped taking ______ _ 
47. When did you stop this medicine? (--'--) 
month' year 
48. Why did you stop? 
1 LJ I felt I didn't need it any longer 
2 ,1 The doctor said I didn't need it any longer 
3 - The doctor told me to stop because I was having problems with it 
4 - I decided to stop because I was having problems with it 
5 0 I felt it wasn't helping me 
6 0 Other (please explain) _________________ _ 
49. Have any of the symptoms you have described gone away? 
1 ~ Yes 2 0 No 
If yes, please say which ones. 
50. Have any other symptoms started after stopping _______ ? 
1 0 Yes 2 [] No 
If yes, please describe them here. 
Thank you for your time and co-operation. 
Appendix C: Pilot questionnaire 
[)ear Patient 
FACULTY OF HEALTH 
AND FOOD 
School of Pharmacy 
Appendix C1 
Schoolhill 
Aberdeen 
AB101FR 
United Kingdom 
Tel: 01224 262000 
Fax: 01224 626559 
Reply to: 
TIlE 
ROBERT GORDON 
UNIVERSITY 
•••• O •• N 
I am writing to patients in Grampian who have been prescribed certain medicines. You have been 
scribed one of these medicines and we are interested to know about your experiences since you 
~e been taking it. Your name has been obtained from your prescription, but your doctor is aware of 
this study. 
All medicines can still occasionally cause side effects. This study is going to be looking mainly at side 
effects of these medicines. To do this I would like you to fill in this questionnaire. It should take about 
10-15 minutes for you to complete. 
The q~tionnaire will ask you questions about: 
1) 
2) 
3) 
4) 
general information about yourself 
the medicines you take 
any symptoms you feel after taking your medicine 
whether you have told your doctor about any symptoms you have had. 
Th's information will help us identify side effects which may be related to your medicine. This will then 
be lof benefit to all patients who are prescribed this medicine. 
Once you have .com~le~ed the questionnaire, please send it back to me in the enclosed pre-paid 
envelOpe, if possible within 2 weeks. 
Please don't worry. 
All 'nformation collected will be treated in the strictest confidence. There is no need for you to take part 
. thl e study if you don't want to. You can pull out at any time and there will be no effect on your future In . 
medical care.. . 
I would like to thank ,you for taking the~ime to fill in the questionnaire. 
• ' •• 4/,' 
Jsnet Krska 
Dr 01 of Pharmacy scno~obert Gordon University 
",e f" 
I' , 
Head of School 
Professor R M E Richards OBI 
81'1u1rm I'hD D5c Dl'lulnnSci FRI'IuI...re 
I'h('(Th.,) 1'h('(7.,mt.) 
Appendix C2 
CONFIDENTIAL 
Please answer all the questions in parts 1 and 2 by ticking or filling in where appropriate 
PART 1 : GENERAL INFORMATION ABOUT YOU AND YOUR MEDICINE 
1. Your Name: ____________________________________________________ _ 
2: Sex: 1 0 Male 2 0 Female 
3. Age: _______ years old 
4. How many times a day are/were you taking Doxepin ( Sinequen ®) ? 
5. 
6. 
1 0 Once a day 4 0 Four times a day 
2 0 Twice a day 5 0 Other (please indicate) 
3 0 Three times a day 
How many tablets are/were you taking each time? 
1 0 One 4 0 Four 
2 0 Two 5 0 Other (please indicate) 
3 0 Three 
When did you start taking your Doxepin ( Sinequen ®) ? 
(Please try to fill this in , because it is important 
that we know this) 
(-_ / _-) 
month / year 
7. What condition did your doctor prescribe this medicine for? ________________ _ 
8. Please list all other medicines that you have taken regularly since starting Doxepin 
( Sinequen ®). For each medicine please tick whether you started taking it before or after 
Doxepin ( Sinequen ®). Please also tick whether you have now stopped taking any of 
these medicines. Again it is important that you try to remember. 
Name of Medicine Started? Stopped? 
Before After 0 Yes 0 No 
Before After Yes No 
Before After Yes 0 
0 Before After Yes No 
Before After Yes No 
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9. Do you have any other medical conditions? 
1 0 Yes 2 0 No 
If yes, please list them ______________________ _ 
10. Since you started taking Doxepin ( Sinequen ®), have you been in hospital for any 
reason? 
1 0 Yes 2 0 No 
If yes, what was the reason? ____________________ __ 
-PART 2 : EXPERIENCES OF POSSIBLE SIDE EFFECTS 
The purpose of this questionnaire is to find out whether you have experienced any side effects 
hile taking your medicine. Please be assured this does not mean your medicine can cause 
:11 of the effects Ii~ted ~ere. If you are no longer taking your medicine, we would still like you to 
complete the questIOnnaIre. 
During the last 12 months, have you ~ad a~y of the following sym.ptoms which you think 
ay be side effects caused by Doxepln ( Slnequen ®)? Please tick all the boxes which 
:pplY and only indicate the problems which were not present before. 
11 . 
12. 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your skin? 
1 0 bleeding 7 0 pale skin 
2 0 bruising 8 0 puffy skin 
3 0 burning sensation 9 0 pins and needles sensation 
4 0 flushing of skint hot flush 10 0 skin rash 
5 0 increased sensitivity 11 0 yellowing of skin 
of skin to light 12 0 Other (please indicate) 
6 0 itching of skin 
130 None 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your hair or nails? 
1 0 change in fingernails 
2 0 hair loss 
3 0 Other (please indicate) 
4 0 None 
3 
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Remember, only tick the boxes that represent symptoms you have had since starting 
Doxepin ( Sinequen ®) . 
13. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your muscles, bones or joints? 
1 0 bone or joint pain 
2 0 muscle pain 
3 0 muscle weakness 
4 0 trembling & shaking of 
fingers & hands 
5 0 unsteadiness on feet 
6 0 unusual or uncontrolled body movement 
7 0 Other (please indicate) 
8 0 None 
14. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your head? 
o headache 3 0 Other (please indicate) 
2 0 migraine headache 
4 0 None 
15. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your vision? 
1 0 reduced vision 
2 0 double vision 
3 0 Other (please indicate) 
4 0 None 
16. Have you had any of the following symptoms wh ich you think may be due to side effects 
from this medicine re lated to your eyes? 
o itchy or irritated or inflamed 
eyes or eyelids 
2 0 inability to move eyes 
3 0 unusual movement of the eyes 
4 0 Other (please indicate) 
5 0 None 
17. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your hearing or ears? 
1 0 change or difficulty in hearing 
2 0 fee ling of fullness in the ears 
3 0 ringing, buzzing or noises in ears 
4 0 Other (please indicate) 
5 0 None 
4 
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Remember, only tick the boxes that represent symptoms you have had since starting 
Do)Cepin ( Sinequen ®) . 
18. 
19. 
20. 
21. 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your mouth or gums? 
1 0 bleeding from gums 
2 0 dry mouth or throat 
3 0 Other (please indicate) 
4 0 None 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your nose, throat, neck or voice? 
1 0 difficulty talking 
2 0 slurred speech 
3 0 runny or stuffy nose 
4 0 sore throat 
5 0 Other (please indicate) 
6 0 None 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your breathing or lungs? 
1 0 cough 
2 0 difficulty breathing 
3 0 fast breathing 
4 0 slow breathing 
5 0 Other (please indicate) 
6 0 None 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your heart or circulation? 
1 0 palpitations! racing heart 
2 0 missed heart beat 
3 0 Other (please indicate) 
4 0 None 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your stomach or digestive system? 
1 0 bloated feeling or gas 6 0 vomiting 
2 0 decrease in appetite 7 0 vomiting blood or material that looks like 
3 0 indigestion or heartburn coffee grounds 
4 0 increase in appetite 8 0 Other (please indicate) 
5 0 pain or cramps in 
lower abdomen 
9 0 None 
5 
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Remember, only tick the boxes that represent symptoms you have had since starting 
Doxepin ( Sinequen ®) . 
23. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your rectum or bowel movements? 
1 0 black tarry stool 
2 0 constipation 
3 0 diarrhoea 
4 0 Other (please indicate) 
5 0 None 
24. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your kidneys, bladder or urinary system? 
1 0 burning, discomfort or pain 5 0 passing water more often 
while passing water 6 0 bloody urine 
2 0 dark brown urine 7 0 Other (please indicate) 
3 0 difficulty in passing water 
4 0 passing water less often 
8 0 None 
25. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your sexual function (ability)? 
1 0 decrease in sexual desire 
2 0 decrease in sexual ability 
3 0 increase in sexual desire 
4 0 Other (please indicate) 
5 0 None 
26. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your reproductive (sex) organ? 
1 0 abnormal or change in 
vaginal bleeding 
2 0 burning or irritated penis 
3 0 Other (please indicate) 
4 0 None 
27. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your nervous system? 
1 0 confusion or delirium 
2 0 light-headed when getting up 
from a lying or sitting position 
or feeling faint 
3 0 dizziness or staggering (vertigo) 
4 0 increase in convulsions (seizures) 
5 0 Other (please indicate) 
6 0 None 
6 
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Remember, only tick the boxes that represent symptoms you have had since starting 
DoXepin ( Sinequen ®) . 
28. 
30. 
31. 
32. 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your mental health? 
1 0 anxiety (nervousness) or 5 0 anger 
agitation 6 0 loss of memory 
2 0 change in mood 7 0 thought of suicide 
3 0 difficulty concentrating or 8 0 reduction in sleeping 
learning 9 0 increase sleep or drowsiness 
4 0 hallucinations (seeing, 10 0 Other (please indicate) 
hearing or feeling things 
that are not there) 
11 0 None 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine? 
1 0 increased sensitivity to cold 6 0 unusual tiredness or weakness 
2 0 excessive thirst 7 0 weight gain 
3 0 fever 8 0 weight loss 
4 0 flu-like symptoms 9 0 Other (please indicate) 
5 0 increase sweating 
10 0 None 
Which, if any, of the symptoms in question 11 - 29 have bothered you most? 
HoW much has this symptom(s) in question 30 bothered you at its worst? 
1 0 minimally 4 0 severely 
2 0 mildly 5 0 very severely 
3 0 moderately 6 0 does not apply 
Have you told your doctor about any of these symptom(s)? 
1 o All 3 0 None 
2 o Some 4 0 I'm not sure 
"-»se ensure you have answered all questions in parts 1 and 2. 
plep 
If>'o 
L..I have stopped taking your medicine, please answer the questions overleaf. 
Plea 
se return the completed questionnaire in the pre-paid envelope provided. 
7 
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PART 3 : ONLY COMPLETE THIS SECTION IF YOU HAVE STOPPED TAKING 
Doxepin ( Sinequen ®) . 
33. When did you stop this medicine? ( __ 1 __ ) 
month I year 
34. Why did you stop? 
1 0 I felt I didn 't need it any longer 
2 0 The doctor said I didn 't need it any longer 
3 0 The doctor told me to stop because I was having problems with it 
4 0 I decided to stop because I was having problems with it 
5 0 I felt it wasn 't helping me 
6 0 Other (please explain) ___________________ _ 
35. Have any of the symptoms you have described gone away? 
1 0 Yes 2 0 No 3 0 Does not apply 
If yes, please say which ones. 
36 . Have any other symptoms started after stopping Doxepin ( Sinequen ®) ? 
1 0 Yes 2 0 No 
If yes, please describe them here. 
Thank you for your time and co-operation. 
Please return the completed questionnaire in the pre-paid envelope provided. 
Number 
8 
Appendix D: Reminder letter to patients in pilot study 
Appendix D1 
13th March 1997 
Dear 
A few weeks ago in February, I sent you a questionnaire asking about any side effects 
related to your medicine. So far, I have not received it yet. In case you have lost it, I 
am sending you another copy of the questionnaire which is enclosed. I would be most 
grateful if you return it in the enclosed pre-paid envelope no later than 27th March 
1997. 
I am working with doctors in a few practices, including Denburn Health Centre and 
Albyn Medical Practice, to study side effects of certain medicines. This information 
from you will help pharmacists and doctors everywhere to identify side effects which 
may be related to the medicine you are taking. This will then be of benefit to all 
patients who are prescribed this medicine. 
Thank you very much in anticipation of your help. 
Yours sincerely 
Dr Janet Krska 
School of Pharmacy 
The Robert Gordon University 
Appendix E: Data collection form from medical notes 
Appendix E1 
Date ......................... GP ............................ Questionnaire No ............................... . 
Last name ................................ First name .............................. Age ........ Sex ...... . 
Dose .......................................... Start date in Q : ...................... in C : .................. . 
Questionnaire Case note (add) 
concomitant drugs 1-------------- --------------------------.-------------
-------.--.----1---------------------------
._-----------.j-._----------_._--_._----------_. 
I--------------l-----------------------------------.------.------------------.---.-----. 
other diseases 
------------------ -------------------------------------------------
Side effects 
Questionnaire Case note as 
Date Symptom Side effect 
------------------
--------_. __ ._---------- ----- ------------------ -----------------
------ ------------------ ------------------------------
--_. --------------- ------------------- --------------
---------------------- ------ ----------------------------------- ----------------------------
Informed doctor in Q inC 
Stop this medicine _ yes No 
Side effects which have gone away ........................................................................... . 
Note: 
.......................................................................................................................... 
Appendix F: Main study questionnaire 
Dear Patient 
Appendix F1 
FACULTY OF HEALTH Schoolhill 
AND FOOD Aberdeen 
AB101FR 
School of Pharmacy United Kingdom 
Te/: 01224 262000 
Fax: 01224 626559 
Reply to: 
THE 
ROBERT GORDON 
UNIVERSITY 
...... D •• N 
I am writing to patients in Grampian who have been prescribed recently introduced medicines. You 
have been prescribed one of these medicines and we are interested to know about your experiences 
since you have been taking it Your name has been obtained from your prescription, but your general 
practitioner is aware of this study. 
These new medicines are often safer than older medicines. However, they can still occasionally cause 
side effects. 
The main purpose of this study is to see if you have experienced any side effects from your medicine. 
To do this we would like you to fill in this questionnaire. It should take about 10-15 minutes for you to 
complete. 
The questionnaire will ask you questions about 
1) general information about yourself 
2) the medicines you take 
3) any symptoms you feel after taking your new medicine 
4) whether you have told your doctor about any symptoms you have had. 
If yOU are no longer taking the ~edicine, we would still like you to complete the questionnaire. This 
information will help us identify sIde effects which may be related to new medicines more quickly. This 
will then be of benefit to all patients who are prescribed these medicines. 
Once you have completed the questionnaire, please send it back to me in the enclosed pre-paid 
envelope, if possible within 2 weeks. 
Please be assured this does not mean your medicine can cause all of the side effects listed in 
the questionnaire. 
All information collected will be treated in the strictest confidence. There is no need for you to take 
part in the study if you don't want to. You can pull out at any time and there will be no effect on your 
tutu re medical care. 
I would like to thank you for taking the time to fill in the questionnaire. 
Dr Janet Krska 
School of Pharmacy Head of Se/lOol 
Professor R M E Richards, 
BPlwrnn ""0 DSc Ol'lwnnSo FRrh.,' 
PhCfTh.o,) rhCfZ'm~' 
Appendix F2 
CONFIDENTIAL 
Please answer all the questions in parts 1 and 2 by ticking or filling in where appropriate 
PART 1 : GENERAL INFORMATION ABOUT YOU AND YOUR MEDICINE 
1 : Sex: 1 0 Male 2 0 Female 
2. Age: ___ years old 
3. How many times a day are/were you taking Tramadol ( Zydol@) ? 
1 0 Once a day 
2 0 Twice a day 
3 0 Three times a day 
4 0 Four times a day 
5 0 Other (please indicate) 
4. How many tablets or capsules are/were you taking each time? 
5. 
6. 
1 0 One 4 0 Four 
2 0 Two 
3 0 Three 
5 0 Other (please indicate) ____ --
When did you start taking your Tramadol (Zydol@) ? 
(Please try to fill this in, because it is important 
that we know this) 
(-_/ _ -) 
month / year 
What condition did your doctor prescribe this medicine for? ________ --
7. Please list all other medicines that you have taken regu larly during the last 12 months. 
For each medicine please tick whether you started taking it before or after Tramadol 
( Zydol@) . Please also tick whether you have now stopped taking any of these medicines. 
Again it is important that you try to remember. 
Name of Medicine Started? Stopped? 
0 Before 0 After 0 Yes 0 No 
0 Before 0 After 0 Yes 0 No 
0 Before 0 After 0 Yes 0 No 
0 Before 0 After 0 Yes 0 No 
0 Before 0 After 0 Yes 0 No 
2 
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8. Do you have any other medical conditions? 
1 0 Yes 2 0 No 
If yes, please list them ______________________ _ 
9. Since you started taking Tramadol (Zydol®) ,have you been in hospital for any reason? 
1 0 Yes 2 0 No 
If yes, what was the reason? ____________________ _ 
PART 2 : EXPERIENCES OF POSSIBLE SIDE EFFECTS 
the purpose of this questionnaire is to find out whether you have experienced any side effects 
while taking your medicine. Please be assured this does not mean your medicine can cause all of 
the side effects listed here. If you are no longer taking your medicine, we would still like you to 
Complete the questionnaire. 
During the last 12 months, have you had any of the following symptoms which you think 
Iltay be side effects caused by Tramadol ( Zydol®)? Please tick all the boxes which you think 
apPly. Only indicate the problems which were not present before you started taking Tramadol 
(~YdOI®) . 
10, 
l 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your skin? 
1 0 bleeding 7 0 pale skin 
2 0 bruising 8 0 puffy skin 
3 0 burning sensation 9 0 pins and needles sensation 
4 0 flushing of skin/ hot flush 10 0 skin rash 
5 0 increased sensitivity 11 0 yellowing of skin 
of skin to light 12 0 Other (please indicate) 
6 0 itching of skin 
130 None 
Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your hair or nails? 
o change in fingernails 
2 0 hair loss 
3 0 Other (please indicate) 
4 0 None 
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During the last 12 months, have you had any of the following symptoms which you think 
may be side effects caused by Tramadol ( Zydol@) ? Only indicate the problems which 
were not present before you started taking Tramadol ( Zydol@) . 
12. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your muscles, bones or joints? 
1 0 bone or joint pain 5 0 unsteadiness on feet 
2 0 muscle pain 6 0 unusual or uncontrolled body movement 
3 0 muscle weakness 7 0 Other (please indicate) 
4 0 trembling & shaking of 
fingers & hands 
8 0 None 
13. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your head? 
1 0 headache 3 0 Other (please indicate) 
2 0 migraine headache 
------------------------------
4 0 None 
14. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your vision? 
1 0 blurred vision 
2 0 double vision 
3 0 Other (please indicate) 
------------------------------
4 0 None 
15. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your eyes? 
1 0 itchy or irritated or inflamed 
eyes or eyelids 
2 0 inability to move eyes 
3 0 unusual movement of the eyes 
4 0 Other (please indicate) 
-------------------------------
5 0 None 
16. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your hearing or ears? 
1 0 change or difficulty in hearing 
2 0 feeling of fullness in the ears 
3 0 ringing, buzzing or noises in ears 
4 0 Other (please indicate) 
------------------------------
5 0 None 
4 
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During the last 12 months, have you had any of the following symptoms which you think 
Illay be side effects caused by Tramadol ( Zydol@) ? Only indicate the problems which 
Were not present before you started taking Tramadol ( Zydol@) . 
17. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your mouth or gums? 
1 0 bleeding from gums 
2 0 dry mouth or throat 
3 0 Other (please indicate) 
4 0 None 
18. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your nose, throat, neck or voice? 
1 0 difficulty talking 
2 0 slurred speech 
3 0 runny or stuffy nose 
4 0 sore throat 
5 0 Other (please indicate) 
6 0 None 
19. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your breathing or lungs? 
1 0 cough 
2 0 difficulty breathing 
3 0 fast breathing 
4 0 slow breathing 
5 0 Other (please indicate) 
6 0 None 
<0. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your heart or circulation? 
1 0 palpitations/ racing heart 
2 0 missed heart beat 
3 0 Other (please indicate) 
4 0 None 
<1. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your stomach or digestive system? 
1 0 bloated feeling or gas 6 0 nausea or vomiting 
2 0 decrease in appetite 7 0 vomiting blood or material that looks like 
3 0 indigestion or heartburn coffee grounds 
4 0 increase in appetite 8 0 Other (please indicate) 
5 0 pain or cramps in 
lower abdomen 
9 0 None 
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During the last 12 months, have you had any of the following symptoms which you think 
may be side effects caused by Tramadol ( Zydol@) ? Only indicate the problems which 
were not present before you started taking Tramadol ( Zydol@) . 
22. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your rectum or bowel movements? 
1 0 black tarry stool 4 o Other (please indicate) 
2 0 constipation 
3 0 diarrhoea 
5 0 None 
23. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your kidneys, bladder or urinary system? 
1 0 burning, discomfort or pain 5 0 passing water more often 
while passing water 6 0 bloody urine 
2 0 dark brown urine 7 0 Other (please indicate) 
3 0 difficulty in passing water 
-
4 0 passing water less often 
8 0 None 
24. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your sexual function (ability)? 
1 0 decrease in sexual desire 
2 0 decrease in sexual ability 
3 0 increase in sexual desire 
4 0 Other (please indicate) 
5 0 None 
6 0 Does not apply 
25. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your reproductive (sex) organ? 
1 0 abnormal or change in 
vaginal bleeding 
2 0 burning or irritated penis 
3 0 Other (please indicate) 
4 0 None 
26. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your nervous system? 
1 0 confusion or delirium 3 0 dizziness or staggering (vertigo) 
2 0 light-headed when getting up 4 0 increase in convulsions (seizures) 
from a lying or sitting position 5 0 Other (please indicate) 
or feeling faint 
-
6 0 None 
6 
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During the last 12 months, have you had any ofthe following symptoms which you think 
may be side effects caused by Tramadol ( Zydol@) ? Only indicate the problems which 
Were not present before you started taking Tramadol ( Zydol@) . 
27. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine related to your mental health? 
1 0 
2 0 
3 0 
4 0 
5 0 
anxiety (nervousness) or 
agitation 
change in mood 
difficulty concentrating or 
learning 
hallucinations (seeing, 
hearing or feeling things 
that are not there) 
nightmares 
6 0 anger or aggression 
7 0 loss of memory 
8 0 thought of suicide 
9 0 reduction in sleeping 
10 0 increase sleep or drowsiness 
11 0 Other (please indicate) 
12 0 None 
28. Have you had any of the following symptoms which you think may be due to side effects 
from this medicine? 
1 0 increased sensitivity to cold 6 0 unusual tiredness or weakness 
2 0 excessive thirst 7 0 weight gain 
3 0 fever 8 0 weight loss 
4 0 flu-like symptoms 9 0 Other (please indicate) 
5 0 increase sweating 
10 0 None 
29. Which, if any, of the symptoms in question 11 - 29 have bothered you most? 
30. How much has this symptom(s) in question 30 bothered you at its worst? 
1 0 minimally 
2 0 mildly 
3 0 moderately 
4 0 severely 
5 0 very severely 
6 0 does not apply 
31 . Have you told your doctor about any of these symptom(s)? 
1 0 all 3 0 none 
2 0 some 4 0 I'm not sure 
5 0 does not apply 
j:)lease ensure you have answered all questions in parts 1 and 2. 
If You have stopped taking your medicine, please answer the questions overleaf. 
j:)lease return the completed questionnaire in the pre-paid envelope provided. 
7 
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PART 3 : ONLY COMPLETE THIS SECTION IF YOU HAVE STOPPED TAKING 
Tramadol ( Zydol@) . 
32. When did you stop this medicine? ( __ 1 __ ) 
month I year 
33 . Why did you stop? 
1 0 I felt I didn't need it any longer 
2 0 The doctor said I didn't need it any longer 
3 0 The doctor told me to stop because I was having problems with it 
4 0 I decided to stop because I was having problems with it 
5 0 I felt it wasn't helping me 
6 0 Other (please explain) ____________ ______ --
34. Have any of the symptoms you have described gone away? 
1 0 Yes 2 0 No 3 0 Does not apply 
If yes, please say which ones. 
35. Have any other symptoms started after stopping Tramadol ( Zydol®) ? 
1 0 Yes 2 0 No 
If yes, please describe them here. 
- - - - ---------------------------
Thank you for your time and co-operation. 
Please return the completed questionnaire in the pre-paid envelope provided. 
Number 
-------
8 .......... 
Appendix G: Letter to senior general practitioners 
Appendix G1 
8 August 1996 
«ADDRESS» 
Dear «NAME» 
We are writing to you to ask for your co-operation in a study which aims to identify 
adverse drug reactions to new CNS drugs by patient self-monitoring. The drugs we 
are interested in are tramadol, fentanyl patch, moclobemide, citalopram, nefazodone, 
venlafaxine, lamotrigine, gabapentin, and topiramate because they are black triangle 
drugs. Reporting rates to the CSM are relatively low and this study is designed to 
evaluate patient self-monitoring as a method of increasing the reporting. All GPs in the 
Grampian area are being approached. We would like all your patients for whom you 
have prescribed these new drugs to complete a questionnaire. The questionnaire will 
ask your patients for demographic details, the other medicines they take, any symptoms 
they feel after taking the new medicine, and whether they have told you about any 
symptoms they have experienced. 
The project team would particularly value your contribution and would be grateful if you 
would give your permission for questionnaires to be sent to your patients. The patients 
will be identified using prescription data from the Pharmacy Practice Division. We plan 
to compare the patients' perceived adverse reaction rates to the rates of reporting to the 
CSM. We would therefore also like your permission to obtain data from the CSM on any 
cases you have reported concerning the study drugs. 
If you are happy for your patients to take part in this study, you need take no further 
action. However, if you wish to be excluded from the study, please complete and return 
the enclosed form as soon as possible, but no later than 31 August 1996. 
With many thanks in anticipation on behalf of the project team. 
Or Janet Krska 
Project Director 
Project Team: Professor RME Richards (Head of School of Pharmacy), Or P Capps 
(Lecturer/Practitioner), and Narumol Jarernsiripornkul (PhD Student, The Robert Gordon 
University) 
Appendix G2 
The partners in medical practice do not wish their 
patients to be included in the adverse drug reaction reporting study. 
Signed ____________________ _ 
Status 
Date 
Please return to: Dr Janet Krska, Project Director, School of Pharmacy, The Robert 
Gordon University, Aberdeen AB9 1 FR 
Appendix H: Reminder letter to senior general practitioners 
Appendix H1 
23rd May 1997 
Dear Or 
You may recall that we wrote to you last year ( ref. 24th June 1996) requesting your 
co-operation in a study we are conducting which aims to identify adverse reactions to 
black triangle CNS drugs. Reporting rates to the CSM are relatively low and this study 
is designed to evaluate the use of a patient self- completion questionnaire as a means 
of increasing the reporting. The drugs we are interested in are: tramadol, fentanyl 
patch, moclobemide, citalopram, nefazodone, venlafaxine, lamotrigine, gabapentin 
and topiramate. Patients taking these medicines will be identified using prescription 
data from the Pharmacy Practice Division. 
All GP's in Grampian have been approached and 79 practices have opted to take part 
in the study. As one of those practices, we are taking this opportunity to inform you 
that patients in your practice who are currently taking one of the above medicines, will 
shortly receive one of the questionnaires to fill in. This has undergone piloting and we 
now enclose the final version for your information. 
We must emphasise that any information provided by patients is entirely confidential 
and at their discretion. If any patient would like further information or reassurance 
before filling in the questionnaire, we will be happy to discuss the study with them ( tel 
01224262500). 
With many thanks for your help. 
Yours sincerely 
Or Janet Krska 
Project Director 
On behalf of the Project Team: Professor RME Richards ( Head of school of 
Pharmacy), Or P Capps ( Project Supervisor), Narumol Jarernsiripornkul ( PhD 
Student) 
Appendix I: Frequency of reported symptoms in pilot study 
Appendix 11 
Table 1.1 Frequency of symptoms reported by responden prescribed trazodone and 
doxepin 
number of patients (%) 
ADRs . __ . __ .•.••...•.••.•.•••••.•.••...•••...•.•........•....•••.• 
Trazodone Doxepin 
(n=41 ) (n=52) 
skin 
bleeding 1 (2.4%) 
bruising 4 (9.8%) 2 (3.8%) 
burning sensation 3 (7.3%) 2 (3.8%) 
flushing 4 (9.8%) 6 (11.5%) 
photosensitivity 2 (4.9%) 
itching 12 (29.3%) 4 (7.7%) 
pale skin 3 (7.3%) 1 (1.9%) 
puffy skin 3 (7.3%) 1 (1.9%) 
pins and needles sensation 7 (17.1%) 7 (13.5%) 
skin rash 4 (9.8%) 
yellowing of skin 1 (1.9%) 
other 2 (4.9%) 1 (1.9%) 
none 20 (48.8%) 35 (67.3%) 
hair or nails 
change in fingernails 2 (4.9%) 2 (3.8%) 
hair loss 1 (2.4%) 2 (3.8%) 
other 2 (4.9%) 
none 33 (80.5%) 46 (88.5%) 
muscles, bone and joints 
bone or joint pain 7 (17.1%) 4 (7.7%) 
muscle pain 4 (9.8%) 5 (9.6%) 
muscle weakness 3 (7.3%) 4 (7.7%) 
trembling of fingers or hands 10 (24.4%) 4 (7.7%) 
unsteadiness on feet 14 (34.1%) 4 (7.7%) 
unusual body movement 2 (4.9%) 1 (1.9%) 
none 18 (43.9%) 37 (71.2%) 
head 
headache 2 (4.9%) 5 (9.6%) 
migraine headache 4 (9.8%) 
none 31 (75.6%) 45 (86.5%) 
vision 
reduced vision 8 (19.5%) 4 (7.7%) 
double vision 4 (9.8%) 1 (1.9%) 
none 28 (68.3%) 44 (84.5%) 
Appendix 12 
number of patients (%) 
ADRs ............................................•................ 
Trazodone Doxepin 
(n=41 ) (n=52) 
eyes 
itchy or irritated or inflamed eyes 10 (24.4%) 7 (13.5%) 
inability to move eyes 1 (2.4%) 
unusual movement of eyes 1 (2.4%) 2 (3.8%) 
none 28 (68.3%) 43 (82.7%) 
hearing or ears 
change or difficulty in hearing 7(17.1%) 2 (3.8%) 
feeling or fullness in ears 2 (4.9%) 1 (1.9%) 
ringing. buzzing or noises in ears 2 (4.9%) 9 (17.3%) 
other 1 (2.4%) 
none 29 (70.7%) 40 (76.9%) 
mouth or gums 
bleeding from gums 1 (2.4%) 
dry mouth or throat 20 (48.8%) 26 (50.0%) 
none 20 (48.8%) 24 (46.2%) 
nose, throat, neck or voice 
difficulty talking 2 (4.9%) 2 (3.8%) 
slurred speech 4 (9.8%) 1 (1.9%) 
runny or stuffy nose 11 (26.8%) 7 (13.5%) 
sore throat 3 (7.3%) 1 (1.9%) 
other 1 (1.9%) 
none 23 (56.1%) 40 (76.9%) 
breathing or lungs 
cough 5(12.2%) 3 (5.8%) 
difficulty breathing 5(12.2%) 1 (1.9%) 
fast breathing 7(17.1%) 2 (3.8%) 
slow breathing 1 (2.4%) 1 (1.9%) 
other 1 (2.4%) 
none 25 (61.0%) 44 (84.6%) 
heart or circulation 
palpitations/racing heart 8 (19.5%) 9 (17.3%) 
missed heart beat 1 (2.4%) 2 (3.8%) 
other 1 (2.4%) 
none 29 (70.7%) 41 (78.8%) 
Appendix 13 
number of patients (0/0) 
ADRs 
Trazodone Doxepin 
(n=41 ) (n=52) 
stomach or digestive system 
bloated feeling or gas 5(12.2%) 7 (13.5%) 
decrease in appetite 5(12.2%) 3 (5.8%) 
indigestion or heartburn 6 (14.6%) 11 (21.2%) 
increase in appetite 5 (12.2%) 7 (13.5%) 
pain or cramps in lower abdomen 4 (9.8%) 1 (1.9%) 
vomiting 1 (2.4%) 1 (1.9%) 
vomiting blood 1 (2.4%) 
none 23 (56.1%) 30 (57.7%) 
rectum or bowel movements 
black tarry stool 1 (2.4%) 1 (1.9%) 
constipation 13 (31.7%) 9 (17.3%) 
diarrhoea 4 (9.8%) 2 (3.8%) 
other 2 (3.8%) 
none 22 (53.7%) 36 (69.2%) 
kidneys, bladder or urinary system 
burning while passing water 2 (4.9%) 2 (3.8%) 
dark brown urine 6 (14.6%) 4 (7.7%) 
difficult in passing urine 1 (2.4%) 2 (3.8%) 
passing water less often 6 (14.6%) 5 (9.6%) 
passing water more often 8(19.5%) 5 (9.6%) 
other 1 (1.9%) 
none 25 (61.0%) 39 (75.0%) 
sexual function 
decrease in sexual desire 9 (22.0%) 7 (13.5%) 
decrease in sexual ability 3 (7.3%) 2 (3.8%) 
increase in sexual desire 1 (2.4%) 2 (3.8%) 
other 
none 26 (63.4%) 41 (78.8%) 
sexual organ 
burning or irritated penis 1 (6.6%)* 1 (7.1%)* 
other 1 (2.4%) 1 (1.9%) 
none 35 (85.4%) 44 (84.6%) 
nervous system 
confusion or delirium 4 (9.8%) 2 (3.8%) 
light-headed or hypotension 16 (39.0%) 9 (17.3%) 
dizziness or staggering 10 (24.4%) 6(11.5%) 
increase in convulsion 1 (1.9%) 
other 1 (2.4%) 
none 18 (43.9%) 37 (71.2%) 
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number of patients (%) 
ADRs 
mental health 
Trazodone 
(n=41 ) 
anxiety( nervousness)or agitation 19 (46.3%) 
change in mood 12 (29.3%) 
difficulty concentrating or learning 13 (31.7%) 
hallucinations 1 (2.4%) 
anger 6 (14.3%) 
loss of memory 9 (22.0%) 
thought of suicide 2 (4.9%) 
reduction in sleeping 8 (19.5%) 
increase sleep or drowsiness 17 (41.5%) 
other 1 (2.4%) 
none 5 (12.2%) 
other ADRs 
increase sensitivity to cold 
excessive thirst 
fever 
flu-like symptoms 
hot flush 
increase sweating 
unusual tiredness or weakness 
weight gain 
weight loss 
none 
9 (22.2%) 
12 (29.3%) 
2 (4.9%) 
3 (7.3%) 
14 (34.1%) 
11 (26.8%) 
2 (4.9%) 
11 (26.8%) 
* denominator = number of male respondents 
Doxepin 
(n=52) 
4 (7.7%) 
4 (7.7%) 
7 (13.5%) 
1 (1.9%) 
7 (13.4%) 
6(11.5%) 
2 (3.8%) 
4 (7.7%) 
10 (19.2%) 
23 (44.2%) 
3 (5.8%) 
9 (17.3%) 
1 (1.9%) 
1 (1.9%) 
4 (7.7%) 
9 (17.3%) 
9 (17.3%) 
2 (3.8%) 
24 (46.2%) 
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Table 1.2 Frequency of symptoms reported by patients prescribed sodium valproate 
and carbamazepine 
number of patients (%) 
ADRs ._-_ ... _-----_ ...... _-------_ .. __ .. __ .. __ .. _._-_ ... _ ...•.•..• 
Valproate Carbamazepine 
(n=25) (n=44) 
skin 
bleeding 1 (4.0%) 1 (2.3%) 
bruising 2 (8.0%) 1 (2.3%) 
burning sensation 1 (4.0%) 1 (2.3%) 
flushing 3 (12.0%) 
photosensitivity 1 (4.0%) 
itching 1 (4.0%) 5 (11.4%) 
pale skin 2 (8.0%) 3 (6.8%) 
puffy skin 
pins and needles sensation 3 (12.0%) 2 (4.5%) 
skin rash 3 (12.0%) 3 (6.8%) 
yellowing of skin 
other 2 (8.0%) 1 (2.3%) 
none 15 (60.0%) 31 (70.5%) 
hair or nails 
change in fingernails 3 (12.0%) 1 (2.3%) 
hair loss 7 (28.0%) 2 (4.5%) 
other 1 (4.0%) 
none 15 (60.0%) 37 (84.1%) 
muscles, bone and jOints 
bone or joint pain 5 (20.0%) 4(9.1%) 
muscle pain 4 (16.0%) 6 (13.6%) 
muscle weakness 4 (16.0%) 3 (6.8%) 
trembling of fingers or hands 11 (44.0%) 9 (20.5%) 
unsteadiness on feet 5 (20.0%) 6 (13.6%) 
unusual body movement 1 (4.0%) 1 (2.3%) 
other 1 (4.0%) 
none 6 (24.0%) 22 (50.0%) 
head 
headache 6 (24.0%) 7 (15.9%) 
migraine headache 4(16.0%) 6 (13.6%) 
none 13 (52.0%) 32 (72.7%) 
vision 
reduced vision 3 (12.0%) 10 (22.7%) 
double vision 3(12.0%) 7 (15.9%) 
other 
none 19 (76.0%) 28 (63.6%) 
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Table 1.2 Frequency of symptoms reported by patients prescribed sodium valproate 
and carbamazepine 
number of patients (%) 
ADRs ............................................. __ ....... --_ ... -
Valproate Carbamazepine 
(n=25) (n=44) 
skin 
bleeding 1 (4.0%) 1 (2.3%) 
bruising 2 (8.0%) 1 (2.3%) 
burning sensation 1 (4.0%) 1 (2.3%) 
flushing 3 (12.0%) 
photosensitivity 1 (4.0%) 
itching 1 (4.0%) 5 (11.4%) 
pale skin 2 (8.0%) 3 (6.8%) 
puffy skin 
pins and needles sensation 3(12.0%) 2 (4.5%) 
skin rash 3(12.0%) 3 (6.8%) 
yellowing of skin 
other 2 (8.0%) 1 (2.3%) 
none 15 (60.0%) 31 (70.5%) 
hair or nails 
change in fingernails 3(12.0%) 1 (2.3%) 
hair loss 7 (28.0%) 2 (4.5%) 
other 1 (4.0%) 
none 15 (60.0%) 37 (84.1%) 
muscles, bone and jOints 
bone or joint pain 5 (20.0%) 4(9.1%) 
muscle pain 4 (16.0%) 6 (13.6%) 
muscle weakness 4 (16.0%) 3 (6.8%) 
trembling of fingers or hands 11 (44.0%) 9 (20.5%) 
unsteadiness on feet 5 (20.0%) 6 (13.6%) 
unusual body movement 1 (4.0%) 1 (2.3%) 
other 1 (4.0%) 
none 6 (24.0%) 22 (50.0%) 
head 
headache 6 (24.0%) 7 (15.9%) 
migraine headache 4 (16.0%) 6 (13.6%) 
none 13 (52.0%) 32 (72.7%) 
vision 
reduced vision 3 (12.0%) 10 (22.7%) 
double vision 3 (12.0%) 7 (15.9%) 
other 
none 19 (76.0%) 28 (63.6%) 
Appendix 16 
number of patients (%) 
ADRs ... ----... ---......... _ ...•..•......... _--_ ...... _-... ----_.-
Valproate Carbamazepi ne 
(n=25) (n=44) 
eyes 
itchy or irritated or inflamed eyes 2 (8.0%) 6 (113.6%) 
inability to move eyes 1 (2.3%) 
unusual movement of eyes 2 (8.0%) 2 (4.5%) 
none 19 (76.0%) 36 (81.8%) 
hearing or ears 
change or difficulty in hearing 1 (4.0%) 2 (4.5%) 
feeling or fullness in ears 2 (4.5%) 
ringing, buzzing or noises in ears 4 (16.0%) 2 (4.5%) 
none 18 (72.0%) 36 (81.8%) 
mouth or gums 
bleeding from gums 1 (4.0%) 
dry mouth or throat 4 (16.0%) 7 (15.9%) 
none 18 (72.0%) 35 (79.5%) 
nose, throat, neck or voice 
difficulty talking 2 (4.5%) 
slurred speech 2 (8.0%) 4(9.1%) 
runny or stuffy nose 5 (20.0%) 3 (6.8%) 
sore throat 4 (16.0%) 3 (6.8%) 
other 1 (4.0%) 1 (2.3%) 
none 15 (60.0%) 29 (65.9%) 
breathing or lungs 
cough 2 (8.0%) 3 (6.8%) 
difficulty breathing 2 (8.0%) 
fast breathing 1 (4.0%) 1 (2.3%) 
slow breathing 1 (4.0%) 1 (2.3%) 
none 16 (64.0%) 36 (81.8%) 
heart or circulation 
palpitations/racing heart 2 (8.0%) 6 (13.6%) 
missed heart beat 1 (2.3%) 
none 19 (76.0%) 33 (75.0%) 
Appendix 17 
number of patients (%) 
ADRs ... -•.•.•.•••••••..........•.......•..• ---........... -_._ .... 
Valproate Carbamazepine 
(n=25) (n=44) 
stomach or digestive system 
bloated feeling or gas 5 (20.0%) 2 (4.5%) 
decrease in appetite 5 (20.0%) 3 (6.8%) 
indigestion or heartburn 6 (24.0%) 6 (13.6%) 
increase in appetite 5 (20.0%) 4(9.1%) 
pain or cramps in lower abdomen 3 (12.0%) 2 (4.5%) 
vomiting 3 (12.0%) 3 (6.8%) 
vomiting blood 1 (2.3%) 
none 10 (40.0%) 26 (59.1%) 
rectum or bowel movements 
black tarry stool 2 (8.0%) 
constipation 4 (16.0%) 6(13.6%) 
diarrhoea 7 (28.0%) 2(4.5%) 
none 15 (60.0%) 33 (75.0%) 
kidneys, bladder or urinary system 
burning while passing water 1 (4.0%) 1 (2.3%) 
dark brown urine 2 (8.0%) 1 (2.3%) 
difficult in passing urine 1 (4.0%) 
passing water less often 1 (4.0%) 3 (6.8%) 
passing water more often 6 (24.0%) 6 (13.6%) 
bloody urine 
none 13 (52.0%) 30 (68.2%) 
sexual function 
decrease in sexual desire 4 (16.0%) 5(11.4%) 
decrease in sexual ability 5 (20.0%) 1 (2.3%) 
increase in sexual desire 1 (4.0%) 2 (4.5%) 
other 1 (4.0%) 
none 14 (56.0%) 33 (75.0%) 
sexual organ 
abnormal vaginal bleeding 
burning or irritated penis 1 (14.3%)* 
other 2 (8.0%) 
none 17 (68.0%) 41 (93.2%) 
nervous system 
confusion or delirium 4 (16.0%) 3 (6.8%) 
light-headed or hypotension 4 (16.0%) 9 (20.5%) 
dizziness or staggering 3 (12.0%) 8 (18.2%) 
increase in convulsion 1 (4.0%) 5(11.4%) 
other 1 (2.3%) 
none 12 (48.0%) 26 (59.1%) 
Appendix 18 
number of patients (%) 
ADRs 
mental health 
Valproate 
(n=25) 
anxiety( nervousness)or agitation 6 (24.0%) 
change in mood 6 (24.0%) 
difficulty concentrating or learning 9 (36.0%) 
hallucinations 
anger 
loss of memory 
thought of suicide 
reduction in sleeping 
increase sleep or drowsiness 
other 
none 
other ADRs 
increase sensitivity to cold 
excessive thirst 
fever 
flu-like symptoms 
increase sweating 
unusual tiredness or weakness 
weight gain 
other 
none 
5 (20.0%) 
9 (36.0%) 
1 (4.0%) 
4 (16.0%) 
8 (32.0%) 
5 (20.0%) 
6 (24.0%) 
2 (8.0%) 
2 (8.0%) 
4(16.0%) 
14 (56.0%) 
6 (24.0%) 
8 (32.0%) 
* denominator = number of male respondents 
Carbamazepine 
(n=44) 
4 (9.1%) 
4 (9.1%) 
10 (22.7%) 
4 (9.1%) 
8 (18.2%) 
1 (2.3%) 
6 (13.6%) 
15 (34.1%) 
1 (2.3%) 
17 (38.6%) 
5(11.4%) 
3 (6.8%) 
1 (2.3%) 
12 (27.3%) 
4(9.1%) 
22 (50.0%) 
Appendix 19 
Table 1.3 frequency of symptoms reported by respondents prescribed co-proxamol 
ADRs 
skin 
bleeding 
bruising 
burning sensation 
flushing 
photosensitivity 
itching 
pale skin 
pins and needles sensation 
skin rash 
yellowing of skin 
other 
none 
hair or nails 
change in fingernails 
hair loss 
none 
muscles, bone and joints 
bone or joint pain 
muscle pain 
muscle weakness 
trembling of fingers or hands 
unsteadiness on feet 
unusual body movement 
none 
head 
headache 
migraine headache 
none 
vision 
reduced vision 
double vision 
none 
number of patients (%) 
Co-proxamol 
(n=45) 
2 (4.4%) 
3 (6.7%) 
2 (4.4%) 
10 (22.2%) 
9 (20.0%) 
2 (4.4%) 
6 (13.3%) 
3 (6.7%) 
4 (8.8%) 
3 (6.7%) 
24 (53.3%) 
9 (20.0%) 
5(11.1%) 
30 (66.7%) 
6 (13.3%) 
3 (6.7%) 
2 (4.4%) 
4 (8.9%) 
7 (15.6%) 
1 (2.2%) 
32 (71.1%) 
4 (8.9%) 
3 (6.7%) 
35 (77.8%) 
4 (8.9%) 
37 (82.2%) 
ADRs 
eyes 
itchy or irritated or inflamed eyes 
inability to move eyes 
unusual movement of eyes 
none 
hearing or ears 
change or difficulty in hearing 
feeling or fullness in ears 
ringing, buzzing or noises in ears 
none 
mouth or gums 
bleeding from gums 
dry mouth or throat 
none 
nose, throat, neck or voice 
difficulty talking 
slurred speech 
runny or stuffy nose 
sore throat 
other 
none 
breathing or lungs 
cough 
difficulty breathing 
fast breathing 
slow breathing 
none 
heart or circulation 
palpitations/racing heart 
missed heart beat 
none 
Appendix 110 
number of patients (%) 
Co-proxamol 
(n=45) 
10 (22.2%) 
1 (2.2%) 
1 (2.2%) 
4 (8.9%) 
2 (4.4%) 
4 (8.9%) 
35 (77.8%) 
1 (2.2%) 
10 (22.2%) 
31 (68.9%) 
2 (4.4%) 
1 (2.2%) 
3 (6.7%) 
3 (6.7%) 
1 (2.2%) 
34 (75.6%) 
3 (6.7%) 
3 (6.7%) 
2 (4.4%) 
34 (75.6%) 
4 (8.9%) 
1 (2.2%) 
35 (77.8%) 
ADRs 
stomach or digestive system 
bloated feeling or gas 
decrease in appetite 
indigestion or heartburn 
increase in appetite 
pain or cramps in lower abdomen 
vomiting 
vomiting blood 
none 
rectum or bowel movements 
black tarry stool 
constipation 
diarrhoea 
none 
kidneys, bladder or urinary system 
burning while passing water 
dark brown urine 
difficult in passing urine 
passing water less often 
passing water more often 
none 
sexual function 
decrease in sexual desire 
decrease in sexual ability 
increase in sexual desire 
none 
sexual organ 
burning or irritated penis 
other 
none 
nervous system 
confusion or delirium 
light-headed or hypotension 
dizziness or staggering 
increase in convulsion 
none 
Appendix 111 
number of patients (%) 
Co-proxamol 
(n=45) 
6 (13.3%) 
5(11.1%) 
7 (15.6%) 
2 (4.4%) 
6 (13.3%) 
1 (2.2%) 
29 (64.4%) 
1 (2.2%) 
11 (24.4%) 
3 (6.7%) 
30 (66.7%) 
2 (4.4%) 
4 (8.9%) 
1 (2.2%) 
1 (2.2%) 
7 (15.6%) 
32 (71.1%) 
7 (15.6%) 
2 (4.4%) 
32 (71.1%) 
1 (6.25%)* 
1 (2.2%) 
39 (86.7%) 
1 (2.2%) 
6 (13.3%) 
8 (17.8%) 
33 (73.3%) 
ADRs 
mental health 
anxiety( nervousness)or agitation 
change in mood 
difficulty concentrating or learning 
hallucinations 
anger 
loss of memory 
thought of suicide 
reduction in sleeping 
increase sleep or drowsiness 
none 
other ADRs 
increase sensitivity to cold 
excessive thirst 
fever 
flu-like symptoms 
increase sweating 
unusual tiredness or weakness 
weight gain 
weight loss 
none 
* denominator = number of male respondents 
Appendix 112 
number of patients (%) 
Co-proxamol 
(n=45) 
5(11.1%) 
4 (8.9%) 
5(11.1%) 
3 (6.7%) 
2 (4.4%) 
5(11.1%) 
3 (6.7%) 
6 (13.3%) 
4 (8.9%) 
24 (53.3%) 
9 (20.0%) 
7 (15.6%) 
1 (2.2%) 
2 (4.4%) 
5(11.1%) 
7 (15.6%) 
3 (6.7%) 
1 (2.2%) 
Appendix J: Frequency of reported symptoms in main study 
Appendix J1 
Table J.1 Frequency of symptoms reported by patients prescribed tramadol and 
fentanyl patch 
Number of patients (%) 
Symptom .................••....•.•.•.•••.•..••.••.•.............. __ ....... 
Tramadol Fentanyl Patch 
(n=344) (n=8) 
skin 
bleeding 5 ( 1.5%) 
bruising 14 ( 4.1%) 
burning sensation 18 ( 5.2%) 
flushing 67 (19.5%) 1 (12.5%) 
photosensitivity 4 ( 1.2%) 
itching 65 (18.9%) 3 (37.5%) 
pale skin 7 ( 2.0%) 
puffy skin 11 ( 3.2%) 1 (12.5%) 
pins and needles sensation 46 (13.4%) 
skin rash 20 ( 5.8%) 
yellowing of skin 4 ( 1.2%) 
other 2 (25.0%) 
none 194 (56.4%) 3 (37.5%) 
hair or nails 
change in fingernails 28 ( 8.1%) 
hair loss 22 ( 6.4%) 
other 3 ( 0.9%) 
none 273 (79.4%) 8 (100%) 
muscles, bone and joints 
bone or joint pain 37 (10.8%) 
muscle pain 30 ( 8.7%) 1 (12.5%) 
muscle weakness 27 ( 7.8%) 2 (25.0%) 
trembling of fingers or hands 45 (13.1%) 
unsteadiness on feet 54 (15.7%) 3 (37.5%) 
unusual body movement 13 ( 3.8%) 
other 
none 226 (65.7%) 4 (50.0%) 
head 
headache 40 (11.6%) 1 (12.5%) 
migraine headache 17 ( 4.9%) 1 (12.5%) 
other 
none 263 (76.5%) 4 (50.0%) 
vision 
blurred vision 40 (11.6%) 2 (25.0%) 
double vision 4 ( 1.2%) 1 (12.5%) 
other 
none 272 (79.1%) 4 (50.0%) 
Appendix J2 
Number of patients (%) 
Symptom .•.•.....•.•.••.•.. -.... -....................................•.•.. 
Tramadol Fentanyl Patch 
(n=344) (n=8) 
eyes 
itchy or irritated or inflamed eyes 49 (14.2%) 
inability to move eyes 1 ( 0.3%) 
unusual movement of eyes 4 ( 1.2%) 
other 1 ( 0.3%) 
none 266 (77.3%) 7 (87.5%) 
hearing or ears 
change or difficulty in hearing 26 ( 7.6%) 
feeling or fullness in ears 12 ( 3.5%) 1 (12.5%) 
ringing, buzzing or noises in ears 40 (11.6%) 1 (12.5%) 
other 2 ( 0.6%) 
none 257 (74.7%) 5 (62.5%) 
mouth or gums 
bleeding from gums 5 ( 1.5%) 
dry mouth or throat 112 (32.6%) 3 (37.5%) 
other 206 (59.9%) 
none 6 ( 1.7%) 4 (50.0%) 
nose, throat, neck or voice 
difficulty talking 8 ( 2.3%) 
slurred speech 15 ( 4.4%) 
runny or stuffy nose 44 (12.8%) 2 (25.0%) 
sore throat 16 ( 4.7%) 
other 2 ( 0.6%) 
none 245 (71.2%) 4 (50.0%) 
breathing or lungs 
cough 10 ( 2.9%) 1 (12.5%) 
difficulty breathing 10 ( 2.9%) 3 (37.5%) 
fast breathing 11 ( 3.2%) 
slow breathing 3 ( 0.9%) 1 (12.5%) 
other 
none 281 (81.7%) 3 (37.5%) 
heart or circulation 
palpitations/racing heart 29 ( 8.4%) 
missed heart beat 9 ( 2.6%) 
other 
none 277 (80.5%) 6 (75.0%) 
Appendix J3 
Number of patients (%) 
Symptom -_._-............... __ ....... _-_ .................................. 
Tramadol Fentanyl Patch 
(n=344) (n=8) 
stomach or digestive system 
bloated feeling or gas 45 (13.1%) 2 (25.0%) 
decrease in appetite 37 (10.8%) 4 (50.0%) 
indigestion or heartburn 54 (15.7%) 2 (25.0%) 
increase in appetite 10 ( 2.9%) 
pain or cramps in lower abdomen 39 (11.3%) 3 (37.5%) 
nausea or vomiting 66 (19.2%) 4 (50.0%) 
vomiting blood 7 ( 2.0%) 1 (12.5%) 
other 
none 171 (49.7%) 1 (12.5%) 
rectum or bowel movements 
black tarry stool 10 ( 2.9%) 1 (12.5%) 
constipation 84 (24.4%) 5 (62.5%) 
diarrhoea 25 ( 7.3%) 
other 2 ( 0.6%) 
none 222 (64.5%) 2 (25.0%) 
kidneys, bladder or urinary system 
burning while passing water 17 ( 4.9%) 1 (12.5%) 
dark brown urine 19 ( 5.5%) 
difficult in passing urine 25 ( 7.3%) 
passing water less often 13 ( 3.8%) 1 (12.5%) 
passing water more often 40 (11.6%) 1 (12.5%) 
bloody urine 4 ( 1.2%) 
other 2 ( 0.6%) 
none 232 (67.4%) 5 (12.5%) 
sexual function 
decrease in sexual desire 30 ( 8.7%) 3 (37.5%) 
decrease in sexual ability 21 ( 6.1%) 1 (12.5%) 
increase in sexual desire 3 ( 0.9%) 
other 
none 162 (47.1 %) 2 (25.0%) 
does not apply 120 (34.9%) 3 (37.5%) 
sexual organ 
abnormal vaginal bleeding 8 ( 3.5%)* 
burning or irritated penis 4 ( 3.5%)** 
other 1 ( 0.3%) 
none 301 (87.5%) 7 (87.5%) 
Appendix J4 
Number of patients (%) 
Symptom 
Tramadol Fentanyl Patch 
(n=344) (n=8) 
nervous system 
confusion or delirium 13 ( 3.8%) 1 (12.5%) 
light-headed or hypotension 85 (24.7%) 3 (37.5%) 
dizziness or staggering 56 (16.3%) 1 (12.5%) 
increase in convulsion 4 ( 1.2%) 
other 
none 211 (61.3%) 4 (50.0%) 
mental health 
anxiety( nervousness )or agitation 37 (10.8%) 2 (25.0%) 
change in mood 40 (11.6%) 2 (25.0%) 
difficulty concentrating or learning 27 ( 7.8%) 1 (25.0%) 
hallucinations 8 ( 2.3%) 
nightmares 21 ( 6.1%) 
anger 27 ( 7.8%) 2 (25.0%) 
loss of memory 20 ( 5.8%) 2 (25.0%) 
thought of suicide 6 ( 1.7%) 
reduction in sleeping 49 (14.2%) 2 (25.0%) 
increase sleep or drowsiness 70 (20.3%) 2 (25.0%) 
other 
none 171 (49.7%) 3 (37.5%) 
other ADRs 
increase sensitivity to cold 28 ( 8.1 %) 3 (37.5%) 
excessive thirst 46 (13.4%) 3 (37.5%) 
fever 5 ( 1.5%) 
flu-like symptoms 10 ( 2.9%) 1 (12.5%) 
increase sweating 69 (20.1%) 3 (37.5%) 
unusual tiredness or weakness 65 (18.9%) 3 (37.5%) 
weight gain 29 ( 8.4%) 
weight loss 16 ( 4.7%) 4 (50.0%) 
other 
none 163 (47.4%) 2 (25.0%) 
* denominator = number of female respondents 
** denominator = number of male respondents 
Appendix J5 
Table J.2 Frequency of symptoms reported by patients prescribed venlafaxine and 
nefazodone 
Number of patients (%) 
Symptom •....•... __ ..... _ .•.............••••.......... --.....••.•...••..•• 
Venlafaxine Nefazodone 
(n=263) (n=64) 
skin 
bleeding 3 ( 1.1 %) 1 ( 1.6%) 
bruising 23 ( 8.7%) 2 ( 3.1%) 
burning sensation 10 ( 3.8%) 3 ( 4.7%) 
flushing 78 (29.7%) 10 (15.6%) 
photosensitivity 11 ( 4.2%) 6 ( 9.4%) 
itching 52 (19.8%) 10 (15.6%) 
pale skin 11 ( 4.2%) 2 ( 3.1 %) 
puffy skin 14 ( 5.3%) 3 ( 4.7%) 
pins and needles sensation 46 (17.5%) 19 (29.7%) 
skin rash 15 ( 5.7%) 2 ( 3.1%) 
yellowing of skin 3 ( 1.1 %) 
other 4 ( 1.5%) 2 ( 3.1%) 
none 119 (45.2%) 30 (46.9%) 
hair or nails 
change in fingernails 19 ( 7.2%) 8 (12.5%) 
hair loss 21 ( 8.0%) 4 ( 6.3%) 
other 4 ( 1.5%) 1 ( 1.6%) 
none 208 (79.1%) 52 (81.3%) 
muscles, bone and joints 
bone or joint pain 29 (11.0%) 13 (20.3%) 
muscle pain 26 ( 9.9%) 8 (12.5%) 
muscle weakness 17 ( 6.5%) 9 (14.1%) 
trembling of fingers or hands 56 (21.3%) 16 (25.0%) 
unsteadiness on feet 41 (15.6%) 14 (21.9%) 
unusual body movement 17 ( 6.5%) 4 ( 6.3%) 
other 1 ( 0.4%) 
none 150 (57.0%) 31 (48.4%) 
head 
headache 50 (19.0%) 15 (23.4%) 
migraine headache 17 ( 6.5%) 1 ( 1.6%) 
other 
none 192 (73.0%) 47 (73.4%) 
vision 
blurred vision 44 (16.7%) 11 (17.2%) 
double vision 5 ( 1.9%) 1 ( 1.6%) 
other 2 ( 0.8%) 
none 205 (77.9%) 48 (75.0%) 
Appendix J6 
Number of patients (%) 
Symptom .......•••.•...................•.•.••.• -_ ......................... 
Venlafaxine Nefazodone 
(n=263) (n=64) 
eyes 
itchy or irritated or inflamed eyes 36 (13.7%) 9 (14.1%) 
inability to move eyes 5 ( 1.9%) 
unusual movement of eyes 9 ( 3.4%) 2 ( 3.1%) 
other 9 ( 3.4%) 3 ( 4.7%) 
none 205 (72.9%) 49 (76.6%) 
hearing or ears 
change or difficulty in hearing 19 ( 7.2%) 7 (10.9%) 
feeling or fullness in ears 16 ( 6.1%) 3 ( 4.7%) 
ringing, buzzing or noises in ears 37 (14.1 %) 10 (15.6%) 
other 2 ( 0.8%) 
none 194 (73.8%) 42 (65.6%) 
mouth or gums 
bleeding from gums 4 ( 1.5%) 2 ( 3.1 %) 
dry mouth or throat 121 (46.0%) 29 (45.3%) 
other 9 ( 3.4%) 
none 125 (47.5%) 32 (50.0%) 
nose, throat, neck or voice 
difficulty talking 13 ( 4.9%) 1 ( 1.6%) 
slurred speech 23 ( 8.7%) 7 (10.9%) 
runny or stuffy nose 36 (13.7%) 12 (18.8%) 
sore throat 17 ( 6.5%) 6 ( 9.4%) 
other 2 ( 0.6%) 
none 187 (71.1%) 45 (70.3%) 
breathing or lungs 
cough 11 ( 4.2%) 4 ( 6.3%) 
difficulty breathing 19 ( 7.2%) 3 ( 4.7%) 
fast breathing 18 ( 6.8%) 3 ( 4.7%) 
slow breathing 6 ( 2.3%) 1 ( 1.6%) 
other 1 ( 0.4%) 
none 206 (78.3%) 53 (82.8%) 
heart or circulation 
palpitations/racing heart 58 (22.1%) 13 (20.3%) 
missed heart beat 13 ( 4.9%) 3 ( 4.7%) 
other 1 ( 0.4%) 
none 189 (71.9%) 48 (75.0%) 
Appendix J7 
Number of patients (%) 
Symptom -_ ..•••...• -_ ............... __ ............. ---.................... 
Venlafaxine Nefazodone 
(n=263) (n=64) 
stomach or digestive system 
bloated feeling or gas 63 (24.0%) 12 (18.8%) 
decrease in appetite 37 (14.1 %) 13 (20.3%) 
indigestion or heartburn 36 (13.7%) 13 (20.3%) 
increase in appetite 38 (14.4%) 6 ( 9.4%) 
pain or cramps in lower abdomen 28 (10.6%) 11 (17.2%) 
nausea or vomiting 64 (24.3%) 14 (21.9%) 
vomiting blood 1 ( 0.4%) 1 ( 1.6%) 
other 
none 103 (39.2%) 22 (34.4%) 
rectum or bowel movements 
black tarry stool 3 ( 1.1%) 3 ( 4.7%) 
constipation 71 (27.0%) 11 (17.2%) 
diarrhoea 22 ( 8.4%) 12 (18.8%) 
other 1 ( 0.4%) 
none 167 (63.5%) 41 (64.1%) 
kidneys, bladder or urinary system 
burning while passing water 7 ( 2.7%) 2 ( 3.1%) 
dark brown urine 10 ( 3.8%) 6 ( 9.4%) 
difficult in passing urine 7 ( 2.7%) 2 ( 3.1 %) 
passing water less often 14 ( 5.3%) 2 ( 3.1%) 
passing water more often 33 (12.5%) 8 (12.5%) 
bloody urine 2 ( 0.8%) 1 ( 1.6%) 
other 3 ( 1.1%) 1 ( 1.6%) 
none 185 (70.3%) 41 (64.1%) 
sexual function 
decrease in sexual desire 89 (33.8%) 17 (26.6%) 
decrease in sexual ability 50 (19.0%) 7 (10.9%) 
increase in sexual desire 12 ( 4.6%) 4 ( 6.3%) 
other 
none 84 (31.9%) 27 (42.2%) 
does not apply 54 (20.5%) 11 (17.2%) 
sexual organ 
abnormal vaginal bleeding 13 ( 7.1%)* 1 ( 2.6%)* 
burning or irritated penis 2 ( 2.6%)** 2 ( 8.0%)** 
other 2 ( 0.8%) 
none 232 (88.2%) 57 (89.1%) 
Appendix J8 
Number of patients (%) 
Symptom ..... __ ..•...•.••.• -_ .. ---........................................ 
Venlafaxine Nefazodone 
(n=263) (n=64) 
nervous system 
confusion or delirium 20 ( 7.6%) 7 (10.9%) 
light-headed or hypotension 91 (34.6%) 22 (34.4%) 
dizziness or staggering 48 (18.3%) 17 (26.6%) 
increase in convulsion 
other 
none 138 (52.5%) 33 (51.6%) 
mental health 
anxiety( nervousness)or agitation 59 (22.4%) 16 (25.0%) 
change in mood 66 (25.1%) 14 (21.9%) 
difficulty concentrating or learning 59 (22.4%) 20 (31.3%) 
hallucinations 12 ( 4.6%) 4 ( 6.3%) 
nightmares 39 (14.8%) 4 ( 6.3%) 
anger 29 (11.0%) 7 (10.9%) 
loss of memory 44 (16.7%) 13 (20.3%) 
thought of suicide 20 ( 7.6%) 9 (14.1 %) 
reduction in sleeping 64 (24.3%) 19 (29.7%) 
increase sleep or drowsiness 45 (17.1%) 12 (18.8%) 
other 4 ( 1.5%) 
none 91 (34.6%) 19 (29.7%) 
other ADRs 
increase sensitivity to cold 23 ( 8.7%) 9 (14.1%) 
excessive thirst 68 (25.9%) 13 (20.3%) 
fever 1 ( 1.6%) 
flu-like symptoms 11 ( 4.2%) 5 ( 7.8%) 
increase sweating 107 (40.7%) 10 (15.6%) 
unusual tiredness or weakness 88 (33.5%) 24 (37.5%) 
weight gain 70 (26.6%) 12 (18.8%) 
weight loss 20 ( 7.6%) 7 (10.9%) 
other 1 ( 0.4%) 
none 64 (24.3%) 21 (32.8%) 
* denominator = number of female respondents 
** denominator = number of male respondents 
Appendix J9 
Table J.3 Frequency of symptoms reported by patients prescribed citalopram and 
moclobemide 
Symptom 
skin 
bleeding 
bruising 
burning sensation 
flushing 
photosensitivity 
itching 
pale skin 
puffy skin 
pins and needles sensation 
skin rash 
yellowing of skin 
other 
none 
hair or nails 
change in fingernails 
hair loss 
other 
none 
muscles, bone and joints 
bone or joint pain 
muscle pain 
muscle weakness 
trembling of fingers or hands 
unsteadiness on feet 
unusual body movement 
other 
none 
head 
headache 
migraine headache 
other 
none 
vision 
blurred vision 
double vision 
other 
none 
Number of patients (%) 
Citalopam 
(n=43) 
2 ( 4.7%) 
2 ( 4.7%) 
10 (23.3%) 
1 ( 2.3%) 
5 (11.6%) 
3 ( 7.0%) 
2 ( 4.7%) 
7 (16.3%) 
4 ( 9.3%) 
1 ( 2.3%) 
1 ( 2.3%) 
26 (60.5%) 
5 (11.6%) 
3 ( 7.0%) 
36 (83.7%) 
2 ( 4.7%) 
3 ( 7.0%) 
3 ( 7.0%) 
13 (30.2%) 
6 (14.0%) 
3 ( 7.0%) 
25 (58.1 %) 
11 (25.6%) 
2 ( 4.7%) 
28 (65.1%) 
6 (14.0%) 
2 ( 4.7%) 
34 (79.1%) 
Moclobemide 
(n=16) 
1 (6.3%) 
2 (12.5%) 
1 (6.3%) 
13 (81.3%) 
16 (100%) 
1 (6.3%) 
1 (6.3%) 
2 (12.5%) 
12 (75.0%) 
5 (31.3%) 
2 (12.5%) 
9 (56.3%) 
1 (6.3%) 
1 (6.3%) 
14 (87.5%) 
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Number of patients (%) 
Symptom .. -._----_ ... __ ... __ .---_._---_ .............. __ ........ _._._------
eyes 
itchy or irritated or inflamed eyes 
inability to move eyes 
unusual movement of eyes 
other 
none 
hearing or ears 
change or difficulty in hearing 
feeling or fullness in ears 
ringing, buzzing or noises in ears 
other 
none 
mouth or gums 
bleeding from gums 
dry mouth or throat 
other 
none 
nose, throat, neck or voice 
difficulty talking 
slurred speech 
runny or stuffy nose 
sore throat 
other 
none 
breathing or lungs 
cough 
difficulty breathing 
fast breathing 
slow breathing 
other 
none 
heart or circu lation 
palpitations/racing heart 
missed heart beat 
other 
none 
Citalopam 
(n=43) 
3 (7.0%) 
36 (83.7%) 
5 (11.6%) 
2 ( 4.7%) 
8 (18.6%) 
32 (74.4%) 
16 (37.2%) 
1 (2.3%) 
24 (55.8%) 
3 (7.0%) 
4 (9.3%) 
1 (2.3%) 
36 (83.7%) 
6 (14.0%) 
2 (4.7%) 
2 (4.7%) 
33 (76.7%) 
6 (14.0%) 
3 (7.0%) 
35 (81.4%) 
Moclobemide 
(n=16) 
2 (12.5%) 
1 (6.3%) 
1 (6.3%) 
10 (62.5%) 
1 (6.3%) 
1 (6.3%) 
14 (87.5%) 
6 (37.5%) 
1 (6.3%) 
10 (62.5%) 
1 (6.3%) 
1 (6.3%) 
14 (87.5%) 
2 (12.5%) 
14 (87.5%) 
4 (25.0%) 
12 (75.0%) 
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Number of patients (%) 
Symptom 
-----------._ .. -----._._-_._-----------------------.--------------
Citalopam Moclobemide 
(n=43) (n=16) 
stomach or digestive system 
bloated feeling or gas 5 (11.6%) 2 (12.5%) 
decrease in appetite 6 (14.0%) 2 (12.5%) 
indigestion or heartburn 6 (14.0%) 1 ( 6.3%) 
increase in appetite 1 ( 2.3%) 1 ( 6.3%) 
pain or cramps in lower abdomen 6 (14.0%) 2 (12.5%) 
nausea or vomiting 8 (18.6%) 3 (18.8%) 
vomiting blood 1 ( 2.3%) 
other 
none 25 (58.1%) 9 (56.3%) 
rectum or bowel movements 
black tarry stool 2 ( 4.7%) 
constipation 8 (18.6%) 1 ( 6.3%) 
diarrhoea 3 ( 7.0%) 1 ( 6.3%) 
other 
none 30 (69.8%) 14 (87.5%) 
kidneys, bladder or urinary system 
burning while passing water 2 ( 4.7%) 
dark brown urine 1 ( 2.3%) 
difficult in passing urine 1 ( 2.3%) 
passing water less often 2 ( 4.7%) 
passing water more often 5 (11.6%) 2 (12.5%) 
bloody urine 1 ( 2.3%) 
other 1 ( 2.3%) 1 ( 6.3%) 
none 33 (76.7%) 13 (81.3%) 
sexual function 
decrease in sexual desire 10 (23.3%) 3 (18.8%) 
decrease in sexual ability 7 (16.3%) 2 (12.5%) 
increase in sexual desire 2 ( 4.7%) 
other 
none 15 (34.9%) 9 (56.3%) 
does not apply 14 (32.6%) 3 (18.8%) 
sexual organ 
abnormal vaginal bleeding 2 (15.4%)* 
burning or irritated penis 
other 1 ( 2.3%) 1 ( 2.3%) 
none 37 (86.0%) 14 (87.5%) 
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Number of patients (%) 
Symptom 
Citalopam Moclobemide 
(n=43) (n=16) 
nervous system 
confusion or delirium 3 ( 7.0%) 3 (18.8%) 
light-headed or hypotension 15 (34.9%) 1 ( 6.3%) 
dizziness or staggering 6 (14.0%) 4 (25.0%) 
increase in convulsion 
other 
none 25 (58.1 %) 10 (62.5%) 
mental health 
anxiety( nervousness )or agitation 9 (20.9%) 2 (12.5%) 
change in mood 4 ( 9.3%) 2 (12.5%) 
difficulty concentrating or learning 3 ( 7.0%) 3 (18.8%) 
hallucinations 
nightmares 1 ( 2.3%) 3 (18.8%) 
anger 3 ( 7.0%) 1 ( 6.3%) 
loss of memory 7 (16.3%) 3 (18.8%) 
thought of suicide 2 ( 4.7%) 
reduction in sleeping 7 (16.3%) 4 (25.0%) 
increase sleep or drowsiness 14 (32.6%) 2 (12.5%) 
other 1 ( 2.3%) 
none 17 (39.5%) 7 (43.8%) 
other ADRs 
increase sensitivity to cold 4 ( 9.3%) 3 (18.8%) 
excessive thirst 6 (14.0%) 1 ( 6.3%) 
fever 
flu-like symptoms 1 ( 2.3%) 
increase sweating 12 (27.9%) 2 (12.5%) 
unusual tiredness or weakness 14 (32.6%) 3 (18.8%) 
weight gain 6 (14.0%) 2 (12.5%) 
weight loss 2 ( 4.7%) 2 (12.5%) 
other 
none 12 (27.9%) 7 (43.8%) 
* denominator = number of female respondents 
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Table J.4 Frequency of symptoms reported by patients precribed gabapentin, 
lamotrigine and topiramate 
Number of patients (%) 
Symptom •.......•..............•...••.•.•••.••.• --_ ..••....•.•.••......••• 
Gabapentin Lamotrigine Topiramate 
(n=68) (n=18) (n=13) 
skin 
bleeding 
bruising 9 (13.2%) 
burning sensation 2 ( 2.9%) 
flushing 9 (13.2%) 2 (11.1%) 
photosensitivity 5 ( 7.4%) 
itching 8 (11.8%) 2 (11.1%) 1 ( 7.7%) 
pale skin 1 ( 7.7%) 
puffy skin 2 ( 2.9%) 
pins and needles sensation 13 (19.1%) 3 (16.7%) 2 (15.4%) 
skin rash 4 ( 5.9%) 
yellowing of skin 
other 
none 40 (58.8%) 14 (77.8%) 8 (61.5%) 
hair or nails 
change in fingernails 10 (14.7%) 1 ( 5.6%) 1 ( 7.7%) 
hair loss 10 (14.7%) 11 (11.1%) 1 ( 7.7%) 
other 
none 48 (70.6%) 15 (83.3%) 10 (76.9%) 
muscles, bone and joints 
bone or joint pain 8 (11.8%) 
muscle pain 8 (11.8%) 
muscle weakness 5 ( 7.4%) 
trembling of fingers or hands 13 (19.1%) 4 (22.2%) 1 ( 7.7%) 
unsteadiness on feet 14 (20.6%) 4 (22.2%) 3(23.1%) 
unusual body movement 4 ( 5.9%) 1 ( 5.6%) 
other 
none 40 (58.8%) 10 (55.6%) 10 (76.9%) 
head 
headache 16 (23.5%) 2 (11.1%) 2 (15.4%) 
migraine headache 5 ( 7.4%) 2 (11.1%) 1 ( 7.7%) 
other 
none 46 (67.6%) 15 (83.3%) 10 (76.9%) 
vision 
blurred vision 11 (16.2%) 3 (16.7%) 1 ( 7.7%) 
double vision 3 ( 4.4%) 
other 
none 50 (73.5%) 15 (83.3%) 12 (92.3%) 
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Number of patients (%) 
Symptom .-._-------_ .... _._._ ...... _. __ ._ ....... _._._._ ... _._ ........ _--_. 
Gabapentin Lamotrigine Topiramate 
(n=68) (n=18) (n=13) 
eyes 
itchy or irritated or inflamed eyes 8 (11.8%) 1 ( 5.6%) 1 ( 7.7%) 
inability to move eyes 
unusual movement of eyes 2 ( 2.9%) 1 ( 5.6%) 
other 
none 54 (79.4%) 14 (77.8%) 11 (84.6%) 
hearing or ears 
change or difficulty in hearing 7 (10.3%) 4 (22.2%) 
feeling or fullness in ears 4 ( 5.9%) 2 (11.1%) 
ringing, buzzing or noises in ears 10 (14.7%) 2 (11.1%) 
other 
none 50 (73.5%) 13 (72.2%) 12 (92.3%) 
mouth or gums 
bleeding from gums 5 ( 7.4%) 1 ( 7.7%) 
dry mouth or throat 14 (20.6%) 1 ( 5.6%) 1 ( 7.7%) 
other 3 ( 4.4%) 1 ( 5.6%) 
none 45 (66.2%) 16 (88.9%) 11 (84.6%) 
nose, throat, neck or voice 
difficulty talking 4 ( 5.9%) 1 ( 5.6%) 1 ( 7.7%) 
slurred speech 5 ( 7.4%) 1 ( 5.6%) 1 ( 7.7%) 
runny or stuffy nose 9 (13.2%) 2(15.4%) 
sore throat 4 ( 5.9%) 
other 2 ( 2.9%) 
none 45 (66.2%) 16 (88.9%) 9 (69.2%) 
breathing or lungs 
cough 1 ( 1.5%) 
difficulty breathing 4 ( 5.9%) 1 ( 7.7%) 
fast breathing 2 ( 2.9%) 1 ( 7.7%) 
slow breathing 3 ( 4.4%) 
other 
none 53 (77.9%) 18 (100%) 11 (84.6%) 
heart or circulation 
palpitations/racing heart 11 (16.2%) 1 ( 5.6%) 
missed heart beat 2 ( 2.9%) 
other 
none 51 (75.0%) 17 (94.4%) 12 (92.3%) 
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Number of patients (%) 
Symptom •...........•.••.... __ ......•..••.........••..•...••.....••....••• 
Gabapentin Lamotrigine Topiramate 
(n=68) (n=18) (n=13) 
stomach or digestive system 
bloated feeling or gas 9 (13.2%) 3 (16.7%) 3 (23.1 %) 
decrease in appetite 3 ( 4.4%) 2 (11.1%) 
indigestion or heartburn 5 ( 7.4%) 1 ( 7.7%) 
increase in appetite 9 (13.2%) 3 (16.7%) 1 ( 7.7%) 
pain or cramps in lower abdomen 7 (10.3%) 1 ( 5.6%) 
nausea or vomiting 4 ( 5.9%) 
vomiting blood 
other 3 ( 4.4%) 
none 41 (60.3%) 14 (77.8%) 8 (61.5%) 
rectum or bowel movements 
black tarry stool 2 ( 2.9%) 
constipation 13 (19.1%) 2 (11.1%) 1 ( 7.7%) 
diarrhoea 10 (14.7%) 2 (15.4%) 
other 
none 44 (64.7%) 16 (88.9%) 9 (69.2%) 
kidneys. bladder or urinary system 
burning while passing water 2 ( 2.9%) 
dark brown urine 8 (11.8%) 1 ( 7.7%) 
difficult in passing urine 4 ( 5.9%) 
passing water less often 1 ( 1.5%) 
passing water more often 11 (16.2%) 3 (16.7%) 
bloody urine 
other 
none 47 (69.1 %) 15 (83.3%) 11 (84.6%) 
sexual function 
decrease in sexual desire 6 ( 8.8%) 4 (22.2%) 
decrease in sexual ability 4 ( 5.9%) 1 ( 5.6%) 
increase in sexual desire 2 ( 2.9%) 
other 1 ( 1.5%) 
none 32 (47.1%) 13 (72.2%) 7 (53.8%) 
does not apply 21 (30.9%) 1 ( 5.6%) 6 (46.2%) 
sexual organ 
abnormal vaginal bleeding 1 ( 2.9%)* 2 (16.7%)* 
burning or irritated penis 1 (16.7%)** 
other 
none 59 (86.8%) 14 (77.8%) 11 (84.6%) 
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Number of patients (%) 
Symptom •......•••.. __ .....•.••••••••••..........••............•...•••••.• 
Gabapentin Lamotrigine Topiramate 
(n=68) (n=18) (n=13) 
nervous system 
confusion or delirium 4 ( 5.9%) 3 (16.7%) 
light-headed or hypotension 14 (20.6%) 5 (27.8%) 1 ( 7.7%) 
dizziness or staggering 14 (20.6%) 4 (22.2%) 2(15.4%) 
increase in convulsion 7 (10.3%) 1 ( 5.6%) 
other 
none 39 (57.4%) 10 (55.6%) 10 (76.9%) 
mental health 
anxiety( nervousness)or agitation 17 (25.0%) 1 ( 5.6%) 1 ( 7.7%) 
change in mood 17 (25.0%) 4 (22.2%) 1 ( 7.7%) 
difficulty concentrating or learning 17 (25.0%) 6 (33.3%) 3 (23.1%) 
hallucinations 4 ( 5.9%) 
nightmares 1 ( 7.7%) 
anger 13 (19.1%) 3 (16.7%) 1 ( 7.7%) 
loss of memory 21 (30.9%) 8 (44.4%) 2(15.4%) 
thought of suicide 2 ( 2.9%) 
reduction in sleeping 8 (11.8%) 4 (22.2%) 
increase sleep or drowsiness 16 (23.5%) 3 (16.7%) 2(15.4%) 
other 
none 27 (39.7%) 7 (38.9%) 5 (38.5%) 
other ADRs 
increase sensitivity to cold 4 ( 5.9%) 2 (11.1%) 1 ( 7.7%) 
excessive thirst 5 ( 7.4%) 2(15.4%) 
fever 
flu-like symptoms 
increase sweating 13 (19.1%) 2 (11.1%) 2 (15.4%) 
unusual tiredness or weakness 13 (19.1%) 3 (16.7%) 2(15.4%) 
weight gain 24 (35.3%) 4 (22.2%) 1 ( 7.7%) 
weight loss 1 ( 1.5%) 3(23.1%) 
other 
none 30 (44.1%) 10 (55.6%) 6 (46.2%) 
* denominator = number of female respondents 
** denominator = number of male respondents 
